From: Brian Bird <bhbird@ucdavis.edu>
To: Jonna Mazet <jkmazet@ucdavis.edu>;Jon Epstein <epstein@ecohealthalliance.org>;William B. Karesh <karesh@ecohealthalliance.org>;Tracey Goldstein <tgoldstein@ucdavis.edu>;Christine Kreuder Johnson <ckjohnson@ucdavis.edu>
CC: Elizabeth S Chase <eschase@ucdavis.edu>
Sent: 1/3/2017 4:59:30 PM
Subject: CDC visit this week -agenda and flights

The folks at CDC are getting us a finalized agenda in the next couple of hours. They have a question about the flights out on Friday. Basically they are wondering how much extra meeting time to build in on Friday morning. If folks are heading out relatively early then they won't worry about it too much, but they want to make sure that our time is used well if we are staying till mid-afternoon etc.

Could you please let me know when you are flying back home from ATL on Friday?

-b

From: Elizabeth S Chase <eschase@ucdavis.edu>
To: Alison Andre <andre@ecohealthalliance.org>;Peter Daszak <daszak@ecohealthalliance.org>;William B. Karesh" <karesh@ecohealthalliance.org>
CC: Jonna Mazet <jkmazet@UCDAVIS.EDU>;Amanda Fuchs <fuchs@ecohealthalliance.org>;Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>;Tracey Goldstein <tgoldstein@UCDAVIS.EDU>;David John Wolking <djwolking@UCDAVIS.EDU>;Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Sent: 2/13/2017 11:58:37 PM
Subject: RE: EcoHealth/UCDavis meeting in New York

Hello All,
As time is of the essence for the Country by Country review, we have been considering options for this meeting and we are suggesting that since your folks are in Washington April 6, we could possibly schedule the meeting there. Would your team be available in DC April 7?

The CUGH conference is taking place at that time, and Jonna is in attendance, but we may be able to find time during the day to hold this meeting.

After April 7, the Davis team's ability to travel to the east coast is greatly diminished and at that point, the meeting will have to be moved to Davis sometime in mid-April. Please take a look at the schedule and see if the April 7 in DC is at all a possibility.
Hope to hear back soon,
Liz Chase

Liz Chase
Executive Assistant to Dr. Jonna Mazet
One Health Institute
University of California, Davis

530-752-3630
eschase@ucdavis.edu

From: Alison Andre [mailto:andre@ecohealthalliance.org]
Sent: Tuesday, February 07, 2017 1:26 PM
To: Elizabeth S Chase ; Peter Daszak ; William B. Karesh
Cc: Jonna Mazet ; Amanda Fuchs ; Christine Kreuder Johnson ; Tracey Goldstein ; David John Wolking ; Elizabeth Leasure
Subject: Re: EcoHealth/UCDavis meeting in New York

Hi Liz,

EHA has an event in DC on April 6th so April 7th wouldn't work for us here. Let me check the availability of the folks here and I'll get back to you as soon as possible.

Best,
Alison

Alison Andre
Program Assistant

EcoHealth Alliance

460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4462 (direct)
1.212.380.4465 (fax)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: Elizabeth S Chase <eschase@ucdavis.edu>
Date: Friday, February 3, 2017 at 12:48 PM
To: Peter Daszak <daszak@ecohealthalliance.org>, "William B. Karesh" <karesh@ecohealthalliance.org>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Amanda Fuchs <fuchs@ecohealthalliance.org>, Alison Andre <andre@ecohealthalliance.org>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Elizabeth Leasure <ealeasure@ucdavis.edu>
Subject: EcoHealth/UCDavis meeting in New York

Greetings,
Jonna has asked me to find a time for the UCDavis group to travel to New York to meet with EcoHealth Alliance for a country-by-country review. The plan would be for UCDavis to meet at your convenience throughout the day with the country representatives you designate. Currently we have Jonna Mazet, Tracey Goldstein, Christine Kreuder Johnson, David Walking and Liz Leasure hoping to attend.

The proposed date for the meeting is April 7, 2017. Is that date be a possibility for your EcoHealth group? If you have different dates to suggest, kindly consider dates after April 7, as this is the earliest that the UCDavis group could gather. I look forward to scheduling at a meeting time convenient for all.

Sincerely, Liz Chase

Liz Chase
Executive Assistant to Dr. Jonna Mazet
One Health Institute
University of California, Davis

530-752-3630
eschase@ucdavis.edu

From: Dennis Carroll <dcarroll@usaid.gov>
Sent: Mon, 25 Sep 2017 12:44:30 +0200
Subject: Re: One Health Platform cooperation request
To: Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com>
Cc: John Mackenzie <[redacted]>, [redacted], Jonna Mazet <[redacted]>, Andrew Clements <aclements@usaid.gov>, Ricardo Echalar <rechalar@usaid.gov>, Cassandra Louis Duthil <clouisduthil@usaid.gov>

Chris, thanks for the email. I'm pleased to hear preparations for the conference are in "full gear". I welcome the chance to explore how our Predict and P&R teams can be supportive. I have copied Cassandra on our team who can coordinate a time for a phone call that could include Andrew, Ricardo and possibly Jonna. Look forward to talking with you.

d

Dr Dennis Carroll
Director, Emerging Threats Program
U.S. Agency for International Development
Office: (202) 712-5009
Mobile: [redacted]

On Sep 22, 2017, at 11:41 AM, Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com> wrote:

Dear Dennis

On behalf of John and Ab, I would like to pick up our conversation about a possible collaboration between Predict and Preparedness and Response and the One Health Platform.
We are indeed in full gear - organizing our Canada Congress. Several organizations took an option on slots for satellite symposia. We hope we can still include your scientific projects!
It would be our pleasure to set up a TC with you and your colleagues to explore possible pathways of collaboration - if you think that could be useful.

I am very much looking forward to receiving your feedback. Many thanks in advance.

Kind regards
Chris

ONE HEALTH PLATFORM
it's all connected
Chris Vanlangendonck
co-founder / management
[redacted]
www.onehealthplatform.com

Op 23 jun. 2017, om 20:53 heeft Dennis Carroll <dcarroll@usaid.gov> het volgende geschreven:

Dear John and Ab, my apologies for being so no-responsive. Let me just way Washington is a place to be avoided right now. Its hard to keep ahead, particularly of emails. That said, we would be delighted for Predict and Preparedness and Response (formerly Respond) to construct symposia to be held as satellite symposia. In addition to Jonna I am copying Andrew Clements and Ricardo Echalar to help move this process along. Thank you for the opportunity to engage in this important forum.

All my best

dennis

On Tue, May 23, 2017 at 5:00 AM, John Mackenzie REDACTED wrote:

Dear Dennis,

I write to follow up on the letter sent to you last month by my colleague, Ab Osterhaus. We are really excited by the 5th congress as the One Health Platform will be hosting it for the first time, and doing so in collaboration with the University of Saskatchewan and our African partners (the Southern African Centre for Infectious Disease Surveillance (SACIDS), One Health CDC Kenya and the One Health Central and Eastern Africa (OHCEA)).

We are very keen to have a strong input into the congress and the scientific program from you and USAID, especially with the PREDICT and RESPOND projects, but not necessarily confined to these projects. With the success of the symposia in Melbourne, I would like to suggest that PREDICT and RESPOND once again construct symposia to be held as satellite symposia. They provide an excellent international window into their respective projects, as well as giving your international partners the opportunity to present their work at a large gathering and to meet and network with others with similar interests.

As Ab mentioned, we are establishing a One Health Fellowship fund which incorporates a 'leaders of tomorrow' concept. While I am certain some of your international partners in PREDICT, RESPOND and other relevant projects will fit into this concept, we would be very grateful for any additional help you could find to help this worthy cause.

I have attached the first announcement and Ab's letter again, for your information, and would like to remind you again of the program construction – the congress will have 4 principal streams: two will be scientific presentations and form the scientific basis of the congress; one will be devoted to antimicrobial resistance, underlining its importance to human health; and the final stream will be concerned with science policy and will be directed at policy makers.

We look forward to hearing from you.

With warm personal regards,

John

Professor John S Mackenzie,

REDACTED

REDACTED

Begin doorgestuurd bericht:

Van: Ab Osterhaus <a.osterhaus@onehealthplatform.com>

Onderwerp: One Health Platform cooperation request

Datum: 20 april 2017 10:47:51 CEST

Aan: Dennis Carroll <dcarroll@usaid.gov>

Kopie: David Heymann REDACTED

Dear Dr. Carroll,

Dear Dennis,

I hope this e-mail finds you well.

I'm attaching an official request for collaboration in view of the upcoming 5th International One Health Congress, to be held in Saskatoon, Canada.

Looking forward to getting in touch.

Best regards,

Prof. A.D.M.E. Osterhaus
ONE HEALTH PLATFORM Chair
It's all connected
www.onehealthplatform.com

<OHP_5OHC_bannerMelbourne_press.jpg>

--
Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
Mobile: REDACTED

From: REDACTED
To: Dennis Carroll <dcarroll@usaid.gov>
Cc: Cara Chrisman <cchrisman@usaid.gov>, "watson@ecohealthalliance.org" <watson@ecohealthalliance.org>, Nathan Wolfe <nwolfe@metabiota.com>, "Jonna Mazet" <jkmazet@ucdavis.edu>, Eddy Rubin <erubin@metabiota.com>, Peter Daszak <daszak@ecohealthalliance.org>
Subject: RE: GVP call and updates
Sent: Wed, 25 Apr 2018 23:24:50 +0000

Hi Dennis,

Thank you very much! Yes, I will be on vacation REDACTED I'm looking forward to speaking with everybody next time.

Best,
REDACTED

From: Dennis Carroll [mailto:dcarroll@usaid.gov]
Sent: Wednesday, April 25, 2018 3:23 PM
To: REDACTED
Cc: Cara Chrisman <cchrisman@usaid.gov>; watson@ecohealthalliance.org; Nathan Wolfe <nwolfe@metabiota.com>; Jonna Mazet <jkmazet@ucdavis.edu>; Eddy Rubin <erubin@metabiota.com>; Peter Daszak <daszak@ecohealthalliance.org>
Subject: Re: GVP call and updates

REDACTED thanks for the update. I hope "being out of the office" means you are getting a well deserved vacation :). Enjoy

Sent from my iPhone
On Apr 25, 2018, at 5:48 PM REDACTED wrote:

Hi team,

I wanted to let you know that I will be out of the office starting tomorrow and will be back on May 8. Jonna will also be on the airplane tomorrow and will not be able to call in.

Here are updates from my end:

- **Thailand**: I am coordinating with CII, Mahidol University, and PREDICT colleagues (Chulalongkorn University) to have lab technicians trained at CII in June.
- **Steering committee meeting**: Brooke, Cara and I have sent out the doodle poll for the potential DC meeting
- **Japan outreach**: I am working closely with LaToya (USAID) to organize Dennis's talk, now confirmed for June 28. I will have a call with the USAID Tokyo office in a few days.
- **BioHub**: I am working with the PREDICT data management team to have the data shared with BioHub. The summary of data structure was shared with Jim on April 23.
- **SOP list**: I will send the excel worksheet in a separate email

Best,

REDACTED

Fellow
One Health Institute
School of Veterinary Medicine
University of California, Davis

From: Andrew Clements <aclements@usaid.gov>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: PREDICTMGT <predictmgt@usaid.gov>;isimmons@usaid.gov <isimmons@usaid.gov>;bhaberer@usaid.gov <bhaberer@usaid.gov>;Jean-Felly Numbi <jnumbi@usaid.gov>;Linda Mobula <rmmobula@usaid.gov>;PREDICT-outbreak <predict-outbreak@ucdavis.edu>;Karen Saylors <ksaylors@metabiota.com>;Brian Bird <bhbird@ucdavis.edu>
Sent: 6/15/2018 10:40:17 AM
Subject: Re: UPDATE PREDICT DRC EVD outbreak 13 & 14 June 2018

Sounds reasonable, Jonna. Thanks!

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jun 15, 2018, at 5:35 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Dear All,
I'd like to suggest that, since we are not providing much detail above what you all likely already have, that we stop the daily reporting from Predict now and only provide updates when we have something to add to what is generally available. So unless I hear otherwise, we will plan to send an update only when when we have a Predict contribution to make to the report.
Let me know if that doesn't sound like a reasonable plan,
Jonna

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/CAO5tDrGG0wWiFEmVR1Ysh4E7v8H5xKcyMSSad2uo8Jb%2BrFs7hA%s40mail.gmail.com.

From: Andrew Clements <aclements@usaid.gov>
Sent: Mon, 30 Jul 2018 14:00:09 -0700
Subject: Re: Re-Allocating GHSA Country Levels
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
Cc: Amalhin Shek <ashek@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Cara Christman <cchristman@usaid.gov>, Hannah R Chale <hrchale@ucdavis.edu>, Alisa Pereira <apereira@usaid.gov>

Hi Liz,
We were discussing this among the management team and thought it would be confusing to the GHSA team to include the additional 3M.

So I propose that Alisa, Amalhin, and I sit down tomorrow and come up with some suggested country totals by shifting from countries that have expended a lower percentage of their funds to those that have expended a higher percentage. We'll share that with you to either get your blessing or for you to tweak if there are reasons our suggestions are not good. To minimize confusion, we're going to use the format that the GHSA team uses to track funding by country so that it's in their "language".

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jul 24, 2018, at 12:16 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Amalhin and Andrew. After reviewing Y5 budgets received from partners and evaluating funding needs for each Ebola-funded country through the end of the project in 2019, we propose increasing the combined cap for the EHP countries by $4.149M to $19.149M (inclusive of the last $3M obligation that is currently pending) and increasing the combined cap for the Phase II countries by $335K to $9.335M. As a result of these increases, the combined cap for the non-EHP, Phase I Ebola-funded countries would decrease by $4.484M to $27.816M. Since we have been advised that only the combined caps for the EHP and Phase II countries are still in effect, we have not broken the requested changes down by country in an effort to avoid possible confusion and the erroneous application of these caps in the future.

A quick comparison of the revised EHP cap and the updated LOP expenditure figures for the EHP countries through June 2018 (comprehensive updated LOP expenditure by country report is forthcoming) shows that we have spent approximately 70% of the proposed revised EHP combined cap (inclusive of the last $3M obligation as noted above), which is in line with guidance received on our last SMT call. With regard to the small requested increase to the combined Phase II country cap, please note that the cap must be increased by the requested amount in order to continue activities through Y5 and wrap up the project by September 2019. Without the requested increase, activities in both countries would cease at the end of Y4.

Thank you for your consideration, and please let me know if you have any questions.

Thank you!
Liz

Elizabeth Leasure
Financial Operations Manager
One Health Institute
[redacted] *(cell)*
530-754-9034 (office)

Skype: ealeasure

From: Amalhin Shek <ashek@usaid.gov>
Sent: Thursday, June 21, 2018 11:12 AM
To: PREDICTMGT <predictmgt@usaid.gov>; Jonna Mazet <jkmazet@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Andrew <aclements@usaid.gov>; David John Wolking <djwolking@ucdavis.edu>; Cara Chrisman <cchrisman@usaid.gov>
Subject: Re-Allocating GHSA Country Levels

Hi team,

Per our last MT call, please see attached the tracker currently in use to document country level GHSA expenditures against obligation and planning levels. I have modified it to include a column for a new re-distribution of country levels, which should be updated based on planned implementation.

The GHSA team would like to receive the new distribution of budgets prior to receiving the June 30 expenditure report, as this will prevent any concerns with those countries above 90% expended (column H).

As a heads up, I will be out of the country Starting next Monday through July 13, but Andrew, Alisa, or Cara will be able to answer or relay any questions related to country levels. Please let us know if you have any questions as you prepare this for submission before the as of June 30 LOP report!

Thanks in advance,

Amalhin Shek | **Budget & Communications Analyst**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
Phone: 571-551-7102(o) [redacted] c) | CP3 8092
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

USAID **Contractor**
GHSI-III - Social Solutions International, Inc.

From: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
To: Andrew Clements <aclements@usaid.gov>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Amalhin Shek <ashek@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, David John Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>, Hannah R Chale <hrchale@UCDAVIS.EDU>, Alisa Pereira <apereira@usaid.gov>
Subject: Re: Re-Allocating GHSA Country Levels
Sent: Thu, 2 Aug 2018 15:47:18 +0000

Hi Andrew. I'm certainly available for a call, but I'll need to check in with Joena and David about their availability and get back to you.

Thanks,
Liz

Elizabeth Leasure
Financial Operations Manager
One Health Institute
University of California, Davis
Cell: REDACTED

From: Andrew Clements <aclements@usaid.gov>
Sent: Thursday, August 2, 2018 8:40 AM
To: Elizabeth Leasure
Cc: Jonna Mazet; Amalhin Shek; predict@ucdavis.edu; PREDICTMGT; David John Wolking; Cara Chrisman; Hannah R Chale; Alisa Pereira
Subject: Re: Re-Allocating GHSA Country Levels

Hi Liz
Can we walk through this later today (before 4:00 EDT) to make sure we are all on the same page?

Thanks

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Aug 1, 2018, at 4:55 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Andrew. I spoke with Jonna, and we are supportive of the arguments you presented for the obligation of the last $3M. With our proposed reallocations, all Ebola-funded countries are on track to spend out by Sept 2019, and no single country has a pipeline that exceeds the number of months remaining in the PREDICT-2 performance period. These changes were determined through an extensive and carefully thought out exercise using actual and projected Y4 costs and requested Y5 budgets, and substantial amounts of funds were moved from several non-EHP countries, including Cameroon, Ethiopia, Tanzania, and Uganda. As it is, we have had to go back to partners and ask them to cut their budgets for Y5 in order to stay within the $56.3M overall cap on Ebola funds.

As of the LOP expenditure report through June 2018, we have already spent the full $12M obligated for EHP to date, as well as approximately half of the last $3M that is pending obligation. Furthermore, our projections indicate that the full $15M for EHP (which includes funds obligated to date plus the pending $3M) will be spent out by the end of September 2018.

To clarify, are you are proposing to move $2M from non-EHP to EHP countries instead of the $4.149M we proposed as an interim measure while you work on the obligation of the last $3M or in place of our requested reallocations? Given that the EHP cap is a minimum spending cap, I don't see any major issues with your proposal as long as this course of action won't result in new country-specific caps, meaning we will have some flexibility with regard to shifts among the Ebola-funded countries as previously specified.

As always, thank you for your continued support and efforts to get the funding we need to complete the project. If there is anything I can do or further information I can provide to assist with this, please let me know.

Thanks,

Liz

From: Andrew Clements <aclements@usaid.gov>
Sent: Tuesday, July 31, 2018 10:10:17 AM
To: Jonna Mazet
Cc: Elizabeth Leasure; Amalhin Shek; predict@ucdavis.edu; PREDICTMGT; David John Wolking; Cara Chrisman; Hannah R Chale; Alisa Pereira
Subject: Re: Re-Allocating GHSA Country Levels

Thanks, Jonna. I appreciate the additional input.
Our strongest argument for getting the additional 3M is:

1) if all of the countries have 17 months of pipeline or less (which means they are on track to spend all funds by 9/30/18).

AND

2) the 3 EHP countries currently have 12 months of pipeline or less (so that adding the 3M won't cause any of them to exceed 17 months of pipeline).

I believe #2 is no problem, but Ethiopia and Uganda both have pipelines of 20 or more months which looks like they will not be able to spend down completely. (If this is incorrect, please let us know.). I'm not sure we can avoid "moving" funds from these countries to others while still trying to make an argument for the new 3M.

To me, the least disruptive fix (in terms of number of countries with budget/agreements to be adjusted) is to move 500,000 from Ethiopia and 1,500,000 from Uganda (which would effectively reduce both of their pipelines to 15 months) and combine it with the new 3,000,000 for distribution to the 3 EHP countries as follows: country totals for Guinea and Liberia each increase by 1,500,000 and Sierra Leone increases by 2,000,000.

Overall, all countries would now have pipelines less than 17 months (less than 11 months for the 3 EHP countries) and budgets/agreements would only have to be adjusted for 5 countries. I would be happy to grant an extension for submitting work plans for those 5 countries.

Let me know how this sounds.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infections Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jul 31, 2018, at 9:28 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Hi Andrew,
> You can, of course, do that, but it will potentially rock our whole workplanning effort and schedule, since we have been aligning country workplans with these levels, as instructed when we started the workplanning process. Additionally, we were given explicit instructions that those country caps are no longer in play, except for the Ghana & DRC combined maximum.
> If you think it best for you to try the exercise and see what we can do with your projections, fine, but I don't want to go back to the drawing board on the workplans and with Missions unless absolutely necessary. The numbers we provided to you represent bare bones budgets for actual plans in all of the other Ebola-funded countries.
> As discussed previously, if those funds, that allow us to achieve our intended scope, are not forthcoming, we will need time to do layoffs according to specific country rules, etc. And as you promised, we will expect that USAID will assume the responsibility of informing the Missions and partners that we will end early and will take responsibility and deal with the fall-out.
> From my perspective, the EHP countries and that part of the project were the ones that were told that P-2 may not be able to continue, because the yet-to-be received funds were targeted for them. In addition, despite funding level ambiguity, we have been trying to accommodate shifting goals for these three countries as USAID plans change and in response to GHSA targets. Therefore, while devastating for progress there, the three most Ebola affected countries are the ones that should either be funded or not this year in my opinion, which is informed by our instructions and planning and incremental funding distribution for EHP.
> Appreciate your allowing me to provide my input to inform your discussion.
> We, of course, defer to your collective wisdom on the way forward,
> Jonna

On Mon, Jul 30, 2018 at 2:00 PM, Andrew Clements <aclements@usaid.gov> wrote:

> Hi Liz,
> We were discussing this among the management team and thought it would be confusing to the GHSA team to include the additional 3M.

So I propose that Alisa, Amalbin, and I sit down tomorrow and come up with some suggested country totals by shifting from countries that have expended a lower percentage of their funds to those that have expended a higher percentage. We'll share that with you to either get your blessing or for you to tweak if there are reasons our suggestions are not good. To minimize confusion, we're going to use the format that the GHSA team uses to track funding by country so that it's in their "language".

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jul 24, 2018, at 12:16 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Amalhin and Andrew. After reviewing Y5 budgets received from partners and evaluating funding needs for each Ebola-funded country through the end of the project in 2019, we propose increasing the combined cap for the EHP countries by $4.149M to $19.149M (inclusive of the last $3M obligation that is currently pending) and increasing the combined cap for the Phase II countries by $335K to $9.335M. As a result of these increases, the combined cap for the non-EHP, Phase I Ebola-funded countries would decrease by $4.484M to $27.816M. Since we have been advised that only the combined caps for the EHP and Phase II countries are still in effect, we have not broken the requested changes down by country in an effort to avoid possible confusion and the erroneous application of these caps in the future.

A quick comparison of the revised EHP cap and the updated LOP expenditure figures for the EHP countries through June 2018 (comprehensive updated LOP expenditure by country report is forthcoming) shows that we have spent approximately 70% of the proposed revised EHP combined cap (inclusive of the last $3M obligation as noted above), which is in line with guidance received on our last SMT call. With regard to the small requested increase to the combined Phase II country cap, please note that the cap must be increased by the requested amount in order to continue activities through Y5 and wrap up the project by September 2019. Without the requested increase, activities in both countries would cease at the end of Y4.

Thank you for your consideration, and please let me know if you have any questions.

Thank you!

Liz

Elizabeth Leasure

Financial Operations Manager

One Health Institute

REDACTED (cell)

530-754-9034 (office)

Skype: ealeasure

From: Amalhin Shek <ashek@usaid.gov>
Sent: Thursday, June 21, 2018 11:12 AM
To: PREDICTMGT <predictmgt@usaid.gov>; Jonna Mazet <jkmazet@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Andrew <aclements@usaid.gov>; David John Wolking <djwolking@ucdavis.edu>; Cara Chrisman <cchrisman@usaid.gov>
Subject: Re-Allocating GHSA Country Levels

Hi team,

Per our last MT call, please see attached the tracker currently in use to document country level GHSA expenditures against obligation and planning levels. I have modified it to include a column for a new re-distribution of country levels, which should be updated based on planned implementation.

The GHSA team would like to receive the new distribution of budgets prior to receiving the June 30 expenditure report, as this will prevent any concerns with those countries above 90% expended (column H).

As a heads up, I will be out of the country Starting next Monday through July 13, but Andrew, Alisa, or Cara will be able to answer or relay any questions related to country levels. Please let us know if you have any questions as you prepare this for submission before the as of June 30 LOP report!

Thanks in advance,

Amalhin Shek | **Budget & Communications Analyst**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
Phone: 571-551-7102(o)[REDACTED](c) | CP3 8092
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

USAID **Contractor**
GHSI-III - Social Solutions International, Inc.

From: Nathan Wolfe <nwolfe@metabiota.com>
To: Jonna Mazet <jkmazet@ucdavis.edu>
Subject: Re: Can't make it today
Sent: Wed, 25 Jan 2017 14:43:30 +0000

No worries, we're on it

Hope all is ok and sending good wishes.

From: [redacted] on behalf of Jonna Mazet <jkmazet@ucdavis.edu>
Sent: Wednesday, January 25, 2017 6:20:33 AM
To: Dennis Carroll; Eddy Rubin; Nathan Wolfe; Robert Mann
Cc: Taylor Elnicki; Elizabeth S Chase
Subject: Can't make it today

Hi Guys,
I've had an emergency come up this morning, and I'm afraid that I need to cancel today. I'll join you again tomorrow. Very sorry for the change & for missing dinner at REDACTED. Call me if you need anything from me today.
See you tomorrow,
Jonna

From: Alisa Pereira <apereira@usaid.gov>
To: David J Wolking <djwolking@ucdavis.edu>
CC: Clements, Andrew (GH/HIDN) <AClements@usaid.gov> Elizabeth Leasure <ealeasure@ucdavis.edu> PREDICTMGT <predictmgt@usaid.gov> Prof. Jonna Mazet <jkmazet@ucdavis.edu>
Sent: 1/25/2017 11:50:01 PM
Subject: Re: January 2017 GHSA Africa Report

Let me ask Ashna. I have been parts of these conversations, but honestly cannot remember the conclusion.

I will let you know tmw.

Thanks
Alisa

Sent from my iPhone

> On Jan 25, 2017, at 7:17 PM, David J Wolking <djwolking@ucdavis.edu> wrote:
>
> Hi Alisa and Andrew,
>
> Just wanted to check in with you on this month's Africa GHSA report. With the new guidance on reporting against capacity levels received in Pacifica and activities in the meetings in DC this week set to define those levels and talk through reporting ideas, we were wondering if we should slow play this month's submission in case we need to restructure or reformat our progress bullets.
>
> Please advise how best to proceed given the moving target nature of these reports.
>
> Best,
>
> David

From: Andrew Clements <aclements@usaid.gov>
Sent: Wed, 8 Feb 2017 17:24:39 +0100
Subject: Highly Pathogenic Avian Influenza A(H5N8) Virus in Wild Migratory Birds, Qinghai Lake, China (2016)
To: "Schar, Daniel (RDMA/OPH)" <dSchar@usaid.gov>, "Damrongwatanapokin, Sudarat (RDMA/OPH)" <sDamrongwatanapokin@usaid.gov>, "Claes, Filip (AGAH)" <REDACTED>, William Karesh <Karesh@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, "Carroll, Dennis(GH/HIDN)" <DCarroll@usaid.gov>

https://wwwnc.cdc.gov/eid/article/23/4/16-1866_article

--

Andrew Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see http://www.usaid.gov/ept2

Sent: Mon, 13 Feb 2017 20:18:36 -0800
Subject: Re: CBEP Global Bat Alliance meeting
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Abel Ekiri <abekiri@ucdavis.edu>

Thanks!
J

On Mon, Feb 13, 2017 at 7:19 AM, Abel Ekiri <abekiri@ucdavis.edu> wrote:

Hi Jonna,

Mary shared that the idea of putting together a Global Bat Alliance is in its infancy. DTRA is still discussing details and plans to call a meeting of potential network members in the coming months. So will update us of progress in near future.

Best regards,

Abel

From: [redacted] on behalf of Jonna Mazet <jkmazet@ucdavis.edu>
Sent: Wednesday, February 8, 2017 1:58 PM
To: Abel Ekiri; Christopher kilonzo
Cc: Woutrina A Smith; David John Wolking; Falgunee K. Parekh; Rudovick Kazwala
Subject: Fwd: CBEP Global Bat Alliance meeting

Hi Abel & Chris,
Hope you're travels were okay. Please see the invite below. Not sure how it all fits, but you could discuss with Mary if you haven't already.
Good luck,
Jonna

---------- Forwarded message ----------
From: **Flegler, Ayanna J CTR (US)** <ayanna.j.flegler.ctr@mail.mil>
Date: Tue, Feb 7, 2017 at 8:22 AM
Subject: CBEP Global Bat Alliance meeting
To: "Stokes, Martha M CIV (US)" <martha.m.stokes.civ@mail.mil>, "Lancaster, Mary J CIV (US)" <mary.j.lancaster5.civ@mail.mil>, Jon Epstein <epstein@ecohealthalliance.org>, Gavin James Smith [redacted], Ian Mendenhall <[redacted]>, "oliva@ecohealthalliance.org" <oliva@ecohealthalliance.org>, "Rebekah.Kading@colostate.edu" <Rebekah.Kading@colostate.edu>, "vkapur@psu.edu" <vkapur@psu.edu>, "jkmazet@ucdavis.edu" <jkmazet@ucdavis.edu>, [redacted] [redacted]

CBEP would like to convene researchers from all CBEP-engaged regions to discuss formation of a Global Bat Alliance (GBA). The GBA will aim to build and leverage country and regional capabilities to generate an enhanced understanding of bats and their ecology within the context of pathogens of security concern. This meeting will serve to discuss future collaborative efforts of the Global Bat Alliance.

UCDUSR00003829

From: Kevin Olival, PhD <olival@ecohealthalliance.org>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: Peter Daszak <daszak@ecohealthalliance.org>
Sent: 2/14/2017 7:04:17 PM
Subject: Re: NPR: Why Killer Viruses Are On The Rise

Thanks Jonna. They didn't fully represent a few things, but overall not bad. The radio piece should come out later today on All Things Considered.

On Feb 14, 2017, at 2:06 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Great job, Kevin, on the NPR story!
Good stuff,
J

Why Killer Viruses Are On The Rise
NPR

If you think there are more dangerous infectious diseases than ever, you're right. One big reason: pushing animals like this one out of their homes. Read the full story

From: "William B. Karesh" <karesh@ecohealthalliance.org>
To: David Wolking <dpwolking@ucdavis.edu>, Amanda Fine [REDACTED], "Brian Bird" [REDACTED], Chris Johnson <ckjohnson@ucdavis.edu>, "Dr. Damien Joly" <djoly@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Jon Epstein <epstein@ecohealthalliance.org>, Karen Saylors <ksaylors@metabiota.com>, Suzan Murray <MurrayS@si.edu>, Peter Daszak <daszak@ecohealthalliance.org>, "Prof. Woutrina Smith" <wasmith@ucdavis.edu>, "Dr. Simon Anthony" <sja2127@columbia.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, "Alison Andre" <andre@ecohealthalliance.org>, Amanda Fuchs <fuchs@ecohealthalliance.org>, Taylor Einicki <teinicki@metabiota.com>, Evelyn Luciano <luciano@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Emma Lane <lane@ecohealthalliance.org>, Sarah Olson [REDACTED], Molly Turner <turner@ecohealthalliance.org>, Megan Doyle <mmdoyle@ucdavis.edu>, "Kevin Olival, PhD" <olival@ecohealthalliance.org>, Patrick Dawson <dawson@ecohealthalliance.org>, "Zimmerman, Dawn" <ZimmermanD@si.edu>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Subject: FAO Pivot and coordinated sampling with PREDICT
Sent: Thu, 23 Feb 2017 17:44:22 +0000

Dear All,
Jonna and I just had a quick call with Subhash Morzaria from FAO regarding their new plan with USAID to focus on capacity building for the priority animal pathogens identified by countries under GHSA (for Africa GHSA Phase 1 countries).

He wanted to give us a heads up on the most likely changes as discussed between USAID and FAO.

It is likely that all the FAO country level staff have not yet been briefed. SO, AT THIS POINT IN TIME, THERE IS NO NEED FOR URGENT COMMS WITH COUNTRY COORDINATORS, unless they were planning a joint trip with FAO in the next week or something really pressing. On the other hand, please feel free to let them know if you are talking with them anyway, and I don't see any reason why you can't discuss it on an upcoming surveillance call just to let people know this is likely to happen.

Subhash will confirm final decisions in the next week or so, and Jonna will follow-up with USAID in one format or another. This is not set in stone, but is how they see things most likely working out unless USAID provides additional funding (or there is another change in plans).

All Asia Countries: Business as usual, no changes

Egypt and Jordan: Business as usual, no changes

Kenya, Tanzania, and Uganda: The livestock samples they have already collected will be made available to be tested by PREDICT if we want them and we can find the money to pay for the testing. If we are able to do the testing, they MIGHT be able to include funding (per diems, etc.) for local FAO partners to be trained in the techniques, this would be allowable in their budget under their "capacity building" goals.

S.L., Guinea, Liberia: They most likely will not be doing the domestic animal sampling or testing, though there is a slim possibility depending on priority setting. Similar to above, they might be able to include funding (per diems, etc.) for local FAO partners to be trained in the field or lab techniques, under their "capacity building" goals (but currently we are not doing in-country testing). If their budgets allow, they may also be able to do some domestic animal sampling and testing, but they are not sure about it at this point in time.

All other African countries: They will not be doing any of the sampling and testing coordinated with PREDICT or using PREDICT protocols as we had been planning.

That's it in a nutshell.

BK

William B. Karesh, D.V.M
Executive Vice President for Health and Policy

EcoHealth Alliance
460 West 34th Street - 17th Floor

New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: Ana S. Ayala <Ana.Ayala@law.georgetown.edu>
To: Dennis Carroll <dcarroll@usaid.gov>
CC: Jonna Mazet <jkmazet@ucdavis.edu>;Cara Chrisman <cchrisman@usaid.gov>
Sent: 3/8/2017 4:07:31 PM
Subject: Re: My O'Neill blog post on the GVP

Dear Dennis,

Hope all is well! We never scheduled a time for our meeting after your trip to Rome to discuss the ELSI budget, so I wanted to touch base to see if you'd be interested in scheduling something this week or the next, or if your plan was to discuss this during the 3/24 call.

All the best,

Ana

Ana S. Ayala, J.D., LL.M.
Director, Global Health Law LL.M. Program
O'Neill Institute for National and Global Health Law
Georgetown University Law Center
(202) 662-9462 | (202) 662-4045 fax
Ana.Ayala@law.georgetown.edu
www.oneillinstitute.org

On Wed, Feb 15, 2017 at 3:26 PM, Ana S. Ayala <Ana.Ayala@law.georgetown.edu> wrote:
Thanks, Dennis. Glad you liked it.

It was also great seeing you in Beijing and be part of the continued discussions. I look forward to touching base with you when you return from Rome. I'm flexible on Tuesday and Friday during the afternoon. Just let me know your availability when you get a chance.

Have a safe trip!

Ana S. Ayala, J.D., LL.M.
Director, Global Health Law LL.M. Program
O'Neill Institute for National and Global Health Law
Georgetown University Law Center
(202) 662-9462 | (202) 662-4045 fax
Ana.Ayala@law.georgetown.edu
www.oneillinstitute.org

On Tue, Feb 14, 2017 at 4:43 PM, Dennis Carroll <dcarroll@usaid.gov> wrote:
Excellent blog. Well done. Glad you were in Beijing. You and Luca are doing a great job Need to circle back on what the 5 requirements are to finish the ELSI work. I am off to Rome but will be back in the office on Tuesday. Let's chat next week when you are free

d

Dr Dennis Carroll

Director, Emerging Threats Program
U.S. Agency for International Development
Office: (202) 712-5009
Mobile: (301) 646-6235

On Feb 14, 2017, at 3:01 PM, Ana S. Ayala <Ana.Ayala@law.georgetown.edu> wrote:

Thanks, Cara and Jonna! Happy Valentine's Day to you too!

Ana S. Ayala, J.D., LL.M.
Director, Global Health Law LL.M. Program
O'Neill Institute for National and Global Health Law
Georgetown University Law Center
(202) 662-9462 | (202) 662-4045 fax
Ana.Ayala@law.georgetown.edu
www.oneillinstitute.org

On Tue, Feb 14, 2017 at 2:37 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:
Wonderful -- thank you so much for keeping up the momentum, Ana!
Happy Valentine's Day,
Jonna

On Tue, Feb 14, 2017 at 11:37 AM, Ana S. Ayala <Ana.Ayala@law.georgetown.edu> wrote:

Dear Dennis and Cara,

I wanted to let you know that I've just published a quick and short piece on the O'Neill Institute's blog on the GVP: http://www.oneillinstituteblog.org/the-global-virome-project-understanding-our-viral-enemies-to-create-a-safer-world/#. The O'Neill blog is intended to raise awareness about global public health law issues in an informal and concise way. We should always look at this forum as a way to advertise the legal aspects of the GVP.

If it's alright with you, I can submit it for inclusion in the newsletter.

All the best,

Ana

Ana S. Ayala, J.D., LL.M.

Director, Global Health Law LL.M. Program

O'Neill Institute for National and Global Health Law

Georgetown University Law Center

(202) 662-9862 | (202) 662-4045 fax

Ana.Ayala@law.georgetown.edu

www.omelinstitute.org

From: [redacted]
Sent: Sat, 01 Apr 2017 02:36:30 +0000
Subject: Re: URGENT - need to edit the figure for the GVP paper
To: Peter Daszak <daszak@ecohealthalliance.org>
Cc: David J Wolking <djwolking@ucdavis.edu>, "Elizabeth S Chase (eschase@ucdavis.edu)" <eschase@ucdavis.edu>, "Jonna Mazet (jkmazet@ucdavis.edu)" <jkmazet@ucdavis.edu>

Great, glad it worked out!

Best wishes,

[redacted]

On Fri, Mar 31, 2017 at 7:25 PM Peter Daszak <daszak@ecohealthalliance.org> wrote:

Brilliant – thanks Nistara!!!

V. much appreciated – it means I can get this paper cranked out tonight…

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

+1.212.380.4473 (direct)

+1.212.380.4465 (fax)

www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: REDACTED
Sent: Friday, March 31, 2017 9:49 PM
To: Peter Daszak

Subject: Re: URGENT - need to edit the figure for the GVP paper

I saved the image to a powerpoint file and added the text to it so you can edit it there if you want. It can then be saved as an image and the white bottom cropped up. I'm also sending you just the image, if you want to add text in a different way.

My number is REDACTED, if you need to reach out for it.

Hope this helps!

Best,

REDACTED

REDACTED

PhD candidate, Epidemiology
One Health Institute
UC Davis School of Veterinary Medicine
REDACTED

On Fri, Mar 31, 2017 at 6:32 PM, REDACTED > wrote:

I just called you, and spoke with Alexi. My number is REDACTED if you need to reach out to me today.

Best wishes,

Nistara

REDACTED

PhD candidate, Epidemiology
One Health Institute
UC Davis School of Veterinary Medicine
REDACTED

On Fri, Mar 31, 2017 at 6:27 PM, REDACTED > wrote:

Hello Dr. Daszak,

I just saw your email, so I hope it's still in time. I've attached the original editable version, which is an adobe illustrate file. If you don't have Illustrate, let me know and I'll change the figure here. I'll keep checking for your email today if you need more help.

Best wishes,

REDACTED

REDACTED

PhD candidate, Epidemiology
One Health Institute
UC Davis School of Veterinary Medicine
REDACTED

On Fri, Mar 31, 2017 at 1:33 PM, Peter Daszak <daszak@ecohealthalliance.org> wrote:

Hi REDACTED

Jonna said I should send you an email because she's not got email access today. I'm finishing off edits to the GVP paper and need to change the text on the figure that we're using. It's the 'hairy eyeball' figure, see attached.

The problem is that I only have the un-editable version. Could you email me the editable version. I'm going to change some of the numbers in the text so that it fits what the revised paper says.

Thanks very much – I'm trying to get this submitted tonight so we can push it along, and didn't realize it's a holiday in CA.

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

+1.212.380.4473 (direct)

+1.212.380.4465 (fax)

www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

--

REDACTED
PhD candidate, Epidemiology
One Health Institute
UC Davis School of Veterinary Medicine
REDACTED

From: Jon Epstein <epstein@ecohealthalliance.org>
Sent: Mon, 3 Apr 2017 15:26:49 -0400
To: "Sudarat Damrongwatanapokin D.V.M., Ph" <sdamrongwatanapokin@usaid.gov>
Cc: Dan Schar <dschar@usaid.gov>, Tom Hughes <tom.hughes@ecohealthalliance.org>, Andrew Clements <AClements@usaid.gov>, "Alisa Pereira (GH/HIDN)" <apereira@usaid.gov>, Evelyn Luciano <luciano@ecohealthalliance.org>, predict@ucdavis.edu, Allison White <white@ecohealthalliance.org>, Molly Turner <turner@ecohealthalliance.org>
Subject: [predict] Malaysia CIP
Y3CIP_Malaysia_04012017.xlsx

Dear Sudarat,
It was great to see you while in Bangkok. Please find the Malaysia CIP attached, and let Tom and I know if you have any questions.

Cheers,
Jon

--

Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4467 (direct)
REDACTED (mobile)

web: ecohealthalliance.org

Twitter: @epsteingon

-

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

PRODUCED IN NATIVE FORMAT

Sent: Wed, 12 Apr 2017 15:43:44 -0700
Subject: REMINDER: PREDICT Sierra Leone, Guinea, Libera (EHP) CALL Thursday April 13 11AM Pacific-2PM Eastern
From: Brian Bird <bhbird@ucdavis.edu>
To: David J Wolking <djwolking@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, "William B. Karesh, D.V.M" <karesh@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Matthew LeBreton <mlebreton@metabiota.com>, Damien Joly <djoly@metabiota.com>, Manjunatha N Belaganahalli <mbelaganahalli@ucdavis.edu>, Eddy Rubin <erubin@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, Jason Eurek <jeurek@metabiota.com>, Frantz Jean Louis <fjeanlouis@metabiota.com>, Emma Lane <lane@ecohealthalliance.org>, Emily Hagan <hagan@ecohealthalliance.org>
Cc: "(andre@ecohealthalliance.org)" <andre@ecohealthalliance.org>, Katherine Leasure <kaleasure@ucdavis.edu>, Elizabeth S Chase <eschase@ucdavis.edu>, Amanda Fuchs <fuchs@ecohealthalliance.org>
PREDICT-SL-Gui-Lib_Sampling Tracker-April-12-2017.xlsx

PREDICT Sierra Leone, Guinea, Liberia
"EBOLA HOST PROJECT"
COORDINATION CALL
Thursday April 13: 11AM Pacific, 2PM Eastern.
Toll-free number: REDACTED
Access Code: REDACTED
International Dial-in number: REDACTED (toll charges apply)

Hi all just a reminder,

Please let me know if you have any other late breaker agenda items. I've attached the updated specimen sampling tracker current through today for the three countries.

Please let me know if you have any additions you'd like to discuss and I'll add them to this agenda.

Items on the agenda:

1. **Funding and USAID HQ communications (Jonna, all)**
   a. If funding goes down, how to manage expectations regarding the 54,000 animal target?
2. **Country Specific Mission Communications and Challenges (Karen, Jon)**
   a. Country specific updates/plans
   b. Update on Sierra Leone Moa Wharf pig "outbreak" and impact on activities
   c. Guinea CDC communications (*covered in last EB call; but attached here again for reference*)

3. **Livestock sampling (All)**
   a. FAO offer of assistance; implications for lab testing and budgets? How to manage expectations of FAD-Min Livestock staff if we engage with them?
   b. How much longer do the livestock remain relevant scientifically? Do we set a cap on livestock numbers and/or locations then stop sampling those taxa to focus on wildlife and other domestic animals?
3. **Field sampling team updates (Frantz/Karen, Jon)**
   a. Sierra Leone: update on LN2 generator and Mali LN2 supply run situation
   b. Guinea: USG and GoG MOU on Ebola human clinical outbreak specimens; Guinean Ethics committee submission update.
   c. Liberia: Update from new site in Foya county. Status of MOUs or agreements with NRL-LIBR?
4. **Laboratory updates (Tracey, Simon, Manju)**

6. **Human behavioral work updates (Karen, Jon)**
   a. IRB Updates and training/implementation plans

7. **Last call's discussion on animal morphometric data vs. animal target numbers**
   a. Last call consensus was to be take representative detailed measurements from a subset only. Do we want to formalize that or have more discussion etc.?
7. **Other partner updates (Billy)**

Talk to you all tomorrow!

-b

PRODUCED IN NATIVE FORMAT

From: "Kevin Olival, PhD" <olival@ecohealthalliance.org>
To: Peter Daszak <daszak@ecohealthalliance.org>, "Dr. Jonna Mazet" <jkmazet@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Damien Joly <djoly@metabiota.com>
Cc: Anna Willoughby <willoughby@ecohealthalliance.org>, Alison Andre <andre@ecohealthalliance.org>
Subject: Re: Notes from today's P2-wide M&A call
Sent: Mon, 8 May 2017 21:56:49 +0000
EPT_M&E_P2_Y3_SAR_1.1b_MAPS&MODELS_8May2017.xlsx
ATT00001.htm

Dear Christine, Damien, and Jonna,
Peter and I look forward to speaking with you all tomorrow for our monthly P2-wide M&A call! The call-in details: REDACTED REDACTED Please let me know if you have other agenda items to add, but for now let's keep in simple...

Agenda:
1. Review P2 M&E for M&A (see attached Excel and link below for powerpoint).

As previously agreed, we want to be sure to included M&A activities from non-EHA PREDICT partners in our M&E reporting. Please be ready to discuss additional "models or maps" that you would like to include, and to give any comments on the draft we have put together.

Please download the draft powerpoint with details for each model described in the M&E spreadsheet here: https://www.dropbox.com[redacted]

Cheers,
Kevin

PRODUCED IN NATIVE FORMAT

Kevin J. Olival, PhD
Associate Vice President for Research

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4478 (direct)
REDACTED mobile)
1.212.380.4465 (fax)
@nycbat (twitter)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

On Apr 4, 2017, at 3:14 PM, Anna Willoughby <willoughby@ecohealthalliance.org> wrote:

Dear all,

The next meeting is scheduled for May 9th at 11 am PST/ 2 pm PST. The conference line is REDACTED Please circulate any agenda items you would like to discuss.

Thanks,
Anna

On Tue, Apr 4, 2017 at 3:00 PM, Kevin Olival, PhD <olival@ecohealthalliance.org> wrote:

Thank you for your time today for another productive P2-wide M&A call.

Attached are the notes, with action items in **bold**.

Cheers,
Kevin

--

Anna Willoughby
Research Assistant

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.646.868.4713 (direct)
1.212.380.4465 (fax)
REDACTED cell)

www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
To: Andrew Clements <aclements@usaid.gov>
Cc: Alisa Pereira <apereira@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Sent: Wed, 10 May 2017 19:03:48 +0000
Subject: [predict] RE: PREDICT Year 3 Equipment Purchase Request #5

Ha! You do have a lot of "A" names going on over there... ☺

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
REDACTED (cell)

From: Andrew Clements [mailto:aclements@usaid.gov]
Sent: Wednesday, May 10, 2017 11:37 AM
To: Elizabeth Leasure
Cc: Alisa Pereira; Jonna Mazet; David John Wolking; predict@ucdavis.edu
Subject: Re: PREDICT Year 3 Equipment Purchase Request #5

Received.

(I'll assume you called me August because I look so young and not because our management team seems like a bunch of interchangeable bureaucrats whose names generally start with the letter 'A'.)

:)

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On May 10, 2017, at 8:21 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi August. Please find attached a request for authorization to purchase equipment to enable in-country work for PREDICT in DRC and Nepal. These items were not originally included in the proposal budget and now require approval. Please let me know if you have any questions or require any additional information to proceed.

Thanks!
Liz

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
REDACTED (cell)

> <Year 3 Equipment Approval Request No. 5_5-10-17.pdf>
> <Vendor quotes_Year 3 Equipment Request No. 5.pdf>

Sent: Wed, 10 May 2017 14:18:20 -0700
Subject: Re: Next GVP Call - 5/11 is on!
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Cara Chrisman <cchrisman@usaid.gov>
Cc: Nathan Wolfe <nwolfe@metabiota.com>, Peter Daszak <daszak@ecohealthalliance.org>, Eddy Rubin <erubin@metabiota.com>, Dennis Carroll <dcarroll@usaid.gov>, Brooke Watson <watson@ecohealthalliance.org>, Elizabeth S Chase <eschase@ucdavis.edu>, Alison Andre <andre@ecohealthalliance.org>, Rebecca Benmahdi <rbenmahdi@metabiota.com>, Taylor Elnicki <delnicki@metabiota.com>

My only add is to review and discuss the working group reports.
Talk to you tomorrow,
Jonna

On Fri, May 5, 2017 at 9:42 AM, Cara Chrisman <cchrisman@usaid.gov> wrote:

Hi Team,
We're looking forward to the opportunity to catch up a bit with everyone next week. Please note that we will plan to keep our regularly scheduled meeting on Thursday, 5/11. We will use this time to reflect on the webinar and feedback, update one another on progress since our last call, and plan next steps.

We also will need to cancel the 5/18 meeting, as Dennis will be traveling during that time. Below are the "to do" lists. Please let me know if anything is completed, but not indicated and will update the list for everyone.

Best,
Cara

Action Items 4/13

Nathan & Peter - Coordinate working with Dan Jansen
Nathan - Follow up with Lance Brooks at DTRA
Peter - Follow up on not for profit
Dennis - Follow up with UNESCO individual
Jonna - Discuss with DTRA AAAS Fellow (completed)
Cara - Follow up with Katherine Littler (completed)
All - Consider next steps with DARPA
All - Continue to follow up with Skoll/Mark/Larry

Remaining 3/2 - 3/30 Actions

Peter - finalize and resubmit paper (in progress)

Dennis - Set up f/u meeting with Chris Elias

Dennis – Keep Larry in the loop as we move forward and run the "ask" by him when completed

Nathan – Update post-call with Richard Wilcox

Eddy/Nathan – Follow up regarding Verily and decide about inclusion as a partner on the website

Eddy – align with Peter and reach out to Sir Michael Stratton about GVP (in progress)

Cara – Start list of who to target (including WT) in May with refined "ask"

Cara – Connect Katherine L with ELSI group

Peter -- align with Eddy and reach out to Brian Granfeld about GVP

Peter - Send modeling timeline to core group

Dennis - Reach out to Richard Hatchett (CEPI)

All - Identify other key individuals to engage with the core group (Keiji, Steve, Kathleen, etc.) on particular topics

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: (202) 712-1161
Cell: REDACTED
E-mail: cchrisman@usaid.gov

From: gaof <gaof@im.ac.cn>
To: Jonna Mazet <jkmazet@ucdavis.edu>
Sent: 6/12/2017 4:10:38 PM
Subject: Re: National Academy of Medicine

Jonna
Still have not got any news from you about the section classifications
Best
George

发自我的 iPhone

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Dear George,
Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate. I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
Hope you are well,
Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Hope this emial finds you well. I wonder if you have some time to find any our friencds who is in Section 2 as we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: gaof <gaof@im.ac.cn>
Sent: 6/30/2017 2:07:32 AM
Subject: Re: National Academy of Medicine

Hi George,
How are you? Hope all is well there. Attached, you will find the current listing of all of the Section 2 members. Please have a look and let me know which of them you think might be willing to be a co-nominator(s) for your submission. As I said, I am happy to nominate you for Section 10 with a cross-listing in Section 2, if we can find a good Section 2 member who will agree to co-nominate with me.

We will also need to submit all of the following information with the materials taking the following into consideration, in that the application must:
1. Convey this clearly: WHY SHOULD THE CANDIDATE BE AN NAM MEMBER?
a. The sections on sponsor statement, contributions (past/future), and citation are critical.
b. Identify candidate's impact in terms that are understandable to those less familiar with the field.
c. For international candidates: i. Place the candidate's accomplishments into the context of the national/regional/international sphere; ii. Note the level of prestige associated with institutions or prizes in the candidate's background that may be unfamiliar to others; iii. Where appropriate, use phrases such as: 1. ….is the leader of Organization X, the most prestigious organization in this field in the nation/region. 2. …is distinguished professor at X university, one of the top institutions in the nation/region 3. ….is an internationally recognized leader in this field
2. Avoid these common errors in the candidate's personal information:
a. Missing or excessive contact information
b. Missing demographic information
c. Incorrect date of birth, citizenship information
3. Avoid these common errors in nomination details:
a. Wrong section or subsection
b. Missing bridging section where applicable
c. Institutional affiliation of both sponsors is the same as the candidate (at least one must be from an entirely separate institution)
d. >10 (maximum allowed) bibliographic citations

In addition to a co-nominator, I will need the following information in a Word document:

CANDIDATE: Name, Credentials, Institution

Type of Nomination: Regular/66+/Intl Section/Subsection: (#)(s) Bridging Section(s): (#)

Demographics: ? Female ? Racial & Ethnic Diversity

Geographic Location: [state/country] Age: [effective October 1]

Subject Emphasis ? This info is not yet available for this year's nominations, but I will get it to you as soon as it comes out.

SPONSORS: Name, Institution
Name, Institution

PAST AND POTENTIAL CONTRIBUTIONS TO NAM:
[~6 lines]

CITATION OF ACCOMPLISHMENT: (50 words)
PROPOSERS' STATEMENT:
[~13 lines]

PRIMARY FIELD & AREA OF SPECIALIZATION OR EXPERTISE:
[3 lines]

CURRENT EMPLOYMENT:
[up to 3]

PRINCIPAL PREVIOUS EMPLOYMENT:
[up to 3]

RESIDENCIES OR FELLOWSHIPS:
[up to 5]

EDUCATION:
[up to 3, highest first]

PRINCIPAL HONORS, AWARDS:
[~6 lines]

CURRENT MAJOR GRANT(s):
[~2 lines]

MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
[~5 lines]

SELECTED BIBLIOGRAPHY:
[up to 10 items]

Please let me know if you can provide the name and contact of a co-nominator and the information above, then we can move forward. We should aim to have the co-nominator on board and the materials all pulled together by November.

Hope to see you soon,
Jonna

On Mon, Jun 12, 2017 at 9:10 AM, gaof <gaof@im.ac.cn> wrote:
Jonna
Still have not got any news flom you about the section classifications
Best
George

发自我的 iPhone

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Dear George,
Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate. I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
Hope you are well,
Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jorma,

Hope this emial finds you well. I wonder if you have some time to find any our friends who is in Section 2 as we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

National Academy of Medicine
Section: 2
Sub-section: Immunology and Microbiology

Agre, Peter C.
Bloomberg Distinguished Professor and Director
Johns Hopkins Bloomberg School of Public Health

Regular, 2c
Elected 2005
Male
Maryland
pagre@jhu.edu

Ahmed, Rafi
Georgia Research Alliance Eminent Scholar
Director, Emory Vaccine Center
Emory University School of Medicine

Regular, 2c
Elected 2014
Male
Georgia
rahmed@emory.edu

Allison, James P.
Chairman, Department of Immunology;
Director Immunology Platform and Deputy Director
The University of Texas MD Anderson Cancer Center

Regular, 2c
Elected 2007
Male
Texas
jallison@mdanderson.org

Austen, K. Frank
AstraZeneca Professor of Respiratory
and Inflammatory Diseases, Harvard Medical School
Brigham and Women's Hospital

Regular, 2c
Elected 1991
Male
Massachusetts
fausten@rics.bwh.harvard.edu

Berns, Kenneth I.
University of Florida College of Medicine

Regular, 2c
Elected 1992
Male
Florida
kberns@ufl.edu

Beutler, Bruce
Regental Professor and Director
The University of Texas Southwestern Medical Center

Regular, 2c
Elected 2008
Male
Texas
Bruce.Beutler@utsouthwestern.edu

Bloom, Barry R.
Distinguished University Service Professor and
Joan and Jack Jacobson Professor of Public Health
Harvard School of Public Health

Regular, 2c
Elected 1988
Male
Massachusetts
bbloom@hsph.harvard.edu

Bluestone, Jeffrey A.

A.W. and Mary Margaret Clausen Distinguished Professor
University of California, San Francisco

Regular, 2c
Elected 2013
Male
California
jeff.bluestone@ucsf.edu

Calame, Kathryn
Columbia University

Regular, 2c
Elected 2007
Female
New York
REDACTED

Cantley, Lewis C.
Meyer Dir., Sandra and Edward Meyer Cancer Center,
Margaret and Herman Sokol Prof. in Oncology Res.
Weill Cornell Medical College

Regular, 2c
Elected 2014
Male
New York
lcantley@med.cornell.edu

Cassell, Gail H.
Senior Lecturer, Department of Global Health
and Social Medicine
Harvard Medical School

Regular, 2c
Elected 1995
Female
Indiana
REDACTED

Chisari, Francis V.
Professor Emeritus
The Scripps Research Institute

Regular, 2c
Elected 2003
Male
California
fchisari@scripps.edu

Choppin, Purnell W.
President Emeritus
Howard Hughes Medical Institute

Regular, 2c
Elected 1984
Male
Maryland
choppinp@hhmi.org

Cooper, Max D.
Eminent Scholar, Georgia Research Alliance;
Professor of Pathology and Laboratory Medicine
Emory University

Regular, 2c
Elected 1990
Male
Georgia
mdcoope@emory.edu

Cresswell, Peter
Investigator, Howard Hughes Medical Institute;
Eugene Higgins Professor of Immunobiology
Yale University School of Medicine

Regular, 2c
Elected 2010
Male

Connecticut
peter.cresswell@yale.edu

David, John R.
Richard Pearson Strong Professor (Emeritus)
Harvard School of Public Health

Regular, 2c
Elected 1988
Male
Massachusetts
jdavid@hsph.harvard.edu

Davie, Joseph M.
No Affiliation

Regular, 2c
Elected 1987
Male
Florida
REDACTED

Davis, Mark M.
Investigator, Howard Hughes Medical Institute;
Professor
Stanford University School of Medicine

Regular, 2c
Elected 2004
Male
California
mmdavis@stanford.edu

Deuel, Thomas F.
Professor of Molecular and Experimental Medicine
and Cell Biology
The Scripps Research Institute

Regular, 2c
Elected 1993

Male
California
REDACTED

Essex, Myron E.
Mary Woodard Lasker Professor of Health Sciences
Harvard School of Public Health

Regular, 2c
Elected 1989
Male
Massachusetts
messex@hsph.harvard.edu

Estes, Mary K.
Professor
Baylor College of Medicine

Regular, 2c
Elected 2005
Female
Texas
mestes@bcm.edu

Falkow, Stanley
Robert W. and Vivian K. Cahill Professor Emeritus (Active) of Microbiology and Immunology and Med.
Stanford University

Regular, 2c
Elected 1997
Male
California
falkow@stanford.edu

Gallo, Robert C.

Director, Institute of Human Virology
The Homer & Martha Gudelsky Distinguished
University of Maryland at Baltimore

Regular, 2c
Elected 1989
Male
Maryland
rgallo@ihv.umaryland.edu

Ganem, Don
Global Head, Infectious Diseases Research,
and Vice President
Novartis Institutes for Biomedical Research, Inc.

Regular, 2c
Elected 2003
Male
California
don.ganem@novartis.com

Garcia, K. Christopher
Professor
Stanford University

Regular, 2c
Elected 2016
Male
California
kcgarcia@stanford.edu

Germain, Ronald N.
Chief, Laboratory of Systems Biology
National Institutes of Health

Regular, 2c
Elected 2013
Male
Maryland
rgermain@niaid.nih.gov

Gillison, Maura L.
Professor of Medicine
The University of Texas M. D. Anderson Cancer Ctr

Regular, 2c
Elected 2016
Female
Texas
mgillison@mdanderson.org

Glimcher, Laurie H.
CEO and President
Dana-Farber Cancer Institute

Regular, 2c
Elected 1998
Female
Massachusetts
Laurie_Glimcher@dfci.harvard.edu

Gordon, Jeffrey I.
Dr. Robert J. Glaser Distinguished University
Professor and Director
Washington University School of Medicine

Regular, 2c
Elected 2008
Male
Missouri
jgordon@wustl.edu

Gotschlich, Emil C.
Professor Emeritus
The Rockefeller University

Regular, 2c
Elected 1988
Male
New York

eca@rockefeller.edu

Griffin, Diane E.
Distinguished University Service Professor
Johns Hopkins Bloomberg School of Public Health

Regular, 2c
Elected 2004
Female
Maryland
dgriffi6@jhu.edu

Haynes, Barton F.
Frederic M. Hanes Professor and Director
Duke Human Vaccine Institute
Duke University Medical Center

Regular, 2c
Elected 1997
Male
North Carolina
barton.haynes@duke.edu

Hildreth, James E.
President
Meharry Medical College

Regular, 2c
Elected 2008
Male
Tennessee
jhildreth@mmc.edu

Ho, David D.

Director and Chief Executive Officer
The Aaron Diamond AIDS Research Center
The Rockefeller University

Regular, 2c
Elected 1997
Male
New York
dho@adarc.org

Howley, Peter M.
Shattuck Professor of Pathological Anatomy
Harvard Medical School

Regular, 2c
Elected 1994
Male
Massachusetts
peter_howley@hms.harvard.edu

Joklik, Wolfgang K.
James B. Duke Professor, Emeritus
Duke University Medical Center

Regular, 2c
Elected 1982
Male
North Carolina

Kappler, John W.
Investigator, Howard Hughes Medical Institute;
Professor
National Jewish Health

Regular, 2c
Elected 2008
Male
Colorado
kapplerj@njhealth.org

Kieff, Elliott D.
Albee Professor
Harvard University

Regular, 2c
Elected 2001
Male
Massachusetts
ekieff@rics.bwh.harvard.edu

Littman, Dan R.
Investigator, Howard Hughes Medical Institute;
Kimmel Professor of Molecular Immunology
New York University School of Medicine

Regular, 2c
Elected 2012
Male
New York
dan.littman@med.nyu.edu

Marrack, Philippa
Investigator, Howard Hughes Medical Institute;
Professor
National Jewish Health

McDevitt, Hugh O.
Professor Emeritus of Microbiology and Immunology
and Medicine
Stanford University School of Medicine

Emeritus, 2c
Elected 1984
Male
California
hughmcd@stanford.edu

Medzhitov, Ruslan

Investigator, Howard Hughes Medical Institute;
David W. Wallace Professor of Immunobiology
Yale University School of Medicine

Regular, 2c
Elected 2013
Male
Connecticut
ruslan.medzhitov@yale.edu

Miller, I. George
John F. Enders Professor of Pediatric
Infectious Diseases
Yale University School of Medicine

Regular, 2c
Elected 1997
Male
Connecticut
george.miller@yale.edu

Miller, Louis H.
Head, Malaria Cell Biology Section
National Institutes of Health

Regular, 2c
Elected 1991
Male
Maryland
lmiller@niaid.nih.gov

Nathan, Carl F.
Chairman
Weill Medical College of Cornell University

Regular, 2c
Elected 1998
Male
New York
cnathan@med.cornell.edu

Nussenzweig, Michel C.
Investigator, Howard Hughes Medical Institute;
Zanvil A. Cohn and Ralph M. Steinman Professor
The Rockefeller University

Regular, 2c
Elected 2009
Male
New York
nussen@mail.rockefeller.edu

Nussenzweig, Ruth S.
C.V. Starr Professor of Medical and Molecular Parasitology
New York University School of Medicine

Emeritus, 2c
Elected 2006
Female
New York
ruth.nussenzweig@nyumc.org

Oldstone, Michael B.A.
Professor
The Scripps Research Institute

Regular, 2c
Elected 1996
Male
California
mbaobo@scripps.edu

Pagano, Joseph S.
Lineberger Professor of Cancer Research and Director Emeritus
The University of North Carolina at Chapel Hill

Regular, 2c
Elected 1998

Male
North Carolina
joseph_pagano@med.unc.edu

Palese, Peter
Horace W. Goldsmith Professor and Chair
Icahn School of Medicine at Mount Sinai

Regular, 2c
Elected 2012
Male
New York
peter.palese@mssm.edu

Rabson, Alan S.
Deputy Director
National Institutes of Health

Regular, 2c
Elected 1987
Male
Maryland

Robbins, John B.
Co-Director, Program on Developmental
and Molecular Immunity
National Institutes of Health

Emeritus, 2c
Elected 1993
Male
Maryland

REDACTED

Roizman, Bernard
Joseph Regenstein Distinguished Service
Professor of Virology
The University of Chicago

Regular, 2c
Elected 2001

Male
Illinois
bernard.roizman@bsd.uchicago.edu

Rudensky, Alexander
Investigator, Howard Hughes Medical Institute;
Chairman
Memorial Sloan-Kettering Cancer Center

Regular, 2c
Elected 2015
Male
New York
rudenska@mskcc.org

Schlossman, Stuart F.
Baruj Benacerraf Professor of Medicine,
Emeritus
Dana-Farber Cancer Institute

Regular, 2c
Elected 1993
Male
Massachusetts
stuart_schlossman@dfci.harvard.edu

Shenk, Thomas E.
Elkins Professor
Princeton University

Regular, 2c
Elected 1996
Male
New Jersey
tshenk@princeton.edu

Silverstein, Samuel C.
John C. Dalton Professor
Columbia University College of Physicians and Surgeons

Regular, 2c
Elected 1996
Male
New York
scs3@columbia.edu

Snyderman, Ralph
Chancellor Emeritus
James B. Duke Professor of Medicine
Duke University

Regular, 2c
Elected 1992
Male
North Carolina
ralph.snyderman@duke.edu

Strominger, Jack L.
Higgins Professor of Biochemistry
Harvard University

Emeritus, 2c
Elected 1975
Male
Massachusetts
jlstrom@fas.harvard.edu

Taniguchi, Tadatsugu
Professor Emeritus and Project Professor
University of Tokyo

International, 2c
Elected 2016
Male
Japan
tada-t@iis.u-tokyo.ac.jp

Unanue, Emil R.

Paul and Ellen Lacy Professor
Washington University School of Medicine

Regular, 2c
Elected 1995
Male
Missouri
unanue@wustl.edu

Varmus, Harold E.
Lewis Thomas University Professor
Weill Medical College of Cornell University

Regular, 2c
Elected 1991
Male
New York
varmus@med.cornell.edu

Vitetta, Ellen S.
Professor of Immunology/Microbiology
Sheryle Simmons Patigian Distinguished Chair
The University of Texas Southwestern Medical Center

Regular, 2c
Elected 2006
Female
Texas
ellen.vitetta@utsouthwestern.edu

Vogt, Peter K.
Professor
The Scripps Research Institute

Regular, 2c
Elected 2003
Male
California
pkvogt@scripps.edu

Waldmann, Thomas A.
Chief, Lymphoid Malignancies Branch
National Institutes of Health

Regular, 2c
Elected 1992
Male
Maryland
tawald@mail.nih.gov

Weiss, Arthur
Investigator, Howard Hughes Medical Institute;
Ephraim P. Engleman Distinguished Professor
University of California, San Francisco School of Medicine

Regular, 2c
Elected 2004
Male
California
aweiss@medicine.ucsf.edu

Weissman, Irving L.
Professor of Pathology and Developmental Biology
Stanford University School of Medicine

Regular, 2c
Elected 2002
Male
California
irv@stanford.edu

Wellems, Thomas E.
Chief, Laboratory of Malaria and Vector Research
National Institutes of Health

Regular, 2c
Elected 2010
Male
Maryland
twellems@niaid.nih.gov

Witte, Owen N.
University Professor, Microbiology
and Pharmacology, and Director
University of California, Los Angeles

Regular, 2c
Elected 2003
Male
California
owenwitte@mednet.ucla.edu

Wong-Staal, Flossie
iTherx Pharmaceuticals, Inc.

Regular, 2c
Elected 1994
Female
California
fwongstaal@ucsd.edu

Yokoyama, Wayne M.
Investigator, Howard Hughes Medical Institute;
Sam J. and Audrey Loew Levin Professor of Medicine
Washington University School of Medicine

Regular, 2c
Elected 2012
Male
Missouri
yokoyama@im.wustl.edu

Young, Frank E.
Executive Vice President
Cosmos Alliance Group

Regular, 2c
Elected 1980

Male
North Carolina
frank@braeburnpharma-us.com

zur Hausen, Harald
Scientific Director, Emeritus
German Cancer Research Center

International, 2c
Elected 2002
Male
Germany
zurhausen@dkfz.de

Sent: Thu, 29 Jun 2017 19:34:18 -0700
Subject: Re: National Academy of Medicine
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: George GAO <gaof@im.ac.cn>

Hi again,
I was all over India for a couple of different projects.
There are definitely some good potential collaborators for you there.

You may want to check into our Predict-affiliated leadership:
Dr. Rajesh Bhatia [redacted]
Dr. Manish Kakkar <manish.kakkar@phfi.org>

Drs. Kakkar and Bhatia are based in Delhi, and are part of our senior management team. They bring a wealth of expertise related to zoonotic disease surveillance and research in India and have been instrumental in guiding us through the permitting and approval processes. Manish works at the Public Health Foundation, India, and Rajesh is previously from WHO and is currently a consultant working with us, as well as others developing and implementing India's antimicrobial resistance action plan. I'm happy to make introductions if you're interested.

In addition, during my trip, I met and discussed surveillance and interesting plans with Professor Sudhir Krishna at the National Centre for Biological Sciences <skrishna@ncbs.res.in>; https://www.ncbs.res.in/faculty/sudhir

Here's an example of discussions;
>
>> Dear Jonna,
>> Pleasure having you over for the talk at the NCBS campus and then
>> catching
>> up over dinner. I thought it might be useful to give you a few more
>> details on what I mentioned over dinner. The program is dengue vaccine
>> centric, but hopefully will function as both a broad enabler in
>> infectious
>> diseases and help facilitate partnerships. I should add that my role is
>> purely supportive.
>> The egovernance foundation of India
>> https://egovernments.org
>> will host the dengue density heat maps
>> Dr. Manoj Murhekar, Director, National Institute of Epidemiology, ICMR,
>> Chennai,
>> http://nie.gov.in
>> will be one of the key investigators on the grant along with other
>> colleagues that ICMR involves in the program.
>> The involvement of egovernance foundation and the ICMR epidemiology
>> institute should enable objective 1 to visualize rapidly by digital
>> means
>> the patterns of Dengue cases in the country using ongoing record
>> keeping.
>> To build standard operating procedures (SOPs) for augmented dengue data
>> collection, we have roped in the Public health Institute, Bangalore
>> http://iphindia.org
>> Along with units that ICMR suggests, this should take care of objective
>> 2,
>> which is figuring out how to estimate Dengue prevalence from the
>> community.
>> There are now several first generation Dengue vaccine products in
>> various
>> stages of development.
>> Vaccination roll outs typically face challenges with diversity and
>> evolution of the viruses in the community, defining preferential target
>> groups (personalized vaccination) and predicting disease dynamics.
>> Typically, this then leads to the creation of the next generation of
>> vaccines, in the case of Influenza in fact every season, there are new
>> sub-units manufactured.
>> I think Satish Rao, Mary Diaz (Microbiology, St. Johns€™s) and the
>> collaborating ICMR team have a clear sense of the experiments they want
>> to
>> undertake to estimate viral diversity, understood immune profiles and
>> lay

>> the foundation for a bio-marker program.
>> Some of the Dengue vaccine products in development are with Serum
>> Institute
>> http://www.serumindia.com
>> and two other companies. Building synergy with them would be vital to
>> enable the Dengue vaccine rollout.
>> My sense is that the program should really be embedded within ICMR to
>> make
>> this a success. They are also significantly investing monetary resources
>> into the program. Might take a few more weeks while ICMR sorts out the
>> role of the various units and puts MOU's in place and so on.
>> Trust this helps and I assume you are having both fun and a productive
>> time on your trip to Wynad.
>> With regards,
>> Sudhir
>>

Let me know if you'd like an intro to anyone there that I might know,
Jonna

On Sat, Apr 29, 2017 at 9:40 AM, George GAO <gaof@im.ac.cn> wrote:

Jonna. Where RU in India ? I also would like to visit India and start some collaborations there. Pls link me with some virologists/public health experts there.
Best
George

发自我的 iPhone George Gao

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Dear George,
Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate. I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
Hope you are well,
Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Hope this emial finds you well. I wonder if you have some time to find any our friends who is in Section 2 as we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

George

UCDUSR00038 78

From: Enkhtuvshin Shilegdamba [redacted]
Sent: Fri, 30 Jun 2017 16:02:39 +0800
Subject: Re: EPT2 Evaluation- Host government counterparts
To: Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov>
Cc: Tom Hughes <tom.hughes@ecohealthalliance.org>, dibesh@cmdn.org, Daniel Schar <dSchar@usaid.gov>, "Clements, Andrew/ANE/TSI" <AClements@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, predict@ucdavis.edu, Amanda Fine
[redacted]

Dear Sudarat,
As requested below please see 2 main contact information from Mongolia EPT 2 Government Counterpart.

Director Ganzorig may not respond in English however Bodisaikhan will be able to respond.

Best,
Enkee

5) Mongolia

Name: Basan Ganzorig
Title: Director
Organization: The State Central Veterinary Laboratory
Contact info: [redacted]
E-mail address: [redacted]

Name: Bodisaikhan Khishgee
Title: BSL-3 Laboratory
Organization: The State Central Veterinary Laboratory
Contact info: [redacted]
E-mail address: [redacted]

WCS

Enkhtuvshin Shilegdamba
Country Director-Mongolia, Mongolia
Wildlife Conservation Society
tel: [redacted]
[redacted]

web: www.wcs.org
twitter: www.twitter.com/thewcs

On Thu, Jun 29, 2017 at 2:04 PM, Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov> wrote:

Dear Marc and Ohnmar Aung, ZhengLi, Soubanh,Supaporn, Tom, Enkee, Dibesh, and Supaorn

Emerging Threat Division is now starting an external evaluation of the EPT2 program. This evaluation will identify whether the objectives of the program are on track for completion. The evaluation identifies on how well the EPT2 program has contributed to the knowledge base, implementation and sustainability of efforts to prevent, detect and respond to emerging pandemic threats, and furthered "One Health." It also focuses on the contribution of the EPT2 program in achieving the objectives of Global Health Security Agenda (GHSA.) Projects that make up the EPT2 program include: PREDICT (Prime - University of California-Davis), Preparedness and Response (P&R) (Prime - DAI Global), and One Health Workforce (OHW) (Prime - University of Minnesota), as well as agreements with WHO and FAO."

We are collecting contact info of the appropriate host government counterparts **(name, title, organization, email)** that you have worked with who will be able to comment on the EPT2 program. The evaluation team will be sending a survey

questionnaire to them.

Please email us the contact info (name, title, organization, email) of the appropriate host government counterparts by Friday, June 30 COB.

The country list that required information of appropriate government counterparts from PREDICT2:

1) Burma:

Name:
Title:
Organization:
Contact info:
E-mail address:

2) China:
Name:
Title:
Organization:
Contact info:
E-mail address:

3) Laos:
Name:
Title:
Organization:
Contact info:
E-mail address:

4) Malaysia
Name:
Title:
Organization:
Contact info:
E-mail address:

5) Mongolia
Name:
Title:
Organization:
Contact info:
E-mail address:

6) Nepal:
Name:
Title:
Organization:
Contact info:
E-mail address:

7)Thailand:
Name:
Title:
Organization:
Contact info:
E-mail address:

Thank you very much and apologize for such a short notice.

Best regards,
Sudarat Damrongwatanapokin, D.V.M., Ph.D.
Regional Animal Health Advisor
USAID Regional Development Mission Asia
REDACTED
E-mail: sdamrongwatanapokin@usaid.gov
Tel: REDACTED Fax REDACTED

Click here to report this email as spam.

From: Leilani Francisco <francisco@ecohealthalliance.org>
Sent: Tue, 18 Jul 2017 12:58:31 -0400
Subject: RE: behavioural surveillance
To: Amanda MCCLELLAND [redacted]
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, "William B. Karesh" <karesh@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Andrew Clements <aclements@usaid.gov>

Hi Amanda,
It's nice to meet you virtually. I would be happy to help. Would you like to set up a time to discuss?
If yes, please let me know what times might work well and we can go from there.
Best regards,
Leilani

From: Andrew Clements [mailto:aclements@usaid.gov]
Sent: Saturday, July 15, 2017 9:23 AM
To: Amanda MCCLELLAND [redacted]
Cc: Jonna Mazet <jkmazet@ucdavis.edu>; William Karesh <Karesh@ecohealthalliance.org>; francisco@ecohealthalliance.org
Subject: Re: behavioural surveillance

Hi Amanda,

I'm copying Jonna Mazet (Predict COP), Billy Karesh (Predict liaison to other EPT partners), and Leilani Francisco (Predict behavioral surveillance lead) on your request so one of them can follow up with you.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov
On Jul 15, 2017, at 2:28 PM, Amanda MCCLELLAND [redacted] wrote:

Hi Andrew
Hope you are enjoying the Geneva summer
I wanted to follow up something you mentioned a few weeks ago n the EP3 kick off meeting. You mentioned that under the Protect project there was a behavioural surveillance component. I am interested to see how we could use behavioural surveillance and join in with our mapping team to help visualise behavioural risk. Do you have any more information about the project or a contact I could discuss with?

Amanda

Amanda McClelland
Health Security and Risk Management
Community and Emergency Health Unit
Health Department

International Federation of Red Cross and Red Crescent Societies
[redacted]
Tel: [redacted]
Email: [redacted]

Saving lives, changing minds
Find out more on www.ifrc.org

From: Amy Kircher <akircher@umn.edu>
To: Dominic Travis <datravis@umn.edu>
CC: Kristine Smith, DVM, Dipl. ACZM <ksmith@ecohealthalliance.org>;Shaun Kennedy <skennedy@foodsysteminstitute.com>;Tracey Goldstein <tgoldstein@ucdavis.edu>;Randy Singer <singe024@umn.edu>;Tiffany Wolf <wolfx305@umn.edu>;Stephen S <stephen@umn.edu>;Jonna Mazet <jkmazet@ucdavis.edu>;William Karesh <karesh@ecohealthalliance.org>
Sent: 7/28/2017 6:12:57 PM
Subject: Re: today's draft

Thanks Dom. I am combing through proposals now and will have guidance for you waiting on Monday am when you come into the office. Amy

Amy Kircher, DrPH
Director
Food Protection and Defense Institute

For scheduling please contact fpdidir@umn.edu

On Fri, Jul 28, 2017 at 1:01 PM, Dominic Travis <datravis@umn.edu> wrote:
Amy,

Here a mostly full draft from our combined discussions to date. It is my understanding that you all want to provide feedback on these before you package them for the Center proposal. So, Im giving you this version to peruse - its too long, but im not sure where to tighten for this audience - I need guidance from Stephen?? Im really not sure how to make this 4 pages, but conciseness is rarely my gift.

Im back in the office on Monday and available to tighten, clean and finalize based upon you and Stephen's thoughts on above.

From our previous lessons, central to this work is a 100% post doc for two years, but there are many others here needed for the different deliverables. It is my understanding that we are allowed the full budget slot (200K/year), which will allow for just under 100K for the actual costs/year once all of the overhead tastes are taken. With that in mind, it would be good to review the deliverables we have here for the money in that light. Maybe we can flesh them out more if chosen for full proposal.

All, please think about budget needs. I have estimates from Kristine already and our preliminary discussions said we would be no cost on Goldstein et al preprop, while Davis would be no cost on this one. We should confirm that final plan. Tiffany, Shaun and Randy, Ill contact you next week.

Thanks all for your patience this week. I will be traveling and out of touch now till Monday.

612 626 5911

www.facebook.com/biodiversitydoctors.

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: richard.hatchett@cepi.net <richard.hatchett@cepi.net>
CC: Dennis Carroll <DCarroll@usaid.gov>;Cara Chrisman <cchrisman@usaid.gov>;Peter Daszak <daszak@ecohealthalliance.org>
Sent: 8/22/2017 4:21:15 PM
Subject: Follow-up on Dennis Carroll's visit & Global Virome Project

Dear Dr. Hatchett,
Please forgive this email somewhat out of the blue, but Dennis Carroll and I very much want to follow-up on your good meetings and make sure that we develop ways for CEPI and the Global Virome Project (GVP) to move forward together and provide synergistic benefits. You and I met a few years ago at the White House when Dennis and I and Peter Daszak briefed you on the USAID PREDICT Project, which I direct. I'm sorry Peter and I weren't with Dennis on his last visit, but I am sure that he updated you on our progress, which has helped to form the proof-of-concept for the GVP. If you want more, you can find info here: www.globalviromeproject.org and www.predict.global. While continuing to lead PREDICT, I have also assumed leadership of the implementation arm of the GVP.

Dennis, Peter, and I have been discussing ways to more functionally connect the two projects, and in our brainstorming, we landed upon an option that might be mutually beneficial. We are currently employing a full-time research scientist living just outside of London to work with us to refine our risk ranking strategy for all of the new viruses that we are identifying. For the first time, we will incorporate, not just virological factors, but the epidemiological characteristics and ecological circumstances surrounding newly-identified viruses when considering the risk they pose to the human populations where they are being identified. Dr. Zoe Grange is an computational ecologist and also brings animal expertise and antimicrobial resistance background to the team. In thinking about how to cement our relationship for the two projects, we thought you might want to explore housing Zoe with your team in London? We would continue to pay her full-time and expect her to be productive in our efforts, but we would also be willing to dedicate a portion of her time to being a liaison for the two projects and to bringing her expertise to bear for CEPI when you identify areas that could use the animal/ecological perspective. Perhaps you already have that expertise on your team, but we are aware that it sometimes feels like a stretch to invest in that perspective while building a human health initiative.

I would be very happy to discuss further and provide Zoe's CV if this idea is of remote interest to you.

Hope everything is going fantastically,
Jonna

Jonna AK Mazet, DVM, MPVM, PhD

Professor of Epidemiology & Disease Ecology

Executive Director, One Health Institute

Global Director, PREDICT Project of USAID Emerging Pandemic Threats Program

School of Veterinary Medicine

University of California

1089 Veterinary Medicine Drive

Davis, CA 95616, USA

+1-530-752-3630

onehealthinstitute.net

For scheduling and logistical issues, please contact:

Ms. Brooke Genovese

bgenovese@ucdavis.edu

+1-530-752-3630

From: gaof <gaof@im.ac.cn>
To: Jonna Mazet <jkmazet@ucdavis.edu>
Sent: 9/11/2017 4:27:30 PM
Subject: Re: National Academy of Medicine

Will get to you in a week

发自我的 iPhone George Gao

在 2017年9月11日，下午11:59，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Great news -- I'll contact him.
It would be good if I could get the materials by end of October. Will that work for you?
Have a good day,
Jonna

On Sat, Sep 9, 2017 at 7:39 AM, George F GAO <gaof@im.ac.cn> wrote:

Jonna,

David Ho is a good seconder in Section 2. He knows me very well.

Director and Chief Executive Officer
The Aaron Diamond AIDS Research Center
The Rockefeller University

Regular, 2c

Elected 1997

Male

New York

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-06-30 10:07:32 (星期五)
收件人: gaof <gaof@im.ac.cn>
抄送:
主题: Re: National Academy of Medicine

Hi George,
How are you? Hope all is well there. Attached, you will find the current listing of all of the Section 2 members. Please have a look and let me know which of them you think might be willing to be a co-nominator(s) for your submission. As I said, I am happy to nominate you for Section 10 with a cross-listing in Section 2, if we can find a good Section 2 member who will agree to co-nominate with me.

We will also need to submit all of the following information with the materials taking the following into consideration, in that the application must:

1. Convey this clearly: WHY SHOULD THE CANDIDATE BE AN NAM MEMBER?

a. The sections on sponsor statement, contributions (past/future), and citation are critical.

b. Identify candidate's impact in terms that are understandable to those less familiar with the field.

c. For international candidates: i. Place the candidate's accomplishments into the context of the national/regional/international sphere; ii. Note the level of prestige associated with institutions or prizes in the candidate's background that may be unfamiliar to others; iii. Where appropriate, use phrases such as: 1. ...is the leader of Organization X, the most prestigious organization in this field in the nation/region 2. ...is distinguished professor at X university, one of the top institutions in the nation/region 3. ...is an internationally recognized leader in this field

2. Avoid these common errors in the candidate's personal information:

a. Missing or excessive contact information

b. Missing demographic information

c. Incorrect date of birth, citizenship information

3. Avoid these common errors in nomination details:

a. Wrong section or subsection

b. Missing bridging section where applicable

c. Institutional affiliation of both sponsors is the same as the candidate (at least one must be from an entirely separate institution)

d. >10 (maximum allowed) bibliographic citations

In addition to a co-nominator, I will need the following information in a Word document:

CANDIDATE: Name, Credentials, Institution

Type of Nomination: Regular/66+/Intl Section/Subsection: (#)(A) Bridging Section(s): (#)

Demographics: ☒ Female ☒ Racial & Ethnic Diversity

Geographic Location: [state/country] Age: [effective October 1]

Subject Emphasis ☒ This info is not yet available for this year's nominations, but I will get it to you as soon as it comes out.

SPONSORS: Name, Institution
Name, Institution

PAST AND POTENTIAL CONTRIBUTIONS TO NAM:
[~6 lines]

CITATION OF ACCOMPLISHMENT: (50 words)
PROPOSERS' STATEMENT:
[~13 lines]

PRIMARY FIELD & AREA OF SPECIALIZATION OR EXPERTISE:
[3 lines]

CURRENT EMPLOYMENT:
[up to 3]

PRINCIPAL PREVIOUS EMPLOYMENT:
[up to 3]

RESIDENCIES OR FELLOWSHIPS:
[up to 5]

EDUCATION:
[up to 3, highest first]

PRINCIPAL HONORS, AWARDS:
[~6 lines]

CURRENT MAJOR GRANT(s):
[~2 lines]

MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
[~5 lines]

SELECTED BIBLIOGRAPHY:
[up to 10 items]

Please let me know if you can provide the name and contact of a co-nominator and the information above, then we can move forward. We should aim to have the co-nominator on board and the materials all pulled together by November.

Hope to see you soon,
Jonna

On Mon, Jun 12, 2017 at 9:10 AM, gaof <gaof@im.ac.cn> wrote:
Jonna
Still have not got any news from you about the section classifications
Best
George

发自我的 iPhone

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Dear George,
Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate. I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
Hope you are well.
Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Hope this emial finds you well. I wonder if you have some time to find any our friends who is in Section 2 as we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

From: George F GAO <gaof@im.ac.cn>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: baiyu <baiyu@im.ac.cn>
Sent: 10/2/2017 7:41:41 PM
Subject: Re: Re: Re: Re: National Academy of Medicine

Dear Jonna,

Here is another document related to your nomination.

All the best

George

-----原始邮件-----
发件人:"George F GAO"
发送时间:2017-09-18 05:53:42 (星期一)
收件人: "Jonna Mazet"
抄送: baiyu
主题: Re: Re: Re: National Academy of Medicine

Dear Jonna,

Here are the tentative filled form and my updated publication list.

Many thanks and do let me know if you need anything more.

All the best

George

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-09-11 23:59:08 (星期一)
收件人: "George F GAO" <gaof@im.ac.cn>
抄送:
主题: Re: Re: National Academy of Medicine

Great news -- I'll contact him.
It would be good if I could get the materials by end of October. Will that work for you?
Have a good day,
Jonna

On Sat, Sep 9, 2017 at 7:39 AM, George F GAO <gaof@im.ac.cn> wrote:

Jonna,

David Ho is a good seconder in Section 2. He knows me very well.

Director and Chief Executive Officer

The Aaron Diamond AIDS Research Center
The Rockefeller University

Regular, 2c

Elected 1997

Male

New York

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-06-30 10:07:32 (星期五)
收件人: gaof <gaof@im.ac.cn>
抄送:
主题: Re: National Academy of Medicine

Hi George,
How are you? Hope all is well there. Attached, you will find the current listing of all of the Section 2 members. Please have a look and let me know which of them you think might be willing to be a co-nominator(s) for your submission. As I said, I am happy to nominate you for Section 10 with a cross-listing in Section 2, if we can find a good Section 2 member who will agree to co-nominate with me.

We will also need to submit all of the following information with the materials taking the following into consideration, in that the application must:
1. Convey this clearly: WHY SHOULD THE CANDIDATE BE AN NAM MEMBER?
a. The sections on sponsor statement, contributions (past/future), and citation are critical.
b. Identify candidate's impact in terms that are understandable to those less familiar with the field.
c. For international candidates: i. Place the candidate's accomplishments into the context of the national/regional/international sphere; ii. Note the level of prestige associated with institutions or prizes in the candidate's background that may be unfamiliar to others; iii. Where appropriate, use phrases such as: 1. …is the leader of Organization X, the most prestigious organization in this field in the nation/region 2. …is distinguished professor at X university, one of the top institutions in the nation/region 3. …is an internationally recognized leader in this field
2. Avoid these common errors in the candidate's personal information:
a. Missing or excessive contact information
b. Missing demographic information
c. Incorrect date of birth, citizenship information
3. Avoid these common errors in nomination details:
a. Wrong section or subsection
b. Missing bridging section where applicable
c. Institutional affiliation of both sponsors is the same as the candidate (at least one must be from an entirely separate institution)
d. >10 (maximum allowed) bibliographic citations

In addition to a co-nominator, I will need the following information in a Word document:

CANDIDATE: Name, Credentials, Institution

Type of Nomination: Regular/66+ Intl Section/Subsection: (#)(x) Bridging Section(s): (#)

Demographics: ☒ Female ☒ Racial & Ethnic Diversity

Geographic Location: [state/country] Age: [effective October 1]

Subject Emphasis ☒: This info is not yet available for this year's nominations, but I will get it to you as soon as it comes out.

SPONSORS: Name, Institution
Name, Institution

PAST AND POTENTIAL CONTRIBUTIONS TO NAM:
[~6 lines]

CITATION OF ACCOMPLISHMENT: (50 words)
PROPOSERS' STATEMENT:
[~13 lines]

PRIMARY FIELD & AREA OF SPECIALIZATION OR EXPERTISE
[3 lines]

CURRENT EMPLOYMENT:
[up to 3]

PRINCIPAL PREVIOUS EMPLOYMENT:
[up to 3]

RESIDENCIES OR FELLOWSHIPS:
[up to 5]

EDUCATION:
[up to 3, highest first]

PRINCIPAL HONORS, AWARDS:
[~6 lines]

CURRENT MAJOR GRANT(s):
[~2 lines]

MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
[~5 lines]

SELECTED BIBLIOGRAPHY:
[up to 10 items]

Please let me know if you can provide the name and contact of a co-nominator and the information above, then we can move forward. We should aim to have the co-nominator on board and the materials all pulled together by November.

Hope to see you soon,
Jonna

On Mon, Jun 12, 2017 at 9:10 AM, gaof <gaof@im.ac.cn> wrote:
Jonna
Still have not got any news from you about the section classifications
Best
George

发自我的 iPhone

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Dear George,
Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate. I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
Hope you are well,
Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Hope this emial finds you well. I wonder if you have some time to find any our friends who is in Section 2 as

we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

Brief description of scientific contributions and links with USA

GAO has pioneered the research work of origins, interspecies transmission (host jump), and pathogenesis of emerging pathogens-esp. influenza and coronaviruses, by using multidisciplinary techniques, including virology, immunology and structural biology, etc. In particular, he has demonstrated molecular basis of pathogen "host jump", virus entry/release, and host T-cell molecular recognition of several important viruses. His related work includes: molecular basis of "host jump" or host-pathogen interaction of (zoonotic) pathogens, including influenza, measles, herpesvirus, MERS-CoV, Ebola, and Zika viruses, providing insights for the development of vaccines and therapeutic agents. His laboratory has contributed to the discovery of emerging pathogens, new pathogen-infected hosts, and new disease forms of infectious diseases using molecular epidemiology, and pathogen isolation. He has also developed a new ELISPOT-based TB diagnostic kit, now widely used in China. Most recently, his group has made a great contribution for our understanding of the pathogenesis of Zika virus, especially related to the cause of infertility. He is always in the frontline on war against emerging pathogens and a leading figure in advocating a public health strategy for the control of infectious diseases in China and worldwide. His work in leading China's Mobile Laboratory Testing Team to fight against Ebola in Sierra Leone in 2014 was highly appreciated worldwide. He has been coordinating the collaborative work between China and the international organizations (including WHO) for field work on Ebola and other infectious diseases in West Africa.

Gao has been an excellent coordinator for the scientific research between the US and China scientists, for which has already organized the collaborative work on avian influenza, new bunyavirus and Ebola virus with institutions from US-CDC, NIH and some universities etc. As a leading scientist in public health in China, he has been playing a key role in the joint efforts for the disease control worldwide. Gao has been involved in many scientific activities organized by NAM/NAS, e.g., financing global pandemic response (Aug 25-28, 2015, DC); Gain of function (GOF) research (Mar 10-11, 2016, DC). Gao will continuously be an important figure for the NAM interests. He has been playing an important role in China-US collaboration on disease control and prevention, and global public health as director-general (previously deputy DG) of China CDC. In the future, this, esp. in the collaboration for the establishment of African CDC, with US CDC and WHO, will be even enhanced.

Subject: Debrief of our TC
From: Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com>
Sent: Tue, 3 Oct 2017 18:10:29 +0200
Cc: John Mackenzie [redacted], [redacted] [redacted], David De Pooter <d.depooter@onehealthplatform.com>, Cassandra Louis Duthil <clouisduthil@usaid.gov>
To: Ricardo Echalar <rechalar@usaid.gov>, Dennis Carroll <dcarroll@usaid.gov>, Jonna Mazet [redacted], Andrew Clements <aclements@usaid.gov>

OHP_5OHC_fellowshipfund.pdf
fl-OH Fellows Fund-concept.pdf
SPI.docx
FLU : AMR.pdf
OHP_5OHC_sponsorprospectus_Eur.pdf

Dear all

Many thanks for your time just now over the phone. And many thanks for your engagement in the Congress!

As promised I am sending you some documents as a starting point. The Fellowship Fund flyer is to inform Fellows that they are welcome at our Congress- we are distributing the flyer as widely as possible. As mentioned it is our aim to get 100 Fellows at the meeting. Extra support here is welcome. For that purpose I am enclosing the Fellowship Fund document in which we describe the concept / process and the budget per Fellow.

We welcome the organization of a PREDICT satellite symposium and the symposium on Preparedness that Ricardo was referring to. It will be our pleasure to assist you wherever possible. To be continued when we receive Ricardo's information.
In the sponsor prospectus (enclosure) that we developed, prices for satellites are mentioned. Also for your information, Jonna. We know that research projects are under budget constraints, therefore we can offer the symposium to PREDICT for 50.000 euro - we do the same for other research projects, it is part of the Congress' policy.

It goes without saying that financial support to the Congress is crucial to make it all happen. So thank you very much, Dennis for looking into (other) possibilities to fund us.

We will be organizing a satellite on vaccination and AMR in Saskatoon too. We will be able to make the subject more concrete by presenting the "influenza case". I am enclosing the draft programme (and set-up of this project) to this mail. We can indeed find "links" between the symposium at the PMAC meeting and the Saskatoon meeting. For this project / symposium we have reached out to companies that are putting this topic high on their agenda: Pfizer, Seqirus, Astra Zeneca, GSK and Sanofi. It is currently under their review. This can be discussed more in depth during our next TC.

Finally, it is my pleasure to formally invite you to the SPI Programme Committee, Dennis. We are currently organizing the first SPI Committee meeting - TC end of October. My colleague David De Pooter will circulate some dates very soon. The first possible framework of the SPI programme has been developed (enclosure to this mail). This will be subject of discussion of the first SPI Committee meeting. We are very much looking forward to start discussing it with the Committee members and to shaping a good programme!

As agreed upon, we will plan a follow up TC. Kindly let me know if you are available on Tuesday 17 October, 17:00 PM CET. Do let me know if you need additional information in the meantime.

Also on behalf of John and Ab, I want to express our gratitude. It is great to have you on board; we are very much looking forward to our collaboration and to making the Congress a big success !

Kind regards
Chris

ONE HEALTH PLATFORMIt's all connected
Chris Vanlangendonck
co-founder / management
[redacted]
www.onehealthplatform.com

> Op 3 okt. 2017, om 17:05 heeft Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com>
het volgende geschreven:
>
> <AccessNumbers.pdf>
>
> code [redacted]
>
>
> ONE HEALTH PLATFORM
> It's all connected
> Chris Vanlangendonck
> co-founder / management
> [redacted]
> www.onehealthplatform.com <http://www.onehealthplatform.com/>
>
>
> <unknown.jpg>
>
>> Op 3 okt. 2017, om 17:03 heeft Ricardo Echalar <rechalar@usaid.gov <mailto:rechalar@usaid.gov>>
het volgende geschreven:
>>
>> Chris,
>>
>>
>> Could you resend the call-in coordinates. I believe the number for the US was incorrect.
>>
>> Thank you.
>>
>> Ricardo
>>
>>

>> – –
>>
>> Ricardo Echalar, MPH
>> Senior Public Health Advisor
>> Office of Infectious Diseases, Emerging Threats Division <https://www.usaid.gov/what-we-do/global-health/pandemic-influenza-and-other-emerging-threats/programs>
>> Bureau for Global Health
>> U.S. Agency for International Development (USAID)
>> 1300 Pennsylvania Ave, NW, 3.6-53, 3rd Floor, RRB
>> Washington, DC 20523
>> (M) REDACTED | (W) +1.202.712.4003 | E-mail: rechalar@usaid.gov
<mailto:rechalar@usaid.gov>
>>
>>
>>
>>
>> On Tue, Oct 3, 2017 at 9:28 AM, Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com
<mailto:c.vanlangendonck@onehealthplatform.com>> wrote:
>> Dear all
>>
>> On behalf of Ab and John, I am sending you the PPT of the Congress and the state of the art programme tracks OHS and AMR.
>> This might serve as a kick off for our 17:00 PM CET meeting.
>>
>> Looking forward to talking to you soon !
>>
>> Best regards
>> Chris
>>
>>
>>
>> ONE HEALTH PLATFORM
>> It's all connected
>> Chris Vanlangendonck
>> co-founder / management
>> REDACTED
>> www.onehealthplatform.com <http://www.onehealthplatform.com/>
>>
>>
>>
>>
>>> Op 25 sep. 2017, om 12:44 heeft Dennis Carroll <dcarroll@usaid.gov <mailto:dcarroll@usaid.gov>> het volgende geschreven:
>>>
>>> Chris, thanks for the email. I'm pleased to hear preparations for the conference are in "full gear". I welcome the chance to explore how our Predict and P&R teams can be supportive. I have copied Cassandra on our team who can coordinate a time for a phone call that could include Andrew, Ricardo and possibly Jonna. Look forward to talking with you. >>>
>>> d
>>>
>>> Dr Dennis Carroll
>>> Director, Emerging Threats Program
>>> U.S. Agency for International Development
>>> Office: (202) 712-5009 <tel:(202)%20712-5009>
>>> Mobile: REDACTED tel: REDACTED
>>>

>>> On Sep 22, 2017, at 11:41 AM, Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com <mailto:c.vanlangendonck@onehealthplatform.com>> wrote:
>>>
>>>> Dear Dennis
>>>>
>>>> On behalf of John and Ab, I would like to pick up our conversation about a possible collaboration between Predict and Preparedness and Response and the One Health Platform.
>>>> We are indeed in full gear - organizing our Canada Congress. Several organizations took an option on slots for satellite symposia. We hope we can still include your scientific projects!
>>>> It would be our pleasure to set up a TC with you and your colleagues to explore possible pathways of collaboration - if you think that could be useful.
>>>>
>>>> I am very much looking forward to receiving your feedback. Many thanks in advance.
>>>>
>>>> Kind regards
>>>> Chris
>>>>
>>>>
>>>> ONE HEALTH PLATFORM
>>>> It's all connected
>>>> Chris Vanlangendonck
>>>> co-founder / management
>>>> REDACTED
>>>> www.onehealthplatform.com <http://www.onehealthplatform.com/>
>>>> <unknown.jpg>
>>>>
>>>>
>>>>> Op 23 jun. 2017, om 20:53 heeft Dennis Carroll <dcarroll@usaid.gov <mailto:dcarroll@usaid.gov>> het volgende geschreven:
>>>>>
>>>>> Dear John and Ab, my apologies for being so no-responsive. Let me just way Washington is a place to be avoided right now. Its hard to keep ahead, particularly of emails. That said, we would be delighted for Predict and Preparedness and Response (formerly Respond) to construct symposia to be held as satellite symposia. In addition to Jonna I am copying Andrew Clements and Ricardo Echalar to help move this process along. Thank you for the opportunity to engage in this important forum
>>>>>
>>>>> All my best
>>>>>
>>>>> dennis
>>>>>
>>>>> On Tue, May 23, 2017 at 5:00 AM, John Mackenzie REDACTED <mailto:REDACTED> wrote:
>>>>> Dear Dennis,
>>>>>
>>>>>
>>>>>
>>>>> I write to follow up on the letter sent to you last month by my colleague, Ab Osterhaus. We are really excited by the 5th congress as the One Health Platform will be hosting it for the first time, and doing so in collaboration with the University of Saskatchewan and our African partners (the Southern African Centre for Infectious Disease Surveillance (SACIDS), One Health CDC Kenya and the One Health Central and Eastern Africa (OHCEA)).
>>>>>
>>>>>
>>>>>
>>>>> We are very keen to have a strong input into the congress and the scientific program from you and USAID, especially with the PREDICT and RESPOND projects, but not necessarily confined to these

projects. With the success of the symposia in Melbourne, I would like to suggest that PREDICT and RESPOND once again construct symposia to be held as satellite symposia. They provide an excellent international window into their respective projects, as well as giving your international partners the opportunity to present their work at a large gathering and to meet and network with others with similar interests.
>>>>>
>>>>>
>>>>>
>>>>> As Ab mentioned, we are establishing a One Health Fellowship fund which incorporates a 'leaders of tomorrow' concept. While I am certain some of your international partners in PREDICT, RESPOND and other relevant projects will fit into this concept, we would be very grateful for any additional help you could find to help this worthy cause.
>>>>>
>>>>>
>>>>>
>>>>> I have attached the first announcement and Ab's letter again, for your information, and would like to remind you again of the program construction – the congress will have 4 principal streams: two will be scientific presentations and form the scientific basis of the congress; one will be devoted to antimicrobial resistance, underlining its importance to human health; and the final stream will be concerned with science policy and will be directed at policy makers.
>>>>>
>>>>>
>>>>>
>>>>> We look forward to hearing from you.
>>>>>
>>>>>
>>>>>
>>>>> With warm personal regards,
>>>>>
>>>>>
>>>>>
>>>>> John
>>>>>
>>>>>
>>>>>
>>>>> Professor John S Mackenzie,
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
REDACTED
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>> Begin doorgestuurd bericht:

REDACTED

>>>>>
>>>>>
>>>>>
>>>>> Van: Ab Osterhaus <a.osterhaus@onehealthplatform.com
<mailto:a.osterhaus@onehealthplatform.com>>
>>>>>
>>>>> Onderwerp: One Health Platform cooperation request
>>>>>
>>>>> Datum: 20 april 2017 10:47:51 CEST
>>>>>
>>>>> Aan: Dennis Carroll <dcarroll@usaid.gov <mailto:dcarroll@usaid.gov>>
>>>>>
>>>>> Kopie: David Heymann [redacted]
>>>>>
>>>>>
>>>>>
>>>>> Dear Dr. Carroll,
>>>>>
>>>>> Dear Dennis,
>>>>>
>>>>>
>>>>>
>>>>> I hope this e-mail finds you well.
>>>>>
>>>>>
>>>>>
>>>>> I'm attaching an official request for collaboration in view of the upcoming 5th International One Health Congress, to be held in Saskatoon, Canada.
>>>>>
>>>>>
>>>>>
>>>>> Looking forward to getting in touch.
>>>>>
>>>>>
>>>>>
>>>>> Best regards,
>>>>>
>>>>>
>>>>>
>>>>> Prof. A.D.M.E. Osterhaus
>>>>> ONE HEALTH PLATFORM Chair
>>>>> It's all connected
>>>>> www.onehealthplatform.com <https://onehealthplatform.com/>
>>>>>
>>>>>
>>>>> <OHP_5OHC_bannerMelbourne_press.jpg>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>

>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>>
>>>>> --
>>>>> Dr. Dennis Carroll
>>>>> Director, Emerging Threats Program
>>>>> Bureau for Global Health
>>>>> U.S. Agency for International Development
>>>>>
>>>>> Office: 202-712-5009 <tel:(202)%20712-5009>
>>>>> Mobile: REDACTED <tel: REDACTED
>>
>>
>>
>

Dear all
Many thanks for your time just now over the phone. And many thanks for your engagement in the Congress!

As promised I am sending you some documents as a starting point. The Fellowship Fund flyer is to inform Fellows that they are welcome at our Congress- we are distributing the flyer as widely as possible.
As mentioned it is our aim to get 100 Fellows at the meeting. Extra support here is welcome. For that purpose I am enclosing the Fellowship Fund document in which we describe the concept / process and the budget per Fellow.

We welcome the organization of a PREDICT satellite symposium and the symposium on Preparedness that Ricardo was referring to. It will be our pleasure to assist you wherever possible. To be continued when we receive Ricardo's information. In the sponsor prospectus (enclosure) that we developed, prices for satellites are mentioned. Also for your information, Jonna. We know that research projects are under budget constraints, therefore we can offer the symposium to PREDICT for 50.000 euro - we do the same for other research projects, it is part of the Congress' policy.

It goes without saying that financial support to the Congress is crucial to make it all happen. So thank you very much, Dennis for looking into (other) possibilities to fund us.

We will be organizing a satellite on vaccination and AMR in Saskatoon too. We will be able to make the subject more concrete by presenting the "influenza case". I am enclosing the draft programme (and set-up of this project) to this mail. We can indeed find "links" between the symposium at the PMAC meeting and the Saskatoon meeting. For this project / symposium we have reached out to companies that are putting this topic high on their agenda: Pfizer, Seqirus, Astra Zeneca, GSK and Sanofi. It is currently under their review. This can be discussed more in depth during our next TC.

Finally, it is my pleasure to formally invite you to the SPI Programme Committee, Dennis. We are currently organizing the

first SPI Committee meeting - TC end of October. My colleague David De Pooter will circulate some dates very soon. The first possible framework of the SPI programme has been developed (enclosure to this mail). This will be subject of discussion of the first SPI Committee meeting. We are very much looking forward to start discussing it with the Committee members and to shaping a good programme!

As agreed upon, we will plan a follow up TC. Kindly let me know if you are available on Tuesday 17 October, 17:00 PM CET. Do let me know if you need additional information in the meantime.

Also on behalf of John and Ab, I want to express our gratitude. It is great to have you on board; we are very much looking forward to our collaboration and to making the Congress a big success !

Kind regards
Chris

Potential impact of vaccination on antibiotic usage and antibiotic resistance- "the influenza case".

LITERATURE REVIEW AND SCIENTIFIC PUBLICATION

DISSEMINATION OF RESULTS – SATELLITE SYMPOSIUM 5TH INTERNATIONAL ONE HEALTH CONGRESS, 22-25 JUNE 2018, CANADA

With unrestricted grants from pharmaceutical companies

Background

Antibiotic resistance is considered one of the biggest threats to global health as over the past decade multiple resistant bacteria have emerged and spread, while at the same time the number of new antibiotics has significantly declined. And when antibiotics are used, resistance occurs naturally and inevitably, while misuse of antibiotics accelerates the process. On the other hand, the role of vaccines, limiting the use of antibiotics by preventing bacterial infection and bacterial co-infections, is yet to be fully recognized. Research and development programs for vaccines against main multi-drug resistant bacteria are ongoing, but too few, most of them at early stage, and not for all troublesome bacteria. At the same time, prevention of viral infections by vaccination, in combination with state of the art diagnostics for viral infections, will lead to reduction of antibiotic use and thus development of resistance against antibiotics.

The One Health Platform is dedicated to highlighting the role of vaccines in the prevention of AMR by putting the "influenza case" forward as a good example. To that end, a review of the literature on the potential impact of influenza vaccination on antibiotic usage and antibiotic resistance should be conducted and published in a high impact scientific journal first. Secondly, the One Health Platform will organize a satellite symposium on the role of vaccines in reducing antibiotic resistance during the 5th International One

Health Congress, Saskatoon, 22-25 June 2018, with the main objective of fostering a positive policy environment. The influenza case will be presented as a possible vaccine priority for AMR, bringing the highlights of the systematic review of the literature on the impact of influenza vaccination on antibiotic use.

1. Literature review on the potential impact of influenza vaccination on antibiotic usage and antibiotic resistance.

Potential collateral benefit of influenza vaccination: reduction of antibiotic usage and antibiotic resistance

Abstract

Introduction
General introduction on influenza burdens, at risk groups, availability of vaccines and their performance, vaccination recommendations and the potential impact of vaccination on antibiotic usage and antibiotic resistance.

Clinical presentation of influenza and its complications
Overview of influenza signs and symptoms, the range of complications, more detailed synopsis on bacterial co-infections, treatment options and review of antibiotic usage during influenza season/in influenza patients.

Prevention of influenza with vaccination
Impact of current vaccination coverage on reducing influenza burdens, and review of influenza vaccine effectiveness in particular against complications and bacterial co-infections.

Influenza vaccination and antibiotic usage
Rationale on the potential link between vaccination and reduction of antibiotic usage, review of the literature on correlations between vaccination against viruses other than influenza virus and reduction in bacterial co-infection and/or antibiotic usage, review of the literature on correlations between vaccination against influenza virus and reduction in bacterial co-infection and/or antibiotic usage.

Influenza vaccination and antibiotic resistance
Rationale on the potential link between vaccination and reduction in the rise of antibiotic resistance, review of the literature on correlations between vaccination against viruses other than influenza virus and reduction in the rise of antibiotic resistance, review of the literature on correlations between vaccination against influenza virus and reduction in the rise of antibiotic resistance.

Conclusions
Summary of the findings and perspectives.

Dissemination
The paper will be published in a scientific Journal such as Vaccine.

2. Satellite Symposium, 5th International One Health Congress Saskatoon, Canada, 22-25 June 2018 - "The Role of Vaccines in Reducing Antibiotic Resistance: the Influenza Case"

Audience and Organization

The satellite symposium will be an integral part of the program of the 5th International One Health Congress. The audience will be key opinion leaders in One Health: public health officials, regulatory authorities and academic researchers. The One Health Platform Foundation will organize the Symposium.

About the 5th International One Health Congress

In June 2018 the 5th International One Health Congress will bring to Saskatoon (Canada) 1.500 researchers, policy makers and practitioners from universities, governments and industry who are working towards integrated approaches and effective responses to complex global health challenges.

The interlinked health of humans, animals and their environment a concept called "One Health", has many ramifications that extend beyond the traditional concepts of "well-being". For instance, sustained economic

benefits are inextricably linked to One Health and disease of humans, animals and the environment adversely affect economic growth. One Health problems are often complex and their solutions require the collaborative efforts of several disciplines.

The meeting is organized by the One Health Platform, the University of Saskatchewan and our African partners: the Southern African Centre for Infectious Disease Surveillance (SACIDS), One Health CDC Kenya and the One Health Central and Eastern Africa (OHCEA).

The Congress has 3 separate programme tracks. ***"One Health Science (OHS)"*** track focuses on zoonoses and emerging and re-emerging infectious diseases. The ***"Antimicrobial Resistance (AMR)"*** track is developed – also in response to WHO's warning that antimicrobial resistance is a global societal challenge and threat and is an urgent issue. Preventing and controlling antibiotic resistance is a complex issue that involves many different sectors and requires a comprehensive approach and international cooperation.

Next to the highly science-focused sessions, the Congress will also have a third tailor-made programme for public health officials and government representatives. The ***"Science Policy Interface (SPI)"*** track is a successful concept to integrate science and health policy as it offers information and practical application based on the most recent scientific insights.

A series of plenary sessions and **satellite symposia** will provide a platform for trans-disciplinary interaction and exchange of ideas in a true One Health spirit. The purpose of the satellite symposia is to "bridge" the 3 programme tracks.

Draft programme of the Symposium

The One Health Platform will assemble a selected panel of speakers in the satellite symposium. Panelists will address the issue from a wide variety of perspectives:

Chairs:

- Surbhi Malhotra-Kumar (University of Antwerp)
- Ab Osterhaus (chair One Health Platform Foundation)

Topics and speakers:

1. Quantifying the problem of antibiotic resistance
   Surbhi Malhotra-Kumar (University of Antwerp)

2. The role of diagnostics and viral vaccines in reducing antibiotic resistance
   Richard Moxon (Oxford University)

3. Assessing the full economic value of vaccines in reducing AMR
   David Bloom (Harvard University)

4. Vaccination and antibiotic resistance in developing countries
   David Salisbury (Chatham House)

5. The influenza case: a systematic literature review on the impact of influenza vaccination on antibiotic use
   Janet McElhaney (Advanced Medical Research Institute of Canada)

AUDIENCE DEBATE: What is the path forward? What do we need? What do we do?

Symposium set-up

Lecture time will be limited to 12 min each (total 60 minutes). All speakers will gather on stage to form a discussion panel (30 minutes). Satellite symposium attendees will be given the chance to raise additional questions to the speakers' panel. The colloquium chairs will moderate the discussions, ensuring a lively and fruitful debate.

Dissemination

- Scientific publication: a dedicated issue of the *One Health Journal*
- Easy to grasp report for wider dissemination.

UCDUSR0003906

3. TIMELINE

Literature review on the potential impact of influenza vaccination on antibiotic usage and antibiotic resistance.

Activity	Estimated timeline
Literature review on vaccine effectiveness with a focus on reduction of complications and bacterial co-infections Literature review on vaccination and antibiotic usage Literature review of vaccination and antibiotic resistance	End December 2017
Compilation of first draft First review by all co-authors	January 2018
Compilation of final draft Submission	February 2018

Organisation of the satellite symposium - "The Role of Vaccines in Reducing Antibiotic Resistance: the Influenza Case", 5th International One Health Congress Saskatoon, Canada, 22-25 June 2018

Activity	Estimated timeline
Developement of programme	End November 2017
Contact speakers Briefing speakers	End November 2017
Final programme ready Organisation of the Satellite symposium IOCH18	June 2018

SCIENCE POLICY INTERFACE
DRAFT PROGRAMME

1. **Emerging diseases in a changing world: pathogens and interface / Understanding the dynamics of emerging and re-emerging infectious diseases – *Ab Osterhaus***

    a. The socio-economic impact of emerging and re-emerging infectious diseases – *Jonathon Rushton*

2. **Expect the unexpected: understanding the drivers of emergence, and can we predict and prepare for future pandemics? - *John MacKenzie***

3. **Policy implications and development of zoonotic diseases in underserved communities – Mark Rweyemamu**

4. **Emerging and re-emerging infectious diseases: challenges for policy makers and scientists / International funding implications for emerging zoonotic and pandemic diseases.**

    a. Preventing Emerging Infectious Diseases
    b. Creation of virus Platforms (WHO Blueprints)
    c. CEPI
    d. Bill & Melinda Gates Foundation
    e. DTRA / American Defense
    f. Welcome Trust

5. **MAJOR FACTS ON AMR / all you need to know about AMR – *Surbhi Malhotra***

    a. What is AMR?
    b. Drug resistance is a global problem
    c. What causes drug resistance – what accelerates the emergence and spread of antimicrobial resistance?
    d. Inappropriate use of medicines worsens drug resistance
    e. Lack of quality medicines contributes to drug resistance
    f. Animal husbandry is a source of resistance of antibiotics
    g. Poor infection prevention and control amplifies drug resistance
    h. Weak surveillance systems contribute to the spread of drug resistance
    i. The pipeline for new tools to combat drug resistance is almost dry
    j. Environmental concerns / concerns on the environmental impact of antibiotics

UCDUSR0003908

6. **AMR: challenges for policy makers and scientists – *David Heymann***

    a. Strengthen the knowledge : identification of knowledge gaps / development of a strategic research agenda (Joint Programming Initiative on AMR, The Hague, JPIAMR, 2013)
    b. Rapid sharing of information: towards a global forum (WHO Global Report on surveillance of antimicrobial resistance, 2014)
    c. Develop the economic case for sustainable investment that takes into account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions
    d. Adapting the regulatory framework to enable efficient pathways for drug development in the AMR area.
    e. Innovation and investment in research / development of new antimicrobial medicines, vaccines and diagnostic tools
    f. AMR as a core competent of professional education, training, certification in the health and veterinary sectors and agricultural practice

7. **A call to stakeholders to combat drug resistance – *Gerard Wright***

    a. Tripartite collaboration FAO/WHO/OIE
    b. Need for a coordinated action: National action plans on AMR
    c. G20
    d. Optimize the use of antimicrobial medicines in human and animal health
    e. Reduction in global human consumption of antibiotics (with allowance for the need of improved access in some settings) and reduction in the volume of antibiotic use in food production and the use of medical and veterinary antimicrobial agents for applications other than human and animal health.
    f. Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures
    g. Alternative approaches to tackling resistant infections

Separate satellites (to be included in the main programme):

1. **Potential impact of vaccination on antibiotic usage and antibiotic resistance – "the influenza case"**
2. **National and International Disease Monitoring and Risk Assessment: Impact on Policy Development**
3. **Neglected Zoonoses with high risk impact**

UCDUSR0003910

THE 5TH INTERNATIONAL

ONE HEALTH PLATFORM

one health CONGRESS

OHS

SPONSORSHIP PROSPECTUS

AMR

SPI

Saskatoon

CANADA 22-25 June

2018

www.onehealthcongress.com

UCDUSR0003911

THE 5TH INTERNATIONAL

ONE HEALTH PLATFORM

one health CONGRESS

UCDUSR0003912

INVITATION

We are delighted to invite you to join us at the 5th International One Health Congress, which will be held in Saskatoon, Canada, on 22 - 25 June 2018.

The congress will build upon the excellent sessions and debates at previous International One Health Congresses organized in Melbourne, Bangkok and Amsterdam to give the floor to the most renowned experts and researchers. Since the first congress in 2011, the One Health approach has been increasingly accepted by major international health oriented organizations, academic research institutes, field workers and the pharmaceutical industry. We warmly welcome the growing movement of One Health advocates who strongly support the idea of an integrated approach to human, animal and environmental health as the best solution to complex and urgent health threats.

On behalf of the Organizing Committee, we are looking forward to welcoming you to Saskatoon in June 2018.

Prof. Ab Osterhaus
One Health Platform

Prof. John Mackenzie
One Health Platform

Prof. Karen Chad
University of Saskatchewan

CO-CHAIRS 5TH INTERNATIONAL ONE HEALTH CONGRESS

UCDUSR0003813

INTRODUCTION

Many of the major challenges facing global health need a One Health approach to both better understand the threats and seek some of the answers. These challenges include food and water safety and security as the population grows ever larger, the threats faced by antimicrobial resistance, and the future challenge of global climate change. Indeed vector-borne diseases that continue to cause major outbreaks such as yellow fever, Zika and West Nile viruses are excellent examples of zoonotic diseases at the human, animal and environmental interfaces, and which may be particularly susceptible to further spread due to increased global warming.

To capture this multifaceted One Health paradigm, the organizers of the 5th International One Health Congress have developed a unique congress concept. World experts will showcase recent advances in pathogen discovery, diagnostics, drivers for emerging infections, vaccinology, ecology, food and water safety, and political and social science. In response to WHO's warning that antimicrobial resistance is a global societal challenge and threat, the conference will have a separate programme track dedicated to AMR. Additionally, the conference will have a tailor-made programme for public health officials and government representatives.

'One Health in underserved communities' is the overarching theme of the congress, in recognition of the complex interplay of environmental, animal and human health in underprivileged societies around the world.

UCDUSR0003914

OHS

ONE
HEALTH
SCIENCE

AMR

ANTIMICROBIAL
AGENTS AND
RESISTANCE

SPI

SCIENCE
POLICY
INTERFACE

UCDUSR0003815

SCIENTIFIC EXCELLENCE

Complementing the scientific expertise of the Scientific Programme Committee is the Canadian One Health Network, initiated by the University of Saskatchewan, the Southern African Centre for Infectious Disease Surveillance (SACIDS), CDC Kenya and One Health Eastern & Central Africa (OHCEA).

Our unique position in the One Health arena allows us to capitalize on the growing interest and believe in an integrated approach to solving global health threats. Recent global disease events, like the outbreaks of Ebola, MERS and Zika, have underpinned the increasing impact of zoonotic diseases on human and animal health. It has also become clear that changes in the environment, like population growth and climate change, impact heavily on animal and human health. The 5th International One Health Congress will therefore carefully evaluate the most imminent potential hazards from various perspectives. Urgent issues like food safety, water security and integrity of the environment will be high on the congress agenda. World experts will address the social and cultural determinants of One Health.

UCDUSR0003916

SCIENTIFIC PROGRAMME COMMITTEE

Ab Osterhaus
BIZ HANNOVER, GERMANY

John Mackenzie
CURTIN UNIVERSITY, AUSTRALIA

Martyn Jeggo
GEELONG CENTRE FOR EMERGING INFECTIOUS DISEASES, AUSTRALIA

Amadou Alpha Sall
INSTITUT PASTEUR DE DAKAR, SENEGAL

Mark Rweyemamu
DIRECTOR OF THE SOUTHERN AFRICAN CENTRE FOR INFECTIOUS DISEASES AND SURVEILLANCE (SACIDS)

Linfa Wang
DUKE-NUS MEDICAL SCHOOL, SINGAPORE

Bill Karesh
ECOHEALTH ALLIANCE

Patrick Leighton
UNIVERSITY OF MONTREAL, CANADA

Ottorino Cosivi
WHO BRAZIL

Andrew Dobson
PRINCETON UNIVERSITY, USA

Casey Barton-Beravesh
CDC, USA

Malik Peiris
UNIVERSITY OF HONG KONG

Baljit Singh
UNIVERSITY OF CALGARY, CANADA

Volker Gerdts
UNIVERSITY OF SASKATCHEWAN, CANADA

Jonna Mazet
UC DAVIS, USA

Pesina Munyua
ONE HEALTH DIRECTOR CDC KENYA

Lorne Babiuk
UNIVERSITY OF ALBERTA, CANADA

Susan Kutz
UNIVERSITY OF CALGARY, CANADA

Craig Stephen
UNIVERSITY OF SASKATCHEWAN, CANADA

Marietjie Venter
UNIVERSITY OF PRETORIA, SA

UCDUSR0003817

ONE HEALTH SCIENCE

IMPORTANT TOPICS

- Wildlife trade as a mechanism for exotic disease spill overs
- Food safety and security
- Rabies virus: treatment protocols and control measures
- Vaccine development and new testing platforms
- Mathematical modelling and scenario evaluation
- Tackling coronaviruses at the source: vaccinating camels and humans against MERS
- Climate change and its effects on human and animal diseases
- Marine environments and public health

UCDUSR0003918

"One Health aims to prevent disease at a very high level, it addresses the root causes of what is driving diseases to emerge."

Laura H. Kahn, Princeton University, USA

OHS

ONE
HEALTH
SCIENCE

UCDUSR00038919

ADDRESSING ANTIMICROBIAL RESISTANCE

In September 2016, the World Health Organization officially stated that "antimicrobial resistance is a global societal challenge and threat".

Antimicrobial resistance, however, is not a new problem. To bring international attention to a growing public health threat, WHO launched its policy package to combat AMR in 2011. These principles will be at the core of the discussions during the 5th International One Health Congress as they include:

- Strengthening surveillance and laboratory capacity
- Ensuring uninterrupted access to essential medicines of assured quality
- Regulation and promotion of rational use of medicines
- Enhancing infection prevention and control
- Fostering research and development for new medicines and tools

The 2016 Declaration on Combating Antimicrobial Resistance, issued at the occasion of the World Economic Forum in Davos, complements WHO's policy package as it calls for urgent measures to reduce the development of drug resistance, increased investment in research into new antibiotics, diagnostics and vaccines, and ensuring that these new generations of products are available to all those who need them.

The 5th International One Health Congress will bring together the world's leading experts to present and discuss the latest scientific data and advances on the above topics in a separate programme track dedicated to antimicrobial resistance.

UCDUSR0003620

AMR

ANTIMICROBIAL AGENTS AND RESISTANCE

SCIENTIFIC PROGRAMME COMMITTEE ON ANTIMICROBIAL RESISTANCE

Giuseppe Cornaglia
VERONA UNIVERSITY, ITALY

Jørgen Schlundt
NANYANG TECHNOLOGICAL UNIVERSITY, SINGAPORE

Cheryl Waldner
UNIVERSITY OF SASKATCHEWAN, CANADA

Gerard Wright
M.G. DEGROOTE INSTITUTE FOR INFECTIOUS DISEASE RESEARCH, CANADA

Britta Lassman
INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES

Rafael Canton
UNIVERSITY HOSPITAL OF MADRID, SPAIN

Robert Skov
STATENS SERUM INSTITUT, DENMARK

Surbhi Malhotra
UNIVERSITY OF ANTWERP, BELGIUM

Cornelia Lass-Flörl
UNIVERSITY OF INNSBRUCK, AUSTRIA

Laura H. Kahn
PRINCETON UNIVERSITY, USA

David Heymann
CHATHAM HOUSE LONDON

Tamika Sims
INTERNATIONAL FOOD INFORMATION COUNCIL

"The emergence of AMR really threatens to send us backwards. By 2050 more people will die from antibiotic-resistant infections than currently die from cancer."

Keiji Fukuda, Assistant Director-General of the World Health Organization

UCDUSR0003821

ADDRESSING ANTIMICROBIAL RESISTANCE

IMPORTANT TOPICS

Prevalence of resistance

Systems epidemiology of transmission

The use of antibiotics in humans and animals

The role of mass-movements and migration in the emergence of AMR

Intensive care and immune-compromised patients as potential drivers for AMR

The importance of large-scale studies in AMR

Infection prevention and control

Antimicrobial resistance in underserved communities

Surveillance and stewardship

Successful initiatives to prevent/address antimicrobial resistance

UCDUSR0003922

"The emergence of infections that are resistant to drugs is the most pressing health issue of our time."

Jeremy Farrar, Director of the Wellcome Trust

UCDUSR0003623

TRANSLATIONAL SCIENCE

The Science Policy Interface track is a tailor-made programme for public health officials, government representatives and academics and students of public policy. It is specifically designed to bridge the gap between evidence and health policy and to that end, our scientific faculty will discuss the policy implications of their research on the most intriguing topics with leading policy makers. Experts will use high-quality data to guide discussions, and - ultimately - to improve the health of humans, animals and the environment through evidence-based policy.

IMPORTANT TOPICS

Policies in response to antimicrobial resistance

Equitable access to medicines and tools

The role of livestock in poverty reduction

Successful management of pandemic virus outbreaks

The need for innovative medicines and prevention tools

WHO SHOULD ATTEND?

The target audience of the science policy interface includes Chief Veterinary Officers, Chief Medical Officers, Director-Generals of Public Health, representatives of national and international public health organisations, and pharmaceutical industry policy experts.

UCDUSR0003824

SPI

SCIENCE
POLICY
INTERFACE

"Some of the most devastating new human infections, like Ebola, HIV and dengue, have naturally transmitted from animals to humans. Health scientists and public health officials therefore need to work together to attain optimal health for people, animals, and our environment. The Science Policy Interface programme at the 5th International One Health Congress offers an excellent platform for such interaction."

Chris Vanlangendonck, One Health Platform

SCIENCE POLICY INTERFACE PROGRAMME COMMITTEE

Ab Osterhaus
FIZ HANNOVER, GERMANY

Peter W.B. Phillips
UNIVERSITY OF SASKATCHEWAN, CANADA

John Mackenzie
CURTIN UNIVERSITY AUSTRALIA

Bill Karesh
ECOHEALTH ALLIANCE

Chris Vanlangendonck
DIRECTOR OF SEMIOTICS, BELGIUM

Bart Staes
MEMBER OF EUROPEAN PARLIAMENT, BELGIUM

UCDUSR0003625

PROGRAMME AT A GLANCE

THE 5TH INTERNATIONAL

Friday 22 June 2018	
[illegible]	Satellite symposium
[illegible]	Satellite symposium
[illegible]	Satellite symposium
[illegible]	Opening ceremony
[illegible]	Welcome reception

Saturday 23 June 2018				
[illegible]	Satellite symposium			
[illegible]	Plenary session			
[illegible]	Coffee break			
[illegible]	Parallel sessions			
	OHS One health science	OHS One health science	AMR Antimicrobial agents and resistance	SPI Science policy interface
[illegible]	Lunch/ satellite symposium			
[illegible]	Parallel sessions			
	OHS	OHS	AMR	SPI
[illegible]	Coffee break			
[illegible]	Parallel sessions			
	OHS	OHS	AMR	SPI
[illegible]	Satellite symposium			

UCDUSR0003626

Sunday 24 June 2018				
7:30 - 9:00	Satellite symposium			
9:15 - 10:15	Plenary session			
10:15 - 10:45	Coffee break			
10:45 - 12:30	Parallel sessions			
	OHS One health science	OHS One health science	AMR Antimicrobial agents and resistance	SPI Science policy interface
12:30 - 14:00	Lunch/ satellite symposium			
14:00 - 15:45	Parallel sessions			
	OHS	OHS	AMR	SPI
15:45 - 16:15	Coffee break			
16:15 - 18:30	Parallel sessions			
	OHS	OHS	AMR	SPI
18:00 - 19:30	Satellite symposium			
20:00 - 23:00	Farewell dinner			

Monday 25 June 2018				
7:30 - 9:00	Satellite symposium			
9:00 - 10:00	Plenary session - YOUNG ONE HEALTH session			
10:00 - 10:30	Coffee break			
10:30 - 12:15	Parallel sessions			
	OHS One health science	OHS One health science	AMR Antimicrobial agents and resistance	SPI Science policy interface
12:15 - 13:45	Plenary Session Late Breakers And Closing Ceremony			
13:45 - 14:30	Lunch buffet			
14:30 -	Guided excursion			

UCDUSR0003827

ABOUT SASKATOON

The city of Saskatoon is favourably positioned with the South Saskatchewan River winding through it. Eight bridges span its gentle flow, linking east to west. An active city, residents and visitors alike flock to the Meewasin Valley trails, traversing sixty kilometres of pathways in all seasons. The city's youthful vitality and cultural richness are evident in every neighbourhood, thanks in part to the University of Saskatchewan, where leading-edge technology such as the Canadian Light Source synchrotron draws the best minds from around the world.

Saskatoon's John Diefenbaker International Airport is only 10 minutes from downtown, with daily flights available to and from major Canadian and U.S. destinations: Vancouver, Toronto, Ottawa, Calgary, Edmonton, Minneapolis, Phoenix and Las Vegas.

THE VENUE

TCU Place
35 22nd Street East
SK S7K 0C8
Saskatoon, Canada
tcuplace.com

Situated in beautiful downtown Saskatoon, TCU Place, Saskatoon's Arts & Convention Centre is considered one of the best conference facilities in western Canada.

UCDUSR0003928

UCDUSR0003829

ONE HEALTH IN UNDERSERVED COMMUNITIES

In many parts of the world, especially in developing countries and underserved communities, society is confronted with urban sprawl, spread of infectious diseases, rampant foodborne disease outbreaks, sick livestock and companion animals, and chronic water shortages. These challenges require global solutions in a One Health approach. The 5th International One Health Congress will therefore pay special attention to implementing One Health in underserved communities, in recognition of the complex interplay of environmental, animal and human health in underprivileged or subsistent societies around the world. At the same time, we wish to reinforce the increasing number of excellent One Health activities in developing countries.

"On a national level, we see an increasing number of excellent One Health activities, notably in South-East Asian and African countries."

John Mackenzie, One Health Platform

ONE HEALTH FELLOWSHIP FUND

The One Health Platform actively encourages the careers of promising researchers. The conference organizers therefore intend to establish a One Health Fellowship Fund to provide travel grants to young scientists. In addition, early career scientists will act as co-chairs during the scientific conference sessions while the most promising academics may be offered the chance to present their work in a plenary session entirely devoted to the work of promising scientists (Monday 25 June 2018).

UCDUSR0003930

The benefits of sponsoring

The Fifth International One Health Congress is the premier event on the One Health calendar. The attractive and accessible congress location combined with the Organizing Committee's determination to develop a unique and outstanding programme will allow the Fifth International One Health Congress to grow into a successful event attracting One Health researchers and advocates from all over the globe. Its wide audience and the excellent congress facilities provide unparalleled corporate visibility, as demonstrated by the opportunities outlined in this document.

UCDUSR0003931

Sponsor opportunities at a glance

1. Scientific Support

- Unrestricted grant in support of the scientific congress programme
- Unrestricted grant to the Young One Health Fund

2. Symposia and meeting opportunities

- One Health Platform symposia
- Corporate Symposia
- Company Lectures
- Stand-Alone Meetings
- Hospitality Suites

3. Communication Support

- Exhibition Booths
- Poster Tours
- Delegate Bags
- Lanyards
- Congress programme Book
- Abstract Book USB
- Delegate Bag Inserts
- One Health Platform Communicator
- Twitter Wall
- Mobile Event App
- Hotel Room Key Cards

4. Event Support

- Welcome Reception Supporter
- Farewell Dinner Supporter

5. Support Packages

- Privileged Congress Partner
- Bulk Registrations

GENERAL BENEFITS

- excellent opportunities to enhance corporate visibility and engage in (commercial) networking
- highlight your organization's sustained commitment to the One Health concept
- access and interaction with the core of the global One Health community
- meeting facilities located in a single venue, conveniently configured to generate maximal traffic to the exhibition area
- premium satellite symposium slots to generate maximal attention for your organization's messages
- stand alone meetings to maximize interaction with specific delegate group(s)

IMPORTANT NOTICES

- The IOHC 2018 support opportunities are open to all interested organizations. They are available at a first come first-served basis.
- All prices are in EURO (€) and inclusive of VAT
- Information in the following sections may be subject to change

UCDUSR0003832

1. SCIENTIFIC SUPPORT

Unrestricted grant in support of the scientific congress programme

General support to the Organizing Committee's objective to give the floor to the most renowned scientists and to ensure the active involvement of participants and lecturers from low and middle income countries. Special attention will go to the active participation of One Health stakeholders from Africa, in the aim to reinforce the increasing number of excellent One Health activities on the continent.

An unrestricted grant implies that the donor financially supports the congress, but is not involved in the preparation of the event in any way.

No pre-defined amount

Unrestricted grant to the One Health Fellowship Fund

Since young scientists are the lifeblood of the One Health field, the One Health Platform has established the Early Career Researchers Circle as a separate working group within its structure. Through dedicated educational programmes, the Circle aims to have a positive impact on the lives of young researchers and faculty and thus to nurture the future of One Health Science. In keeping with these objectives, the congress organizers have established a One Health Fellowship Fund to provide travel grants to young scientists. In addition, young scientists will act as co-chairs during the scientific congress sessions while the most promising academics may be offered the chance to present their work in a plenary session entirely devoted to the work of young scientists (Monday 25 June 2018). The One Health Fellowship Fund also includes:

- Early Career Award for best body of work in One Health research
- Best Poster Presentation at the IOHC 2018
- Best Oral Presentation Award at the IOHC 2018
- Networking event for young scientists (informal gathering at a separate venue on the evening of 23 June 2018)

This opportunity allows organizations to contribute to the future of One Health research.

No pre-defined amount

BENEFITS

Scientific support to the congress will be acknowledged according to the funder's wishes. This may include:

- Recognition in the announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (+10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

UCDUSR0003833

2. SATELLITE SYMPOSIA AND MEETING OPPORTUNITIES

SATELLITE SYMPOSIA

Satellite symposia are uniquely designed opportunities for organizations to provide informative sessions in conjunction with the Fifth International One Health Congress.

Satellite symposia are free of any concurrent congress programming (except private stand alone meetings), they are advertised as an integral part of the congress schedule and are open to all congress participants.

The 2018 ICHC will see two types of satellite symposia: One Health Platform symposia and Corporate Symposia. Depending on their position in the congress schedule, symposia are either premium or regular.

UCDUSR0003934

PROGRAMME AT A GLANCE

Friday 22 June 2018

[illegible]	Satellite symposium (SLOT 1)
[illegible]	Satellite symposium (SLOT 2)
[illegible]	Satellite symposium (SLOT 3)
[illegible]	Opening ceremony
[illegible]	Welcome reception

Saturday 23 June 2018

[illegible]	Satellite symposium (SLOT 4)			
[illegible]	Plenary session			
[illegible]	Coffee break			
[illegible]	Parallel sessions			
	OHS One health science	OHS One health science	AMR Antimicrobial agents and resistance	SPI Science policy interface
[illegible]	Lunch/ satellite symposium (SLOT 5)			
[illegible]	Parallel sessions			
	OHS	OHS	AMR	SPI
[illegible]	Coffee break			
[illegible]	Parallel sessions			
	OHS	OHS	AMR	SPI
[illegible]	Satellite symposium (SLOT 6)			

Sunday 24 June 2018

[illegible]	Satellite symposium (SLOT 7)			
[illegible]	Plenary session			
[illegible]	Coffee break			
[illegible]	Parallel sessions			
	OHS	OHS	AMR	SPI
[illegible]	Lunch/ satellite symposium (SLOT 8)			
[illegible]	Parallel sessions			
	OHS	OHS	AMR	SPI
[illegible]	Coffee break			
[illegible]	Parallel sessions			
	OHS	OHS	AMR	SPI
[illegible]	Satellite symposium (SLOT 9)			
[illegible]	Farewell dinner			

Monday 25 June 2018

[illegible]	Satellite symposium (SLOT 10)			
[illegible]	Plenary session - YOUNG ONE HEALTH session			
[illegible]	Coffee break			
[illegible]	Parallel sessions			
	OHS	OHS	AMR	SPI
[illegible]	Plenary Session Late Breakers And Closing Ceremony			
[illegible]	Lunch buffet			
[illegible]	Guided excursion			

UCDUSR0003835

One Health Platform Symposium

One Health Platform Symposia are organized by the One Health Platform, on demand of and with the financial support of a company or institution. The One Health Platform vouches for the developement of an high-level scientific programme and speakers panel. The sponsor decides on the symposium topic, but is not involved in the preparation of the event in any way.

- scientific symposium open to all participants
- does not coincide with other congress sessions/events (except private stand alone meetings)

€75,000

Slots 3, 5, 8 (see congress schedule on page 21)

BENEFITS:

- Free full page announcement in congress programme book
- Announcement flyer inserted in delegate bag
- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (+10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

ADDITIONAL OPPORTUNITIES:

Live broadcast of the symposium

€17,500

Edited recording of the symposium for educational or promotional purposes

€10,000

Corporate Symposium

Corporate Symposia are organized by private companies, not-for profit organizations or institutions. The organizer is free to decide on the symposium topic and is fully responsible for the organization of this scientific meeting in terms of programme and speakers.

- scientific symposium open to all participants
- symposium title to include sponsors name
- does not coincide with other congress sessions/events (except private stand alone meetings)

Premium €75,000

Slots 1, 5, 8 (see congress schedule on page 21)

Regular €60,000

Slots 1, 2, 4, 6, 9, 10
(see congress schedule on page 21)

BENEFITS:

- Free full page announcement in congress programme book
- Announcement flyer inserted in delegate bag
- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (+10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

ADDITIONAL OPPORTUNITIES:

Live broadcast of the symposium

€17,500

Edited recording of the symposium for educational or promotional purposes

€10,000

UCDUSR0003936

Company lectures

€15,000 (four opportunities available)

This opportunity is a tailored solution that will allow companies to deliver scientific messages in a format that smoothly connects with the congress's regular scientific programme: the early morning symposium slot on Tuesday 12 September 2017 (slot 7) provides room for four separate company lectures.

Slot: 7 (see congress schedule on page 20)

BENEFITS:

- Announcement flyer inserted in delegate bag
- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (>10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

ADDITIONAL OPPORTUNITIES:

Live broadcast of your lecture

€2,500

Edited recording of your lecture for educational or promotional purposes

€2,500

MEETING OPPORTUNITIES

Stand-Alone Meeting

Stand-alone meetings are organized by private companies, not-for profit organizations or institutions. The organizer is free to decide on the meeting topic and is fully responsible for the organization in terms of programme and speakers. Stand-alone meetings are accessible on invitation only and are hence not open to all congress participants. Stand-alone meetings offer an excellent opportunity to reach out to specific target groups.

- Need to be held in a satellite symposium slot and can hence coincide with other satellite symposia
- Can be held at the congress venue or any of the congress hotels
- Access restricted to invited delegates and hence not publically advertised as part of the official congress programme
- Target group selection made by organizers
- Invitations extended to specific delegate groups or to a selection of registered participants by the One Health Platform (compliance with privacy regulations)

If so desired, the One Health Platform is ready assist the organizer in selecting the target audience. Selection can be made from the congress participants' list, but may also include participants who have not registered as congress attendees. The One Health Platform is also ready to advise on the meeting venue.

Premium: €80,000
Slots 1, 5, 8
(see congress schedule on page 20)

Regular: €55,000
Slots 1, 2, 4, 6, 9, 10
(see congress schedule on page 20)

UCDUSR0003937

BENEFITS:

- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (>10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

COMPLIMENTARY BENEFITS FOR STAND-ALONE MEETINGS:

- Congress registration desk staff will extend personal invitations to the pre-selected meeting audience
- e-alerts sent to invited registrants/participants to announce the stand-alone meeting

ADDITIONAL OPPORTUNITIES:

Live broadcast of the symposium

€17,500

Edited recording of the symposium for educational or promotional purposes

€10,000

GENERAL BROADCASTING OPPORTUNITIES

Live broadcast of a session of choice, either from the scientific programme or the science policy interface track (edited recording included)

€17,500

Education and promotion: recording and editing of a session of choice, either from the scientific programme or the science policy interface track

€10,000 /session

BENEFITS:

- Verbal and visual recognition of support at the start of the broadcasted session
- Recognition on the congress website supporters page

Hospitality suite

€45,000

Supporters can hire a room at the congress venue or in any of the congress hotels and use it to host their guests or meet with colleagues throughout the event. Hospitality provided will be in compliance with all relevant industry codes. Supporters will have the option to order catering at an additional cost.

BENEFITS:

- Opportunity to brand the hospitality suite
- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (>10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)
- Branded direction signs to the hospitality suite/ hospitality suite indicated on congress floor plan in the congress programme book (optional)

UCDUSR0003938

3. COMMUNICATION SUPPORT

Exhibition booth

The exhibition area is strategically situated, with the purpose of optimizing your exposure to the four-day event's traffic. Furthermore, coffee breaks may be held in the exhibition space to provide attendees with ample opportunity to visit your booths and network with your representatives.

36 sqm booth: €35,000

9 sqm booth: €16,000

BENEFITS:

- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (>10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

Poster Tour Supporter

€10,000

Three opportunities available

Ab Osterhaus, John Mackenzie and Martyn Jeggo will guide the conference participants through the poster exhibitions on Saturday 23 June, Sunday 24 June and Monday 25 June (always 10:15h – 10:45h) respectively. A limited number of poster authors will be invited to present their posters at these occasions.

BENEFITS INCLUDE:

- Company logo on pull-up banner displayed in poster exhibition area for the duration of the poster tour
- Verbal acknowledgement at the opening of the poster reception
- Recognition on the congress website supporters page

Delegate Bag Supporter

€19,500

All registered delegates attending the congress will receive a delegate bag at the registration desk.

Limited to one sponsor

BENEFITS:

- Company logo discretely (size 2.5x8 cm) displayed on delegate bag
- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (>10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

The choice of size, colour and concept and the production of the delegate bags are in the hands of the congress organizers. The congress organizers will bear the production and shipment costs.

UCDUSR0003939

Lanyard Supporter

€17,500

Ideal for companies or organizations seeking a strong visual positioning, the lanyard opportunity represents excellent value.

Limited to one sponsor

BENEFITS:

- Company logo printed on delegate lanyard
- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (>10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

The concept of the lanyards will be determined by the congress organizers. Production and shipping costs are at the expense of the congress organizers.

Congress programme book

The programme book is an indispensable reference guide for all congress delegates. Provided to each delegate at registration, the programme book contains colour-coded information regarding times and session halls for the various topics, together with a map of the congress centre. It also includes information about presented abstracts and practical arrangements.

Colour advertisements can be included at the following rates:

Back Cover : €7,500

Inside front cover : €7,500

Inside back cover : €7,500

Full page : €5,000

Half page : €2,500

ADDITIONAL BENEFIT:

- Recognition on the congress website supporters page

Abstract book USB card

€19,500

Limited to one sponsor

All registered delegates will receive a copy of the Congress abstracts on a
USB card. This opportunity allows the sponsor to have their logo prominently printed on the USB card.

ADDITIONAL BENEFITS:

- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (>10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

Delegate bag insert

€4,200

An insert (leaflet or giveaway) in the delegate bags will allow supporters to reach the congress audience with appropriate news and information.

One Health Platform Communicator (2)

€9,500 (one edition)

€14,500 (two editions)

The One Health Platform Communicator is the congress newspaper (4-page). It reports on a limited number of pre-selected congress sessions and will be published twice during the congress. In fact, it will be printed and distributed to all delegates in the plenary meeting room on Tuesday and Wednesday morning. The One Health Platform Communicator will be edited and published by a dedicated team of Young One Health Scientists.

BENEFIT:

- Half page colour advertisement
- Recognition on the congress website supporters page

UCDUSR0003940

Twitter Wall

€14,500

To enhance delegate interaction, the One Health Platform will launch the #ohc18 Twitter hashtag at the occasion of the congress. #ohc18 tweets will appear automatically and instantly on the congress Twitter wall, strategically located in the main hall.

BENEFITS:

- Company logo or message permanently displayed on Twitter wall screen
- Recognition on the congress website supporters page

Hotel Room Key Card Sponsorship

€14,500

Branding the room keys with a company logo or message is an exclusive opportunity to enhance your visibility among congress delegates.

BENEFIT:

- Company logo printed on key cards in all five official congress hotels: Sheraton Cavalier (1), Delta Beauborough (2), Radisson (3), Holiday Inn (4) and Hilton Garden inn (5)
- Recognition on the congress website supporters page

Mobile Event App

€19,000

This opportunity puts your company's brand and message right in attendees' hands. Attendees will have the ability to access a schedule of events, exhibitor listings, all general event information and a map of the exhibit hall floor plan using their mobile devices. The mobile application will be promoted via a comprehensive marketing plan in the months leading up to the congress.

BENEFITS:

- Corporate logo on app opening pages
- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (>10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

UCDUSR0003941

4. EVENT SUPPORT

Welcome Reception Supporter

€14,500

The Welcome Reception brings together all congress delegates in an informal setting on Sunday evening. Refreshments and musical entertainment will be provided at the premises of the Remai Modern, a brand new art gallery at the banks of the River Saskatchewan. It provides different spaces, with an atrium and outdoor terraces offering stunning views of the river and sky. The Welcome Reception is hence the ideal occasion for delegates to network and to meet up with their colleagues and peers.

BENEFITS:

- Two company banners displayed in the Welcome Reception area
- Company logo displayed on the welcome reception menu
- Secured VIP space to accommodate up to 20 guests
- Branded direction signs to the Remai Modern art gallery
- Verbal acknowledgement at the opening of the Welcome Reception
- Opportunity to hand out a gift to all participants (not included in sponsorship package)
- Recognition on the conference website sponsors page

Farewell Dinner Supporter

€20,000

The Farewell Dinner will take congress delegates to the beautiful Delta Bessborough Gardens along the west bank of the South Saskatchewan River. As a fortunate coincidence, the Fifth International One Health Congress coincides with the yearly Saskatchewan Jazz Festival. Delegates will enjoy the exclusive jazz performances brought to them by internationally renowned artists, while the Farewell Dinner also includes a five course meal.

BENEFITS:

- Two company banners displayed in the Farewell Dinner area
- Company logo displayed on the farewell Dinner menu
- Secured VIP space to accommodate up to 30 guests
- Branded direction signs to the Delta Bessborough Gardens.
- Verbal acknowledgement at the opening of the Farewell Dinner
- Opportunity to hand out a gift to all participants (not included in sponsorship package)
- Recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- Recognition in the congress e-news alerts (+10,000 recipients)
- Recognition on the general congress opening and closing slides (verbal and visual recognition during Opening Ceremony and Closing Ceremony)

UCDUSR0003942

5. SUPPORT PACKAGES

Privilaged Congress Partner

Additional benefits for support in excess of €150,000

- Free full page advertisement in congress programme book
- Use of Pre and Post Congress Mailing List allows to reach all registered Congress delegates with a simple e-mail blast (content provided by sponsor, mailing sent by the One Health Platform Foundation)
- Company banner displayed in the Welcome Reception and Farewell Dinner area

Bulk registrations

The One Health Platform offers reduced fees for companies covering the registration of non-company delegates.

As of 10 registrations:
- CAD 1,015 in stead of CAD 1,090 (early bird)
- CAD 1,310 in stead of CAD 1,385 (full registration)

Registration of delegates must occur via the One Health Platform.

6. UNIVERSITIES LOUNGE

University presence

Demonstrate your academic institution's dedication to One Health, engage with other leading universities and share information on courses, post-doc positions and consortia.

Participants in the Universities Lounge receive:

- a 9 sqm booth in the Universities area
- recognition in the congress announcement brochure and the congress programme book
- Recognition on the congress website supporters page
- One (1) complimentary congress registration

€6,000

UCDUSR0003943

ABOUT THE ORGANIZERS

The 5th International One Health Congress is a co-organization of the One Health Platform Foundation and the University of Saskatchewan.

The **ONE HEALTH PLATFORM** is a strategic forum of One Health stakeholders and advocates who strongly support the idea of an integrated approach to human, animal and environmental health as the best solution to complex and urgent health threats.

The fight against antimicrobial resistance and the development of better and safer medicines for zoonoses and emerging infectious diseases are among the main objectives of the One Health Platform. To address these challenges successfully, however, we urgently need to integrate know-how, evidence and technologies from key players involved in healthcare research, including academic institutions and pharmaceutical companies. The One Health Platform therefore brings together academics (Scientific Advisory Board), the pharmaceutical industry (Industry Advisory Board) and public health officials (International One Health Coalition) to determine the most urgent research gaps, coordinate research, disseminate study results, advocate and implement the One Health Agenda in order to improve the health of humans, animals and the environment through evidence-based policy.

Membership of the Industry Advisory Board is open to all interested pharmaceutical companies for an annual fee of €25,000. The One Health Platform brings together all One Health stakeholders, since we will only be able to address the great challenges that lie ahead when all parties involved are ready to cooperate. Membership of the Industry Advisory Board is hence a token of involvement and engagement in the fast growing One Health Community.

Join our Annual General Assembly Meetings, where policy makers, scientists and international institutions discuss the One Health challenges. Participate in the organisation of the international One Health Congresses, and share your views One Health Science, AMR and the Science Policy Interface. Let's join forces to shape a favourable One Health environment!

www.onehealthplatform.com
Join the One Health Platform on Facebook and Twitter

UCDUSR0003944

The **UNIVERSITY OF SASKATCHEWAN** is one of Canada's leading medical-doctoral research-intensive universities, and offers the widest array of human and animal health science programs in the country. "One Health: Solutions at the Animal-Human-Environment Interface" is one of six signature areas and, importantly, the University of Saskatchewan has substantial expertise in working with underserved communities. In 2014, the UoS proposed the concept for a Canadian One Health Network that brings together more than 150 researchers from 18 universities, 5 Government Agencies and more than 10 industry partners. In collaboration with the One Health Platform, the UoS will draw assistance from these experts and others in developing an outstanding congress program. More information about the University of Saskatchewan is to be found on **www.usask.ca**

ORGANIZING EXECUTIVE BOARD

Ab Osterhaus
NIZ HANNOVER, GERMANY
CO-FOUNDER ONE HEALTH PLATFORM FOUNDATION
CO-CHAIR
5TH INTERNATIONAL ONE HEALTH CONGRESS

John Mackenzie
CURTIN UNIVERSITY, AUSTRALIA
CO-FOUNDER ONE HEALTH PLATFORM FOUNDATION
CO-CHAIR
5TH INTERNATIONAL ONE HEALTH CONGRESS

Karen Chad
UNIVERSITY OF SASKATCHEWAN, CANADA
CO-CHAIR
5TH INTERNATIONAL ONE HEALTH CONGRESS

Chris Vanlangendonck
CO-FOUNDER ONE HEALTH PLATFORM FOUNDATION
DIRECTOR OF SEMIOTICS, BELGIUM

Mark Rweyemamu
DIRECTOR OF THE SOUTHERN AFRICAN CENTRE FOR INFECTIOUS DISEASES AND SURVEILLANCE (SACIDS)

Bruce Kaplan
ONE HEALTH INITIATIVE

Baljit Singh
UNIVERSITY OF CALGARY, CANADA

Doug Freeman
UNIVERSITY OF SASKATCHEWAN, CANADA
CHAIR LOCAL ORGANIZING COMMITTEE
5TH INTERNATIONAL ONE HEALTH CONGRESS

Kim Ali
ON PURPOSE LEADERSHIP (POD)

LOCAL ORGANIZING COMMITTEE

Doug Freeman
UNIVERSITY OF SASKATCHEWAN, CANADA
CHAIR LOCAL ORGANIZING COMMITTEE
5TH INTERNATIONAL ONE HEALTH CONGRESS

Volker Gerdts
UNIVERSITY OF SASKATCHEWAN, CANADA

Vikram Misra
UNIVERSITY OF SASKATCHEWAN, CANADA

UCDUSR0003945

IMPORTANT DATES

Online registration via www.onehealthcongress.com as of 1 July 2017

Online abstract submission as of 02 November 2017

www.onehealthcongress.com

If you have any questions about the 5th International One Health Congress, please contact:

semiotics

CHRIS VANLANGENDONCK

Co-founder One Health Platform Foundation
Director of Semiotics, experts in science communication
Member of the IOHC 2018 Organizing Committee

c.vanlangendonck@onehealthplatform.com

UCDUSR0003946

THE 5TH INTERNATIONAL

one health CONGRESS

Saskatoon
CANADA 22-25 June
2018

Open Call for Congress Fellowship Applications

The 5th International One Health Congress offers early career scientists a unique opportunity to present their latest work, and to meet and foster collaborations with the international One Health community in a four days high-level congress.

The Open Call for Congress Fellowship Applications has been launched on 1 August 2017. The competition is open to participants from all over the globe. One Health Fellows will receive financial support to cover the registration fee, accommodation for the duration of the conference, and travel (economy class).

If you're interested in applying for the One Health Fellowships, check the eligibility and application guidelines and download the application form from **www.onehealthcongress.com**

Deadline for submitting your application is 15 October 2017.

The 5th International One Health Congress will be held in Saskatoon, Canada, from 22 to 25 June 2018. To capture the multifaceted One Health paradigm, the Congress will have distinct program tracks on One Health Science (zoonoses, climate change, food and water safety), antimicrobial resistance and translational science. The organizers recognize the critical role the next generation of scientists, care providers and policy makers will have in developing and implementing measures to mitigate the effects of current and future challenges to public, animal and environmental health. They have therefore created a special fund to ensure that these decision makers of tomorrow from all parts of the world can attend the Congress.

UNIVERSITY OF SASKATCHEWAN

The 5th International One Health Congress is organized by the **One Health Platform** and the **University of Saskatchewan**, in close collaboration with the **Southern African Centre for Infectious Disease Surveillance (SACIDS)**, **CDC Kenya** and **One Health Eastern & Central Africa (OHCEA)**

OHS AMR SPI

UCDUSR0003947

One Health Fellowship Fund

5th IOHC, Saskatoon, 22-25 June 2018

Since some of the best and most innovative ideas come from early career scientists, the conference organizers will actively encourage the careers of promising researchers. They therefore intend to establish a **One Health Fellowship Fund** to provide fellowships to young scientists, with special attention for promising scientists from resource-challenged countries as part of the congress's overarching theme: One Health in Underserved Communities. Indeed, the 5th International One Health Congress is organized by the One Health Platform and the University of Saskatchewan, in close collaboration with our African partners: the Southern African Centre for Infectious Disease Surveillance (SACIDS), One Health CDC Kenya and the One Health Central and Eastern Africa (OHCEA). These intercontinental partnerships are an essential tool to implement the overarching theme. Their active participation, combined with the involvement of other underserved communities (First Nations) and of international associations like WHO, FAO, World Veterinary Association, World Medical Association, EcoHealth Alliance and CDC, will guarantee capacity building at the meeting and far beyond. In this way, the congress will provide young One Health advocates with a unique opportunity to interact with world experts, gain further insights into their fields of interest and get inspired with new ideas and possibilities.

1. Application process

The One Health Platform Early Career Researchers Circle, coordinated by Dr. Leslie Reperant, launches the **Open Call for Congress Fellowship Applications** on 1 August 2017. The competition will be open to participants from all over the globe. To be eligible, however, applicants must:

- be senior PhD students (expected to complete their dissertations within a year of the Congress) or must hold a PhD or a clinical qualification for no longer than 3 years at the time of

the application. Special considerations (e.g. maternity/paternity leave) will be taken into account.

- submit the completed One Health Fellowship Fund Application Form, a proof of status (on institution's letterhead from a faculty member or Department Head) and a research abstract (either as an author or a co-author).

Their research must focus on one of the congress main programme themes:

- Pathogen discovery
- Drivers for emerging diseases
- Diagnostics and syndrome surveillance
- Pathogenesis
- Ecology
- Underprivileged communities
- Vaccines
- Intervention strategies
- Politics and social science
- Antimicrobial resistance

2. Selection process

- all applications will be judged by an International Evaluation Committee of One Health experts
- number of fellowships depending on the amount of funding secured

3. Funding

The Organizing Committee will seek resources from potential funders such as the Gates Foundation, the International Development Research Centre (Canada) and CSIRO (Australia). Since fellows will be considered full participants, many of them with a special role in the congress programme, we will request funding of €3,450 per fellow when submitting grant applications at potential supporting organizations. This amount will cover the registration fee, accommodation for

the duration of the conference, and travel (economy class - booked by the congress organizers) to and from the congress venue. All promising scientists supported by the One Health Fellowship Fund will also receive an invitation to attend the One Health Fellows Evening, an informal network opportunity that will be held on Saturday 23 June 2018.

4. Visa

Obtaining visa for fellows in a timely fashion will be a challenge, particularly for fellows coming from resource-challenged regions. To cope with this challenge, the Organizing Committee will consult with the competent Canadian government agency to discuss the most appropriate visa application trajectory. The congress Organizing Committee, however, will not actively assist fellows in the visa process except for providing official invitation letters. For budgetary reasons, travel will not be booked unless a valid visa has been obtained.

5. Important dates

1 August 2017: launch Open Call for Congress Fellowship Applications via e-mailing and social media. Application documents and guidelines will be made available on the congress website. Application forms, proofs of status and research abstracts must be e-mailed to d.depooter@onehealthplatform.com by 15 October 2017

15 October 2017: Fellowship Fund application deadline

1 November 2017: Fellowship Fund grant winners notified

2 November 2017: opening abstract submission system

From: gaof <gaof@im.ac.cn>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: baiyu <baiyu@im.ac.cn>
Sent: 10/9/2017 11:20:02 PM
Subject: Re: National Academy of Medicine

Jonna
Many thanks and safe journey and good meeting in DC. Have you got David Ho's support？
Best
George

发自我的 iPhone George Gao

在 2017年10月10日，上午4:16，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Thanks, George,
I'm headed to Washington DC this weekend to the National Academy meeting, where I will propose your nomination to the head of the section for political support.
All is going well -- hope you are doing great,
Jonna

On Mon, Oct 2, 2017 at 12:41 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Here is another document related to your nomination.

All the best

George

-----原始邮件-----
发件人:"George F GAO" <gaof@im.ac.cn>
发送时间:2017-09-18 05:53:42 (星期一)
收件人: "Jonna Mazet" <jkmazet@ucdavis.edu>
抄送: baiyu <baiyu@im.ac.cn>
主题: Re: Re: Re: National Academy of Medicine

Dear Jonna,

Here are the tentative filled form and my updated publication list.

Many thanks and do let me know if you need anything more.

All the best

George

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-09-11 23:59:08 (星期一)

收件人: "George F GAO" <gaof@im.ac.cn>
抄送:
主题: Re: Re: National Academy of Medicine

Great news -- I'll contact him.
It would be good if I could get the materials by end of October. Will that work for you?
Have a good day,
Jonna

On Sat, Sep 9, 2017 at 7:39 AM, George F GAO <gaof@im.ac.cn> wrote:

Jonna,

David Ho is a good seconder in Section 2. He knows me very well.

Director and Chief Executive Officer
The Aaron Diamond AIDS Research Center
The Rockefeller University

Regular, 2c

Elected 1997

Male

New York

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-06-30 10:07:32 (星期五)
收件人: gaof <gaof@im.ac.cn>
抄送:
主题: Re: National Academy of Medicine

Hi George,
How are you? Hope all is well there. Attached, you will find the current listing of all of the Section 2 members. Please have a look and let me know which of them you think might be willing to be a co-nominator(s) for your submission. As I said, I am happy to nominate you for Section 10 with a cross-listing in Section 2, if we can find a good Section 2 member who will agree to co-nominate with me.

We will also need to submit all of the following information with the materials taking the following into consideration, in that the application must:
1. Convey this clearly: WHY SHOULD THE CANDIDATE BE AN NAM MEMBER?
a. The sections on sponsor statement, contributions (past/future), and citation are critical.
b. Identify candidate's impact in terms that are understandable to those less familiar with the field.
c. For international candidates: i. Place the candidate's accomplishments into the context of the national/regional/international sphere; ii. Note the level of prestige associated with institutions or prizes in the candidate's background that may be unfamiliar to others; iii. Where appropriate, use phrases such as: 1. …is the leader of Organization X, the most prestigious organization in this field in the nation/region 2. …is distinguished professor at X university, one of the top institutions in the nation/region 3. …is an internationally recognized leader in this field
2. Avoid these common errors in the candidate's personal information:
a. Missing or excessive contact information
b. Missing demographic information
c. Incorrect date of birth, citizenship information
3. Avoid these common errors in nomination details:
a. Wrong section or subsection

b. Missing bridging section where applicable
c. Institutional affiliation of both sponsors is the same as the candidate (at least one must be from an entirely separate institution)
d. >10 (maximum allowed) bibliographic citations

In addition to a co-nominator, I will need the following information in a Word document:

CANDIDATE: Name, Credentials, Institution

Type of Nomination: Regular/66+ Intl Section/Subsections (#)/(x) Bridging Section(s) (#)

Demographics: ☒ Female ☒ Racial & Ethnic Diversity

Geographic Location: [state/country] Age: [effective October 1]

Subject Emphasis: ☒ This info is not yet available for this year's nominators, but I will get it to you as soon as it comes out.

SPONSORS: Name, Institution
Name, Institution

PAST AND POTENTIAL CONTRIBUTIONS TO NAM:
[~6 lines]

CITATION OF ACCOMPLISHMENT: (50 words)
PROPOSERS' STATEMENT:
[~13 lines]

PRIMARY FIELD & AREA OF SPECIALIZATION OR EXPERTISE
[3 lines]

CURRENT EMPLOYMENT:
[up to 3]

PRINCIPAL PREVIOUS EMPLOYMENT:
[up to 3]

RESIDENCIES OR FELLOWSHIPS:
[up to 5]

EDUCATION:
[up to 3, highest first]

PRINCIPAL HONORS, AWARDS:
[~6 lines]

CURRENT MAJOR GRANT(s):
[~2 lines]

MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
[~5 lines]

SELECTED BIBLIOGRAPHY:
[up to 10 items]

Please let me know if you can provide the name and contact of a co-nominator and the information above, then we can move forward. We should aim to have the co-nominator on board and the materials all pulled together by November.

Hope to see you soon,
Jonna

On Mon, Jun 12, 2017 at 9:10 AM, gaof <gaof@im.ac.cn> wrote:
Jonna
Still have not got any news from you about the section classifications
Best
George

发自我的 iPhone

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Dear George,
Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate. I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
Hope you are well,
Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Hope this emial finds you well. I wonder if you have some time to find any our friends who is in Section 2 as we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

From: Brooke Genovese <bgenovese@ucdavis.edu>
To: Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com>
Cc: Dennis Carroll <dcarroll@usaid.gov>, Jonna Mazet [redacted], Andrew Clements <aclements@usaid.gov>, John Mackenzie [redacted] David De Pooter <d.depooter@onehealthplatform.com>, Cassandra Louis Duthil <clouisduthil@usaid.gov>, Ricardo Echalar <rechalar@usaid.gov>
Subject: Re: Debrief of our TC
Sent: Fri, 13 Oct 2017 15:55:09 +0000

Hello everyone,

I can confirm that Oct. 17 at 9:00 am PST works for Jonna.

Thank you,

Brooke Genovese
PREDICT Project Support
Executive Analyst
One Health Institute
School of Veterinary Medicine
Tel: 530-752-6459
bgenovese@ucdavis.edu

From: Ricardo Echalar <rechalar@usaid.gov>
Date: Friday, October 13, 2017 at 3:46 AM
To: Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com>
Cc: Dennis Carroll <dcarroll@usaid.gov>, Jonna Mazet [redacted], Andrew Clements <aclements@usaid.gov>, John Mackenzie [redacted] David De Pooter <d.depooter@onehealthplatform.com>, Cassandra Louis Duthil <clouisduthil@usaid.gov>, Brooke Genovese <bgenovese@ucdavis.edu>
Subject: Re: Debrief of our TC

Hi, Chris,

Unfortunately, I will not be available as I am currently in Madagascar. I hope to discuss the possibility of having a side symposium for the National One Health Platform assessment tool with you once I am back in the US after October 25th.

Thank you,
Ricardo

-- --

Ricardo Echalar, MPH
Senior Public Health Advisor
Office of Infectious Diseases, Emerging Threats Division
Bureau for Global Health
U.S. Agency for International Development (USAID)
1300 Pennsylvania Ave, NW, 3.6-53, 3rd Floor, RRB
Washington, DC 20523
(M) [redacted] (W) +1.202.712.4003 | E-mail: rechalar@usaid.gov

On Fri, Oct 13, 2017 at 1:25 PM, Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com> wrote:
Dear all

I hope this mail finds you well !

I am following up on my previous mail. Would 17 October be an option to meet up again? May I propose 18.00 CET (9:00 PST)?
Many thanks in advance for getting back to me!

Very best regards
Chris

ONE HEALTH PLATFORM
It's all connected
Chris Vanlangendonck
co-founder / management
REDACTED
www.onehealthplatform.com

Op 3 okt. 2017, om 18:10 heeft Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com> het volgende geschreven:

Dear all

Many thanks for your time just now over the phone. And many thanks for your engagement in the Congress!

As promised I am sending you some documents as a starting point. The Fellowship Fund flyer is to inform Fellows that they are welcome at our Congress- we are distributing the flyer as widely as possible.
As mentioned it is our aim to get 100 Fellows at the meeting. Extra support here is welcome. For that purpose I am enclosing the Fellowship Fund document in which we describe the concept / process and the budget per Fellow.

We welcome the organization of a PREDICT satellite symposium and the symposium on Preparedness that Ricardo was referring to. It will be our pleasure to assist you wherever possible. To be continued when we receive Ricardo's information.
In the sponsor prospectus (enclosure) that we developed, prices for satellites are mentioned. Also for your information, Jonna. We know that research projects are under budget constraints, therefore we can offer the symposium to PREDICT for 50.000 euro - we do the same for other research projects, it is part of the Congress' policy.

It goes without saying that financial support to the Congress is crucial to make it all happen. So thank you very much, Dennis for looking into (other) possibilities to fund us.

We will be organizing a satellite on vaccination and AMR in Saskatoon too. We will be able to make the subject more concrete by presenting the "influenza case". I am enclosing the draft programme (and set-up of this project) to this mail. We can indeed find "links" between the symposium at the PMAC meeting and the Saskatoon meeting. For this project / symposium we have reached out to companies that are putting this topic high on their agenda: Pfizer, Seqirus, Astra Zeneca, GSK and Sanofi. It is currently under their review. This can be discussed more in depth during our next TC.

Finally, it is my pleasure to formally invite you to the SPI Programme Committee, Dennis. We are currently organizing the first SPI Committee meeting - TC end of October. My colleague David De Pooter will circulate some dates very soon. The first possible framework of the SPI programme has been developed (enclosure to this mail). This will be subject of discussion of the first SPI Committee meeting. We are very much looking forward to start discussing it with the Committee members and to shaping a good programme!

As agreed upon, we will plan a follow up TC. Kindly let me know if you are available on Tuesday 17 October, 17:00 PM CET. Do let me know if you need additional information in the meantime.

Also on behalf of John and Ab, I want to express our gratitude. It is great to have you on board; we are very much looking forward to our collaboration and to making the Congress a big success !

Kind regards
Chris

<OHP_5OHC_fellowshipfund.pdf>

<6-OH Fellows Fund-concept.pdf>
<SPI.docx>
<FLU : AMR.pdf>
<OHP_5OHC_sponsorprospectus_Eur.pdf>

ONE HEALTH PLATFORM
It's all connected
Chris Vanlangendonck
co-founder / management
REDACTED
www.onehealthplatform.com

<unknown.jpg>

Op 3 okt. 2017, om 17:05 heeft Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com> het volgende geschreven:

<AccessNumbers.pdf>

code: REDACTED

ONE HEALTH PLATFORM
It's all connected
Chris Vanlangendonck
co-founder / management
REDACTED
www.onehealthplatform.com

<unknown.jpg>

Op 3 okt. 2017, om 17:03 heeft Ricardo Echalar <rechalar@usaid.gov> het volgende geschreven:

Chris,

Could you resend the call-in coordinates. I believe the number for the US was incorrect.

Thank you,
Ricardo

-- --

Ricardo Echalar, MPH
Senior Public Health Advisor
Office of Infectious Diseases, Emerging Threats Division
Bureau for Global Health
U.S. Agency for International Development (USAID)
1300 Pennsylvania Ave. NW, 3.6-53, 3rd Floor, RRB
Washington, DC 20523
(M) REDACTED (W) +1 202 712 4003 | E-mail: echalar@usaid.gov

On Tue, Oct 3, 2017 at 9:28 AM, Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com> wrote:

Dear all

On behalf of Ab and John, I am sending you the PPT of the Congress and the state of the art programme tracks OHS and AMR.
This might serve as a kick off for our 17:00 PM CET meeting.

Looking forward to talking to you soon !

Best regards
Chris

ONE HEALTH PLATFORM

It's all connected
Chris Vanlangendonck

co-founder / management
REDACTED
www.onehealthplatform.com

Op 25 sep. 2017, om 12:44 heeft Dennis Carroll <dcarroll@usaid.gov> het volgende geschreven:

Chris, thanks for the email. I'm pleased to hear preparations for the conference are in "full gear". I welcome the chance to explore how our Predict and P&R teams can be supportive. I have copied Cassandra on our team who can coordinate a time for a phone call that could include Andrew, Ricardo and possibly Jonna. Look forward to talking with you.

d

Dr Dennis Carroll

Director, Emerging Threats Program
U.S. Agency for International Development
Office: (202) 712-5009
Mobile: REDACTED
On Sep 22, 2017, at 11:41 AM, Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com> wrote:

Dear Dennis

On behalf of John and Ab, I would like to pick up our conversation about a possible collaboration between Predict and Preparedness and Response and the One Health Platform.
We are indeed in full gear - organizing our Canada Congress. Several organizations took an option on slots for satellite symposia. We hope we can still include your scientific projects!
It would be our pleasure to set up a TC with you and your colleagues to explore possible pathways of collaboration - if you think that could be useful.

I am very much looking forward to receiving your feedback. Many thanks in advance.

Kind regards
Chris

ONE HEALTH PLATFORM

It's all connected
Chris Vanlangendonck

co-founder / management
REDACTED

www.onehealthplatform.com

<unknown.jpg>

Op 23 jun. 2017, om 20:53 heeft Dennis Carroll <dcarroll@usaid.gov> het volgende geschreven:

Dear John and Ab, my apologies for being so no-responsive. Let me just way Washington is a place to be avoided right now. Its hard to keep ahead, particularly of emails. That said, we would be delighted for Predict and Preparedness and Response (formerly Respond) to construct symposia to be held as satellite symposia. In addition to Jonna I am copying Andrew Clements and Ricardo Echalar to help move this process along. Thank you for the opportunity to engage in this important forum

All my best

dennis

On Tue, May 23, 2017 at 5:00 AM, John Mackenzie <REDACTED

wrote:

Dear Dennis,

I write to follow up on the letter sent to you last month by my colleague, Ab Osterhaus. We are really excited by the 5th congress as the One Health Platform will be hosting it for the first time, and doing so in collaboration with the University of Saskatchewan and our African partners (the Southern African Centre for Infectious Disease Surveillance (SACIDS), One Health CDC Kenya and the One Health Central and Eastern Africa (OHCEA)).

We are very keen to have a strong input into the congress and the scientific program from you and USAID, especially with the PREDICT and RESPOND projects, but not necessarily confined to these projects. With the success of the symposia in Melbourne, I would like to suggest that PREDICT and RESPOND once again construct symposia to be held as satellite symposia. They provide an excellent international window into their respective projects, as well as giving your international partners the opportunity to present their work at a large gathering and to meet and network with others with similar interests.

As Ab mentioned, we are establishing a One Health Fellowship fund which incorporates a 'leaders of tomorrow' concept. While I am certain some of your international partners in PREDICT, RESPOND and other relevant projects will fit into this concept, we would be very grateful for any additional help you could find to help this worthy cause.

I have attached the first announcement and Ab's letter again, for your information, and would like to remind you again of the program construction – the congress will have 4 principal streams: two will be scientific presentations and form the scientific basis of the congress; one will be devoted to antimicrobial resistance, underlining its importance to human health; and the final stream will be concerned with science policy and will be directed at policy makers.

We look forward to hearing from you.

With warm personal regards,

John

Professor John S Mackenzie,

REDACTED

Begin doorgestuurd bericht:

Van: Ab Osterhaus <a.osterhaus@onehealthplatform.com>
Onderwerp: One Health Platform cooperation request
Datum: 20 april 2017 10:47:51 CEST
Aan: Dennis Carroll <dcarroll@usaid.gov>
Kopie: David Heymann

REDACTED

Dear Dr. Carroll,
Dear Dennis,

I hope this e-mail finds you well.

I'm attaching an official request for collaboration in view of the upcoming 5th International One Health Congress, to be held in Saskatoon, Canada.

Looking forward to getting in touch.

Best regards,

Prof. A.D.M.E.
Osterhaus

ONE HEALTH PLATFORM Chair
It's all connected
www.onehealthplatform.com

<OHP_5OHC_bannerMelbourne_press.jpg>

--
Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
Mobile: REDACTED

Subject: Re: Debrief of our TC
From: Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com>
Sent: Mon, 16 Oct 2017 09:50:56 +0200
Cc: Dennis Carroll <dcarroll@usaid.gov>, Jonna Mazet [redacted], Andrew Clements <aclements@usaid.gov>, John Mackenzie [redacted], David De Pooter <d.depooter@onehealthplatform.com>, Cassandra Louis Duthil <clouisduthil@usaid.gov>, Ricardo Echalar <rechalar@usaid.gov>
To: Brooke Genovese <bgenovese@ucdavis.edu>
Accesshumbers.pdf

Dear Brooke
Dear all

Many thanks for this confirmation. May I suggest that we go ahead with the TC, set on 17 Oct 9:00 AM PST / 18:00 CET. We can use the opportunity to discuss the involvement of PREDICT in the Saskatoon meeting.
We will talk to Ricardo later - after 25 October when he is back in the US. I hope Dennis can call in too tomorrow.

Looking forward !

Best regards
Chris

Dial in numbers are enclosed to this mail. Participant code is [redacted]

ONE HEALTH PLATFORM
It's all connected
Chris Vanlangendonck
co-founder / management
[redacted]
www.onehealthplatform.com

> Op 13 okt. 2017, om 17:55 heeft Brooke Genovese <bgenovese@ucdavis.edu> het volgende geschreven:
>
> Hello everyone,
>
> I can confirm that Oct. 17 at 9:00 am PST works for Jonna.
>
> Thank you,
>
> Brooke Genovese
> PREDICT Project Support
> Executive Analyst
> One Health Institute
> School of Veterinary Medicine
> Tel: 530-752-6459
> bgenovese@ucdavis.edu <mailto:bgenovese@ucdavis.edu>
>
>

>
> > From: Ricardo Echalar <rechalar@usaid.gov <mailto:rechalar@usaid.gov>>
> Date: Friday, October 13, 2017 at 3:46 AM
> To: Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com
<mailto:c.vanlangendonck@onehealthplatform.com>>
> Cc: Dennis Carroll <dcarroll@usaid.gov <mailto:dcarroll@usaid.gov>>, Jonna Mazet
REDACTED, Andrew Clements
<aclements@usaid.gov <mailto:aclements@usaid.gov>>, John Mackenzie REDACTED
REDACTED
REDACTED David De Pooter <d.depooter@onehealthplatform.com
<mailto:d.depooter@onehealthplatform.com>>, Cassandra Louis Duthil <clouisduthil@usaid.gov
<mailto:clouisduthil@usaid.gov>>, Brooke Genovese <bgenovese@ucdavis.edu
<mailto:bgenovese@ucdavis.edu>>
> Subject: Re: Debrief of our TC
>
> Hi, Chris,
>
> Unfortunately, I will not be available as I am currently in Madagascar. I hope to discuss the possibility of having a side symposium for the National One Health Platform assessment tool with you once I am back in the US after October 25th.
>
> Thank you,
>
> Ricardo
>
>
> – –
>
> Ricardo Echalar, MPH
> Senior Public Health Advisor
> Office of Infectious Diseases, Emerging Threats Division <https://www.usaid.gov/what-we-do/global-health/pandemic-influenza-and-other-emerging-threats/programs>
> Bureau for Global Health
> U.S. Agency for International Development (USAID)
> 1300 Pennsylvania Ave, NW, 3.6-53, 3rd Floor, RRB
> Washington, DC 20523
> (M) REDACTED | (W) +1.202.712.4003 | E-mail: rechalar@usaid.gov
<mailto:rechalar@usaid.gov>
>
>
>
>
> On Fri, Oct 13, 2017 at 1:25 PM, Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com
<mailto:c.vanlangendonck@onehealthplatform.com>> wrote:
> Dear all
>
> I hope this mail finds you well !
> I am following up on my previous mail. Would 17 October be an option to meet up again? May I propose 18:00 CET (9:00 PST)?
> Many thanks in advance for getting back to me!
>
> Very best regards
> Chris
>
>

> ONE HEALTH PLATFORM
> It's all connected
> Chris Vanlangendonck
> co-founder / management
[redacted]
> www.onehealthplatform.com <http://www.onehealthplatform.com/>
>
>
> <image001.jpg>
>
> Op 3 okt. 2017, om 18:10 heeft Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com <mailto:c.vanlangendonck@onehealthplatform.com>> het volgende geschreven:
>
> Dear all
>
> Many thanks for your time just now over the phone. And many thanks for your engagement in the Congress!
>
> As promised I am sending you some documents as a starting point. The Fellowship Fund flyer is to inform Fellows that they are welcome at our Congress- we are distributing the flyer as widely as possible.
> As mentioned it is our aim to get 100 Fellows at the meeting. Extra support here is welcome. For that purpose I am enclosing the Fellowship Fund document in which we describe the concept / process and the budget per Fellow.
>
> We welcome the organization of a PREDICT satellite symposium and the symposium on Preparedness that Ricardo was referring to. It will be our pleasure to assist you wherever possible. To be continued when we receive Ricardo's information.
> In the sponsor prospectus (enclosure) that we developed, prices for satellites are mentioned. Also for your information, Jonna. We know that research projects are under budget constraints, therefore we can offer the symposium to PREDICT for 50.000 euro - we do the same for other research projects, it is part of the Congress' policy.
>
> It goes without saying that financial support to the Congress is crucial to make it all happen. So thank you very much, Dennis for looking into (other) possibilities to fund us.
>
> We will be organizing a satellite on vaccination and AMR in Saskatoon too. We will be able to make the subject more concrete by presenting the "influenza case". I am enclosing the draft programme (and set-up of this project) to this mail. We can indeed find "links" between the symposium at the PMAC meeting and the Saskatoon meeting. For this project / symposium we have reached out to companies that are putting this topic high on their agenda: Pfizer, Seqirus, Astra Zeneca, GSK and Sanofi. It is currently under their review. This can be discussed more in depth during our next TC.
>
> Finally, it is my pleasure to formally invite you to the SPI Programme Committee, Dennis. We are currently organizing the first SPI Committee meeting - TC end of October. My colleague David De Pooter will circulate some dates very soon. The first possible framework of the SPI programme has been developed (enclosure to this mail). This will be subject of discussion of the first SPI Committee meeting. We are very much looking forward to start discussing it with the Committee members and to shaping a good programme!
>
> As agreed upon, we will plan a follow up TC. Kindly let me know if you are available on Tuesday 17 October, 17:00 PM CET. Do let me know if you need additional information in the meantime.
>
> Also on behalf of John and Ab, I want to express our gratitude. It is great to have you on board; we are very much looking forward to our collaboration and to making the Congress a big success !
>
> Kind regards

> Chris
>
> <OHP_5OHC_fellowshipfund.pdf>
>
>
>
>
>
>
> <6-OH Fellows Fund-concept.pdf>
> <SPI.docx>
> <FLU : AMR.pdf>
> <OHP_5OHC_sponsorprospectus_Eur.pdf>
>
>
>
>
>
> ONE HEALTH PLATFORM
> It's all connected
> Chris Vanlangendonck
> co-founder / management
REDACTED
> www.onehealthplatform.com <http://www.onehealthplatform.com/>
>
>
>
> <unknown.jpg>
> > Op 3 okt. 2017, om 17:05 heeft Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com <mailto:c.vanlangendonck@onehealthplatform.com>> het volgende geschreven:
>
> <AccessNumbers.pdf>
>
> code REDACTED
>
>
> ONE HEALTH PLATFORM
> It's all connected
> Chris Vanlangendonck
> co-founder / management
> REDACTED
> www.onehealthplatform.com <http://www.onehealthplatform.com/>
>
>
>
> <unknown.jpg>
>
> Op 3 okt. 2017, om 17:03 heeft Ricardo Echalar <rechalar@usaid.gov <mailto:rechalar@usaid.gov>> het volgende geschreven:
>
> Chris,
>
>
> Could you resend the call-in coordinates. I believe the number for the US was incorrect.
>
> Thank you,

>
> Ricardo
>
>
> -- -
>
> Ricardo Echalar, MPH
> Senior Public Health Advisor
> Office of Infectious Diseases, Emerging Threats Division <https://www.usaid.gov/what-we-do/global-health/pandemic-influenza-and-other-emerging-threats/programs>
> Bureau for Global Health
> U.S. Agency for International Development (USAID)
> 1300 Pennsylvania Ave, NW
<https://maps.google.com/?q=1300+Pennsylvania+Ave,+NW&entry=gmail&source=g>, 3.6-53, 3rd Floor, RRB
> Washington, DC 20523
> (M) REDACTED <tel:(571)%20215-6324> | (W) +1.202.712.4003 <tel:(202)%20712-4003> | E-mail: rechalar@usaid.gov <mailto:rechalar@usaid.gov>
>
>
>
>
> On Tue, Oct 3, 2017 at 9:28 AM, Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com <mailto:c.vanlangendonck@onehealthplatform.com>> wrote:
> Dear all
>
> On behalf of Ab and John, I am sending you the PPT of the Congress and the state of the art programme tracks OHS and AMR.
> This might serve as a kick off for our 17:00 PM CET meeting.
>
> Looking forward to talking to you soon !
>
> Best regards
> Chris
>
>
>
> ONE HEALTH PLATFORM
> It's all connected
> Chris Vanlangendonck
> co-founder / management
> REDACTED
> www.onehealthplatform.com <http://www.onehealthplatform.com/>
>
>
>
>
>
> Op 25 sep. 2017, om 12:44 heeft Dennis Carroll <dcarroll@usaid.gov <mailto:dcarroll@usaid.gov>> het volgende geschreven:
>
> Chris, thanks for the email. I'm pleased to hear preparations for the conference are in "full gear". I welcome the chance to explore how our Predict and P&R teams can be supportive. I have copied Cassandra on our team who can coordinate a time for a phone call that could include Andrew, Ricardo and possibly Jonna. Look forward to talking with you. >
> d

>
> Dr Dennis Carroll
> Director, Emerging Threats Program
> U.S. Agency for International Development
> Office: (202) 712-5009 <tel:(202)%20712-5009>
> Mobile: REDACTED <tel:(301)%20646-6235>
>
> On Sep 22, 2017, at 11:41 AM, Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com <mailto:c.vanlangendonck@onehealthplatform.com>> wrote:
>
> Dear Dennis
>
> On behalf of John and Ab, I would like to pick up our conversation about a possible collaboration between Predict and Preparedness and Response and the One Health Platform.
> We are indeed in full gear - organizing our Canada Congress. Several organizations took an option on slots for satellite symposia. We hope we can still include your scientific projects!
> It would be our pleasure to set up a TC with you and your colleagues to explore possible pathways of collaboration - if you think that could be useful.
>
> I am very much looking forward to receiving your feedback. Many thanks in advance.
>
> Kind regards
> Chris
>
>
> ONE HEALTH PLATFORM
> It's all connected
> Chris Vanlangendonck
> co-founder / management
REDACTED
> www.onehealthplatform.com <http://www.onehealthplatform.com/>
> <unknown.jpg>
>
>
> Op 23 jun. 2017, om 20:53 heeft Dennis Carroll <dcarroll@usaid.gov <mailto:dcarroll@usaid.gov>> het volgende geschreven:
>
> Dear John and Ab, my apologies for being so no-responsive. Let me just way Washington is a place to be avoided right now. Its hard to keep ahead, particularly of emails. That said, we would be delighted for Predict and Preparedness and Response (formerly Respond) to construct symposia to be held as satellite symposia. In addition to Jonna I am copying Andrew Clements and Ricardo Echalar to help move this process along. Thank you for the opportunity to engage in this important forum
>
> All my best
>
> dennis
>
> On Tue, May 23, 2017 at 5:00 AM, John Mackenzie <J.Mackenzie@curtin.edu.au <mailto:J.Mackenzie@curtin.edu.au>> wrote:
> Dear Dennis,
>
> I write to follow up on the letter sent to you last month by my colleague, Ab Osterhaus. We are really excited by the 5th congress as the One Health Platform will be hosting it for the first time, and doing so in collaboration with the University of Saskatchewan and our African partners (the Southern African Centre for Infectious Disease Surveillance (SACIDS), One Health CDC Kenya and the One Health Central and Eastern Africa (OHCEA)).

>
> We are very keen to have a strong input into the congress and the scientific program from you and USAID, especially with the PREDICT and RESPOND projects, but not necessarily confined to these projects. With the success of the symposia in Melbourne, I would like to suggest that PREDICT and RESPOND once again construct symposia to be held as satellite symposia. They provide an excellent international window into their respective projects, as well as giving your international partners the opportunity to present their work at a large gathering and to meet and network with others with similar interests.
>
> As Ab mentioned, we are establishing a One Health Fellowship fund which incorporates a 'leaders of tomorrow' concept. While I am certain some of your international partners in PREDICT, RESPOND and other relevant projects will fit into this concept, we would be very grateful for any additional help you could find to help this worthy cause.
>
> I have attached the first announcement and Ab's letter again, for your information, and would like to remind you again of the program construction – the congress will have 4 principal streams: two will be scientific presentations and form the scientific basis of the congress; one will be devoted to antimicrobial resistance, underlining its importance to human health; and the final stream will be concerned with science policy and will be directed at policy makers.
>
> We look forward to hearing from you.
>
> With warm personal regards,
>
> John
>
> Professor John S Mackenzie,

REDACTED

>
>
>
>
> Begin doorgestuurd bericht:
>
> Van: Ab Osterhaus <a.osterhaus@onehealthplatform.com
<mailto:a.osterhaus@onehealthplatform.com>>
> Onderwerp: One Health Platform cooperation request
> Datum: 20 april 2017 10:47:51 CEST
> Aan: Dennis Carroll <dcarroll@usaid.gov <mailto:dcarroll@usaid.gov>>
> Kopie: David Heymann <[redacted]
>
> Dear Dr. Carroll,
> Dear Dennis,
>
> I hope this e-mail finds you well.
>
> I'm attaching an official request for collaboration in view of the upcoming 5th International One Health Congress, to be held in Saskatoon, Canada.

>
> Looking forward to getting in touch.
>
> Best regards,
>
> Prof. A.D.M.E. Osterhaus
> ONE HEALTH PLATFORM Chair
> It's all connected
> www.onehealthplatform.com <https://onehealthplatform.com/>
>
>
> <OHP_5OHC_bannerMelbourne_press.jpg>
>
>
>
>
>
>
>
>
>
>
>
>
> --
> Dr. Dennis Carroll
> Director, Emerging Threats Program
> Bureau for Global Health
> U.S. Agency for International Development
>
> Office: 202-712-5009 <tel:(202)%20712-5009>
> Mobile: REDACTED <tel:(301)%20646-6235>
>
>
>
>
>
>
>
>

Dear Brooke
Dear all

Many thanks for this confirmation. May I suggest that we go ahead with the TC, set on 17 Oct 9:00 AM PST / 18:00 CET.
We can use the opportunity to discuss the involvement of PREDICT in the Saskatoon meeting.
We will talk to Ricardo later - after 25 October when he is back in the US. I hope Dennis can call in too tomorrow.

Looking forward !

Best regards
Chris

Dial in numbers are enclosed to this mail. Participant code is REDACTED

Country	Type	PhoneNumber
Argentina	Toll	+54(0)1152184097
Argentina	Toll Free	08004443006
Australia	Toll	+61(0)290371688
Australia	Toll Free	1800180972
Austria	Toll	+43(0)19282212
Austria	Toll Free	0800006427
Bahamas	Toll Free	18003890667
Bahrain	Toll	+973(0)16199617
Belarus	Toll Free	882000110234
Belgium	Toll	+32(0)27460055 EN
Belgium	Toll	+32(0)27460033 FR
Belgium	Toll	+32(0)27460022 NL
Belgium	Toll Free	080055746 EN
Belgium	Toll Free	080033746 FR
Belgium	Toll Free	080022746 NL
Botswana	Toll Free	002698003001319
Brazil	Toll	+55(0)1131725516
Brazil	Toll Free	08007621105
Brunei Darussalam	Toll Free	8014060
Bulgaria	Toll	+359(0)24917749
Canada	Toll	+1(0)4168493425
Canada	Toll Free	8557226093
Chile	Toll	+56(0)25994947
Chile	Toll Free	12300200313
China	Toll	+86(0)4006815471
China	Toll Free	108007123190
China	Toll Free	10800120190
Colombia	Toll Free	018009157501
Croatia	Toll	+385(0)18848014
Cyprus	Toll	+357(0)22007765
Cyprus	Toll Free	80096477
Czech Republic	Toll	+420(0)228882633
Denmark	Toll	+45(0)32727718
Denmark	Toll Free	80885642
Dominican Republic	Toll	+1829(0)9467500
Dominican Republic	Toll Free	18007514907
El Salvador	Toll Free	8006841
Estonia	Toll	+372(0)6226438
Estonia	Toll Free	8000100318
Finland	Toll	+358(0)931582705
France	Toll	+33(0)170721535
France	Toll Free	0805631583
Germany	Toll	+49(0)6922221004
Germany	Toll Free	08005892946
Greece	Toll	+30(0)2111981808
Greece	Toll Free	00800128773
Hong Kong	Toll	+852(0)58081350
Hong Kong	Toll Free	800905190
Hungary	Toll	+36(0)14088390

Country	Type	PhoneNumber
Italy	Toll Free	800145650
Japan	Toll	+81(0)350501254
Japan	Toll Free	00531122503
Kazakhstan	Toll Free	88003334129
Korea, Republic of	Toll Free	00798142031006
Latvia	Toll	+371(0)67782579
Latvia	Toll Free	880031384
Lithuania	Toll	+370(0)52055222
Lithuania	Toll Free	880031384
Luxembourg	Toll	+352 278 601 22
Luxembourg	Toll Free	80023803
Malaysia	Toll Free	1800815874
Mexico	Toll	+52(0)5547772235
Mexico	Toll Free	0018553477185
Moldova, Republic of	Toll Free	080061412
Monaco	Toll Free	80093801
Netherlands	Toll	+31(0)207168275
Netherlands	Toll Free	08000201227
New Zealand	Toll	+64(0)99291745
New Zealand	Toll Free	0800452528
Norway	Toll	+47(0)21030766
Norway	Toll Free	80017157
Panama	Toll	+507(0)8366127
Panama	Toll Free	008002260006
Philippines	Toll Free	180011101230
Poland	Toll	+48(0)222120691
Poland	Toll Free	008001214291
Portugal	Toll Free	800855558
Puerto Rico	Toll Free	18557461006
Romania	Toll	+40(0)215293913
Romania	Toll Free	0800895789
Russian Federation	Toll	+7(0)4957059771
Russian Federation	Toll Free	81080029603011
Saint Kitts and Nevis	Toll Free	18003001810
Singapore	Toll	+65(0)31580344
Singapore	Toll Free	8001012581
Slovakia	Toll	+421(0)233057799
Slovakia	Toll Free	0800606534
Slovenia	Toll	+386(0)18888205
Slovenia	Toll Free	0800800911
South Africa	Toll	+27(0)110197053
South Africa	Toll Free	0800984043
Spain	Toll	+34(0)911143444
Spain	Toll Free	800600599
Sweden	Toll	+46(0)850336485
Sweden	Toll Free	0200883166
Switzerland	Toll	+41(0)445804661
Switzerland	Toll Free	0800800883
Taiwan	Toll Free	00801136320

Hungary	Toll Free	0680019506
Iceland	Toll Free	8006374
India	Toll	+91(0)2233019439
India	Toll Free	18002001127
Indonesia	Toll Free	07803010478
Ireland	Toll	+353(0)14475800
Ireland	Toll Free	1800937230
Israel	Toll	+972(0)37631152
Israel	Toll Free	1809213064
Italy	Toll	+39(0)236009806

Thailand	Toll Free	001800120667099
Trinidad and Tobago	Toll Free	18002031006
Turkey	Toll Free	00800142031006
Ukraine	Toll Free	0800500273
United Arab Emirates	Toll Free	800119000
United Kingdom	Toll	+44(0)2033645302
United Kingdom	Toll Free	08002794068
United States	Toll	+1(0)6315614572
United States	Toll Free	8553477184
Uruguay	Toll Free	00040190512
Uzbekistan	Toll Free	8108001201084
Venezuela	Toll Free	08001029643
Vietnam	Toll	+84(0)444583283
Virgin Islands, U.S.	Toll Free	18557461006

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Andrew Clements <aclements@usaid.gov>
CC: David J Wolking <djwolking@ucdavis.edu>;Karen L Wood <klwood@ucdavis.edu>;Alisa Pereira <apereira@usaid.gov>;Shana Gillette <sgillette@usaid.gov>
Sent: 11/14/2017 11:52:30 PM
Subject: Re: Brussels is a go!

Wonderful -- thanks!
J

On Tue, Nov 14, 2017 at 12:31 PM, Andrew Clements <aclements@usaid.gov> wrote:
Got a read from the people who wrote the conference language. There is an exception for "grants" which under their definition includes cooperative agreements. So you are good to go forward. Sorry for the unnecessary drama!

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From: "William B. Karesh" <karesh@ecohealthalliance.org>
To: Jonna Mazet <jkmazet@ucdavis.edu>
Cc: David Wolking <djwolking@ucdavis.edu>, Amanda Andre <amanda.andre@ecohealthalliance.org>
Subject: First morning - Brussels meeting
Sent: Tue, 5 Dec 2017 19:26:46 +0000

As I get ready to reach out Europeans about attending the opening session the 9th, I wonder if we should schedule the first morning to be from 10:00 - 1:00, allowing some that want to travel to come on a morning train or flight. WCS wants someone from Germany invited, and if we do that, we should widen the list beyond Brussels and Amsterdam.
What do you think?

BK

William B. Karesh, D.V.M
Executive Vice President for Health and Policy

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Andrew Clements <aclements@usaid.gov>
CC: Pereira, Alisa (GH/HIDN) <apereira@usaid.gov>;Brooke Genovese <bgenovese@ucdavis.edu>
Sent: 12/8/2017 2:00:36 PM
Subject: Re: Ebola funds

Okay -- did you want to talk at either of the times about the Sierra Leone thing?
J

On Thu, Dec 7, 2017 at 11:36 PM, Andrew Clements <aclements@usaid.gov> wrote:
I asked Richard and Robbin to confirm that they are okay with the possible consequences of the shift. Let's wait to see how they respond.

On Fri, Dec 8, 2017 at 12:59 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:
I could do a quick call at 7:30 am my time (4:30 pm Geneva) or 11 am my time (8 pm Geneva) tomorrow. Today was swamped, just getting back to email now.
Thanks,
J

On Thu, Dec 7, 2017 at 1:48 AM, Andrew Clements <aclements@usaid.gov> wrote:
Hi Jonna,

Sounds good. Let me know when you're available today (would have to be between 10:00 AM to 12:00 PM your time) or tomorrow.

Richard said several times yesterday that the country caps have been removed. I did not discuss it with him to verify that it means what I think it means. I will try to get him to put in writing exactly what he means about the caps being removed.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Dec 7, 2017, at 12:13 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

We'll need a call to discuss the potential consequences for other countries of this kind of planning, especially with the imposed country caps. With the constraints your system has contrived, there are complex planning and accounting pieces involved with those kind of swaps that leave other countries out of funds and under their caps if promises for the future are not kept.
Jonna

On Wed, Dec 6, 2017 at 8:50 AM, Andrew Clements <aclements@usaid.gov> wrote:
Hi Jonna,

Just had a phone call with Richard asking if you wanted to redistribute your existing Ebola pipeline among countries so that you do not run out of funds in Guinea, Liberia, and Sierra Leone while other countries still have funds. I think in his ideal world, most all countries would be a similar position in terms of the percentage of their obligated funds that have been expended.

He indicated that new Ebola funding would not be considered for obligation until the previously-obligated Ebola funds have reached about a 75% expenditure rate. (We wouldn't need to wait until you hit 75% expenditures to start the process of requesting the new obligation; in theory, with advanced information from PREDICT on when that threshold will be met, USAID could be ready to do the obligation when that date arrives.)

Your thoughts?

1-571-345-4255
achements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see: http://www.usaid.gov/ept2

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4255
E-mail: achements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see: http://www.usaid.gov/ept2

From: Dennis Carroll <dcarroll@usaid.gov>
Sent: Thu, 25 Jan 2018 12:10:40 -0500
Subject: Re: Slides for open session
To: Brooke Watson <watson@ecohealthalliance.org>
Cc: [redacted], Eddy Rubin <erubin@metabiota.com>, Peter Daszak <daszak@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Nathan Wolfe <nwolfe@metabiota.com>

Looks good Brooke. Thanks.

d

On Thu, Jan 25, 2018 at 11:46 AM, Brooke Watson <watson@ecohealthalliance.org> wrote:

Hi team,
Attached are EHA's edits to Dennis's slide deck - please let me know if you have any questions. Talk soon!

Best,

Brooke

GVP PMAC Open Session 1.25.18_bw.ppt

--

Brooke Watson, MSc
Research Scientist

EcoHealth Alliance
460 West 34th Street - 17th floor
New York, NY 10001

1.212.380.4497 (direct)
[redacted] (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

--

Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
Mobile: [redacted]

From: Andrew Clements <aclements@usaid.gov>
To: Jonna Mazet <jkmazet@ucdavis.edu>;William Karesh <Karesh@ecohealthalliance.org>;Dennis Carroll <dcarroll@usaid.gov>;daszak@ecohealthalliance.org <daszak@ecohealthalliance.org>;Alisa Pereira <apereira@usaid.gov>;djwolking@ucdavis.edu <djwolking@ucdavis.edu>
Sent: 1/30/2018 8:35:18 AM
Subject: Can Virus Hunters Stop The Next Pandemic Before it Happens?

Unfortunately, it appears that Tesh and Rosenberg think that Predict is randomly sampling animals for viruses as a way to find zoonoses.

Guess we need to do a better job communicating that the Predict animal surveillance is targeted where there is human contact and that human surveillance is also being conducted at the same sites to look for zoonoses.

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

https://www.smithsonianmag.com/science-nature/how-to-stop-next-animal-borne-pandemic-180967908/

Sent: Mon, 12 Feb 2018 20:11:46 -0800
Subject: Re: Indonesia IRB Protocol
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: David J Wolking <djwolking@ucdavis.edu>
Cc: Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Megan M Doyle <mmdoyle@ucdavis.edu>, Predict inbox <predict@ucdavis.edu>

Hey, David, please consult with Chris, as she feels strongly that we should try to shut this specific editing stuff down at this point, close to the end of the study & all that.
I'm supportive of the simplest option for keeping the ship up right (least changes),
J

On Fri, Feb 9, 2018 at 3:03 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

> I glanced it over. This has been an oddball exercise with the transition and I think they may have made it more difficult than necessary (simple admin change of personnel and parties doing the work) but without dealing with the local EIMB board it's hard to tell. Emily told me they needed to modify the sites as well but that doesn't seem to be prominently featured as a change, maybe that one is still in the works as she notes the protocol changes are not quite final.
> Agree that there is a lot of specificity on the serology but they also preface it with a "dependent on molecular testing" clause so maybe there is some flexibility. I would advise changing the language that indicates the tests "will be developed and tested at EIMB" as I'm not sure that's the case, wouldn't CII be in charge of that for EHA countries?

Chris - think we need a Tracey/Simon consult here or let it fly as is?

David

On Thu, Feb 8, 2018 at 5:26 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Did you all review? I think the document looks okay, but some of the adds are overkill & I wouldn't want them to be construed as expectations for partners. Okay to over list plans for approval, as long as the in-country institutions don't expect that the work will necessarily get done or be funded. For example, the added (yellow-highlighted) paragraphs at the bottom of page 9 and top of page 10 seem unlikely to be done and not necessarily the only serology, etc., so the specificity seems odd. I think better to remain more general on that topic if you all do, too. I haven't yet provided any feedback to Emily, as you guys usually review these. I don't want to overstep.
> Let me know how you'd like to proceed,
> J

---------- Forwarded message ----------
From: **Emily Hagan** <hagan@ecohealthalliance.org>
Date: Thu, Feb 8, 2018 at 3:22 PM
Subject: Indonesia IRB Protocol
To: Jonna Mazet <jkmazet@ucdavis.edu>
Cc: David J Wolking <djwolking@ucdavis.edu>, Brooke Genovese <bgenovese@ucdavis.edu>, Leilani Francisco <francisco@ecohealthalliance.org>, "Kevin Olival, PhD" <olival@ecohealthalliance.org>

Hi Jonna,
I hope this finds you well.

We are currently submitting an IRB amendment in Indonesia that is for the transition from MB to EHA, specifically name two qualitative sites, and to include data analysis for data that was collected during the pilot study.

The Indonesian team is currently finalizing the protocol edits and submission documents. In preparation for submission, we are collecting permission for the use of e-signatures from PIs.

Because this is an edited version of our approved protocol we have your e-signature from the initial submission. Please let

us know if it is appropriate to use.

Attached please find the current draft of the protocol with changes for the amendment highlighted in teal. The green and yellow highlights are our edits after initial feedback from reviewers.

Please let me know if you have any questions, comments, or concerns.

Sincerely,
Emily

--

Emily Ragan, MPH, CPH
Research Scientist
PREDICT 2 Country Liaison: Bangladesh

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4491 (direct)
[redacted] (mobile)
mariagan (Skype)

www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.

Sent: Thu, 15 Feb 2018 14:05:02 +0000
From: spaige@usaid.gov
To: jnumbi@usaid.gov, isimmons@usaid.gov, jpettit@usaid.gov, rechalar@usaid.gov, diafuka.saila_ngita@tufts.edu, predict@ucdavis.edu, REDACTED REDACTED lkramer@usaid.gov, bhaberer@usaid.gov, REDACTED pmbala@metabiota.com, lparish@usaid.gov, aclements@usaid.gov, REDACTED mcrane@usaid.gov, REDACTED spaige@usaid.gov, pmulembakani@metabiota.com, prince.kimpanga@unikin.ac.cd
Subject: [predict] DRC IP Monthly Coordination Calls

Hello All
Line is open. Let me know if you are having trouble dialing in

DRC IP Monthly Coordination Calls

Dear Teams
Thank you for joining our monthly coordination call. The purpose of the call is to provide greater support from USAID/Washington to the mission and partners through improved communication.

Feb 2018 meeting agenda:

1) USAID Washington updates (timing and cadence of monthly call)
2) Partner updates (accomplishments from past month, plans for current month- 10 minutes each)
3) Issues or Action items
4)

(U.S. and Canada) REDACTED
International dial-in number REDACTED
Conference code REDACTED
Host: REDACTED

When: Thu Feb 15, 2018 9am – 10am Eastern Time

Where: (U.S. and Canada): REDACTED International dial-in number: REDACTED Conference code: REDACTED (map)

Who:

- spaige@usaid.gov - organizer
- jpettit@usaid.gov
- aclements@usaid.gov
- REDACTED
- diafuka.saila_ngita@tufts.edu
- jnumbi@usaid.gov
- REDACTED
- pmulembakani@metabiota.com
- predict@ucdavis.edu
- lparish@usaid.gov
- Prince Kimpanga
- lkramer@usaid.gov
- REDACTED
- pmbala@metabiota.com
- REDACTED
- isimmons@usaid.gov

- bhaberer@usaid.gov
- REDACTED
- Kambale Syaluha Eddy
- rrchalar@usaid.gov
- REDACTED
- mcrane@usaid.gov

From: Leilani Francisco <francisco@ecohealthalliance.org>
Sent: Fri, 16 Mar 2018 11:45:22 -0400
Subject: RE: Bat book: West Africa version
To: Jonna Mazet <jkmazet@ucdavis.edu>
Cc: Peter Daszak <daszak@ecohealthalliance.org>, "William B. Karesh" <karesh@ecohealthalliance.org>, Karen Saylors <ksaylors@metabiota.com>, Jason Euren <jeuren@metabiota.com>, Jon Epstein <epstein@ecohealthalliance.org>, Brian Bird <bhbird@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Kevin Olival <olival@ecohealthalliance.org>, David John Wolking <djwolking@ucdavis.edu> REDACTED

Thanks Jonna, all sounds great.
Best,
Leilani

From: REDACTED [mailto REDACTED] **On Behalf Of** Jonna Mazet
Sent: Thursday, March 15, 2018 11:01 PM
To: Leilani Francisco <francisco@ecohealthalliance.org>
Cc: Peter Daszak <daszak@ecohealthalliance.org>; William B. Karesh <karesh@ecohealthalliance.org>; Karen Saylors <ksaylors@metabiota.com>; Jason Euren <jeuren@metabiota.com>; Jon Epstein <epstein@ecohealthalliance.org>; Brian Bird <bhbird@ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@ucdavis.edu>; Tracey Goldstein <tgoldstein@ucdavis.edu>; Kevin Olival, PhD <olival@ecohealthalliance.org>; David John Wolking <djwolking@ucdavis.edu> REDACTED
Subject: Re: Bat book: West Africa version

Thanks, Leilani,
I do not think we need an official clearance (and we don't have a process for that).
I would like to see us start using it and see how it goes.
We can add to EB agenda to discuss whether or not we need a "clearance" and by whom.
I'd say for now, the teams that are communicating with communities, should consider using it and get us their initial reactions and interpretations on response to the content and delivery.
Of course, I know that you/Karen may have specific plans for more rigorously evaluating its utility in certain areas. So when you're ready, I'd like to discuss that on EB, too.
Exciting,
Jonna

On Mon, Mar 12, 2018 at 3:00 PM, Leilani Francisco <francisco@ecohealthalliance.org> wrote:
Hi everyone,
Please find attached an updated version of the bat book for use in *West Africa*.

As the production of this version was time sensitive, updates include high priority feedback received after the All-Country meeting, as well as additional input gathered through internal focus groups. Please note this version no longer has the "DRAFT" watermark on it.

In the meantime, we will continue working on further edits, e.g., a version for Asia, etc. Also, if there is interest in talking through evaluation options for countries outside of West Africa, perhaps we could discuss on the next EB call.

Jonna,
Is this version now cleared for use in West Africa?

Best,
Leilani

--

Leilani Francisco, PhD, MA, PMP
Senior Scientist | *PREDICT-2 Senior Behavioral Risk Surveillance Coordinator*

EcoHealth Alliance
460 West 34th Street – 17th floor

New York, NY 10001

1.212.380.4493 (direct)
REDACTED (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: [redacted]
To: William Karesh <karesh@ecohealthalliance.org>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, "Clements, Andrew (GH/HIDN" <AClements@usaid.gov>, Eddy Rubin <erubin@metabiota.com>, Leilani Francisco <francisco@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "Alisa Pereira Emerging Threats Division" <apereira@usaid.gov>, Elizabeth Leasure <ealeasure@UCDAVIS.EDU>, David John Wolking <djwolking@ucdavis.edu>
Cc: Lindsay Parish <lparish@usaid.gov>, Cassandra Louis Duthil <clouisduthil@usaid.gov>, Karen Saylors <ksaylors@metabiota.com>, "Amanda Andre" <amanda.andre@ecohealthalliance.org>, Brooke Genovese <bgenovese@ucdavis.edu>, Alison Andre <andre@ecohealthalliance.org>, Catherine Machalaba <Machalaba@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Molly Turner <turner@ecohealthalliance.org>, "predict@ucdavis.edu" <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>
Subject: MT agenda March 28
Sent: Tue, 27 Mar 2018 21:58:45 +0000
3. P2 Napa Semi-annual Meeting Agenda (April 2018) for MT.docx
PREDICT MT Call (3.28.18) final.docx

Hi PREDICT management team,

Here is the agenda for your call tomorrow, March 28 at 9-10am PT/12-1pm ET.

Best wishes,
[redacted]

PREDICT Management Call Agenda
Wednesday, March 28, 2018
9:00-10:00AM PST/12:00-1:00pm EST
[redacted] Access code: [redacted]
International Dial-in number: [redacted] (toll charges apply)

USAID Updates

1. **Administrative items**
   - Requests currently pending AO approval
   - Summer jams or other plans?
   - M&E workshops in Guinea and Sierra Leone (Pillar II)
   - M&E meeting in DC
   - West Africa travel updates

2. **Plans for additional testing**

3. **Bat book roll out and use beyond West Africa and with other interagency partners?**

4. **Napa semi-annual meeting plans (agenda attached)**

5. **Mission communications roundup (as needed)**

6. **Outbreak updates, if any**

7. **EPT partner collaboration/coordination updates (Billy)**

8. **Updates on proposals from consortium members?**

9. **Publication, media, and conference updates**
   - Discovery Channel "Invisible Killers" airing March 29, 2018
   - "Outbreak: Epidemics in a Connected World" exhibit at NMNH (May 18, 2018)
   - NIH Changing Relevance of Material Transfer Agreements for Infectious Diseases, Georgetown (May 3-4, 2018)
   - One Health Congress Saskatoon (June 22-25, 2018)
   - International Conference on Emerging Infectious Diseases (ICEID) in Atlanta (August 26–29, 2018)
   - International Meeting on Emerging Diseases and Surveillance (IMED) 2018 in Vienna, Austria

(November 9-12, 2018)

- International Symposium of Veterinary Epidemiology and Economics (ISVEE) Thailand (November 12-16, 2018).

REDACTED

Fellow
One Health Institute
School of Veterinary Medicine
University of California, Davis

PREDICT Semi-annual Consortium Meeting

Andaz Hotel

1450 First Street, Napa, CA

April 10-11, 2018

Agenda

Day 1 - April 10: Great Room 1

9:00 am	Welcome and plans for the next two days (Jonna)
9:15 am	One Health partnership & evaluation plans (Billy and Catherine)
10:00 am	Capacity team: needs assessment for final push (Woutrina) - Career dev and advancement # no P3?
10:45 am	Break
11:00 am	Lab implementation – update on viral findings to date, needs assessment for testing completion, timelines and sample export assessment; host DNA barcoding check in; government results reporting status (Tracey and Simon)
12:00 pm	Lunch
1:00 pm	Behavioral risk - timeline, targets, and "road maps; updates on BR analysis conducted to date with intervention examples from 6 countries " (Leilani)
1:45 pm	Surveillance update and targets for next 6 months (Chris, Megan + discussion all)
3:00 pm	Break
3:15 pm	Stakeholder engagement, education, and outreach - best practices and lessons learned for successful planning (David + discussion)
7:00 pm	**Team dinner at Celadon (500 Main Street)**

DRAFT

Day 2 - April 11: Sun Room

9:00 am	Overview and plans for the day
9:15 pm	Intervention planning workshop: overview of frameworks and approaches, analysis tools, and opportunities for collaboration (all technical teams)
11:00 am	Strategic plan towards interventions (Jonna)
11:15 am	M&A - additional timelines, targets, and products (Peter)
12:00 pm	Lunch
1:00 pm	Interface risk characterization using P1 data (Chris)
1:15 pm	Spillover viral risk ranking for the world (Zoe and Jonna)
1:30 pm	Deep Forest update (Carlos)
1:45 pm	Livestock 2050 update (Carlos)
2:00 pm	Break
2:15 pm	Ebola Host Project update (Brian)
2:45 pm	Serology discussion
3:15 pm	Telling the "PREDICT story" and final report planning (David et al...)
4:00 pm	Road map for project completion, bridging strategies for sustainability, and the future (Jonna et al)

DRAFT

From: Wang Linfa <linfa.wang@duke-nus.edu.sg>
To: Ab Osterhaus <a.osterhaus@onehealthplatform.com>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Rita Colwell <rcolwell@umiacs.umd.edu>, Larry Madoff <madoff@promedmail.org>, Martyn Jeggo [redacted], Dennis Carroll <dcarroll@usaid.gov>, Tom Monath <tmonath@linkp.com>, Marietjie Venter [redacted], MARK RWEYEMAMU <mark.rweyemamu@btinternet.com>, Amadou Sall <asall@pasteur.sn>, "Penina Munyua" <ikg2@cdc.gov>, Nick Juleff <Nick.Juleff@gatesfoundation.org>, Peter Charles Doherty [redacted], Peter Daszak <daszak@ecohealthalliance.org>, Jonathan Rushton [redacted] "rtheymann@chathamhouse.org" <rtheymann@chathamhouse.org>, John MacKenzie [redacted], Chris Vanlangendonck <c.vanlangendonck@onehealthplatform.com>
Subject: Re: One Health Platform Scientific Advisory Board meeting 21 June 2018 in Saskatoon: agenda
Sent: Fri, 25 May 2018 10:30:30 +0000

Thanks Ab, I will be there
Linfa

Sent from my iPhone

On 25 May 2018, at 6:24 PM, Ab Osterhaus <a.osterhaus@onehealthplatform.com> wrote:

Dear colleagues,

The 5th International One Health Congress is approaching fast, and as per the e-mail below, we'll seize the opportunity to assemble the Scientific Advisory Board of the One Health Platform on 21 June 2018, one day before the actual start of the congress. Since this is a formal One Health Platform gathering, I need to urge you to schedule your travel in such a way as to be able to attend the Board meeting. The One Health Platform was founded 3 years ago, so now is the time to evaluate what has been achieved and to plan ahead. Your comments and suggestions will be of utmost importance, so kindly confirm your presence if you have not done this already. The meeting's agenda is attached to this e-mail.

Looking forward to see you in Canada next month!

Regards,

Prof. Albert Osterhaus
Chair One Health Platform
Co-chair 5th International One Health Congress

Op 17 jan. 2018, om 14:02 heeft David De Pooter <d.depooter@onehealthplatform.com> het volgende geschreven:

Dear members of the Scientific Advisory Board of the One Health Platform,
The 5th International One Health Congress offers an excellent opportunity for the Scientific Advisory Board members to get together and evaluate the current and future plans of the One Health Platform Foundation. The next Scientific Advisory Board meeting will therefore be held in the run-up to the congress on Thursday 21 June 2018 (14:00 - 18:00h local time) and you are kindly invited to join the Board members at this occasion. To continue the discussions in an informal setting and get ready for the actual start of the congress, the One Health Platform Managment Board kindly also invites you for dinner at 19:00h that same day.

The One Health Platform covers all your costs for travel, accommodation and registration. Online congress registration, however, is absolutely necessary, so kindly finalize your free registration following the instructions sent to you on 13 December if you haven't done this already. Should you not be able to attend, please let me know too.

Ixtapa Travel, the congress travel agency, will contact you in the next few days to arrange your travel and accommodation. Kindly make sure you arrive in Saskatoon in time for the Scientific Advisory

Board meeting on the 21th when finalizing your travel schedule.

I'm also seizing this opportunity to provide a quick congress update:

- The preliminary congress programme is attached to this e-mail. You will see that we have reached an interesting balance of keynote lectures, satellite symposia and parallel sessions.
- Speakers for parallel sessions will be selected from submitted abstracts after the submission deadline of 15 February, while the separate Science Policy Interface programme is also open for presentation proposals by international institutions, government agencies, NGO's and other organisations who wish to share their scientific and/or policy knowledge. We hope to receive as many interesting abstracts and presentation proposals as possible, so kindly help us developing a top-quality programme by sharing the attached call for abstracts/call for presentation proposals with your colleagues and contacts.
- The last attachment is a general flyer that you may use to promote the congress.

Additional information is available on the congress website at www.onehealthcongress.com

Do not hesitate to contact me should you have any queries or concerns!

Best regards,

David De Paoli

REDACTED

ONE HEALTH PLATFORM NEW ADDRESS!
Overhaal 49
9290 Berlare, Belgium

<onbekend.jpg>
<IOHC18_programme.pdf>
<OHP_5OHC_callforabstracts.pdf>
<IOHC_SPI_callforpresentations.pdf>
<OneHealthPlatform_folder.pdf>

<OHP SAB meeting agenda.pdf>

Important: This email is confidential and may be privileged. If you are not the intended recipient, please delete it and notify us immediately; you should not copy or use it for any purpose, nor disclose its contents to any other person. Thank you.

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Evan Eskew <eskew@ecohealthalliance.org>
CC: Kevin Olival, PhD <olival@ecohealthalliance.org>;Peter Daszak <daszak@ecohealthalliance.org>;Stephanie Martinez <martinez@ecohealthalliance.org>;Christine Kreuder Johnson <ckjohnson@ucdavis.edu>;Diego Montecino <dmontecino@ucdavis.edu>;Nistara Randhawa <nnrandhawa@ucdavis.edu>
Sent: 6/4/2018 11:07:45 PM
Subject: Re: IMPACT Project 7 initiation

Thanks!
Jonna

On Fri, Jun 1, 2018 at 12:24 PM, Evan Eskew <eskew@ecohealthalliance.org> wrote:
Absolutely, this sounds like a great plan, especially as it prevents undue work by the field teams.

Just keep us apprised of what Diego, Nistara, and others at UC Davis are finding, and we'll do the same. Also, I've already shared this with Diego and Nistara, but in case it's useful to others, here's a publicly available climatic dataset that just came to my attention: http://www.climatologylab.org/terraclimate.html. This is monthly climatic data from 1958-2015 at a relatively fine spatial resolution (the grid squares are ~4 km on each side). Already useful for analyses of P1 data, and as they say they intend to update the data, this might also be used for some P2 stuff in the future.

All my best,
Evan

On Thu, May 31, 2018 at 4:57 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:
Hi Evan,
Thanks for the ping & the offer. We just discussed the project, as well as the rest of the potential intervention modeling projects, on the M&A call.

I think the best steps at this point focus around determining if we can say that we are seeing increased viral shedding at a specific time of the year or even predictable viral shedding in a certain season. If we can do that with the data we have, it is then worth identifying or investing in the identification of hunting seasonality and/or recommended intervention points (e.g. don't hunt at X time of the year or don't hunt when the bats have pups). If we don't see increased shedding or predictability of shedding, I'm not sure that having the hunting seasonality is of use, or at least it doesn't rise to a high enough priority to ask the teams to do extra work on the ground.

So I think the best steps we can take are to discuss what we've found on the deep dive for bat shedding in Tanzania, Rwanda & Uganda. Diego should be ready to have those discussions with us within the month around bat life history events. Also moving your analyses forward, along the lines we have discussed and addressing the comments you have received from Diego & Nistara, could be very helpful. Kevin explained the new rainfall gridded data, which is very exciting.

If the deep dive &/or global analyses show patterns that could be correlated with shedding, we would then ask the country coordinators (or a subset of them) to investigate and ask the questions around hunting seasonality on the ground. On the M&A call, we discussed that a bunch of the intervention modeling projects might have final data questions that could be addressed by country coordinator interviews or surveys that could be administered when those country coordinators go out to the sites to provide the data back to the communities (starting around October). Kevin & Peter seemed very supportive of this plan, as it gets us the info at a time point when we will have determined if it will be useful and doesn't disrupt the teams now with a bunch more work, while they are trying to finish their sampling.

Sound okay?

On Wed, May 16, 2018 at 7:44 AM, Evan Eskew <eskew@ecohealthalliance.org> wrote:
Hi Jonna,

Just reaching out here at the initiation of IMPACT project 7 ("Bat Hunting Seasonality") to begin the conversation between you (the project point person) and all the EHA collaborators. I can personally support the project in whatever way would be most useful. When we know exactly what data we want to look at, I could definitely assist with EIDITH data pulls, analyses, plotting, etc.

I can also coordinate over here with Stephanie since she's leading project 6 ("Hunter Behavioral Risk Hotspots") which might have some topic/country overlap with project 7.

Let me know how I can be of help!

Thanks,
Evan

460 West 34th Street – 17th Floor
New York, NY 10001

www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.

--
Evan Eskew, PhD
Research Scientist, Modeling and Analytics

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

1.646.868.4708 (direct)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.

From: Andrew Clements <aclements@usaid.gov>
Sent: Wed, 6 Jun 2018 05:19:54 -0400
Subject: Re: July brown bag seminars
To: Christine Kreuder Johnson <ckjohnson@ucdavis.edu>
Cc: Alisa Pereira <apereira@usaid.gov>, Cara Chrisman <cchrisman@usaid.gov>, Jonna Mazet REDACTED "predict@ucdavis.edu" <predict@ucdavis.edu>

Hi Chris,
Because of July 4 in the middle of the first week of next month, I recommend avoiding that week. The week of July 9-13 might be good to plan for. Dennis will probably be flying back to DC on the 11th so the 12th or 13th might be best. Fridays are often telework days, so maybe the 12th is the best for that week.

Cara: can you check to see if Richard is in town on the 12th? If not, is he available the following week?

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jun 6, 2018, at 3:05 AM, Christine Kreuder Johnson <ckjohnson@ucdavis.edu> wrote:

> Hi Alisa and Cara,
> Is it good timing for us to try to nail down a date for a brown bag presentation in July? I was hoping that I could do one in early July to highlight surveillance activities and what we've learned about high-risk interfaces.
> Let me know what dates work best for you all - right now my schedule is fairly open but I think it's about to get busy with meetings etc.
> Also, please let me know if there are any other activities I should try to attend, or if there's anything I can do to help the team at USAID with while there. I'm happy to pitch in on anything you think could benefit from the PREDICT implementation perspective and I can try to block off time accordingly (between July 1 - July 23).
> Thank you,
> Chris
>
> Christine Kreuder Johnson, VMD, PhD
> Professor of Epidemiology and Ecosystem Health
> Surveillance | Emerging Pandemic Threats PREDICT Project
> One Health Institute
> VM3B 1089 Veterinary Medicine Drive
> One Health Institute
> School of Veterinary Medicine
> University of California
> Davis, California 95616
> +1.530.752.1238
> Cell phone REDACTED

From: Andrew Clements <aclements@usaid.gov>
To: Jonna Mazet <jkmazet@ucdavis.edu>
Sent: 6/13/2018 12:14:59 PM
Subject: Re: Pandemics: spend on surveillance, not prediction

Thanks

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jun 13, 2018, at 1:20 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Absolutely on the latter, plus we have the Spillover paper, using P-1 viruses, as a risk ranking paradigm being submitted this year.

Looks like we're going ahead with the response, too, but they may not publish it. Either way, we'll put it on our website.

Have a good day,
J

On Wed, Jun 13, 2018 at 6:30 AM Andrew Clements <aclements@usaid.gov> wrote:
Letting it go is probably the better option.

However, what would you think of a publication after Oct 2019 that summarizes all of the Predict 1 and 2 work to show all those people who misunderstood the project what it was able to do?

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jun 12, 2018, at 10:06 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

There is a rebuttal already drafted (thanks Peter & Brooke), but we're debating whether or not it's better to let it drop vs rebut, potentially giving more fuel to the discussion that might otherwise burn out as a sour grape kind of commentary.
Thoughts?
J

On Tue, Jun 12, 2018 at 3:55 PM William B. Karesh <karesh@ecohealthalliance.org> wrote:
Mine was "for really smart people, they are terrible at math."

They compared 10-year budget for all countries with a 1-year budget of one country.

BK

William B. Karesh, D.V.M
Executive Vice President for Health and Policy

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

On Jun 12, 2018, at 3:24 PM, Andrew Clements <aclements@usaid.gov> wrote:

You've probably seen this.... Any desire for a rebuttal?

https://www.nature.com/articles/d41586-018-05373-w

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From: Andrew Clements <aclements@usaid.gov>
Sent: Thu, 5 Jul 2018 08:32:18 -0700
Subject: Fwd: Final version of USAID GHSA's Animal Health Book
To: Tracey Goldstein <tgoldstein@ucdavis.edu>, francisco@ecohealthalliance.org, Jonna Mazet <jkmazet@ucdavis.edu>, djwolking@ucdavis.edu
Cc: predictmgt@usaid.gov
Attachment
AnimalBook_2018JUL3_final.pdf

FYI

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

Begin forwarded message:

From: Dorothy Peprah <dpeprah@usaid.gov>
To: Tamar Bah <tbah@usaid.gov>, Monica Dea <mdea@usaid.gov>, "Dr. Charles W. Oliver Jr." <choliver@usaid.gov>
Cc: Kendra Chittenden <kchittenden@usaid.gov>, Anton Schneider <aschneider@usaid.gov>, Andrew Clements <aclements@usaid.gov>
Subject: Fwd: Final version of USAID GHSA's Animal Health Book

Hi All,
I am forwarding the final version of the "How to Live Safely with Animals..." book ahead of this afternoon's call. Please forward to anyone else who maybe joining.

Thanks,
Dorothy

---------- Forwarded message ----------
From: **Dorothy Peprah** <dpeprah@usaid.gov>
Date: Tue, Jul 3, 2018 at 5:35 PM
Subject: Final version of USAID GHSA's Animal Health Book
To: Mukch Fahrbulleh [REDACTED], Serge Agbo [REDACTED], "Bobo, Germain (TCE)" [REDACTED], "Tseggai, Tesfai (TCE)" [REDACTED], "Lavahun, MomohFonigay (FAOSL)" [REDACTED], Thomas AAPORE [REDACTED], Jeffrey GILBERT [REDACTED], "NJUGUNA, Charles Kuria" [REDACTED], Gama Roberts <groberts@usaid.gov>, "AMUZU, Claudette" [REDACTED], Wilson Gachari [REDACTED]
Cc: Anton Schneider <aschneider@usaid.gov>, James S Fofanah [REDACTED], Kendra Chittenden <kchittenden@usaid.gov>, Tina Dickenson <tina.dickenson@hu.edu>, James Bangura [REDACTED] Brian Bird <bbbird@ucdavis.edu>

Dear USAID GHSA Partners,
I would like to take this opportunity to share the long-awaited final version of the *"How to Live Safely With Animals for Healthier Communities"* book. This book has been developed over the past year beginning with PREDICT and then locally adapted by Breakthrough ACTION. Most of you have been part of the consultation process and provided feedback along the way.

The book is intended as a tool for those involved in health promotion/social mobilization to facilitate community level conversations about the relationship between animal health and human health.

Please take time to look through this book and consider how your program will use it (if I haven't discussed with you already). Please also consider printing to assist MoH and MAF improve disease surveillance efforts.

Breakthrough ACTION is developing a short training of trainers curriculum that can help those who would use it in community engagement.

In the meantime, do let me know of any questions in the meantime.

Dorothy

--

Dorothy Pepeah, Ph.D, MPH
Global Health Security Agenda Advisor
USAID Guinea & Sierra Leone
American Embassy | Freetown, Sierra Leone
REDACTED Email: dpepeah@usaid.gov

How to Live Safely with Animals for Healthier Communities

UCDUSR0003999

How to Use This Book

The purpose of this picture book is to help you talk with community members about how to work with and live safely with animals for healthier individuals, families, and communities.

Key messages on what to do, how to do it, and why we should do it are on the back of each picture.

To use this book, follow the steps below for each page in the book.

1. **SHOW** the picture to the people you are talking to.
2. **ASK** them what they see or understand by the picture.
3. **THANK** them for their ideas – there is no right or wrong answer!
4. **EXPLAIN** the key messages and information on the back of the picture.
5. **CHECK** if the information was understood.
6. **ANSWER** any questions.

UCDUSR0004000

Animal health is important for human health



UCDUSR0004001

Key Message: Animal health is important for human health.

WHY?

- Animals are a source of food, a source of income, and help our forests grow.
- Animals can get sick just like people can, and they can pass some of those sicknesses to people and other animals.

Key Message: It is important we are careful when working with and living near animals, because animals can pass some sicknesses to people even if they look healthy.

Key Message: Some of the sicknesses that animals can pass to people are Rabies, Ebola, Lassa Fever, Plague, Anthrax, and animal flu such as bird flu.

Key Message: Sickness can pass from animals to people when:

- An animal bites or scratches us
- We touch a sick animal or its wet, toilet, blood, or spit
- We touch, eat or drink something that has the animal's wet, toilet, blood, or spit on it.

UCDUSR0004002

How can we stay healthy when working with and living near animals?

UCDUSR0004003

Key Message: There are actions you can take to help keep yourself, your family, and your community healthier when you work with and live near animals. Five key actions to remember are:

1. Stay away from animals that look sick and animals that you find dead.
2. Report any dead animal or animal that looks sick to your community animal health worker or vet/livestock officer.
3. Cover your hands with plastic bags or plastic gloves if you must touch a dead animal or animal that looks sick, and always wash your hands with soap and water immediately after removing the plastic.
4. Always wash your hands with soap and clean water after touching any animal, even if it looks healthy.
5. Wash any animal bite or scratch immediately with soap and clean water for 15 minutes, and go to your nearest health facility or community health worker.

Today, we are going to talk more about each of these key actions to understand why they are important and how we should do them.

Even though this picture book shows mostly bats in the pictures, it is important to remember that what we talk about today is meant for all animals.

UCDUSR0004004

UCDUSR0004305

Key Message: Stay away from animals that look sick and animals that you find dead.

- Do not touch an animal that looks sick or animals that you find dead.
- Do not eat an animal that looks sick or that you find dead.

Key Message: Report any animal that looks sick or that you find dead to your community animal health worker or vet/livestock officer.

WHY?

- Sick animals and animals you find dead can pass their sickness to you if you touch or eat it.
- Reporting an animal that looks sick and that you find dead can help district health and animal health teams know about sicknesses before they become a problem for people.

UCDUSR0004006

UCDUSR0004007

Key Message: If you must touch an animal that looks sick or is dead, cover your hands and arms with clean plastic bags or plastic gloves to protect your skin.

Key Message: When removing the plastic bags or plastic gloves from your hands after handling an animal that looks sick or is dead, be careful you do not touch any wet, toilet, blood, or spit on the plastic, and immediately wash your hands and arms with soap and clean water.

Key Message: Burn or deeply bury the dead animal along with the plastic bags or plastic gloves you used to touch the animal far from where water is collected and where household activities take place, and immediately wash your hands and arms with soap and clean water.

WHY?

- Sickness can pass from animals to people when we touch the animal, its wet, toilet, blood, spit, or anything from the animal that touched the plastic bags or plastic gloves.

UCDUSR0004309

Key Message: Always wash your hands immediately with soap and clean water after touching any animal—even if the animal is alive and looks healthy.

WHY?

- We cannot always see the signs of sickness.
- Washing hands well with soap and clean water after touching an animal can help stop sicknesses passing from animals to people.

UCDUSR0004010

UCDUSR0004011

Key Message: Do not eat fruit or food that has been bitten by an animal.

- Do not cut off the part that was bitten. Do not eat any part of the bitten fruit or food.
- Do not give the bitten fruit or food to an animal to eat.

Key Message: Always wash all fruits and vegetables before eating or cooking.

WHY?

- Sickness can pass from animals to people when we touch, eat or drink something that has an animal's wet, toilet, blood, or spit on it.
- We cannot always see the signs of sickness.



UCDUSR0004013

Key Message: Always cover food and water and their containers to make sure animal wet or toilet, flies, and dirt cannot enter.

Key Message: Make sure to keep your cooking area and all food, cups, spoons, trays, and all cooking items clean and away from animals and animal wet and toilet.

WHY?

- Animal wet or toilet, flies, and dirt that enter our food, water, or containers of the food we eat or water that we drink can make us sick.

- Keeping our food covered and our homes clean helps to stop rats and other animals from visiting us, and from eating and drinking our food and water.

UCDUSR00004015

Key Message: Animals that come into your home leave their wet and toilet in your home. This can pass sickness from animals to people.

Key Message: Sweep the house every day that animals have been inside, and make sure to regularly wash the floor, mats, and walls; the clothes and blankets; and all of the food and water covers and containers to remove any animal wet and toilet.

Key Message: When sweeping your home after animals have been in the house, always make sure to:

- Wet the floor with water before sweeping to stop dust from flying into the air
- Use clean plastic bags to cover your hands
- Tie or use a damp cloth to cover your face
- Use glasses to protect your eyes.

Key Message: Keep animals like chickens, goats, sheep, and pigs outside of the house.

WHY?

Sickness can pass from animals to people when:

- We touch, eat or drink something that has the animal's wet, toilet, blood, or spit on it.

UCDUSR0004017

Key Message: (1) Wash an animal bite or scratch immediately with soap and clean water for 15 minutes.

Why?

- Washing a bite or scratch well with soap and clean water can help stop sickness passing from animals to people.

Key Message: (2) After washing a bite or scratch very well, go to your nearest health facility or community health worker.

Why?

- Reporting an animal bite or scratch can help the district health and animal health teams know about animal sicknesses to help keep our communities healthier.

Key Message: (3) If a person gets sick or dies after contact with a sick or a dead animal, report the person to your nearest health facility or community health worker and call 117.

Why?

- Reporting any sickness or death after contact with an animal can help to identify the cause of the sickness or death and save lives of others in Sierra Leone.

UCDUSR0004018

Our house pledges to take action to live with animals safely. What action will you take?

UCDUSR0004019

This material was developed by Global Health Security Agenda partners, especially PREDICT-2 and Breakthrough ACTION, in collaboration with the Government of Sierra Leone's Ministry of Health and Sanitation and Ministry of Agriculture and Forestry, and made possible by the generous support of the American people through the United States Agency for International Development (USAID).

USAID
FROM THE AMERICAN PEOPLE

MINISTRY OF AGRICULTURE AND FORESTRY
THE REPUBLIC OF SIERRA LEONE

MINISTRY OF HEALTH AND SANITATION
THE REPUBLIC OF SIERRA LEONE

UCDUSR0004020

From: "Tran, Thu Anh" <TTran@nas.edu>
To: "FUKUDA, Keiji" [redacted], 'Dennis Carroll' <dcarroll@usaid.gov>, 'Peter Daszak' <daszak@ecohealthalliance.org>, "Erbelding, Emily (NIH/NIAID) [E]" <emily.erbelding@nih.gov>, "Jernigan, Daniel B. (CDC/OID/NCIRD)" <dbj0@cdc.gov>, "Kent.Kester@sanofi.com" <Kent.Kester@sanofi.com>, "Jay Siegel" [redacted] "Grosser, Karen [JRDUS]" <KGrosser@its.jnj.com>, "Hermsen, Elizabeth D" <elizabeth.hermsen@merck.com>, "RASANATHAN, Kumanan" <rasanathank@who.int>, 'Suerie Moon' <suerie.moon@graduateinstitute.ch>, "peter.sands@theglobalfund.org" <peter.sands@theglobalfund.org>, "Jonna Mazet" <jkmazet@ucdavis.edu>, "david@4sd.info" <david@4sd.info>, "Joanna Ong" [redacted], 'Cassandra Louis Duthil' <clouisduthil@usaid.gov>, 'Alison Andre' <andre@ecohealthalliance.org>, "Jordan, Franshay (CDC/OID/NCIRD) (CTR)" <fvk1@cdc.gov>, "Vivian.Louchie@sanofi.com" <Vivian.Louchie@sanofi.com>, 'Jacqui Moseley' [redacted], "Stefani.Janvier@TheGlobalFund.org" <Stefani.Janvier@TheGlobalFund.org>, 'Brooke Genovese' <bgenovese@ucdavis.edu>, 'Simon Ruf' <simon@4sd.info>, "Shah, Cecilia" <cshah@nas.edu>, "Ogawa, V. Ayano" <VOgawa@nas.edu>
Subject: FMT Readiness 2030 Call #2
Sent: Tue, 10 Jul 2018 13:52:37 +0000

Dear Planning Committee Members,

To join our second planning call on **Tuesday, August 21, 7:00 – 8:30 PM [ET]**, please use the dial-in information below:

Toll Free Number: REDACTED
International Number: REDACTED

Participant Passcode: REDACTED

Best,
Anh

From: Andrew Clements <aclements@usaid.gov>
Sent: Tue, 31 Jul 2018 13:10:17 -0400
Subject: Re: Re-Allocating GHSA Country Levels
To: Jonna Mazet <jkmazet@ucdavis.edu>
Cc: Elizabeth Leasure <ealeasure@ucdavis.edu>, Amalhin Shek <ashek@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, David John Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>, Hannah R Chale <hrchale@ucdavis.edu>, Alisa Pereira <apereira@usaid.gov>

Thanks, Jonna. I appreciate the additional input.
Our strongest argument for getting the additional 3M is:

1) if all of the countries have 17 months of pipeline or less (which means they are on track to spend all funds by 9/30/18).

AND

2) the 3 EHP countries currently have 12 months of pipeline or less (so that adding the 3M won't cause any of them to exceed 17 months of pipeline)

I believe #2 is no problem, but Ethiopia and Uganda both have pipelines of 20 or more months which looks like they will not be able to spend down completely. (If this is incorrect, please let us know.). I'm not sure we can avoid "moving" funds from these countries to others while still trying to make an argument for the new 3M.

To me, the least disruptive fix (in terms of number of countries with budget/agreements to be adjusted) is to move 500,000 from Ethiopia and 1,500,000 from Uganda (which would effectively reduce both of their pipelines to 15 months) and combine it with the new 3,000,000 for distribution to the 3 EHP countries as follows: country totals for Guinea and Liberia each increase by 1,500,000 and Sierra Leone increases by 2,000,000.

Overall, all countries would now have pipelines less than 17 months (less than 11 months for the 3 EHP countries) and budgets/agreements would only have to be adjusted for 5 countries. I would be happy to grant an extension for submitting work plans for those 5 countries.

Let me know how this sounds.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jul 31, 2018, at 9:28 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Hi Andrew,
> You can, of course, do that, but it will potentially rock our whole workplanning effort and schedule, since we have been aligning country workplans with these levels, as instructed when we started the workplanning process. Additionally, we were given explicit instructions that those country caps are no longer in play, except for the Ghana & DRC combined maximum.
> If you think it best for you to try the exercise and see what we can do with your projections, fine, but I don't want to go back to the drawing board on the workplans and with Missions unless absolutely necessary. The numbers we provided to you represent bare bones budgets for actual plans in all of the other Ebola-funded countries.
> As discussed previously, if those funds, that allow us to achieve our intended scope, are not forthcoming, we

will need time to do layoffs according to specific country rules, etc. And as you promised, we will expect that USAID will assume the responsibility of informing the Missions and partners that we will end early and will take responsibility and deal with the fall-out.
From my perspective, the EHP countries and that part of the project were the ones that were told that P-2 may not be able to continue, because the yet-to-be received funds were targeted for them. In addition, despite funding level ambiguity, we have been trying to accommodate shifting goals for these three countries as USAID plans change and in response to GHSA targets. Therefore, while devastating for progress there, the three most Ebola affected countries are the ones that should either be funded or not this year in my opinion, which is informed by our instructions and planning and incremental funding distribution for EHP.
Appreciate your allowing me to provide my input to inform your discussion.
We, of course, defer to your collective wisdom on the way forward,
Jonna

On Mon, Jul 30, 2018 at 2:00 PM, Andrew Clements <aclements@usaid.gov> wrote:

Hi Liz,
We were discussing this among the management team and thought it would be confusing to the GHSA team to include the additional 3M.

So I propose that Alisa, Amalhin, and I sit down tomorrow and come up with some suggested country totals by shifting from countries that have expended a lower percentage of their funds to those that have expended a higher percentage. We'll share that with you to either get your blessing or for you to tweak if there are reasons our suggestions are not good. To minimize confusion, we're going to use the format that the GHSA team uses to track funding by country so that it's in their "language".

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jul 24, 2018, at 12:16 PM, Elizabeth Leasure <caleasure@ucdavis.edu> wrote:

Hi Amalhin and Andrew. After reviewing Y5 budgets received from partners and evaluating funding needs for each Ebola-funded country through the end of the project in 2019, we propose increasing the combined cap for the EHP countries by $4.149M to $19.149M (inclusive of the last $3M obligation that is currently pending) and increasing the combined cap for the Phase II countries by $335K to $9.335M. As a result of these increases, the combined cap for the non-EHP, Phase I Ebola-funded countries would decrease by $4.484M to $27.816M. Since we have been advised that only the combined caps for the EHP and Phase II countries are still in effect, we have not broken the requested changes down by country in an effort to avoid possible confusion and the erroneous application of these caps in the future.

A quick comparison of the revised EHP cap and the updated LOP expenditure figures for the EHP countries through June 2018 (comprehensive updated LOP expenditure by country report is forthcoming) shows that we have spent approximately 70% of the proposed revised EHP combined cap (inclusive of the last $3M obligation as noted above), which is in line with guidance received on our last SMT call. With regard to the small requested increase to the combined Phase II country cap, please note that the cap must be increased by the requested amount in order to continue activities through Y5

and wrap up the project by September 2019. Without the requested increase, activities in both countries would cease at the end of Y4.

Thank you for your consideration, and please let me know if you have any questions.

Thank you!

Liz

Elizabeth Leasure

Financial Operations Manager

One Health Institute

REDACTED (cell)

530-754-9034 (office)

Skype: eeleasure

From: Amalhin Shek <ashek@usaid.gov>
Sent: Thursday, June 21, 2018 11:12 AM
To: PREDICTMGT <predictmgt@usaid.gov>; Jonna Mazet <jkmazet@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Andrew <aclements@usaid.gov>; David John Wolking <djwolking@ucdavis.edu>; Cara Chrisman <cchrisman@usaid.gov>
Subject: Re-Allocating GHSA Country Levels

Hi team,

Per our last MT call, please see attached the tracker currently in use to document country level GHSA expenditures against obligation and planning levels. I have modified it to include a column for a new re-distribution of country levels, which should be updated based on planned implementation.

The GHSA team would like to receive the new distribution of budgets prior to receiving the June 30 expenditure report, as this will prevent any concerns with those countries above 90% expended (column H).

As a heads up, I will be out of the country Starting next Monday through July 13, but Andrew, Alisa, or Cara will be able to answer or relay any questions related to country levels. Please let us know if you have any questions as you prepare this for submission before the as of June 30 LOP report!

Thanks in advance,

Amalkin Shah | **Budget & Communications Analyst**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
Phone: 571-551-7102(o) REDACTED (c) | CP3 8092
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

USAID **Contractor**
GMU-III - Social Solutions International, Inc.

From: David J Wolking <djwolking@ucdavis.edu>
Sent: Thu, 2 Aug 2018 10:17:46 -0700
Subject: Re: Re-Allocating GHSA Country Levels
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
Cc: "Clements, Andrew (GH/HIDN)" <aclements@usaid.gov>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, Amalhin Shek <ashek@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Wolking David <djwolking@ucdavis.edu>, "Cara J. Chrisman" <cchrisman@usaid.gov>, Hannah R Chale <hrchale@ucdavis.edu>, Alisa Pereira Emerging Threats Division <apereira@usaid.gov>

Hi there,
Below is a Zoom link for our call at 11AM Pacific/2PM Eastern.

Talk soon,

David

Topic: P2 Call
Time: Aug 2, 2018 11:00 AM Pacific Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android: https://onehealth.zoom REDACTED

Or iPhone one-tap :
US: +16699006833,_ REDACTED or +16468769923 REDACTED
Or Telephone:
Dial(for higher quality, dial a number based on your current location):
US: +1 669 900 6833 or +1 646 876 9923
Meeting ID: REDACTED
International numbers available: https://zoom.us/u/b9xkzmiqJ

On Thu, Aug 2, 2018 at 8:47 AM Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Andrew. I'm certainly available for a call, but I'll need to check in with Jonna and David about their availability and get back to you.

Thanks,
Liz

Elizabeth Leasure
Financial Operations Manager
One Health Institute
University of California, Davis
Cell: REDACTED

From: Andrew Clements <aclements@usaid.gov>
Sent: Thursday, August 2, 2018 8:40 AM
To: Elizabeth Leasure
Cc: Jonna Mazet; Amalhin Shek; predict@ucdavis.edu; PREDICTMGT; David John Wolking; Cara Chrisman; Hannah R Chale; Alisa Pereira
Subject: Re: Re-Allocating GHSA Country Levels

Hi Liz
Can we walk through this later today (before 4:00 EDT) to make sure we are all on the same page?

Thanks

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Aug 1, 2018, at 4:55 PM, Elizabeth Leasure <calcasure@ucdavis.edu> wrote:

Hi Andrew. I spoke with Jonna, and we are supportive of the arguments you presented for the obligation of the last $3M. With our proposed reallocations, all Ebola-funded countries are on track to spend out by Sept 2019, and no single country has a pipeline that exceeds the number of months remaining in the PREDICT-2 performance period. These changes were determined through an extensive and carefully thought out exercise using actual and projected Y4 costs and requested Y5 budgets, and substantial amounts of funds were moved from several non-EHP countries, including Cameroon, Ethiopia, Tanzania, and Uganda. As it is, we have had to go back to partners and ask them to cut their budgets for Y5 in order to stay within the $56.3M overall cap on Ebola funds.

As of the LOP expenditure report through June 2018, we have already spent the full $12M obligated for EHP to date, as well as approximately half of the last $3M that is pending obligation. Furthermore, our projections indicate that the full $15M for EHP (which includes funds obligated to date plus the pending $3M) will be spent out by the end of September 2018.

To clarify, are you are proposing to move $2M from non-EHP to EHP countries instead of the $4.149M we proposed as an interim measure while you work on the obligation of the last $3M or in place of our requested reallocations? Given that the EHP cap is a minimum spending cap, I don't see any major issues with your proposal as long as this course of action won't result in new country-specific caps, meaning we will have some flexibility with regard to shifts among the Ebola-funded countries as previously specified.

As always, thank you for your continued support and efforts to get the funding we need to complete the project. If there is anything I can do or further information I can provide to assist with this, please let me know.

Thanks,

Liz

From: Andrew Clements <aclements@usaid.gov>
Sent: Tuesday, July 31, 2018 10:10:17 AM
To: Jonna Mazet
Cc: Elizabeth Leasure; Amalhin Shek; predict@ucdavis.edu; PREDICTMGT; David John Wolking; Cara Chrisman; Hannah R Chale; Alisa Pereira
Subject: Re: Re-Allocating GHSA Country Levels

Thanks, Jonna. I appreciate the additional input.

Our strongest argument for getting the additional 3M is:

1) if all of the countries have 17 months of pipeline or less (which means they are on track to spend all funds by 9/30/18).

AND

2) the 3 EHP countries currently have 12 months of pipeline or less (so that adding the 3M won't cause any of them to exceed 17 months of pipeline).

I believe #2 is no problem, but Ethiopia and Uganda both have pipelines of 20 or more months which looks like they will not be able to spend down completely. (If this is incorrect, please let us know.). I'm not sure we can avoid "moving" funds from these countries to others while still trying to make an argument for the new 3M.

To me, the least disruptive fix (in terms of number of countries with budget/agreements to be adjusted) is to move 500,000 from Ethiopia and 1,500,000 from Uganda (which would effectively reduce both of their pipelines to 15 months) and combine it with the new 3,000,000 for distribution to the 3 EHP countries as follows: country totals for Guinea and Liberia each increase by 1,500,000 and Sierra Leone increases by 2,000,000.

Overall, all countries would now have pipelines less than 17 months (less than 11 months for the 3 EHP countries) and budgets/agreements would only have to be adjusted for 5 countries. I would be happy to grant an extension for submitting work plans for those 5 countries.

Let me know how this sounds.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jul 31, 2018, at 9:28 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Hi Andrew,
> You can, of course, do that, but it will potentially rock our whole workplanning effort and schedule, since we have been aligning country workplans with these levels, as instructed when we started the workplanning process. Additionally, we were given explicit instructions that those country caps are no longer in play, except for the Ghana & DRC combined maximum.
> If you think it best for you to try the exercise and see what we can do with your projections, fine, but I don't want to go back to the drawing board on the workplans and with Missions unless absolutely necessary. The numbers we provided to you represent bare bones budgets for actual plans in all of the other Ebola-funded countries.
> As discussed previously, if those funds, that allow us to achieve our intended scope, are not forthcoming, we will need time to do layoffs according to specific country rules, etc. And as you promised, we will expect that USAID will assume the responsibility of informing the Missions and partners that we will end early and will take responsibility and deal with the fall-out.
> From my perspective, the EHP countries and that part of the project were the ones that were told that P-2 may not be able to continue, because the yet-to-be received funds were targeted for them. In addition, despite funding level ambiguity, we have been trying to accommodate shifting goals for these three countries as USAID plans change and in response to GHSA targets.

Therefore, while devastating for progress there, the three most Ebola affected countries are the ones that should either be funded or not this year in my opinion, which is informed by our instructions and planning and incremental funding distribution for EHP.
Appreciate your allowing me to provide my input to inform your discussion.
We, of course, defer to your collective wisdom on the way forward,
Jonna

On Mon, Jul 30, 2018 at 2:00 PM, Andrew Clements <aclements@usaid.gov> wrote:

Hi Liz,
We were discussing this among the management team and thought it would be confusing to the GHSA team to include the additional 3M.

So I propose that Alisa, Amalhin, and I sit down tomorrow and come up with some suggested country totals by shifting from countries that have expended a lower percentage of their funds to those that have expended a higher percentage. We'll share that with you to either get your blessing or for you to tweak if there are reasons our suggestions are not good. To minimize confusion, we're going to use the format that the GHSA team uses to track funding by country so that it's in their "language".

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jul 24, 2018, at 12:16 PM, Elizabeth Leasure <caleasure@ucdavis.edu> wrote:

Hi Amalhin and Andrew. After reviewing Y5 budgets received from partners and evaluating funding needs for each Ebola-funded country through the end of the project in 2019, we propose increasing the combined cap for the EHP countries by $4.149M to $19.149M (inclusive of the last $3M obligation that is currently pending) and increasing the combined cap for the Phase II countries by $335K to $9.335M. As a result of these increases, the combined cap for the non-EHP, Phase I Ebola-funded countries would decrease by $4.484M to $27.816M. Since we have been advised that only the combined caps for the EHP and Phase II countries are still in effect, we have not broken the requested changes down by country in an effort to avoid possible confusion and the erroneous application of these caps in the future.

A quick comparison of the revised EHP cap and the updated LOP expenditure figures for the EHP countries through June 2018 (comprehensive updated LOP expenditure by country report is forthcoming) shows that we have spent approximately 70% of the proposed revised EHP combined cap (inclusive of the last $3M obligation as noted above), which is in line with guidance received on our last SMT call. With regard to the small requested increase to the combined Phase II country cap, please note that the cap must be increased by the requested amount in order to continue activities through Y5 and wrap up the project by September 2019. Without the requested increase, activities in both countries would cease at the end of Y4.

Thank you for your consideration, and please let me know if you have any questions.

Thank you!

Liz

Elizabeth Leasure

Financial Operations Manager

One Health Institute

[redacted] *(cell)*

530-754-9034 (office)

Skype: [redacted]

From: Amalhin Shek <ashek@usaid.gov>
Sent: Thursday, June 21, 2018 11:12 AM
To: PREDICTMGT <predictmgt@usaid.gov>; Jonna Mazet <jkmazet@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Andrew <aclements@usaid.gov>; David John Wolking <djwolking@ucdavis.edu>; Cara Chrisman <cchrisman@usaid.gov>
Subject: Re-Allocating GHSA Country Levels

Hi team,

Per our last MT call, please see attached the tracker currently in use to document country level GHSA expenditures against obligation and planning levels. I have modified it to include a column for a new re-distribution of country levels, which should be updated based on planned implementation.

The GHSA team would like to receive the new distribution of budgets prior to receiving the June 30 expenditure report, as this will prevent any concerns with those countries above 90% expended (column H).

As a heads up, I will be out of the country Starting next Monday through July 13, but Andrew, Alisa, or Cara will be able to answer or relay any questions related to country levels. Please let us know if you have any questions as you prepare this for submission before the as of June 30 LOP report!

Thanks in advance,

Amalhin Shah | **Budget & Communications Analyst**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
Phone: 571-551-7102(o) REDACTED (c) | CP3 8092
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

USAID **Contractor**
GHSI-III - Social Solutions International, Inc.

From: Leilani Francisco <francisco@ecohealthalliance.org>
Sent: Thu, 3 Jan 2019 18:17:43 -0500
Subject: RE: sincere thanks
To: Jonna Mazet <jkmazet@ucdavis.edu>
Cc: Peter Daszak <daszak@ecohealthalliance.org>, Aleksei Chmura <chmura@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, "William B. Karesh" <karesh@ecohealthalliance.org>

Thanks so much Jonna, this means a lot to me.
I look forward to crossing paths again in the near future!
Very best,
Leilani

From: Jonna Mazet <jkmazet@ucdavis.edu>
Sent: Thursday, January 3, 2019 2:04 PM
To: Leilani Francisco <francisco@ecohealthalliance.org>
Cc: Peter Daszak <daszak@ecohealthalliance.org>; Aleksei Chmura <chmura@ecohealthalliance.org>; Evelyn Luciano <luciano@ecohealthalliance.org>; William B. Karesh <karesh@ecohealthalliance.org>
Subject: Re: sincere thanks

Dear Leilani,
Congratulations! While we are sorry to lose you, I definitely understand and support the need to grow and contribute meaningfully in your career. It sounds like a wonderful opportunity. I hope to see and work with you in the future.
Sincere kudos and thanks.
Good luck and have a wonderful 2019,
Jonna

On Thu, Jan 3, 2019 at 10:00 AM Leilani Francisco <francisco@ecohealthalliance.org> wrote:
Dear Jonna,
Hope you had a wonderful winter break.
As you and Peter have now discussed, I was offered an opportunity to be a REDACTED REDACTED and had to make the tough decision to move on from EcoHealth Alliance.

My last day is January 11, 2019 and I'm happy to do everything I can to help support the transition. If you have any questions for me, please don't hesitate to get in touch.
It has been a great pleasure working under your leadership. Thank you for all that you've taught me and all that you do to make the world a better place to live in.
Sincerely,
Leilani
--

Leilani Francisco, PhD, MA, PMP
Senior Scientist | PREDICT-2 Senior Behavioral Risk Surveillance Coordinator

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4491 (direct)
REDACTED (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org
EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.

From: David J Wolking <djwolking@ucdavis.edu>
To: David McIver <dmciver@metabiota.com>
CC: David J Wolking <djwolking@ucdavis.edu>;Karen Saylors <ksaylors@metabiota.com>;predict@ucdavis.edu <predict@ucdavis.edu>
Sent: 1/7/2019 6:06:40 PM
Subject: [predict] Re: URGENT: P2 Qualitative IRB Renewal (due January 4th COB)

Excellent thanks!

On Mon, Jan 7, 2019 at 11:05 AM David McIver <dmciver@metabiota.com> wrote:
Hey David,

Sorry for the deluge of extra information, I guess I got a bit carried away haha!

You are correct, the single person from DRC who revoked consent was not interviewed as part of our normal hospital work. None of the individuals enrolled as syndromic surveillance patients were also enrolled as ethnographic interviews.

Hope this helps - thanks!
Dave

On Jan 7, 2019, at 11:01 AM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hey David,

This renewal is for the UCD IRB that covers just the ethnographic interview and focus groups portions of our work, not our human questionnaire and sampling protocol. I realize this is murky in DRC and Cameroon where you have a "merged" protocol but for our UCD IRB purposes, this renewal is only tracking individuals consented for EIs or FGDs using the non-written consent (e.g., our verbal) procedure consistent with that protocol.

With this perspective, I'm thinking the patient from DR Congo is not applicable unless the team also consented her for ethnographic interviews in the hospital. If you can confirm that point, and whether any of the other patients listed below (the #1 counts) were also enrolled in the qualitative portion of the study at clinics or hospitals that would be amazing. I'm assuming no, but need to confirm for diligence.

Thanks!

David

On Mon, Jan 7, 2019 at 10:38 AM David McIver <dmciver@metabiota.com> wrote:
Hi David - Happy New Year my friend!

I can give you an update on this for all three of our countries.

DRC:

1. Any unanticipated problems? If yes, explain.
    1. No
2. Any withdrawn consents? List #s and why.
    1. One withdrawn consent from our Ebola followup study recently in Mbandaka. The woman

originally consented to having samples taken and short questionnaire conducted. After samples were taken and questionnaire was conducted, the women revoked her consent. All associated materials were destroyed.

3. Any problems requiring prompt reporting that have not been shared?
    1. No
4. Any written reports from study monitors (e.g., local IRBs)? If so, please summarize findings and provide the report (if available).
    1. No
5. Briefly summarize research activity since the last review (January 2018). 1-3 sentences per country is sufficient.
    1. From January 1 2018 - December 31 2018, 161 humans were enrolled from hospitals (all in EIDITH) and 19 humans enrolled from Mbandaka followup ebola study (Mbandaka humans not in EIDITH)
    2. From January 1 2018 - December 31 2018, the team conducted 2 focus groups (19 individuals) and 19 ethnographic interviews from Mbandaka

Cameroon:

1. Any unanticipated problems? If yes, explain.
    1. No
2. Any withdrawn consents? List #s and why.
    1. No
3. Any problems requiring prompt reporting that have not been shared?
    1. No
4. Any written reports from study monitors (e.g., local IRBs)? If so, please summarize findings and provide the report (if available).
    1. No
5. Briefly summarize research activity since the last review (January 2018). 1-3 sentences per country is sufficient.
    1. From January 1 2018 - December 31 2018, 496 humans enrolled from hospitals (all in EIDITH)
    2. From January 1 2018 - December 31 2018, the team conducted 26 ethnographic interviews and 4 focus groups (37 individuals)

Laos:

1. Any unanticipated problems? If yes, explain.
    1. No
2. Any withdrawn consents? List #s and why.
    1. No
3. Any problems requiring prompt reporting that have not been shared?
    1. No
4. Any written reports from study monitors (e.g., local IRBs)? If so, please summarize findings and provide the report (if available).
    1. No
5. Briefly summarize research activity since the last review (January 2018). 1-3 sentences per country is sufficient.
    1. From January 1 2018 - December 31 2018, 200 humans were enrolled from hospitals (all in EIDITH)

I think this should be it. Let me know if there is any more info you need or any clarifications required.

Cheers,
Dave

On Jan 2, 2019, at 10:22 AM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hi global leads,

Our annual renewal for the UC Davis portion of the qualitative research IRB (ethnographic interviews and focus groups) is due to the UCD IRB on January 8th. This is a pretty easy lift, but I do need to confirm a few details along with a very brief summary of research activity over the past year (1-3 sentences max) and reports of any adverse events or new information from the locally-based sites. I plan to pull numbers from the EIDITH app so please let me know if there are any inaccuracies with that data and why.

A list of questions (the "Big 5") requiring response for your countries is below, I'd appreciate if you can get these to me by Friday COB (January 4th) and my apologies for the late notice, this one crept up on us after the holidays.

Happy New Year!

David

Countries reporting: Bangladesh, Cameroon, China, CIV, DR Congo, Indonesia, Lao PDR, Nepal, RoC, Tanzania, Uganda, Viet Nam (Leilani & Stephanie - please make sure I didn't miss any!).

The Big 5:

1. Any unanticipated problems? If yes, explain.
2. Any withdrawn consents? List #s and why.
3. Any problems requiring prompt reporting that have not been shared?
4. Any written reports from study monitors (e.g., local IRBs)? If so, please summarize findings and provide the report (if available).
5. Briefly summarize research activity since the last review (January 2018). 1-3 sentences per country is sufficient.

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Peter Daszak <daszak@ecohealthalliance.org>
CC: David J Wolking <djwolking@ucdavis.edu>;predict@ucdavis.edu <predict@ucdavis.edu>;Jon Epstein <epstein@ecohealthalliance.org>;Anthony Ramos <ramos@ecohealthalliance.org>;Tracey Goldstein <tgoldstein@ucdavis.edu>;Brian Bird <bhbird@ucdavis.edu>;sja2127@cumc.columbia.edu <sja2127@cumc.columbia.edu>
Sent: 1/22/2019 8:32:25 PM
Subject: Re: Liberia - Release of news this week

Thanks -- I'll let you know if USAID has any concerns.
J

On Tue, Jan 22, 2019 at 11:52 AM Peter Daszak <daszak@ecohealthalliance.org> wrote:

Here's the final version of our press release. Let us know if there are any typos or errors – we have plenty of time – the story will be released Thursday, unless there are any hiccups..

I think Simon's working on his now with his Press people.

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

Tel. +1 212-380-4474

Website: www.ecohealthalliance.org

Twitter: @PeterDaszak

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From: Jonna Mazet [mailto:jkmazet@ucdavis.edu]
Sent: Tuesday, January 22, 2019 2:17 PM
To: Peter Daszak
Cc: David J Wolking; predict@ucdavis.edu; Jon Epstein; Anthony Ramos; Tracey Goldstein; Brian Bird; sja2127@cumc.columbia.edu
Subject: Re: Liberia - Release of news this week

Thanks -- some technical problems with the EHA press release that need to be corrected immediately. Please review for technical accuracy overall, as I was going very quickly. USAID has been harassing me for this release since yesterday (earlier, really), so please turn around immediately.

In the MoH release, please ask if they wouldn't mind changing "with funding from" to "in partnership with" in the third paragraph about USAID. My reason is given in the comments on the EHA release. For accuracy in that same paragraph, next sentence, please add "in Liberia" after "the PREDICT project led" and before "by EHA".

Time is of the essence, as USAID is working with a skeleton crew and needs to run these up the chain -- CII's release to me now,too, please,

Jonna

On Tue, Jan 22, 2019 at 10:03 AM Peter Daszak <daszak@ecohealthalliance.org> wrote:

Hi Jonna,

As you know, we heard yesterday from Liberia that they'll be releasing the news about the Ebola finding in a bat on Thursday this week. Jon's arriving in Liberia around now and sent us the final version of the Govt of Liberia's press release (attached) while he was in a stopover.

I've also attached the final version of our own press release. We're working with Simon and his press people at Columbia to cross-link our releases. They're currently finalizing theirs and will send us a copy when it's finished.

Let me know if there's anything you need us to do here at our end, other than keeping our fingers crossed that this goes smoothly – so far, so good!

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

Tel. +1 212-380-4474

Website: www.ecohealthalliance.org

Twitter: @PeterDaszak

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

Sent: Tue, 12 Feb 2019 19:48:32 -0800
Subject: Re: One Health Workforce-Next Gen calls
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Elizabeth Leasure <ealeasure@ucdavis.edu>, Woutrina A Smith <wasmith@ucdavis.edu>
Cc: Matthew Blake <mblake@ucdavis.edu>, Hannah R Chale <hrchale@ucdavis.edu>

Thanks for that guidance, Liz!
Hmm... to make the timing work as described, all partners will have to know their roles and target budgets by Friday. Unless that was already decided, I don't see how that will work with Wout on the road. I'm certainly not prepared to lead that discussion tomorrow on a large group call, especially if Wout's connectivity is poor.
Seems to me that there may need to be some shrinkage in the Feb 15-March 1 window, as well as in the March 4-12 window. The budgets and scopes are certainly the most touchy communication/negotiating pieces. Perhaps share templates as exemplars, but that will initiate the fray, I'm afraid, unless there has been a philosophical agreement on the division of labor and funds.
Just my thoughts,
J

On Tue, Feb 12, 2019 at 5:22 PM Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Wout. Your proposal prep timeline looks good to me. If we can have all subs submit a first draft of their SOWs/Budgets/Cost Narratives by COB March 1st (Friday), that would give Hannah and I sufficient time to work with partners to finalize their documents so they can submit to their SPO offices. Brian's CEPI and CKJ's NIH proposals should be basically done at that point, so the timing is pretty good to dig into OHW. A detailed list of proposed deadlines (for the cost application and SPO review) is below. Any thoughts or suggested changes?

February 15th COB: Instructions, templates, and forms to partners (Liz will draft and send)

March 1st COB: Draft of subrecipent SOW/Budget/Justification submitted to UCD for review

March 4th-12th: Liz/Hannah review subrecipient submissions & work with partners to finalize required documents

March 12th COB: All subrecipient SOWs/Budgets/Justifications must be ready for subs to submit to their SPO for review/approval

March 20th: All fully-approved subrecipient packages must be received at UCD

March 21st-29th: Liz/Hannah/Matt finalize cost application

March 29th COB: Submit full proposal (with working/draft version of technical proposal, if necessary) to SPO for review/approval

April 1st-8th: SPO conducts their review/approves

April 8th (or sooner): SPO (or Liz) submits to USAID by 10 am PT/1 pm ET

Elizabeth Leasure

Financial Operations Manager

One Health Institute

REDACTED *(cell)*

530-754-9034 (office)

Skype: ealeasure

From: Woutrina A Smith <wasmith@ucdavis.edu>
Sent: Tuesday, February 12, 2019 2:53 PM
To: Peter Daszak <daszak@ecohealthalliance.org>; Catherine Machalaba <machalaba@ecohealthalliance.org>; Molly Turner <turner@ecohealthalliance.org>; Evelyn Luciano <luciano@ecohealthalliance.org>; William B. Karesh <Karesh@ecohealthalliance.org>; Kevin Olival <olival@ecohealthalliance.org>; Jon Epstein <epstein@ecohealthalliance.org>; Jonna Mazet <jkmazet@ucdavis.edu>; Kirsten Gilardi <kvgilardi@ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>; Brian H Bird <bhbird@gmx.ucdavis.edu>; Tracey Goldstein <tgoldstein@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; REDACTED >; Brooke Genovese <bgenovese@ucdavis.edu>; Sanzero, George <gsanzer@sandia.gov>; Jutta Lehmer <jLehmer@salud.unm.edu>; Bruce Baird Struminger <BStruminger@salud.unm.edu>; McNeil, Carrie S. <csmcnei@sandia.gov>; Sam Halabi <sfh9@georgetown.edu>; Costa, Cristiane <co121@cumc.columbia.edu>; Parish, Sarah A. <sp3546@cumc.columbia.edu>; Hunt, Christine T. <ch3326@cumc.columbia.edu>; Anthony, Simon J. <sja2127@cumc.columbia.edu>; Wafaa M. El-Sadr <wme1@cumc.columbia.edu>; Jennifer K Lane <jklane@ucdavis.edu>; David John Wolking <djwolking@ucdavis.edu>; Terra Kelly <trkelly@ucdavis.edu>; Omar Romero-hernandez <oromero@haas.berkeley.edu>; Federico Castillo <f.castillo@berkeley.edu>; lane@ecohealthalliance.org; Alison Andre <andre@ecohealthalliance.org>; Nicole R Gardner <nrgardner@ucdavis.edu>; Amy Armistad <AArmistad@salud.unm.edu>; ElRyers@salud.unm.edu; mr84@columbia.edu; Dele Ogunseitan (UCI) <oaogunse@uci.edu>
Cc: Matthew Blake <mblake@ucdavis.edu>
Subject: Re: One Health Workforce-Next Gen calls

Hi OHW-NG group,

A quick reminder for our scheduled OHW-NG calls this week on Wednesday 8am PST and Thursday 9am PST, more detail below. I'm also providing brief agenda and attaching a powerpoint file that can be used during the Wednesday call, as I know some of you may not be on zoom or would like to look this over beforehand. Keep in mind that these slides are works in progress and meant to stimulate discussion to help us plan our proposal prep timeline, our scope of work, and our theory of change ideas. I plan to be on the calls but connectivity in Ethiopia can be intermittent, hence my thanks to Jonna and Matt for facilitating our calls this week. And last but not at all least, I am pleased to introduce Professor Dele Ogunseitan from UC Irvine, who has a wealth of experience in workforce development and has been a joy to work with over recent years through our UC Global Health Institute activities. Here is a link to Dele's bio:

https://faculty.sites.uci.edu/ogunseitan/files/2016/08/ogunseitan-cv.pdf

Best wishes, Woutrina

Wednesday call agenda:

- **Participant roll call and intros for any new people** (usually UCD, Columbia ICAP, EcoHealth Alliance, Sandia National Labs University of New Mexico join)

- **Use ppt to guide discussion as needed:**

- **Consortium partners**

- **Proposal prep timeline**

- **Business application overview**

- **Technical application overview**

- **Scope of work discussion**

- **Consider OHCEA figures to inform our key figures**

- **Theory of change figure creation task**

- **Obj. 1 discussion of scale up and scale out approach**

- **Obj. 2 discussion for workforce assessment**

- **Work towards 5 yr timeline overview figure**

- **Other items of business**

Thursday call agenda:

- **Participant roll call and intros for any new people** (usually UCD, Columbia ICAP, EHA, SNL, UNM, UCB, Georgetown join)

- **Use Wednesday ppt as helpful to guide discussions**

- **Focus on Obj 3 approach and scope instead of Obj 1 and 2**

- **Other items of business**

On Feb 8, 2019, at 12:22 PM, Woutrina A Smith <wasmith@ucdavis.edu> wrote:

Hi OHW-NG Consortium,

Thanks for all of your ideas and enthusiasm to carry this proposal forward. Here are brief updates:

1. Call scheduling - For next week, here are the zoom call days/times along with the same zoom call info. All partners welcome, please let me know which calls your group plans to attend so we can plan accordingly.

Zoom Meeting link: https://onehealth.zoom. REDACTED

Or dial by your location:

+1 669 900 6833 US (San Jose)

+1 646 876 9923 US (New York)

Meeting ID: REDACTED

Wednesday, February 13, 8-9am PST = 11am-12pm EST - Overview and Obj 1 & 2 focus for discussion. All partners welcome. Jonna Mazet to facilitate the call.

Thursday, February 14, 9-10am PST = 12-1pm EST - Overview and Objective 3 focus for discussion. All partners welcome. Matt Blake to facilitate the call.

2. Proposal planning:

- New box folders have been created, one for each organization to use for admin document sharing such as budgets and justifications when the time comes. Each organization lead should change the members of their organization that have access to their folder as needed.

- In person meetings look to be possible in the last week of February or first week of March. I'll get back to you with more specific date ideas early next week, but if you have updates to share on availability and interest just let me know.

- An email will be coming your way on Monday with a timeline, draft proposal writing structure, and task checklists to help align our organizations and coordination efforts.

Best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD

Professor of Infectious Disease Epidemiology

Co-Director, UCGHI Planetary Health Center of Expertise

USAID PREDICT-2 Global Capacity Team and Ethiopia lead

UCD Vet Med: One Health Institute

1042 VM3B Building

1089 Veterinary Medicine Dr

Davis, CA 95616 USA

wasmith@ucdavis.edu

+1 530 219-1369

Subject: Re: One Health Workforce-Next Gen calls
From: Woutrina Smith <wasmith@ucdavis.edu>
Sent: Wed, 13 Feb 2019 07:15:39 +0300
Cc: Elizabeth Leasure <ealeasure@ucdavis.edu>, Matthew Blake <mblake@ucdavis.edu>, Hannah R Chale <hrchale@ucdavis.edu>
To: Jonna Mazet <jkmazet@ucdavis.edu>

J and L, For the OHW call tomorrow I have the draft proposal prep timeline slide and business application overview slide shared as a chance to show people we are working on these ideas. You can say that I have been in touch individually with the various consortium partners to start honing in on best roles and scope, and that we will share budget template docs as well as more detailed guidance on partner budgets by Monday. So I do think the target of March 1 for budgets coming to UCD can work actually, that is two weeks from Monday. OK by me for Liz to talk about or share her draft timeline, I know partners want to plan their own prep timelines. I can provide the PI and admin lead to Liz and Matt for each partner to create direct connections this week too. Thanks! Wout

---

On Feb 13, 2019, at 6:49 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Thanks for that guidance, Liz!
> Hmm... to make the timing work as described, all partners will have to know their roles and target budgets by Friday. Unless that was already decided, I don't see how that will work with Wout on the road. I'm certainly not prepared to lead that discussion tomorrow on a large group call, especially if Wout's connectivity is poor. Seems to me that there may need to be some shrinkage in the Feb 15-March 1 window, as well as in the March 4-12 window.
> The budgets and scopes are certainly the most touchy communication/negotiating pieces. Perhaps share templates as exemplars, but that will initiate the fray, I'm afraid, unless there has been a philosophical agreement on the division of labor and funds.
> Just my thoughts,
> J

On Tue, Feb 12, 2019 at 5:22 PM Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Wout. Your proposal prep timeline looks good to me. If we can have all subs submit a first draft of their SOWs/Budgets/Cost Narratives by COB March 1st (Friday), that would give Hannah and I sufficient time to work with partners to finalize their documents so they can submit to their SPO offices. Brian's CEPI and CKJ's NIH proposals should be basically done at that point, so the timing is pretty good to dig into OHW. A detailed list of proposed deadlines (for the cost application and SPO review) is below. Any thoughts or suggested changes?
>
> **February 15th COB:** Instructions, templates, and forms to partners (Liz will draft and send)
>
> **March 1st COB:** Draft of subrecipient SOW/Budget/Justification submitted to UCD for review
>
> **March 4th-12th:** Liz/Hannah review subrecipient submissions & work with partners to finalize required documents
>
> **March 12th COB:** All subrecipient SOWs/Budgets/Justifications must be ready for subs to submit to their SPO for review/approval
>
> **March 20th:** All fully-approved subrecipient packages must be received at UCD
>
> **March 21st-29th:** Liz/Hannah/Matt finalize cost application
>
> **March 29th COB:** Submit full proposal (with working/draft version of technical proposal, if necessary) to SPO for review/approval

April 1st-8th: SPO conducts their review/approves

April 8th (or sooner): SPO (or Liz) submits to USAID by 10 am PT/1 pm ET

Elizabeth Leasure

Financial Operations Manager

One Health Institute

REDACTED *(cell)*

530-754-9034 (office)

Skype: ealeasure

From: Woutrina A Smith <waasmith@ucdavis.edu>
Sent: Tuesday, February 12, 2019 2:53 PM
To: Peter Daszak <daszak@ecohealthalliance.org>; Catherine Machalaba <machalaba@ecohealthalliance.org>; Molly Turner <turner@ecohealthalliance.org>; Evelyn Luciano <luciano@ecohealthalliance.org>; William B. Karesh <Karesh@ecohealthalliance.org>; Kevin Olival <olival@ecohealthalliance.org>; Jon Epstein <epstein@ecohealthalliance.org>; Jonna Mazet <jkmazet@ucdavis.edu>; Kirsten Gilardi <kvgilardi@ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>; Brian H Bird <bhbird@gmx.ucdavis.edu>; Tracey Goldstein <tgoldstein@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; REDACTED Brooke Genovese <bgenovese@ucdavis.edu>; Sanzero, George <gsanzer@sandia.gov>; Jutta Lehmer <JLehmer@salud.unm.edu>; Bruce Baird Struminger <BStruminger@salud.unm.edu>; McNeil, Carrie S. <csmcnei@sandia.gov>; Sam Halabi <sfh9@georgetown.edu>; Costa, Cristiane <co123@cumc.columbia.edu>; Parish, Sarah A. <sp3546@cumc.columbia.edu>; Hunt, Christine T. <ch3326@cumc.columbia.edu>; Anthony, Simon J. <sja2127@cumc.columbia.edu>; Wafaa M. El-Sadr <wme1@cumc.columbia.edu>; Jennifer K Lane <jklane@ucdavis.edu>; David John Wolking <djwolking@ucdavis.edu>; Terra Kelly <trkelly@ucdavis.edu>; Omar Romero-hernandez <oromero@haas.berkeley.edu>; Federico Castillo <f.castillo@berkeley.edu>; lane@ecohealthalliance.org; Alison Andre <andre@ecohealthalliance.org>; Nicole R Gardner <nrgardner@ucdavis.edu>; Amy Armistad <AArmistad@salud.unm.edu>; EBlyers@salud.unm.edu; mv84@columbia.edu; Dele Ogunseitan (UCI) <oeogunse@uci.edu>
Cc: Matthew Blake <mblake@ucdavis.edu>
Subject: Re: One Health Workforce-Next Gen calls

Hi OHW-NG group,

A quick reminder for our scheduled OHW-NG calls this week on Wednesday 8am PST and Thursday 9am PST, more detail below. I'm also providing brief agenda and attaching a powerpoint file that can be used during the Wednesday call, as I know some of you may not be on zoom or would like to look this over beforehand. Keep in mind that these slides are works in progress and meant to stimulate discussion to help us plan our proposal prep timeline, our scope of work, and our theory of change ideas. I plan to be on the calls but connectivity in Ethiopia can be intermittent, hence my thanks to Jonna and Matt for facilitating our calls this week. And last but not at all least, I am pleased to introduce Professor Dele Ogunseitan from UC Irvine, who has a wealth of experience in workforce development and has been a joy to work with over recent years through our UC Global Health Institute activities. Here is a link to Dele's bio:

https://faculty.sites.uci.edu/ogunscitan/files/2016/08/ogunscitan-cv.pdf

Best wishes, Woutrina

Wednesday call agenda:

- **Participant roll call and intros for any new people** (usually UCD, Columbia ICAP, EcoHealth Alliance, Sandia National Labs University of New Mexico join)

- **Use ppt to guide discussion as needed:**

- **Consortium partners**

- **Proposal prep timeline**

- **Business application overview**

- **Technical application overview**

- **Scope of work discussion**

- **Consider OHCEA figures to inform our key figures**

- **Theory of change figure creation task**

- **Obj. 1 discussion of scale up and scale out approach**

- **Obj. 2 discussion for workforce assessment**

- **Work towards 5 yr timeline overview figure**

- **Other items of business**

Thursday call agenda:

- **Participant roll call and intros for any new people** (usually UCD, Columbia ICAP, EHA, SNL, UNM, UCB, Georgetown join)

- **Use Wednesday ppt as helpful to guide discussions**

- **Focus on Obj 3 approach and scope instead of Obj 1 and 2**

- **Other items of business**

On Feb 8, 2019, at 12:22 PM, Woutrina A Smith <waasmith@ucdavis.edu> wrote:

Hi OHW-NG Consortium,

Thanks for all of your ideas and enthusiasm to carry this proposal forward. Here are brief updates:

1. Call scheduling - For next week, here are the zoom call days/times along with the same zoom call info. All partners welcome, please let me know which calls your group plans to attend so we can plan accordingly.

Zoom Meeting link: https://onehealth.zoom REDACTED

Or dial by your location:

+1 669 900 6833 US (San Jose)

+1 646 876 9923 US (New York)

Meeting ID: REDACTED

Wednesday, February 13, 8-9am PST = 11am-12pm EST - Overview and Obj 1 & 2 focus for discussion. All partners welcome. Jonna Mazet to facilitate the call.

Thursday, February 14, 9-10am PST = 12-1pm EST - Overview and Objective 3 focus for discussion. All partners welcome. Matt Blake to facilitate the call.

2. Proposal planning:

- New box folders have been created, one for each organization to use for admin document sharing such as budgets and justifications when the time comes. Each organization lead should change the members of their organization that have access to their folder as needed.

- In person meetings look to be possible in the last week of February or first week of March. I'll get back to you with more specific date ideas early next week, but if you have updates to share on availability and interest just let me know.

- An email will be coming your way on Monday with a timeline, draft proposal writing structure, and task checklists to help align our organizations and coordination efforts.

Best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD

Professor of Infectious Disease Epidemiology

Co-Director, UCGHI Planetary Health Center of Expertise

USAID PREDICT-2 Global Capacity Team and Ethiopia lead

UCD Vet Med: One Health Institute

1042 VM3B Building

1089 Veterinary Medicine Dr

Davis, CA 95616 USA

wasmith@ucdavis.edu

+1 530 219-1369

From: Andrew Clements <aclements@usaid.gov>
Sent: Fri, 15 Mar 2019 17:13:34 +0100
Subject: Re: [Response Requested] P2 Budget
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, predict Sympa List <predict@ucdavis.edu>

Thanks, Liz.

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see: http://www.usaid.gov/ept2

On Fri, Mar 15, 2019 at 4:53 PM Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Thanks, Andrew! This is fantastic news. I'll setup a separate account internally for the "borrowed" Ebola funds to ensure there is no confusion when "returning" the funds or in a potential audit.

Please extend our thanks to Richard for his flexibility, and thank you to the P2 Management team for making it happen.

Have a great weekend!

Liz

Elizabeth Leasure

Financial Operations Manager

One Health Institute

[redacted] *(cell)*

330-754-9034 (office)

Skype: ealeasure

From: Andrew Clements <aclements@usaid.gov>
Sent: Friday, March 15, 2019 8:21 AM
To: Jonna Mazet <jkmazet@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; David John Wolking <djwolking@ucdavis.edu>
Cc: PREDICTMGT <predictmgt@usaid.gov>
Subject: Fwd: [Response Requested] P2 Budget

Hi Jonna, Liz, and David,

I'm forwarding an email showing Richard Greene concurring with the temporary borrowing of $2,200,000 of Ebola funds already obligated to PREDICT-2 to cover year 5 core-funded activities until new FY2018 core funds are obligated for year 5 activities.

Please ensure that you track this temporary usage of Ebola funds and document in a way that will be sufficient for an audit (if there is one).

Please let me know if you have any questions.

Andrew

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health

U.S. Agency for International Development

Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see http://www.usaid.gov/ept2

---------- Forwarded message ---------
From: **Richard Greene** <rgreene@usaid.gov>
Date: Thu, Mar 14, 2019 at 6:47 PM
Subject: Re: [Response Requested] P2 Budget
To: Cara Chrisman <cchrisman@usaid.gov>
Cc: Andrew Clements <aclements@usaid.gov>, Dennis Carroll <dcarroll@usaid.gov>, PREDICTMGT <predictmgt@usaid.gov>, Robbin Boyer <rboyer@usaid.gov>, Jane Pyon <jpyon@usaid.gov>

Hi Cara

Thanks for summarizing our discussion. I concur in this email.

Best

Richard

On Thu, Mar 14, 2019 at 12:38 PM Cara Chrisman <cchrisman@usaid.gov> wrote:

Hi Richard,

As per our earlier conversation, on behalf of the PREDICT-2 (P2) management team, I'd like to confirm that you are

okay with our proposed plan and subsequent communications to the partner.

Given that P2 will be running out of core funding at the end of this month and that we are in a very unique situation in which it is mid-March 2019 and ETD has not yet received core (GH-C-AI) FY18 funding, the proposal is that Andrew (as the AOR) will communicate to UC Davis (prime for the P2 project) that they can immediately use $2.2M of GH-C-XEB funding previously obligated to the project to allow them to continue core-funded programs uninterrupted.

The hope is that this utilization of GH-C-XEB funds will enable the project to continue activities until the ETD core funding is received. At that time, the aforementioned utilization of funding will be reconciled within the project. Throughout this process, the partner will be directed to keep track of this usage of funds and appropriately document.

Please confirm your approval of this proposed plan.

Thanks,
Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
U.S. Agency for International Development (USAID) Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-8091A, Arlington, VA 22202

Desk: (571) 551-7413
Cell: REDACTED
E-mail: cchrisman@usaid.gov

GHSI-III - Social Solutions International, Inc. prime contractor

--

Richard S. Greene
Senior Infectious Disease Strategy Advisor

Office of Health, Infectious Diseases, and Nutrition

Bureau for Global Health

USAID
Tel: (571) 551-7364

E-mail: rgreene@usaid.gov

From: Peter Daszak <daszak@ecohealthalliance.org>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: Anthony Ramos <ramos@ecohealthalliance.org>;William B. Karesh" <karesh@ecohealthalliance.org>
Sent: 3/19/2019 9:29:59 PM
Subject: Would June 13th work for you for a Cosmos Club event re. the 10th Anniv. of the NAM Committee report/EPT

Hi Jonna,

I asked Anthony to look for possible dates for the Cosmos Club and the best availability that the Cosmos Club has, that's before Congress leaves town, and works for my calendar is June 13th. Dennis is also available.

Dennis' idea was to have a neutral way of focusing on EPT without it being just about EPT/PREDICT so the goal is to do a celebration of the 10th Anniversary of the IOM/NAM Committee report "Sustaining Global Surveillance and Response to Emerging Diseases". I'm reaching out to the Co-Chairs of the Committee and Ceci to see if they can do the date also. I'm pretty sure Ceci is free and prob some other FMT members would come along.

I thought this might also work for you because we're in NYC the day before at the Rockefeller Ctr for a FMT meeting (11th, 12th June). I know you hinted on the phone that the date is not ideal, but let me know and hopefully you can do it – it'll be a fun evening with food, wine, and then some more wine….

If you definitely can't do it, we'll try to work around…

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
Website: www.ecohealthalliance.org
Twitter: @PeterDaszak

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From: Dennis Carroll <dcarroll@usaid.gov>
Sent: Wed, 3 Apr 2019 21:00:25 -0400
Subject: Re: letters for the Board
To: REDACTED
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>

Excellent. Thanks

Dr Dennis Carroll
Director
Emerging Threats
Global Health
USAID
REDACTED

On Apr 3, 2019, at 8:06 PM, REDACTED > wrote:

Hi Dennis,
I just sent all eight BOD letters!
Best,
[redacted]

From: Dennis Carroll [mailto:dcarroll@usaid.gov]
Sent: Friday, March 29, 2019 11:26 AM
To: REDACTED >; Cara Chrisman <cchrisman@usaid.gov>
Subject: letters for the Board

[redacted] the letters are attached. I presume you have all the emails, with the possible exception of Christian Brechot - cbrechot@gvn.org

let me know if you have any issues or questions

Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 571-551-7109
Mobile: REDACTED

From: Jutta Lehmer <JLehmer@salud.unm.edu>
To: 'Woutrina A Smith' <wasmith@ucdavis.edu>, Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, "Hunt, Christine T." <ch3326@cumc.columbia.edu>, "Parish, Sarah A." <sp3546@cumc.columbia.edu>, "Costa, Cristiane" <co123@cumc.columbia.edu>, "William B. Karesh" <Karesh@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "Peter Daszak" <daszak@ecohealthalliance.org>, Matthew Blake <mblake@ucdavis.edu>, Brian H Bird <bhbird@gmx.ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Nicole R Gardner <nrgardner@ucdavis.edu>, "Molly Turner" <turner@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Kevin Olival <olival@ecohealthalliance.org>, Alexandra Zuber [redacted] Tracey Goldstein <tgoldstein@ucdavis.edu>, "kp2440@cumc.columbia.edu" <kp2440@cumc.columbia.edu>, Amy J Armistad <AArmistad@salud.unm.edu>, "Hannah R Chale" <hrchale@UCDAVIS.EDU>, Michael S Wilkes <mswilkes@ucdavis.edu>, "Martin H. Smith" <mhsmith@ucdavis.edu>, Patricia Ann Conrad <paconrad@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, "Corina Grigorescu Monagin" <cgmonagin@UCDAVIS.EDU>, Federico Castillo <f.castillo@berkeley.edu>, Ndola PRATA <ndola@berkeley.edu>, "Bridgette Phebean Smith" <brpsmith@ucdavis.edu>, Sam Halabi <sfh9@georgetown.edu>, Omar Romero-hernandez <oromero@haas.berkeley.edu>, "mr84@columbia.edu" <mr84@columbia.edu>, Emily L Byers <ElByers@salud.unm.edu>, "McNeil, Carrie S." <csmcnei@sandia.gov>, Alison Andre <andre@ecohealthalliance.org>, [redacted] "Sanzero, George" <gsanzer@sandia.gov>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, Elizabeth Leasure <ealeasure@UCDAVIS.EDU>, Catherine Machalaba <machalaba@ecohealthalliance.org>, Bruce B Struminger <BStruminger@salud.unm.edu>, Jennifer K Lane <jklane@ucdavis.edu>, "Terra Kelly" <trkelly@ucdavis.edu>, "Wafaa M. El-Sadr" <wme1@cumc.columbia.edu>
Subject: RE: Complete! OHW-NG proposal submitted
Sent: Mon, 8 Apr 2019 16:41:45 +0000

Hooray! Congratulations team. It's been a wonderful experience working with you all. Hoping for a positive response, so we can implement this together! Thanks all. Jutta

Jutta Lehmer, BA
Program Planning Manager Global HIV Initiative
ECHO Institute™
University of New Mexico Health Sciences Center
Cell: +1.505.234.6046
jlehmer@salud.unm.edu
http://echo.unm.edu/ @ProjectECHO

From: Woutrina A Smith <wasmith@ucdavis.edu>
Sent: Monday, April 8, 2019 10:34 AM
To: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>; Hunt, Christine T. <ch3326@cumc.columbia.edu>; Parish, Sarah A. <sp3546@cumc.columbia.edu>; Costa, Cristiane <co123@cumc.columbia.edu>; William B. Karesh <Karesh@ecohealthalliance.org>; Evelyn Luciano <luciano@ecohealthalliance.org>; Jonna Mazet <jkmazet@ucdavis.edu>; Peter Daszak <daszak@ecohealthalliance.org>; Matthew Blake <mblake@ucdavis.edu>; Brian H Bird <bhbird@gmx.ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>; Nicole R Gardner <nrgardner@ucdavis.edu>; Molly Turner <turner@ecohealthalliance.org>; Jon Epstein <epstein@ecohealthalliance.org>; Kevin Olival <olival@ecohealthalliance.org>; Alexandra Zuber [redacted]; Tracey Goldstein <tgoldstein@ucdavis.edu>; kp2440@cumc.columbia.edu; Amy J Armistad <AArmistad@salud.unm.edu>; Hannah R Chale <hrchale@UCDAVIS.EDU>; Michael S Wilkes <mswilkes@ucdavis.edu>; Martin H. Smith <mhsmith@ucdavis.edu>; Patricia Ann Conrad <paconrad@ucdavis.edu>; David John Wolking <djwolking@ucdavis.edu>; Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>; Federico Castillo <f.castillo@berkeley.edu>; Ndola PRATA <ndola@berkeley.edu>; Bridgette Phebean Smith <brpsmith@ucdavis.edu>; Sam Halabi <sfh9@georgetown.edu>; Omar Romero-hernandez <oromero@haas.berkeley.edu>; mr84@columbia.edu; Emily L Byers <ElByers@salud.unm.edu>; McNeil, Carrie S. <csmcnei@sandia.gov>; Alison Andre <andre@ecohealthalliance.org> [redacted]; Sanzero, George <gsanzer@sandia.gov>; Anthony, Simon J. <sja2127@cumc.columbia.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Catherine Machalaba <machalaba@ecohealthalliance.org>; Jutta Lehmer <JLehmer@salud.unm.edu>; Bruce B Struminger <BStruminger@salud.unm.edu>; Jennifer K Lane <jklane@ucdavis.edu>; Terra Kelly <trkelly@ucdavis.edu>; Wafaa M. El-Sadr <wme1@cumc.columbia.edu>
Subject: Complete! OHW-NG proposal submitted

[|-- External - this message has been sent from outside the University --|]

Hi OHW-NG consortium,

We've just submitted our One Health Workforce - Next Generation application and have received email confirmation from USAID! Thanks to everyone for contributing your ideas, energy, enthusiasm, and time to this effort. Attached are the final technical narrative and the associated annexes, as two separate files, including 36 letters of commitment and support that speak to the impressive breadth of our teams and networks. We will certainly be in touch as we have updates and look forward to finding more ways to collaborate in the future.

Very best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Acting Director, One Health Institute
Professor of Infectious Disease Epidemiology
USAID PREDICT-2 Global Capacity Team and Ethiopia lead
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis
1089 Veterinary Medicine Dr
Davis, CA 95616 USA
wasmith@ucdavis.edu
+1 530 219-1369

From: Kevin Olival <olival@ecohealthalliance.org>
Subject: Re: Complete! OHW-NG proposal submitted
Sent: Mon, 8 Apr 2019 12:42:32 -0400
Cc: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, "Hunt, Christine T." <ch3326@cumc.columbia.edu>, "Parish, Sarah A." <sp3546@cumc.columbia.edu>, "Costa, Cristiane" <co123@cumc.columbia.edu>, Billy Karesh <Karesh@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>, Matthew Blake <mblake@ucdavis.edu>, Brian H Bird <bhbird@gmx.ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Nicole R Gardner <nrgardner@ucdavis.edu>, Molly Turner <turner@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Alexandra Zuber [redacted] Tracey Goldstein <tgoldstein@ucdavis.edu>, "kp2440@cumc.columbia.edu" <kp2440@cumc.columbia.edu>, Amy Armistad <AArmistad@salud.unm.edu>, Hannah R Chale <hrchale@UCDAVIS.EDU>, Michael S Wilkes <mswilkes@ucdavis.edu>, "Martin H. Smith" <mhsmith@ucdavis.edu>, Patricia Ann Conrad <paconrad@ucdavis.edu>, David J Wolking <djwolking@ucdavis.edu>, Corina Monagin <cgmonagin@UCDAVIS.EDU>, Federico Castillo <f.castillo@berkeley.edu>, Ndola PRATA <ndola@berkeley.edu>, Bridgette Phebean Smith <brpsmith@ucdavis.edu>, Sam Halabi <sfh9@georgetown.edu>, Omar Romero-hernandez <oromero@haas.berkeley.edu>, "mr84@columbia.edu" <mr84@columbia.edu>, "EIByers@salud.unm.edu" <EIByers@salud.unm.edu>, "McNeil, Carrie S." <csmcnei@sandia.gov>, Alison Andre <andre@ecohealthalliance.org> [redacted] [redacted], "Sanzero, George" <gsanzer@sandia.gov>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, Elizabeth Leisure <ealeisure@UCDAVIS.EDU>, Catherine Machalaba <machalaba@ecohealthalliance.org>, Jutta Lehmer <JLehmer@salud.unm.edu>, Bruce Baird Struminger <BStruminger@salud.unm.edu>, Jennifer K Lane <jklane@ucdavis.edu>, Terra Kelly <trkelly@ucdavis.edu>, "Wafaa M. El-Sadr" <wme1@cumc.columbia.edu>
To: Woutrina Miller <wasmith@ucdavis.edu>

Excellent! Thank you Woutrina and the rest of the UCD team for leading the charge on this proposal and bringing everyone together over the last several months…. Fingers crossed that we'll all be able to continue collaborating as a consortium on this important work!
Best regards,
Kevin

Kevin J. Olival, PhD
Vice President for Research

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4478 (direct)
[redacted] (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

On Apr 8, 2019, at 12:34 PM, Woutrina A Smith <wasmith@ucdavis.edu> wrote:

Hi OHW-NG consortium,

We've just submitted our One Health Workforce - Next Generation application and have received email confirmation from USAID! Thanks to everyone for contributing your ideas, energy, enthusiasm, and time to this effort. Attached are the final technical narrative and the associated annexes, as two separate files, including 36 letters of commitment and support that speak to the impressive breadth of our teams and networks. We will certainly be in touch as we have updates and look forward to finding more ways to collaborate in the future.

Very best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Acting Director, One Health Institute
Professor of Infectious Disease Epidemiology
USAID PREDICT-2 Global Capacity Team and Ethiopia lead
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis

1089 Veterinary Medicine Dr
Davis, CA 95616 USA
wasmith@ucdavis.edu
+1 530 219-1369

<Annexes-OHW-NG-UCDavis_Tech_App-4-8-19-final.pdf><Tech-App-No-Annexes-OHW-NG-UCD-4-8-19-final.pdf>

From: [redacted]
To: "William B. Karesh" <karesh@ecohealthalliance.org>, Woutrina A Smith <wasmith@ucdavis.edu>
Cc: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, "Hunt, Christine T." <ch3326@cumc.columbia.edu>, "Parish, Sarah A." <sp3546@cumc.columbia.edu>, "Costa, Cristiane" <co123@cumc.columbia.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>, Matthew Blake <mblake@ucdavis.edu>, Brian H Bird <bhbird@gmx.ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Nicole R Gardner <nrgardner@ucdavis.edu>, Molly Turner <turner@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Kevin Olival <olival@ecohealthalliance.org>, Alexandra Zuber [redacted] Tracey Goldstein <tgoldstein@ucdavis.edu>, "kp2440@cumc.columbia.edu" <kp2440@cumc.columbia.edu>, Amy Armistad <AArmistad@salud.unm.edu>, Hannah R Chale <hrchale@UCDAVIS.EDU>, Michael S Wilkes <mswilkes@ucdavis.edu>, "Martin H. Smith" <mhsmith@ucdavis.edu>, Patricia Ann Conrad <paconrad@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>, Federico Castillo <f.castillo@berkeley.edu>, Ndola PRATA <ndola@berkeley.edu>, Bridgette Phebean Smith <brpsmith@ucdavis.edu>, Sam Halabi <sfh9@georgetown.edu>, Omar Romero-hernandez <oromero@haas.berkeley.edu>, "mr84@columbia.edu" <mr84@columbia.edu>, "ElByers@salud.unm.edu" <ElByers@salud.unm.edu>, "McNeil, Carrie S." <csmcnei@sandia.gov>, Alison Andre <andre@ecohealthalliance.org>, "Sanzero, George" <gsanzer@sandia.gov>, "sja2127@cumc.columbia.edu" <sja2127@cumc.columbia.edu>, Elizabeth Leasure <ealeasure@UCDAVIS.EDU>, Catherine Machalaba <machalaba@ecohealthalliance.org>, Jutta Lehmer <JLehmer@salud.unm.edu>, Bruce Baird Struminger <BStruminger@salud.unm.edu>, Jennifer K Lane <jklane@ucdavis.edu>, Terra Kelly <trkelly@ucdavis.edu>, "Wafaa M. El-Sadr" <wme1@cumc.columbia.edu>
Subject: RE: Complete! OHW-NG proposal submitted
Sent: Mon, 8 Apr 2019 16:48:12 +0000

Congratulations team!

[redacted]

[redacted]
Fellow
One Health Institute
School of Veterinary Medicine
University of California, Davis

From: William B. Karesh [mailto:karesh@ecohealthalliance.org]
Sent: Monday, April 08, 2019 9:47 AM
To: Woutrina A Smith <wasmith@ucdavis.edu>
Cc: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>; Hunt, Christine T. <ch3326@cumc.columbia.edu>; Parish, Sarah A. <sp3546@cumc.columbia.edu>; Costa, Cristiane <co123@cumc.columbia.edu>; Evelyn Luciano <luciano@ecohealthalliance.org>; Jonna Mazet <jkmazet@ucdavis.edu>; Peter Daszak <daszak@ecohealthalliance.org>; Matthew Blake <mblake@ucdavis.edu>; Brian H Bird <bhbird@gmx.ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>; Nicole R Gardner <nrgardner@ucdavis.edu>; Molly Turner <turner@ecohealthalliance.org>; Jon Epstein <epstein@ecohealthalliance.org>; Kevin Olival <olival@ecohealthalliance.org>; Alexandra Zuber [redacted] Tracey Goldstein <tgoldstein@ucdavis.edu>; kp2440@cumc.columbia.edu; Amy Armistad <AArmistad@salud.unm.edu>; Hannah R Chale <hrchale@UCDAVIS.EDU>; Michael S Wilkes <mswilkes@ucdavis.edu>; Martin H. Smith <mhsmith@ucdavis.edu>; Patricia Ann Conrad <paconrad@ucdavis.edu>; David John Wolking <djwolking@ucdavis.edu>; Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>; Federico Castillo <f.castillo@berkeley.edu>; Ndola PRATA <ndola@berkeley.edu>; Bridgette Phebean Smith <brpsmith@ucdavis.edu>; Sam Halabi <sfh9@georgetown.edu>; Omar Romero-hernandez <oromero@haas.berkeley.edu>; mr84@columbia.edu; ElByers@salud.unm.edu; McNeil, Carrie S. <csmcnei@sandia.gov>; Alison Andre <andre@ecohealthalliance.org>; [redacted]; Sanzero, George <gsanzer@sandia.gov>; sja2127@cumc.columbia.edu; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Catherine Machalaba <machalaba@ecohealthalliance.org>; Jutta Lehmer <JLehmer@salud.unm.edu>; Bruce Baird Struminger <BStruminger@salud.unm.edu>; Jennifer K Lane <jklane@ucdavis.edu>; Terra Kelly <trkelly@ucdavis.edu>; Wafaa M. El-Sadr <wme1@cumc.columbia.edu>
Subject: Re: Complete! OHW-NG proposal submitted

Congrats !!! Reads beautifully and looks good too.

BK

William B. Karesh, D.V.M
Executive Vice President for Health and Policy

EcoHealth Alliance

460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

On Apr 8, 2019, at 12:34 PM, Woutrina A Smith <wasmith@ucdavis.edu> wrote:

Hi OHW-NG consortium,

We've just submitted our One Health Workforce - Next Generation application and have received email confirmation from USAID! Thanks to everyone for contributing your ideas, energy, enthusiasm, and time to this effort. Attached are the final technical narrative and the associated annexes, as two separate files, including 36 letters of commitment and support that speak to the impressive breadth of our teams and networks. We will certainly be in touch as we have updates and look forward to finding more ways to collaborate in the future.

Very best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Acting Director, One Health Institute
Professor of Infectious Disease Epidemiology
USAID PREDICT-2 Global Capacity Team and Ethiopia lead
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis
1089 Veterinary Medicine Dr
Davis, CA 95616 USA
wasmith@ucdavis.edu
+1 530 219-1369

<Annexes-OHW-NG-UCDavis_Tech_App-4-8-19-final.pdf><Tech-App-No-Annexes-OHW-NG-UCD-4-8-19-final.pdf>

From: Bruce B Struminger <BStruminger@salud.unm.edu>
To: Woutrina A Smith <wasmith@ucdavis.edu>, Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, "Hunt, Christine T." <ch3326@cumc.columbia.edu>, "Parish, Sarah A." <sp3546@cumc.columbia.edu>, "Costa, Cristiane" <co123@cumc.columbia.edu>, "William B. Karesh" <Karesh@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "Peter Daszak" <daszak@ecohealthalliance.org>, Matthew Blake <mblake@ucdavis.edu>, Brian H Bird <bhbird@gmx.ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Nicole R Gardner <nrgardner@ucdavis.edu>, "Molly Turner" <turner@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Kevin Olival <olival@ecohealthalliance.org>, Alexandra Zuber [redacted], Tracey Goldstein <tgoldstein@ucdavis.edu>, "kp2440@cumc.columbia.edu" <kp2440@cumc.columbia.edu>, Amy J Armistad <AArmistad@salud.unm.edu>, "Hannah R Chale" <hrchale@UCDAVIS.EDU>, Michael S Wilkes <mswilkes@ucdavis.edu>, "Martin H. Smith" <mhsmith@ucdavis.edu>, Patricia Ann Conrad <paconrad@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, "Corina Grigorescu Monagin" <cgmonagin@UCDAVIS.EDU>, Federico Castillo <f.castillo@berkeley.edu>, Ndola PRATA <ndola@berkeley.edu>, "Bridgette Phebean Smith" <brpsmith@ucdavis.edu>, Sam Halabi <sfh9@georgetown.edu>, Omar Romero-hernandez <oromero@haas.berkeley.edu>, "mr84@columbia.edu" <mr84@columbia.edu>, Emily L Byers <ElByers@salud.unm.edu>, "McNeil, Carrie S." <csmcnei@sandia.gov>, Alison Andre <andre@ecohealthalliance.org>, [redacted], "Sanzero, George" <gsanzer@sandia.gov>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, Elizabeth Leasure <ealeasure@UCDAVIS.EDU>, Catherine Machalaba <machalaba@ecohealthalliance.org>, Jutta Lehmer <JLehmer@salud.unm.edu>, Jennifer K Lane <jklane@ucdavis.edu>, Terra Kelly <trkelly@ucdavis.edu>, "Wafaa M. El-Sadr" <wme1@cumc.columbia.edu>
Subject: Re: Complete! OHW-NG proposal submitted
Sent: Mon, 8 Apr 2019 16:49:38 +0000

Dear Woutrina and Colleagues, Congratulations on developing a visionary and comprehensive One Health Workforce proposal!! Working with you all on the proposal development over the past few months has been a wonderful experience and fun!! Woutrina, you really supported a model proposal development process with fantastic communication and coordination and respect. Thank you!! I very much hope we win and have the opportunity to implement together!! Now get some rest and relax!!! Take care! B

Bruce Baird Struminger, MD, MA
Senior Associate Director, ECHO Institute
Associate Professor of Medicine, Division of Infectious Diseases
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
mobile: +1.505.922-5659
http://echo.unm.edu/

From: Woutrina A Smith <wasmith@ucdavis.edu>
Date: Monday, April 8, 2019 at 10:38 AM
To: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, "Hunt, Christine T." <ch3326@cumc.columbia.edu>, "Parish, Sarah A." <sp3546@cumc.columbia.edu>, "Costa, Cristiane" <co123@cumc.columbia.edu>, "William B. Karesh" <Karesh@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>, Matthew Blake <mblake@ucdavis.edu>, Brian H Bird <bhbird@gmx.ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Nicole R Gardner <nrgardner@ucdavis.edu>, Molly Turner <turner@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Kevin Olival <olival@ecohealthalliance.org>, Alexandra Zuber <[redacted]>, Tracey Goldstein <tgoldstein@ucdavis.edu>, "kp2440@cumc.columbia.edu" <kp2440@cumc.columbia.edu>, Amy J Armistad <AArmistad@salud.unm.edu>, Hannah R Chale <hrchale@UCDAVIS.EDU>, Michael S Wilkes <mswilkes@ucdavis.edu>, "Martin H. Smith" <mhsmith@ucdavis.edu>, Patricia Ann Conrad <paconrad@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>, Federico Castillo

<f.castillo@berkeley.edu>, Ndola PRATA <ndola@berkeley.edu>, Bridgette Phebean Smith <brpsmith@ucdavis.edu>, Sam Halabi <sfh9@georgetown.edu>, Omar Romero-hernandez <oromero@haas.berkeley.edu>, "mr84@columbia.edu" <mr84@columbia.edu>, Emily L Byers <ElByers@salud.unm.edu>, "McNeil, Carrie S." <csmcnei@sandia.gov>, Alison Andre <andre@ecohealthalliance.org>, REDACTED, "Sanzero, George" <gsanzer@sandia.gov>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, Elizabeth Leasure <ealeasure@UCDAVIS.EDU>, Catherine Machalaba <machalaba@ecohealthalliance.org>, Jutta Lehmer <JLehmer@salud.unm.edu>, Bruce B Struminger <BStruminger@salud.unm.edu>, Jennifer K Lane <jklane@ucdavis.edu>, Terra Kelly <trkelly@ucdavis.edu>, "Wafaa M. El-Sadr" <wme1@cumc.columbia.edu>

Subject: Complete! OHW-NG proposal submitted

[[-- External - this message has been sent from outside the University --]]

Hi OHW-NG consortium,

We've just submitted our One Health Workforce - Next Generation application and have received email confirmation from USAID! Thanks to everyone for contributing your ideas, energy, enthusiasm, and time to this effort. Attached are the final technical narrative and the associated annexes, as two separate files, including 36 letters of commitment and support that speak to the impressive breadth of our teams and networks. We will certainly be in touch as we have updates and look forward to finding more ways to collaborate in the future.

Very best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Acting Director, One Health Institute
Professor of Infectious Disease Epidemiology
USAID PREDICT-2 Global Capacity Team and Ethiopia lead
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis
1089 Veterinary Medicine Dr
Davis, CA 95616 USA
wasmith@ucdavis.edu
+1 530 219-1369

From: "El-Sadr, Wafaa M." <wme1@cumc.columbia.edu>
To: Woutrina A Smith <wasmith@ucdavis.edu>, Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, "Hunt, Christine T." <ch3326@cumc.columbia.edu>, "Parish, Sarah A." <sp3546@cumc.columbia.edu>, "Costa, Cristiane" <co123@cumc.columbia.edu>, "William B. Karesh" <Karesh@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "Peter Daszak" <daszak@ecohealthalliance.org>, Matthew Blake <mblake@ucdavis.edu>, Brian H Bird <bhbird@gmx.ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Nicole R Gardner <nrgardner@ucdavis.edu>, "Molly Turner" <turner@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Kevin Olival <olival@ecohealthalliance.org>, Alexandra Zuber [redacted], Tracey Goldstein <tgoldstein@ucdavis.edu>, "Parrella, Korin E." <kp2440@cumc.columbia.edu>, Amy Armistad <AArmistad@salud.unm.edu>, Hannah R Chale <hrchale@UCDAVIS.EDU>, Michael S Wilkes <mswilkes@ucdavis.edu>, "Martin H. Smith" <mhsmith@ucdavis.edu>, Patricia Ann Conrad <paconrad@ucdavis.edu>, "David John Wolking" <djwolking@ucdavis.edu>, Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>, Federico Castillo <f.castillo@berkeley.edu>, "Ndola PRATA" <ndola@berkeley.edu>, Bridgette Phebean Smith <brpsmith@ucdavis.edu>, Sam Halabi <sfh9@georgetown.edu>, Omar Romero-hernandez <oromero@haas.berkeley.edu>, "mr84@columbia.edu" <mr84@columbia.edu>, "ElByers@salud.unm.edu" <ElByers@salud.unm.edu>, "McNeil, Carrie S." <csmcnei@sandia.gov>, Alison Andre <andre@ecohealthalliance.org>, [redacted] [redacted] "Sanzero, George" <gsanzer@sandia.gov>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, Elizabeth Leasure <ealeasure@UCDAVIS.EDU>, Catherine Machalaba <machalaba@ecohealthalliance.org>, Jutta Lehmer <JLehmer@salud.unm.edu>, Bruce Baird Struminger <BStruminger@salud.unm.edu>, Jennifer K Lane <jklane@ucdavis.edu>, Terra Kelly <trkelly@ucdavis.edu>
Subject: RE: Complete! OHW-NG proposal submitted
Sent: Mon, 8 Apr 2019 17:21:24 +0000

Great news and hoping for the best.

Wafaa

Wafaa El-Sadr, MD, MPH, MPA
Director, ICAP at Columbia University
University Professor of Epidemiology and Medicine
Mathilde Krim-amfAR Chair of Global Health

From: Woutrina A Smith <wasmith@ucdavis.edu>
Sent: Monday, April 8, 2019 12:34 PM
To: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>; Hunt, Christine T. <ch3326@cumc.columbia.edu>; Parish, Sarah A. <sp3546@cumc.columbia.edu>; Costa, Cristiane <co123@cumc.columbia.edu>; William B. Karesh <Karesh@ecohealthalliance.org>; Evelyn Luciano <luciano@ecohealthalliance.org>; Jonna Mazet <jkmazet@ucdavis.edu>; Peter Daszak <daszak@ecohealthalliance.org>; Matthew Blake <mblake@ucdavis.edu>; Brian H Bird <bhbird@gmx.ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>; Nicole R Gardner <nrgardner@ucdavis.edu>; Molly Turner <turner@ecohealthalliance.org>; Jon Epstein <epstein@ecohealthalliance.org>; Kevin Olival <olival@ecohealthalliance.org>; Alexandra Zuber [redacted]; Tracey Goldstein <tgoldstein@ucdavis.edu>; Parrella, Korin E. <kp2440@cumc.columbia.edu>; Amy Armistad <AArmistad@salud.unm.edu>; Hannah R Chale <hrchale@UCDAVIS.EDU>; Michael S Wilkes <mswilkes@ucdavis.edu>; Martin H. Smith <mhsmith@ucdavis.edu>; Patricia Ann Conrad <paconrad@ucdavis.edu>; David John Wolking <djwolking@ucdavis.edu>; Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>; Federico Castillo <f.castillo@berkeley.edu>; Ndola PRATA <ndola@berkeley.edu>; Bridgette Phebean Smith <brpsmith@ucdavis.edu>; Sam Halabi <sfh9@georgetown.edu>; Omar Romero-hernandez <oromero@haas.berkeley.edu>; mr84@columbia.edu; ElByers@salud.unm.edu; McNeil, Carrie S. <csmcnei@sandia.gov>; Alison Andre <andre@ecohealthalliance.org>; [redacted] [redacted] Sanzero, George <gsanzer@sandia.gov>; Anthony, Simon J. <sja2127@cumc.columbia.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Catherine Machalaba <machalaba@ecohealthalliance.org>; Jutta Lehmer <JLehmer@salud.unm.edu>; Bruce Baird Struminger <BStruminger@salud.unm.edu>; Jennifer K Lane <jklane@ucdavis.edu>; Terra Kelly <trkelly@ucdavis.edu>; El-Sadr, Wafaa M. <wme1@cumc.columbia.edu>
Subject: Complete! OHW-NG proposal submitted

Hi OHW-NG consortium,

We've just submitted our One Health Workforce - Next Generation application and have received email confirmation from USAID! Thanks to everyone for contributing your ideas, energy, enthusiasm, and time to this effort. Attached are the final technical narrative and the associated annexes, as two separate files, including 36 letters of commitment and support that speak to the impressive breadth of our teams and networks. We will certainly be in touch as we have updates and look forward to finding more ways to collaborate in the future.

Very best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Acting Director, One Health Institute
Professor of Infectious Disease Epidemiology
USAID PREDICT-2 Global Capacity Team and Ethiopia lead
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis
1089 Veterinary Medicine Dr
Davis, CA 95616 USA
wasmith@ucdavis.edu
+1 530 219-1369

From: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>
Subject: Re: Complete! OHW-NG proposal submitted
Sent: Mon, 8 Apr 2019 10:32:21 -0700
Cc: "Hunt, Christine T." <ch3326@cumc.columbia.edu>, "Parish, Sarah A." <sp3546@cumc.columbia.edu>, "Costa, Cristiane" <cc123@cumc.columbia.edu>, "William B. Karesh" <Karesh@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>, Matthew Blake <mblake@ucdavis.edu>, Brian H Bird <bhbird@gmx.ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Nicole R Gardner <nrgardner@ucdavis.edu>, Molly Turner <turner@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Kevin Olival <olival@ecohealthalliance.org>, Alexandra Zuber [redacted] Tracey Goldstein <tgoldstein@ucdavis.edu>, "kp2440@cumc.columbia.edu" <kp2440@cumc.columbia.edu>, Amy Armistad <AArmistad@salud.unm.edu>, Hannah R Chale <hrchale@ucdavis.edu>, Michael S Wilkes <mswilkes@ucdavis.edu>, "Martin H Smith" <mhsmith@ucdavis.edu>, Patricia Ann Conrad <paconrad@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>, Federico Castillo <f.castillo@berkeley.edu>, Ndola PRATA <ndola@berkeley.edu>, Bridgette Phebean Smith <brpsmith@ucdavis.edu>, Sam Halabi <sfh9@georgetown.edu>, Omar Romero-hernandez <oromero@haas.berkeley.edu>, "mr84@columbia.edu" <mr84@columbia.edu>, "ElByers@salud.unm.edu" <ElByers@salud.unm.edu>, "McNeil, Carrie S." <csmcnei@sandia.gov>, Alison Andre <andre@ecohealthalliance.org> [redacted] [redacted], "Sanzero, George" <gsanzer@sandia.gov>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, Elizabeth Leisure <eaileisure@ucdavis.edu>, Catherine Machalaba <machalaba@ecohealthalliance.org>, Jutta Lehmer <JLehmer@salud.unm.edu>, Bruce Baird Struminger <BStruminger@salud.unm.edu>, Jennifer K Lane <jklane@ucdavis.edu>, Terra Kelly <trkelly@ucdavis.edu>, "Wafaa M. El-Sadr" <wme1@cumc.columbia.edu>
To: Woutrina A Smith <wasmith@ucdavis.edu>

Congratulations to all, and thanks for your leadership, Woutrina.
- Dele

Oladele A. Ogunseitan, PhD, MPH, BCES
Professor and Founding Chair
Department of Population Health and Disease Prevention
Program in Public Health
Susan and Henry Samueli College of Health Sciences
University of California, Irvine
CA 92697

On Apr 8, 2019, at 9:34 AM, Woutrina A Smith <wasmith@ucdavis.edu> wrote:

Hi OHW-NG consortium,

We've just submitted our One Health Workforce - Next Generation application and have received email confirmation from USAID! Thanks to everyone for contributing your ideas, energy, enthusiasm, and time to this effort. Attached are the final technical narrative and the associated annexes, as two separate files, including 36 letters of commitment and support that speak to the impressive breadth of our teams and networks. We will certainly be in touch as we have updates and look forward to finding more ways to collaborate in the future.

Very best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Acting Director, One Health Institute
Professor of Infectious Disease Epidemiology
USAID PREDICT-2 Global Capacity Team and Ethiopia lead
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis
1089 Veterinary Medicine Dr
Davis, CA 95616 USA
wasmith@ucdavis.edu
+1 530 219-1369

<Annexes-OHW-NG-UCDavis_Tech_App-4-8-19-final.pdf><Tech-App-No-Annexes-OHW-NG-UCD-4-8-19-final.pdf>

From: "McNeil, Carrie S." <csmcnei@sandia.gov>
To: Jutta Lehmer <JLehmer@salud.unm.edu>
Cc: Woutrina A Smith <wasmith@ucdavis.edu>, Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, "Hunt, Christine T." <ch3326@cumc.columbia.edu>, "Parish, Sarah A." <sp3546@cumc.columbia.edu>, "Costa, Cristiane" <co123@cumc.columbia.edu>, "William B. Karesh" <Karesh@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "Peter Daszak" <daszak@ecohealthalliance.org>, Matthew Blake <mblake@ucdavis.edu>, Brian H Bird <bhbird@gmx.ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Nicole R Gardner <nrgardner@ucdavis.edu>, "Molly Turner" <turner@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Kevin Olival <olival@ecohealthalliance.org>, Alexandra Zuber [redacted], Tracey Goldstein <tgoldstein@ucdavis.edu>, "kp2440@cumc.columbia.edu" <kp2440@cumc.columbia.edu>, Amy J Armistad <AArmistad@salud.unm.edu>, "Hannah R Chale" <hrchale@ucdavis.edu>, Michael S Wilkes <mswilkes@ucdavis.edu>, "Martin H. Smith" <mhsmith@ucdavis.edu>, Patricia Ann Conrad <paconrad@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, "Corina Grigorescu Monagin" <cgmonagin@ucdavis.edu>, Federico Castillo <f.castillo@berkeley.edu>, Ndola PRATA <ndola@berkeley.edu>, "Bridgette Phebean Smith" <brpsmith@ucdavis.edu>, Sam Halabi <sfh9@georgetown.edu>, "Omar Romero-hernandez" <oromero@haas.berkeley.edu>, "mr84@columbia.edu" <mr84@columbia.edu>, Emily L Byers <ElByers@salud.unm.edu>, Alison Andre <andre@ecohealthalliance.org>, [redacted], "Sanzero, George" <gsanzer@sandia.gov>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Catherine Machalaba <machalaba@ecohealthalliance.org>, Bruce B Struminger <BStruminger@salud.unm.edu>, Jennifer K Lane <jklane@ucdavis.edu>, "Terra Kelly" <trkelly@ucdavis.edu>, "Wafaa M. El-Sadr" <wme1@cumc.columbia.edu>
Subject: Re: [EXTERNAL] RE: Complete! OHW-NG proposal submitted
Sent: Mon, 8 Apr 2019 17:45:36 +0000

So exciting! We are honored to be part of such a great team. Thank you to Woutrina for all your leadership on this effort and to the UCD group for everything!
Carrie

Sent from my iPhone

On Apr 8, 2019, at 11:41 AM, Jutta Lehmer <JLehmer@salud.unm.edu> wrote:

> Hooray! Congratulations team. It's been a wonderful experience working with you all. Hoping for a positive response, so we can implement this together! Thanks all. Jutta
>
> **Jutta Lehmer, BA**
> Program Planning Manager Global HIV Initiative
> ECHO Institute™
> University of New Mexico Health Sciences Center
> Cell: +1.505.234.6046
> jlehmer@salud.unm.edu
> http://echo.unm.edu/ <image001.png>@ProjectECHO
> <image002.png>

From: Woutrina A Smith <wasmith@ucdavis.edu>
Sent: Monday, April 8, 2019 10:34 AM
To: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>; Hunt, Christine T. <ch3326@cumc.columbia.edu>; Parish, Sarah A. <sp3546@cumc.columbia.edu>; Costa, Cristiane <co123@cumc.columbia.edu>; William B. Karesh <Karesh@ecohealthalliance.org>; Evelyn Luciano <luciano@ecohealthalliance.org>; Jonna Mazet <jkmazet@ucdavis.edu>; Peter Daszak <daszak@ecohealthalliance.org>; Matthew Blake <mblake@ucdavis.edu>; Brian H Bird <bhbird@gmx.ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>; Nicole R Gardner <nrgardner@ucdavis.edu>; Molly Turner <turner@ecohealthalliance.org>; Jon Epstein <epstein@ecohealthalliance.org>; Kevin Olival <olival@ecohealthalliance.org>; Alexandra Zuber [redacted]>; Tracey Goldstein <tgoldstein@ucdavis.edu>; kp2440@cumc.columbia.edu; Amy J Armistad <AArmistad@salud.unm.edu>; Hannah R Chale <hrchale@UCDAVIS.EDU>; Michael S Wilkes <mswilkes@ucdavis.edu>; Martin H. Smith <mhsmith@ucdavis.edu>; Patricia Ann Conrad <paconrad@ucdavis.edu>; David John Wolking <djwolking@ucdavis.edu>; Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>; Federico Castillo <f.castillo@berkeley.edu>; Ndola PRATA <ndola@berkeley.edu>; Bridgette Phebean Smith <brpsmith@ucdavis.edu>; Sam Halabi <sfh9@georgetown.edu>; Omar Romero-hernandez <oromero@haas.berkeley.edu>; mr84@columbia.edu; Emily L Byers <ElByers@salud.unm.edu>; McNeil, Carrie S.

<csmcnei@sandia.gov>; Alison Andre <andre@ecohealthalliance.org>; [redacted]; Sanzero, George <gsanzer@sandia.gov>; Anthony, Simon J. <sja2127@cumc.columbia.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Catherine Machalaba <machalaba@ecohealthalliance.org>; Jutta Lehmer <jlehmer@salud.unm.edu>; Bruce B Struminger <BStruminger@salud.unm.edu>; Jennifer K Lane <jklane@ucdavis.edu>; Terra Kelly <trkelly@ucdavis.edu>; Wafaa M. El-Sadr <wme1@cumc.columbia.edu>

Subject: Complete! OHW-NG proposal submitted

[[-- External - this message has been sent from outside the University --]]

Hi OHW-NG consortium,

We've just submitted our One Health Workforce - Next Generation application and have received email confirmation from USAID! Thanks to everyone for contributing your ideas, energy, enthusiasm, and time to this effort. Attached are the final technical narrative and the associated annexes, as two separate files, including 36 letters of commitment and support that speak to the impressive breadth of our teams and networks. We will certainly be in touch as we have updates and look forward to finding more ways to collaborate in the future.

Very best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Acting Director, One Health Institute
Professor of Infectious Disease Epidemiology
USAID PREDICT-2 Global Capacity Team and Ethiopia lead
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis
1089 Veterinary Medicine Dr
Davis, CA 95616 USA
wasmith@ucdavis.edu
+1 530 219-1369

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: William B. Karesh <karesh@ecohealthalliance.org>
Sent: 6/20/2019 7:57:07 PM
Subject: Re: PREDICT Jordan

Nice job!
J

On Thu, Jun 20, 2019 at 5:47 AM William B. Karesh <karesh@ecohealthalliance.org> wrote:
Hi Maysa,

Out of professional curtesy and respect for all of the help you have given the project, I wanted to update you on why we've been a bit slow on responding to plans for the official opening of the two labs in July that were funded with USAID/J Mission funds, and our planning of project close out activities under the main project budget.

As you may know, the Jordan Mission funds transferred in July of 2018 have not been provided to UC Davis and hence to EHA. In addition, no agreements with USAID/W have been signed for any activities for Year 5 (Oct. 1st, 2018) though we have been working under the assumption that this would occur. USAID/W has been flexible in allowing the use of some other funds from other work streams of the project to be used for our Year 5 work until final approvals could be made. Those funds are now exhausted, as have creative financing ideas, so we may not be able to continue any work.

If approvals come soon, we would very much like to officially open the labs with government partners and hold a project close-out meeting in mid-July as originally hoped, and then provide you with final reports on activities, findings and recommendations at the end of the project. At this point in time, it is unclear what will happen and there may be no funding for any of that work.

Of course, we are still holding out hope that funding will be made available. And, I would be honored to attend the lab and close out meetings if funds become available and Andrew is able to help expedite an ITA.

It's been such a professional pleasure to have worked with you and I can't thank you enough. I hope we can find ways in the future to keep supporting the great efforts being made in Jordan.

All the Best,

Billy

William B. Karesh, D.V.M
Executive Vice President for Health and Policy

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife

health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

UCDUSR00004367

From: Andrew Clements <aclements@usaid.gov>
Sent: Tue, 1 Oct 2019 09:52:49 -0400
Subject: Re: Updated invitation: SMT call @ Tue Oct 1, 2019 6:30pm - 7:30pm (CEST) (aclements@usaid.gov)
To: David J Wolking <djwolking@ucdavis.edu>
Cc: Alisa Pereira Emerging Threats Division <apereira@usaid.gov>, "Prof. Jonna Mazet" [redacted], PREDICTMGT <predictmgt@usaid.gov>

Thanks!

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Oct 1, 2019, at 3:48 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

> No change, this calendar invite is an error we are still on for the usual time of 8:30 a.m. Pacific. Sorry for any confusion and talk to you soon.

David

On Tue, Oct 1, 2019, 3:15 AM Alisa Pereira <apereira@usaid.gov> wrote:

> Cara and I actually have a conflict with the new time

Sent from my iPhone

On Oct 1, 2019, at 4:14 AM, Andrew Clements <aclements@usaid.gov> wrote:

> huh? I thought we were on a regular schedule of 11:30-12:30 EDT. Why the unannounced change?

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see http://www.usaid.gov/ept2

On Mon, Sep 30, 2019 at 11:52 PM <[redacted]> wrote:

This event has been changed.

more details »

SMT call

Reoccurring bi-weekly on Tuesday's from 10-11am PDT / 1-2pm EDT

When: **Changed:** Tue Oct 1, 2019 6:30pm – 7:30pm Central European Time - Zurich

Where: [redacted]

Calendar: aclements@usaid.gov

Who:
- Jonna Mazet - organizer
- erubin@metabiota.com

- David J Wolking
- apereira@usaid.gov
- cchrisman@usaid.gov
- Elizabeth Leasure
- ckjohnson@ucdavis.edu
- Peter Daszak
- karesh@ecohealthalliance.org
- Matthew Blake
- aclements@usaid.gov

Going (aclements@usaid.gov)? Yes - Maybe - No more options »

Invitation from Google Calendar

You are receiving this email at the account aclements@usaid.gov because you are subscribed for updated invitations on calendar aclements@usaid.gov

To stop receiving these emails, please log in to https://www.google.com/calendar/ and change your notification settings for this calendar.

Forwarding this invitation could allow any recipient to send a response to the organizer and be added to the guest list, or invite others regardless of their own invitation status, or to modify your RSVP. Learn More

--

You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to
predictmgt+unsubscribe@usaid.gov.
To view this discussion on the web visit
https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/CAJT_2LHOgqKtJH62S7Y%3Da%2BsLiGJv-EWVG-iO2QAa1ZOzmYFhQw%40mail.gmail.com.

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
To: "William B. Karesh" <karesh@ecohealthalliance.org>
Cc: David John Wolking <djwolking@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Hannah R Chale <hrchale@ucdavis.edu>, predict Sympa List <predict@ucdavis.edu>
Sent: Tue, 5 Nov 2019 21:09:34 +0000
Subject: [predict] RE: Jordan Vehicle disposition

Hi Billy. Looks like we're still waiting on receipt of the equipment disposition request letter and inventory for Jordan, so we won't be able to approve anything until those items are received. Sorry, I thought we had them already, but apparently not.

Thanks,
Liz

Elizabeth Leasure
Financial Operations Manager
One Health Institute
REDACTED *(cell)*
530-754-9034 (office)
Skype: ealeasure

From: Elizabeth Leasure
Sent: Monday, November 4, 2019 8:00 AM
To: William B. Karesh <karesh@ecohealthalliance.org>
Cc: David John Wolking <djwolking@ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>; Evelyn Luciano <luciano@ecohealthalliance.org>; Ava Sullivan <sullivan@ecohealthalliance.org>; Hannah R Chale <hrchale@ucdavis.edu>; predict Sympa List <predict@ucdavis.edu>
Subject: RE: Jordan Vehicle disposition

I'm hoping this week.

Elizabeth Leasure
Financial Operations Manager
One Health Institute
REDACTED *(cell)*
530-754-9034 (office)
Skype: ealeasure

From: William B. Karesh <karesh@ecohealthalliance.org>
Sent: Monday, November 4, 2019 7:59 AM
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Cc: David John Wolking <djwolking@ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>; Evelyn Luciano <luciano@ecohealthalliance.org>; Ava Sullivan <sullivan@ecohealthalliance.org>; Hannah R Chale <hrchale@UCDAVIS.EDU>; predict Sympa List <predict@ucdavis.edu>
Subject: Re: Jordan Vehicle disposition

Thanks Liz!!

Do you have a sense of when that may occur?

BK

On Nov 4, 2019, at 10:48 AM, Elizabeth Leasure <ealeasure@UCDAVIS.EDU> wrote:

Hi Billy. We're just waiting for the disposition approval letter to be finalized, then we'll be able to move forward with sending out official approval notices.

Thanks,
Liz

Elizabeth Leasure
Financial Operations Manager
One Health Institute
REDACTED *(cell)*
530-754-9034 (office)
Skype: eleasure

From: William B. Karesh <karesh@ecohealthalliance.org>
Sent: Monday, November 4, 2019 7:45 AM
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; David John Wolking <djwolking@ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>
Cc: Evelyn Luciano <luciano@ecohealthalliance.org>; Ava Sullivan <sullivan@ecohealthalliance.org>
Subject: Jordan Vehicle disposition

Hi Everyone,

Would it be possible to expedite the Jordan vehicle transfer to the university there as we requested? The license expires in December as does the permission exemption from customs and duty taxes.

The project ended Sept 30th as we were instructed, so the USAID Mission and the local partners are hoping to move forward.

Thanks,

BK

William B. Karesh, D.V.M
Executive Vice President for Health and Policy

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: Andrew Clements <aclements@usaid.gov>
Sent: Tue, 19 Nov 2019 02:56:08 -0500
Subject: Re: Request: Final Obligation-Country Breakdown
To: David J Wolking <djwolking@ucdavis.edu>
Cc: Amalhin Shek <ashek@usaid.gov>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, akibria@usaid.gov, Alisa Pereira <apereira@usaid.gov>

Have not gotten confirmation yet from OAA about the report change being part of the mod, but did ask if it can be done. Cara/Alisa/Amalhin: can you follow up with Anna/Jose/Patricia? You were copied on an email from me to them (sent either 11/15/19 or 11/16/19). Thanks.

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Nov 18, 2019, at 10:45 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

> Hey Amalhin and Andrew,
> Just checking in that the next mod will also include they key personnel change and change in reporting (the 5-year replacing the Year 5 annual report) as discussed in our separate threat correct?

Thanks in advance!

David

On Mon, Nov 18, 2019 at 1:38 PM Amalhin Shek <ashek@usaid.gov> wrote:

> Hi Liz,

Thanks for sending over-- just a clarification, the total obligated will be $1.8M, so the $150K for Liberia, and the remaining $1.65M spread across the rest of the countries.

Thanks in advance,

Amalhin Shek | Budget & Communications Analyst
Bureau for Global Health, Office of Infectious Diseases, Emerging Threats Division
Phone: 202-916-2069(o) [redacted] (c) | UA 4.6.2H

USAID Contractor
GHSI-III - Social Solutions International, Inc.

On Mon, Nov 18, 2019 at 4:23 PM Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Amalhin. Is the attached sufficient (sent separately to Andrew) or do you need me to revise the spreadsheet you sent? Sorry for the delayed response. I'm still getting caught up after my trip to Bangkok last week.
>
> Thanks,
>
> Liz

Elizabeth Leasure

Financial Operations Manager

One Health Institute

REDACTED *(cell)*

530-754-9034 (office)

Skype: eleasure

From: Amalhin Shek <ashek@usaid.gov>
Sent: Friday, November 15, 2019 2:37 PM
To: Elizabeth Leasure <eqleasure@UCDAVIS.EDU>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>; David John Wolking <djwolking@ucdavis.edu>; Cara Chrisman <cchrisman@usaid.gov>; Andrew <aclements@usaid.gov>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>
Subject: Request: Final Obligation-Country Breakdown

Hi Liz,

Per last MT call, we are working with our program office to process an obligation of $150,000 (that can only be used in Africa) while we receive the remaining FY19 funds. Given the change in the extension period, could you help me complete the attached to make sure we have all the necessary documentation regarding the obligations by country? These levels must align with the exact country amounts to be disbursed between their obligation and the end of the award.

Thanks in advance!

Amalhin Shek | **Budget & Communications Analyst**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
Phone: 202-916-2069(o) REDACTED (c) | UA 4.6.2M

USAID **Contractor**
GHSI-III - Social Solutions International, Inc.

From: Andrew Clements <aclements@usaid.gov>
Sent: Mon, 25 Nov 2019 17:38:19 +0100
Subject: Re: Request: Final Obligation-Country Breakdown
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
Cc: Amalhin Shek <ashek@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, predict Sympa List <predict@ucdavis.edu>, "Pereira, Alisa (GH/HIDN)" <apereira@usaid.gov>

Hi Liz,

Given that the Ebola funding was reduced from $150,000 to $120,000 in mod 17, please confirm that the from the $1,680,000 (instead of $1,650,000) or core funds, the "extra" $30,000 should go to Liberia so that the overall totals in the attached country allocations are unchanged.

Thanks!

Andrew

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-349-4151
E-mail: aclements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see http://www.usaid.gov/ept2

On Tue, Nov 19, 2019 at 10:45 PM Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Amalhin, Not sure whether you still need this or not, but an updated spreadsheet is attached per your request.

Thanks,

Liz

Elizabeth Leasure

Financial Operations Manager

One Health Institute

REDACTED *(cell)*

530-754-9034 (office)

Skype: ealeasure

From: Amalhin Shek <ashek@usaid.gov>
Sent: Friday, November 15, 2019 2:37 PM
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>; David John Wolking <djwolking@ucdavis.edu>; Cara Chrisman <cchrisman@usaid.gov>; Andrew <aclements@usaid.gov>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>
Subject: Request: Final Obligation-Country Breakdown

Hi Liz,

Per last MT call, we are working with our program office to process an obligation of $150,000 (that can only be used in Africa) while we receive the remaining FY19 funds. Given the change in the extension period, could you help me complete the attached to make sure we have all the necessary documentation regarding the obligations by country? These levels must align with the exact country amounts to be disbursed between their obligation and the end of the award.

Thanks in advance!

Amalkin Shah | **Budget & Communications Analyst**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
Phone: 202-916-2069(o) [redacted] (c) | UA 4.6.2H

USAID **Contractor**
GHSI-III - Social Solutions International, Inc.

From: Jose Nunez Grullon <jnunezgrullon@usaid.gov>
To: Paula Noble <pnoble@ucdavis.edu>
CC: Elizabeth Leasure <ealeasure@ucdavis.edu>;Jonna Mazet <jkmazet@ucdavis.edu>;Andrew Clements <aclements@usaid.gov>
Sent: 1/6/2020 11:52:40 AM
Subject: Re: AID-OAA-A-14-000102 Mod 19

Dear Ms. Noble,

I hereby confirm receipt of your email below and its attachment. We will be processing and reverting to you in due course.

Sincerely,

JOSE L. NUNEZ
Acquisition and Assistance Specialist, MFOAA/GH
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT
New Location
USAID Annex (UA) Room 11-A2E
508 D St
Washington, DC, 20547
T 202 916 2640
(Contractor-Jefferson Solutions, LLC)

On Fri, Jan 3, 2020 at 12:47 PM Paula Noble <pnoble@ucdavis.edu> wrote:

Dear Jose,

Attached, please find a partially executed copy of Modification 19.

Please return a fully executed copy for our files.

Paula Noble

Assistant Director, Negotiations & Subawards

Office of Research, Sponsored Programs University of California, Davis

(530) 754-8115

From: Jose Nunez Grullon <jnunezgrullon@usaid.gov>
Sent: Thursday, January 2, 2020 7:45 AM
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Paula Noble <pnoble@ucdavis.edu>; Jonna Mazet <jkmazet@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>
Subject: AID-OAA-A-14-000102 Mod 19

Dear Ms. Leasure,

Please find attached draft mod 19 to subject award for your review and signature prior AO's signature.

Should you have any questions, please do not hesitate to contact me.

Sincerely,

JOSE L. NUNEZ
Acquisition and Assistance Specialist, M/OAA/GH
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT
New Location

USAID Annex (UA) Room 11-4.2E
500 D St
Washington, DC, 20547
T 202 916 2640

(Contractor-Jefferson Solutions, LLC)

From: Matthew Blake <mblake@ucdavis.edu>
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>;Matthew Blake <mblake@ucdavis.edu>;oromero@haas.berkeley.edu" <oromero@haas.berkeley.edu>;f.castillo@berkeley.edu" <f.castillo@berkeley.edu>;daszak@ecohealthalliance.org" <daszak@ecohealthalliance.org>;William B. Karesh" <karesh@ecohealthalliance.org>;Sam Halabi <sfh9@georgetown.edu>;Jonna Mazet <jkmazet@ucdavis.edu>;Woutrina A Smith <wasmith@ucdavis.edu>
Sent: 2/10/2020 10:42:27 PM
Subject: AFROHUN NUPAS Taskforce (ANT)

Hello potential ANT member,

I am sending this email as the official kick-off of the OHW-NG NUPAS of AFROHUN. As a reminder, we are performing this exercise as a way of benchmarking AFROHUN on the various criteria that USAID requires of Non-US organizations before those organizations are awarded funds. Our goal in this endeavor is to identify opportunities for improvement within the six criteria of the NUPAS, and incorporate those opportunities into the strategic planning process, in order that improvements may be woven into short- and middle-term tactics and metrics. Our taskforce is not making a funding decision, and so while we are performing the NUPAS, our end goal is slightly different than that prescribed in the guidelines – our goal is to make certain AFROHUN easily aces the NUPAS in 2 years when USAID performs the survey.
We will begin by self-selecting the criterion or criteria (see below) which we individually feel we can best evaluate, and, for criteria with >1 person, form smaller teams for the assessment of the items in each criterion. Additionally, we will list the documents still needed (where applicable), questions raised, and thoughts for next steps for each item.
So, to start, please read the guidelines if you have not already done so, noting that links to the NUPAS itself are on the last page (12 of 12), and then let me know where you see yourself adding the most value to our ANT in review of the criteria below (copied from page 8 of the guidelines). I will note team members and send guidance in return. Please let me know your criteria by EOD Thursday the 13th and I'll circulate next steps on Friday morning. The ANT is scheduled to have completed its efforts by March 14th.
Please let me know if you have any questions.

Best,
Matt

First Criterion: Legal Structure

- 1.1 Local Organization Definition (if competition is limited to local entities)
- 1.2 Legal Requirements
- 1.3 Organizational Structure
- 1.4 Governance
- 1.5 Control Environment

Second Criterion: Financial Management and Internal Control Systems

- 2.1 Banking Relationship and Accounts
- 2.2 Accounting/Bookkeeping System
- 2.3Chart of Accounts, General Ledger and Financial Statements
- 2.4 Variance Analysis (Budget to Actual Cost)
- 2.5 Allowable and Unallowable Cost
- 2.6 Direct and Indirect Cost
- 2.7 Payments –Segregation of Duties
- 2.8 Accounting Cycle –Segregation of Duties
- 2.9 Financial Records Management
- 2.10Sources of Funding
- 2.11 Financial Reporting
- 2.12 Audit and Review of Financial Statements

2.13 Financial Management Personnel

Third Criterion: Procurement Systems

3.1 Procurement Policies, Procedures and Practices

3.2 Compliance with Policies and Procedures –Reasonableness of Price

3.3 Procurement and Sub-awards

Fourth Criterion: Human Resources Systems

4.1 Overall HR Policies and Procedures

4.2 Staff Time Management

4.3 Payroll System

4.4 Travel Policies and Procedures

Fifth Criterion: Project Performance Management

5.1 Technical Evaluation Criteria(TEC to determine)

5.2 Project Management Capacity

Sixth Criterion: Organizational Sustainability

6.1 Cash Flow Management

6.2 Absorptive Capacity

From: alexandra zuber <alexandrazuber@atahealthstrategies.com>
To: Matthew Blake <mblake@ucdavis.edu>;Elizabeth Leasure <ealeasure@ucdavis.edu>;Omar Romero-hernandez <oromero@haas.berkeley.edu>;Federico Castillo, PhD <f.castillo@berkeley.edu>;daszak@ecohealthalliance.org <daszak@ecohealthalliance.org>;William B. Karesh <karesh@ecohealthalliance.org>;Sam Halabi <sfh9@georgetown.edu>;Jonna Mazet <jkmazet@ucdavis.edu>;Woutrina A Smith <wasmith@ucdavis.edu>
Sent: 2/12/2020 6:57:14 PM
Subject: Re: AFROHUN NUPAS Taskforce (ANT)

Hi all,
The Appendix links in the USAID NUPAS guidance document have never worked for me, so I had previously tracked down the documents and put them the Objective 3 Box folder, under "Tools" /"OCA and NUPAS tools": https://app.box.com/folder/93988285244.

In that folder, you'll find things like: NUPAS guidance for facilitators, NUPAS guidance for receiving organizations, NUPAS questions for consideration, and the actual NUPAS tool. I'm attaching the last two for your quick reference.

Alexandra Zuber, MPP, DrPH
Founder and CEO, Ata Health Strategies, LLC
Email: alexandrazuber@atahealthstrategies.com
Phone: +1 (617) 680-3950
LinkedIn: alexandrazuber/
Website: www.atahealthstrategies.com
Twitter: @alexandrazuber

From: Matthew Blake
Date: Monday, February 10, 2020 at 3:42 PM
To: Elizabeth Leasure , Matthew Blake , "oromero@haas.berkeley.edu" , "f.castillo@berkeley.edu" , "daszak@ecohealthalliance.org" , "William B. Karesh" , Sam Halabi , Jonna Mazet , Woutrina A Smith
Subject: AFROHUN NUPAS Taskforce (ANT)

Hello potential ANT member,

I am sending this email as the official kick-off of the OHW-NG NUPAS of AFROHUN. As a reminder, we are performing this exercise as a way of benchmarking AFROHUN on the various criteria that USAID requires of Non-US organizations before those organizations are awarded funds. Our goal in this endeavor is to identify opportunities for improvement within the six criteria of the NUPAS, and incorporate those opportunities into the strategic planning process, in order that improvements may be woven into short- and middle-term tactics and metrics. Our taskforce is not making a funding decision, and so while we are performing the NUPAS, our end goal is slightly different than that prescribed in the guidelines – our goal is to make certain AFROHUN easily aces the NUPAS in 2 years when USAID performs the survey.
We will begin by self-selecting the criterion or criteria (see below) which we individually feel we can best evaluate, and, for criteria with >1 person, form smaller teams for the assessment of the items in each criterion. Additionally, we will list the documents still needed (where applicable), questions raised, and thoughts for next steps for each item.
So, to start, please read the guidelines if you have not already done so, noting that links to the NUPAS itself are on the last page (12 of 12), and then let me know where you see yourself adding the most value to our ANT in review of the criteria below (copied from page 8 of the guidelines). I will note team members and send guidance in return. Please let me know your criteria by EOD Thursday the 13th and I'll circulate next steps on Friday morning. The ANT is scheduled to have completed its efforts by March 14th.
Please let me know if you have any questions.

Best,
Matt

First Criterion: Legal Structure

1.1 Local Organization Definition (if competition is limited to local entities)
1.2 Legal Requirements
1.3 Organizational Structure
1.4 Governance
1.5 Control Environment

Second Criterion: Financial Management and Internal Control Systems

2.1 Banking Relationship and Accounts
2.2 Accounting/Bookkeeping System
2.3Chart of Accounts, General Ledger and Financial Statements
2.4 Variance Analysis (Budget to Actual Cost)
2.5 Allowable and Unallowable Cost
2.6 Direct and Indirect Cost
2.7 Payments –Segregation of Duties
2.8 Accounting Cycle –Segregation of Duties
2.9 Financial Records Management
2.10Sources of Funding
2.11 Financial Reporting
2.12 Audit and Review of Financial Statements
2.13 Financial Management Personnel

Third Criterion: Procurement Systems

3.1 Procurement Policies, Procedures and Practices
3.2 Compliance with Policies and Procedures –Reasonableness of Price
3.3 Procurement and Sub-awards

Fourth Criterion: Human Resources Systems

4.1 Overall HR Policies and Procedures
4.2 Staff Time Management
4.3 Payroll System
4.4 Travel Policies and Procedures

Fifth Criterion: Project Performance Management

5.1 Technical Evaluation Criteria(TEC to determine)
5.2 Project Management Capacity

Sixth Criterion: Organizational Sustainability

6.1 Cash Flow Management
6.2 Absorptive Capacity

Appendix A1 – NON-U.S. ORGANIZATION PRE-AWARD SURVEY (NUPAS)

Name of Organization _____
Type of Organization _____
Proposed Activity/Amount _____
Assessment Conducted by _____
Dates Conducted _____

A **NUPAS**, using the following matrix, should be performed for all non-U.S. awards to assist Agreement Officers in making responsibility determinations through assessment of a potential awardee's likelihood for compliance with the **Standard Provisions for Non-U.S. Nongovernmental Recipients**.

NUPAS Objectives:

1. To determine whether the non-U.S. organization has sufficient financial and managerial capacity to manage USAID funds in accordance with U.S. Government and USAID requirements;
2. To determine the most appropriate method of financing to use under the potential USAID award; and
3. To determine the degree of support and oversight necessary to ensure proper accountability of funds to be potentially provided to the organization.

UCDUSR0004082

y and Risk Review	No.	Scoring: 1 INADEQUATE CAPACITY Key Deficiencies and SW Not Remediable Before Award — High Risk		Scoring: 2 WEAK CAPACITY Some Deficiencies and SW Not Easily Remediable Before Award — Moderate to High Risk		Scoring: 3 ADEQUATE CAPACITY No Deficiencies SW (if any) Remediable Before Award — Low to Moderate Risk		Scoring: 4 (Highest Score) STRONG CAPACITY No Deficiencies or SW — Low Risk		Score	Remarks/ Recommendations
en: LEGAL STRUCTURE											
Organization											
mpliance with al organization" *(Only applicable if + intends to limit n to local inc.)*	1	Organization does not meet the definition and has no plan or capacity to change.		Organization does not meet the definition and has a plan by which it will meet the definition within 2 – 4 months.		Organization meets the definition and there are some contingencies or conditions that make maintaining such status challenging or uncertain.		Organization meets the definition and has stable conditions for maintaining such status.			
								Score			
Requirements											
mpliance with ration its and other enses, permits, gulations.	2	Organization is not legally registered or registration has expired. Organization lacks one or more required permits or licenses to operate. Organization is not aware of its obligations under required licenses and permits or applicable tax, labor, occupational health and safety, environmental, or other material laws and regulations. Or, the organization is aware but has not yet applied for the permits/licenses.		Organization has applied for legal status and is not yet a legally recognized entity in the country in which it operates. Organization has applied for and has not yet obtained one or more required permits or licenses to operate. Organization is aware of its obligations under required licenses and permits or applicable tax, labor, occupational health and safety, environmental, or other material laws and regulations.		Organization is legally registered and has all required permits and licenses to operate. Organization is aware of its obligations under its licenses and permits and applicable tax, labor, occupational health and safety, environmental, and other material laws and regulations; is in substantial compliance with all such legal obligations. The organization is taking (or plans to take,) corrective action where needed.		Organization is legally registered; has, and is fully compliant with, all required permits and licenses to operate; is aware of its tax status and is fully compliant with applicable tax, labor, occupational health and safety, environmental, and other material laws and regulations relevant to its operations.			
								Score			

ence for definitions of "Deficiency," Significant Weakness," and "Weakness." SW = Significant Weaknesses).

UCDUSR0004083

isational Structure											
at the n's charter, by- ther al/operational , support its d goals.	3	Organization has no formal organizational structure; there are clearly inadequate or entirely missing definitions of departmental or functional responsibilities and lines of responsibility; lines of communication among departments or key functions are weak. The organization has no defined mission.		Organization has less than an adequate organizational structure; roles and responsibilities of departments or functions and lines of communication are not well defined, and the organization does not have a defined mission.		Organization has an adequate organizational structure, adequately designed and relevant to its mission and goals, roles and responsibilities of departments or functions and lines of communication are adequately defined and appropriate.		Organization has a strong organizational structure, well designed and highly relevant to its mission and goals, roles and responsibilities of departments or functions and lines of communication are well-defined and highly appropriate.			
								Score			
nance											
at the organization s the importance ctices good governance in all (Refer to OECD of Corporate n: right and reatments of rs (only used for nizations), f other rs, role and ity of the board, d ethical Disclosure and cy.)	4	Management of the organization does not adequately emphasize and the organization does not practice good corporate governance in key areas. Deficiencies and SW in key areas of corporate governance are not remediable prior to award.		There is marginal involvement by organization's management in addressing the importance of good corporate governance in key areas. Deficiencies and SW** in one or more key areas of corporate governance may not be easily remediable.		Organization's management addresses the importance of good corporate governance in key areas, and there are a few weaknesses in one or more areas of corporate governance. These are remediable.		Organization's management regularly and consistently emphasizes the importance of and practices good corporate governance (as broadly defined) in all key areas.			
								Score			
al Environment											

UCDUSR0004084

at adequate exist within the n to ensure iduciary and prevent m obtaining non-financial the basis of ade or actions re official	5	Board does not have terms of reference or a clear understanding of its key functions. Board term limits are not defined or are unreasonable. There is no approved process for electing/ appointing/removing Board members and officers. Organization has no or negligible fiduciary risk controls covering Board members, officers, and employees; there are no credible mechanisms for enforcement of such policies and controls. The control environment is so deficient it presents an unacceptable level of risk.		Board has incomplete or otherwise inadequate terms of reference and lacks an adequate understanding of its key functions; key functions are carried out inconsistently. Board term limits are not defined or are unreasonable. No approved process for electing, appointing or removing Board members and officers is in place. Organization has inadequate fiduciary risk controls covering Board members, officers, and employees; there are inadequate mechanisms for enforcement of such policies and controls.		Board has adequate terms of reference and an adequate understanding of its key functions and those functions are carried out generally well. Board term limits are defined and reasonable. Board members and officers are elected/ appointed/ removed in an acceptable manner. Organization has fiduciary risk controls covering Board members, officers, and employees; adequate mechanisms for enforcement of such policies and controls are in place.		Board has clear terms of reference and a good understanding of its key functions and those key functions are carried out consistently well. Board term limits are defined and reasonable. Board members and officers are elected/appointed/ removed in accordance with applicable laws and approved, written procedures. Organization has fiduciary risk controls covering Board members, officers, and employees; effective mechanisms for enforcement of such policies and controls are in place.			
								Score			
								Average Score for LEGAL STRUCTURE			

UCDUSR0004085

tion: FINANCIAL MANAGEMENT AND INTERNAL CONTROLS SYSTEMS											
g Relationship and Accounts											
e organization has relationship with a commercial bank and that the n has adequate ocedures and place to ensure onciliation of bank ith the accounting	6	Organization has no banking relationship. Organization uses the bank account of a senior employee and funds are commingled with personal funds. Bank accounts are rarely or never reconciled. Overall, the organization's policies, procedures and practices in this area are not adequate.		Organization has no banking relationship, and plans to establish a bank account in a registered banking institution prior to an award. Bank accounts are periodically reconciled. Documentary evidence does not exist to determine, review and approve monthly bank reconciliations. Policies do not stipulate requirements for regular bank reconciliation. Less than adequate action is taken on outstanding items over 60 days.		Organization has a bank account in a registered banking institution and the account is adequate for its mission/goals. Opening and maintaining additional accounts limited to specific purposes may be beneficial. Bank accounts are reconciled on a monthly basis. Adequate documentary evidence exists to determine, review and approve monthly bank reconciliations. Policies stipulate adequate requirements covering regular bank reconciliation. Adequate action is taken on outstanding items over 60 days.		Organization has bank accounts in a registered commercial banking institution that are appropriate for its mission/goals. Bank accounts are accurately reconciled on a monthly basis. Documentary evidence exists to show the dates the monthly bank reconciliations were prepared, and who prepared, reviewed and approved them, with corresponding signatures affixed. *[Note: This includes credible financial management records sufficient for internal and external audit trail purposes.]* Policies stipulate sound requirements covering regular bank reconciliation. Appropriate action is taken on any outstanding item over 60 days.			
								Score			
nting/Bookkeeping System											

UCDUSR0004086

at the organization ounting/ ng system, and al transactions l into the system tent basis in t with applicable policies and . *very small* *ns and awards, a* *ndwritten in* *ble entry* *system may be* *provided it is* *l and used* *y in accordance* *table accounting*	10	Organization does not have an adequate accounting/ bookkeeping system.		Organization's accounting/ bookkeeping system is weak. Financial transactions are not entered into the system on a regular or consistent basis. The bookkeeping system lacks some functionality to automatically reconcile summaries of transactions to the detailed transactions.		Organization has an adequate double entry accounting/ bookkeeping system. Financial transactions are entered into the system on a regular basis. The bookkeeping system has some functionality to automatically reconcile subsidiary ledgers to the main ledger.		Organization has a reliable double entry accounting/bookkeeping system that meets its needs and is otherwise appropriate. Financial transactions are entered into the system on a daily basis. The bookkeeping system has functionalities to automatically reconcile subsidiary ledger to the main ledger.			
								Score			

of Accounts, General Ledger and Financial Statements

UCDUSR0004087

at the organization of accounts and ting General t are used to ancial statements r and consistent r: Request the counts to perform review to ensure ganization has a ance of accounts, dities and owners' (this there is a ature ale" costs.)	11	Organization does not have a chart of accounts or General Ledger or those are not adequate for purposes of the award. The General Ledger numbering system does not follow applicable statutory country requirements (if any). Material financial transactions are not recorded regularly and consistently in accordance with approved accounting standards. Financial Statements are not produced, or if produced, are not derived from the General Ledger (trial balance) in accordance with acceptable accounting standards.		Organization has an incomplete and otherwise weak chart of accounts and General Ledger. The General Ledger numbering system does not follow all applicable statutory country requirements (if any). Material financial transactions are not recorded regularly and consistently in accordance with approved standards. Financial Statements are not derived from the General Ledger (trial balance) in an acceptable manner. Financial Statements are not prepared on a consistent basis in accordance with approved accounting standards.		Organization has a chart of accounts and corresponding General Ledger that is adequate. The General Ledger numbering system follows statutory country requirements (if any) in all material respects. Material financial transactions are recorded regularly and consistently in accordance with approved and otherwise adequate accounting standards, principles and practices. Financial Statements are derived from the General Ledger (trial balance) in an adequate manner. Financial Statements are prepared in accordance with national standards.		Organization has a chart of accounts and corresponding General Ledger that meet its needs and are otherwise appropriate. The General Ledger numbering system follows statutory country requirements (if any) with no exceptions. All financial transactions are recorded regularly and consistently in accordance with approved and otherwise appropriate accounting standards, principles and practices. Financial Statements are regularly and consistently derived from the General Ledger (trial balance). Financial statements are prepared in accordance with applicable national and international standards.			
								Score			
ce Analysis (Budget to Actual Cost)											
at the organization te policies, and practices in sure regular alysis (budget to) of program and nancial data.	14	Organization does not have any or adequate systems to analyze actual data versus budget data. Management is unable to articulate the necessity of variance analysis or to institutionalize the process. Overall, the organization does not have adequate policies, procedures and practices in place.		Financial reports are accompanied by incomplete or otherwise weak budget data and variance analysis (budget to actual cost) reports. Program managers do not have the necessary knowledge, skills, and abilities to objectively review the reports and take corrective action. The organization's policies, procedures and practices for variance analysis are weak.		Adequate financial reports are accompanied by budget data and variance analysis (budget to actual cost) reports. Program managers generally review financial reports and take corrective action. The organization has adequate policies, procedures and practices in place for adequate variance analysis (budget to actual cost) of program and operating financial data.		Appropriate financial reports are accompanied by budget data and variance analysis (budget to actual cost) reports. Program managers consistently review financial reports and take corrective action. The organization has appropriate policies, procedures and practices in place to ensure appropriate regular variance analysis (budget to actual cost) of program and operating financial data.			
								Score			
able and Unallowable Cost											

UCDUSR0004088

at the organization ate policies, and practices in gregate allowable wable and to satisfy donor nts. *(Note: The be as simple as a n.)*	17	Organization's finance personnel or management do not have an adequate understanding or are unable to articulate the concepts surrounding allowable or unallowable cost. Organization does not have adequate policies, procedures and practices in place to segregate allowable and unallowable cost nor to otherwise satisfy other donor requirements.		Organization finance/program personnel have weak understanding of the concept of allowable and unallowable costs from a donor restriction perspective.		Organization finance/program personnel have an adequate level of understanding of the concept of allowable and unallowable costs from a donor restriction perspective. Organization has an adequate system (formal or informal) to adequately track unallowable cost.		Organization finance/program personnel have an appropriate level of understanding of the concept of allowable and unallowable costs from a donor restriction perspective. Organization has an appropriate system to track unallowable cost. Organization has effective policies, procedures and practices in place to ensure clear lines of communication between finance and program staff relative to allowable and unallowable cost.			
								Score			
and Indirect Costs											
at the n's s/bookkeepers derstanding of and indirect costs cost allocation	18	Organization's accountants/bookkeepers do not understand direct costs, indirect costs or cost allocation principles. Organization's accounting records are maintained by personnel with negligible knowledge about direct and indirect costs. The overall capacity of the organization's accountants/ bookkeepers to accurately allocate indirect cost to grants, projects, and other cost objectives according to causal beneficial relationships is negligible. The organization lacks the ability to develop or acquire the minimum acceptable level of capacity in accumulating direct and indirect costs by project.		Organization's accountants/ bookkeepers have a weak understanding of direct costs, indirect cost s and cost allocation principles. Organization's accountants/ bookkeepers have a weak understanding of the concept of "cost objectives" in relation to intermediate and final "cost objectives." Organization's accountants'/ bookkeepers' ability to accurately allocate indirect cost to grants, projects, and other cost objectives according to causal beneficial relationships is weak. Organization's capacity to accumulate direct and indirect costs by project in an acceptable manner is weak.		Organization's accountants/ bookkeepers have an adequate understanding of direct costs, indirect costs and cost allocation principles. Organization's accountants/ bookkeepers have an adequate understanding of the concept of "cost objectives" in relation to intermediate and final "cost objectives." Organization's accountants/ bookkeepers can accurately allocate indirect cost to grants, projects, and other cost objectives according to causal beneficial relationships. Organization has adequate capacity to accumulate direct and indirect costs by project.		Organization's accountants/ bookkeepers have an appropriate understanding of direct costs, indirect costs and cost allocation principles. Organization's accountants/ bookkeepers have an appropriate understanding of the concept of "cost objectives" in relation to intermediate and final "cost objectives." Organization's accountants/ bookkeepers have the requisite level of knowledge, skills and experience in this area to accurately allocate indirect cost to grants, projects, and other cost objectives according to causal beneficial relationships. Organization's skill in accumulating direct and indirect costs by project in an appropriate manner is strong.			

UCDUSR0004089

									Score		
nts - Segregation of Duties											
at the organization , procedures and place regarding of duties to funds above a shold can only be with dual and are supported ntation.	7	There are Deficiencies and SW in the payments cycle that lack proper segregation of duties. Written policies and procedures do not exist, or those that do, are clearly inadequate.		Payments are not supported by complete documentation (e.g., missing vendor invoices). Adequate written financial practices (e.g., internal controls and audit) are absent or deficient.		Payments are supported by adequate documentation. Policies, procedures and practices may fall short of best practices. Approved policies and procedures are generally followed.		There are well thought out and documented policies, procedures and practices that safeguard the payment process. Approved policies and procedures are consistently followed.			
									Score		
unting Cycle - Segregation of Duties											
at the organization its policies, and practices in sure proper of duties with the cycle. *(Note: The of segregation of vary according to the organization rsity of its*	9	Organization does not have the minimum acceptable set of policies, procedures and practices to ensure proper segregation of duties in relation to the management and disbursement of funds.		The organization does not have adequate policies, procedures and practices in place for purposes of the award to ensure proper segregation of duties associated with the accounting cycle. Funds are disbursed without prior approvals and documentation is inadequate.		Organization has an adequate delegation of authority system to ensure that no one person does all the work relating to a full accounting cycle transaction. Approval is usually obtained prior to disbursement of funds and approvals are adequately documented.		Organization has a sound and well documented delegation of authority system appropriate to the size of the organization to ensure that no one person does all the work relating to a full accounting cycle transaction. Organization has sound policies, procedures and practices to ensure that all approvals are documented prior to cash disbursements.			
									Score		
ial Records Management											

UCDUSR0004090

at the organization ste policies, , and practices in sure proper filing ement of Financial d their ease of	1/1	Organization does not have adequate policies, procedures and practices in place to ensure proper filing and management of financial records and their ease of access. Organization has no contingency plan that includes procedures for backup/recovery of financial data for financial and operational continuity.		Organization has incomplete and relatively weak policies, procedures and practices to safeguard financial records. *(The filing system operates on an ad-hoc, informal basis.)* Management does not require filing and records management practices. Organization has a weak contingency plan that has significant gaps in procedures for backup/recovery of financial data for financial and operational continuity.		Organization has adequate policies, procedures and practices in place to safeguard important documents including financial records. *(The filing system is not necessarily centralized or optimal.)* Management supports adequate filing and records management practices throughout the organization. Organization has an adequate contingency plan in place for financial and operational continuity.		Organization has sound policies, procedures and practices in place to safeguard important documents including financial records. *(This includes offsite storage of copies of financial records.)* Management emphasizes and supports standard, practical, efficient and effective filing and records management practices. Organization has a contingency plan for the organization that includes procedures for backup/recovery for financial and operational continuity.			
								Score			
ces of Funding											
at the organization ctivities/programs ential sources of equate for of operations period of the for long term ity. *(Note: This be as simple as parate bank each funding*	1/6	Organization does not have procedures in place to track sources of funding and lacks the capacity to develop and implement such procedures within a reasonable timeframe. The level of professional knowledge, skills and experience of finance personnel in job cost accounting, fund accounting, etc. is negligible. Organization has insufficient sources of funding from other activities /programs and/or from other alternative potential sources of funding.		Organization does not have a system in place to track sources of funding. Organization's bookkeeping system tracks sources of funding through one revenue account. The level of professional knowledge, skills and experience of finance personnel in job cost accounting, fund accounting, etc. is weak. Organization has weak sources of funding from other activities /programs. Organization has weak business development practices in place.		Organization tracks the sources of funding through offline records. Organization's accounting/ bookkeeping system adequately tracks sources of funding. Finance personnel have an adequate level of professional knowledge, skills and experience in job cost accounting, fund accounting, etc. Organization has adequate sources of funding from other activities/ programs and/or from other potential sources of funding. Management articulates the importance diversification of sources of funding. Organization has adequate practices in place for business development and it has a satisfactory reputation for satisfactory work.		Organization has an effective system in place to track sources of funding. Finance personnel have an appropriate level of professional knowledge, skills and experience in job cost accounting, fund accounting, etc. Organization has good sources of funding from other activities/programs and/or from other potential sources of funding. Management clearly articulates the importance of diversification of sources of funding. Organization has good practices in place for business development and has a reputation for good work.			
								Score			
ncial Reporting											

UCDUSR0004091

at the organization ns written ocedures and place to produce nthly and year-to- ial statements d expenditure balance sheet).	1.2	Organization does not have the minimum acceptable set of written policies, procedures and practices in place to produce reliable monthly financial statements (income and expenditure report).		Financial statements are seldom reviewed by management. Management seldom takes corrective actions based its review of financial statements.		Organization produces reasonably adequate financial statements on a regular basis that meet the needs of the organization. Financial statements are reviewed by management. Management generally takes corrective actions based on its review of financial statements.		Organization consistently and accurately produces reliable monthly financial statements from the General Ledger in accordance with its written procedures. The financial statements are reviewed by organization's management and corrective actions are taken when necessary.			
								Score			
t and Review of Financial Statements											
at the organization ne policies and practices in sure that its atements are reviewed on a is by a third party under the laws of y such as a ccounting firm or body or both.	1.3	Financial statements are not usually audited or reviewed. Organization produces internal financial statements with limited or no Notes to the Financial Statements. If Financial Statements were to be audited, an audit firm would be unable to issue an opinion due to the quality of the financial records. If audited, Organization would most likely receive a Qualified Opinion, Adverse Opinion, or Disclaimer of Opinion. An auditor, accountant, regulatory body or other third party has communicated a "Deficiency" or "Significant Deficiency" in internal control that cannot be easily remedied. Review of the financial statements reveals "Going Concern Issues."		Organization has incomplete and otherwise weak policies, procedures and practices. Financial statements are seldom audited or reviewed on a regular basis by a third party recognized under the laws of the country. Organization has received a Qualified Opinion, Adverse Opinion, or Disclaimer of Opinion. An auditor, accountant, regulatory body or other third party has communicated a "Deficiency" or "Significant Deficiency" in internal control. Management is unable to represent that no Deficiency or Significant Deficiency in internal control presently exists. Organization's policies, procedures and practices for managing and closing audit findings and recommendations are weak.		Organization has adequate policies, procedures and practices. Its financial statements are audited or reviewed on a regular basis by a third party recognized under the laws of the country. When financial statements are audited, a Qualified Opinion is acceptable as long as the audit issues raised are not material to financial management and pose either no or very low fiduciary or performance risk. An auditor, accountant, regulatory body or other third party has communicated any "Deficiency" or "Significant Deficiency" in internal control. Organization has adequate policies, procedures and practices in place for managing and closing audit findings.		Organization has appropriate policies, procedures and practices in place. Its financial statements are audited annually by a third party recognized under the laws of the country. Audited financial statements receive an unqualified (unmodified) audit opinion (no Qualified Opinion, Adverse Opinion, or Disclaimer of Opinion). No auditor, accountant, regulatory body or other third party has communicated any "Deficiency" or "Significant Deficiency" in internal control. Organization has appropriate policies, procedures and practices in place for managing and closing audit findings and recommendations.			
								Score			
ntial Management Personnel											

UCDUSR0004092

m that the responsible for accounting and cial management within the m have the counting and cial management ns and	8	The day-to-day financial management is done by a person with neither formal accounting training nor finance related experience. The individuals responsible for discharging accounting and financial management functions do not have the minimum acceptable level of qualifications and experience needed.		The accountant/ bookkeeper is not professionally trained as an accountant and has a limited understanding of management and financial accounting standards, principles and practices. The accountant/ bookkeeper is unable to articulate and apply important concepts, principles and practices and lacks the technical capacity to prepare and monitor operational and project budgets.		The accountant/ bookkeeper is adequately trained and has adequate qualifications and experience. The accountant/ bookkeeper is able to articulate and apply basic concepts, principles and practices of management and financial accounting and reporting. The accountant/bookkeeper has adequate capacity to prepare and monitor budgets including adequate cash flow projections and statements.		The accountant/bookkeeper has professional accounting qualifications that clearly meet the needs of the organization. The accountant/ bookkeeper has strong ability to apply concepts, principles and practices of management and financial accounting and reporting. The accountant/bookkeeper has strong technical capacity and experience to prepare and monitor appropriate budgets including cash flow projections and statements.			
								Score			
Average Score for FINANCIAL MANAGEMENT AND INTERNAL CONTROL SYSTEMS											

UCDUSR0004093

rion: PROCUREMENT SYSTEMS											
rement Policies, Procedures and Practices											
at the organization ement policies, and practices in are adequate. *urement policies, and practices as relating to or purchasing, nd setting d claims; and controls over l related records ot.]*	19	Organization has no or highly inadequate procurement policies, procedures and practices. Staff has not received any or sufficient training in this area. Management has not emphasized the importance of this area.		Organization has less than adequate procurement policies and procedures and practices. In some cases, they are incomplete or otherwise inadequate. Organization's procurement policies, procedures and practices are not well known to staff and are not consistently followed. Staff needs additional training, and management needs to emphasize the importance of procurement procedures.		Organization has adequate procurement policies, procedures and practices in place that are generally appropriate given the country conditions. Any minor exceptions are easily remediable. Organization's procurement policies, procedures and practices are known to staff and are generally adhered to.		Organization complete and well documented procurement policies, procedures and practices that are appropriate to the country conditions. Organization's procurement policies, procedures and practices are known and understood by trained staff and are consistently adhered to, reviewed and updated as necessary.			
								Score			
liance with Policies and Procedures – Reasonableness of Price											
at the organization ith its own d procedures for nations of ness are made for and who in the n is responsible.	21	Organization has no policies and procedures for how determinations of reasonableness are made for purchases and who in the organization is responsible. Little or no supporting documentation exists to verify that competitive procedures are used or that determinations of reasonableness are made in an acceptable manner.		Organization has informal policies and procedures for how determinations of reasonableness are made for purchases and who in the organization is responsible. Supporting documentation to verify compliance is incomplete or otherwise weak.		Organization has adequate policies and procedures that cover competitive procedures, how determinations of reasonableness are to be made, and who is responsible for purchases. Adequate supporting documentation exists to verify compliance.		Organization has well thought out, well documented, and effective policies and procedures that require competitive procedures and dictate how determinations of reasonableness are to be made and specify who is responsible for purchases. Complete and accurate supporting documentation exists to verify compliance.			
								Score			
rement and Sub-awards											

UCDUSR0004094

at the organisation the policies, , and practices in rocurement and processes using h bargaining.	70	Organization does not have adequate procurement and sub-award management policies, procedures and practices in place. There are no effective policies and procedures to prevent or detect conflicts of interest. Training, mentoring and oversight is negligible.		Organization has incomplete and relatively weak policies and procedure covering sub-grant awards and management. Policies, procedures and practices are inappropriate and may lend themselves to potential conflicts of interest and actions that are not in the best interests of the organisation. Formal training in this area is non-existent or weak.		Organization has adequate policies and procedures that are adequately communicated and generally effective. Employees are expected to avoid conflicts of interests and achieve value for money in this area, by acting in a manner consistent with the best interests of the organisation. Employees have been trained and generally follow policies and procedures.		Organization has well documented and communicated policies and procedures that are effective in practice, guiding appropriate sub-grant awards and management. Organization's policies, procedures and practices in this area reflect arm's length bargaining principles and avoid the potential for conflicts of interest. Employees are well trained and consistently follow the organization's policies and procedures.			
								Score			
								Average Score for PROCUREMENT SYSTEMS			

UCDUSR0004095

Section: HUMAN RESOURCES SYSTEMS											
8 Human Resources (HR) Policies and Procedures											
at organization lows HR policies, , and practices. *ending on the size of the* *m, typical HR* *l cover the hiring,* *and recognition,* *retirement,* *ion and benefits,* *, transfer and* *n of employees.)*	2.2	Organization does not have HR policies, procedures and practices (formal or informal) that satisfy its minimum level of needs and those that do exist are clearly inadequate. Organization's approach to hiring, promotion and recognition, retention, retirement, compensation and benefits, supervision, transfer and termination of employees is ad hoc. Organization has no organizational chart or written job descriptions; no standard benefits / compensation practices; and no discernible policies outlining roles and responsibilities and delegations of authority.		Organization has weak HR policies, procedures and practices that fail to satisfy all of its key needs and are otherwise not adequate. There are serious gaps in the organization's HR policies and practices including those related to the collection, management, use and storage of HR information. Organization lacks a reasonably complete organizational chart, up-to-date written position descriptions, a benefits/ compensation plan, and reasonably adequate policies and practices outlining roles and responsibilities and delegations of authority.		Organization has HR policies, procedures and practices that meet its needs and are adequate. Organization has an organizational chart and written job descriptions; adequate benefits/ compensation practices; and adequate policies and practices outlining roles and responsibilities and delegations of authority.		Organization has comprehensive, well thought out, well documented, and effective HR policies, procedures and practices that meet its needs and reflect best practices. Strong approaches for retaining competent staff are reviewed by management and modified to ensure effectiveness. Organization has an up-to-date and complete organizational chart and job descriptions for all key employees; a formal benefits/ compensation plan and practices that meet its needs; and sound policies and practices outlining roles and responsibilities and delegations of authority.			
								Score			
Time Management											

UCDUSR0004096

at the organization blished, reliable ented labor tem that it e., timesheets).	24	Organization does not have an established and appropriately documented labor activity system. Employees do not provide, sign or written timesheets/activity reports that reflect actual time worked on all projects as well as indirect activities. Timesheets/activity reports are often based on rough estimates or plug figures. Labor costs are distributed among projects based on unreliable estimates. Payment of salaries and wages does not consistently correspond to verifiable information provided by employees.		Organization has weak labor activity policies, procedures and practices. Timesheets/activity reports are often based on rough estimates of work hours rather than actual, verifiable data. Timesheets/activity reports are not consistently completed nor verified and approved by supervisors. Labor costs are distributed among projects and indirect activities based on budget estimates or other rough estimates of work hours. Payment of salaries and wages does not consistently correspond to verifiable information derived from timesheets/activity reports.		Organization has an adequate labor activity system that adequately captures, allocates and reports labor time, activities and costs. Employees provide written timesheets/ activity reports that reflect actual time worked on all projects as well as indirect activities. Timesheets/activity reports are not consistently signed and approved by supervisors. Labor costs are generally distributed among projects and indirect activities based on the data derived from the timesheets/activity reports. Payment of salaries and wages generally corresponds to the information documented. Errors or omissions are few or not material.		Organization has a strong, comprehensive, well documented, and regularly and consistently used labor activity system that properly captures, allocates and reports labor time, activities and costs. Employees maintain written timesheets/ activity reports that reflect actual time worked on all projects as well as indirect activities. Timesheets/activity reports are signed/ certified and approved by supervisors. Labor costs are accurately distributed among projects and indirect activities based on the data derived from the timesheets/activity reports. Payment of salaries and wages corresponds to the information documented in the timesheets/activity reports.			
								Score			
ll System											
at the organization ll system that is or purposes of the *te. The payroll* *be either* *r hard copy.)*	23	Organization does not have a payroll system. It disburses pay to employees on an irregular basis. Payroll records are incomplete, and are otherwise not reliable. Payroll is seldom, if ever, reconciled to the General Ledger. Organization has no discernible policy or standard acceptable practices on compensation (salary scales and increases) and benefits for the different types and levels of employees.		Organization has an incomplete and otherwise weak payroll system. Payroll records often contain errors. Payroll is infrequently reconciled to the General Ledger. Organization has less than an adequate documented and followed policy on compensation (scales and increases) and benefits for the different types and levels of employees.		Organization has an adequate payroll system that meets it key needs. Payroll is regularly reconciled to the General Ledger. Organization has and uses an adequate policy on compensation (salary scales and increases) and benefits for the different types and levels of employees.		Organization has a well thought out, well documented, and effective payroll system founded on sound payroll policies and procedures that are consistently followed. Payroll is accurately reconciled to the General Ledger at least monthly. Organization has and uses an appropriate and well documented policy on compensation (salary scales and increases) and benefits for the different types and levels of employees.			
								Score			

UCDUSR0004098

Policies and Procedures												
at the organization lows appropriate ies and	25	Organization does not have adequate travel policies, procedures and practices. Practices are inconsistent and made on an ad hoc basis. Recordkeeping for compliance and other control and verification purposes is inadequate.		Organization has incomplete travel policies and procedures. Acceptable travel policies and procedures are not consistently followed in practice by management or other employees. Records to verify compliance are incomplete and otherwise weak.		Organization has travel policies and procedures that are adequate. Travel policies and procedures are generally followed in practice by management or other employees. Records are kept to verify compliance.		Organization has complete documented travel policies and procedures. Management emphasizes the importance of adherence to approved travel policies and leads by example. Travel policies and procedures are understood by staff and are consistently adhered to, reviewed and monitored for compliance.				
								Score				
Average Score for HUMAN RESOURCES SYSTEMS												
rice: PROJECT PERFORMANCE MANAGEMENT												
ical Evaluation Criteria												

...thing/verification ... technical ... criteria as ...y TEC. *(Note: The ...pleted" criteria is ...r allow, where ... the NUPAS to ...hat the TEC ...s in the technical ... to be ...ential for purposes ...matic ...ce that needs to be ...in order to ... the programmatic ...sponsibility. It is ...sumptions that ...e a couple of ... made by an ...s a technical ...nt, if true, ...elihood of ...programmatic ...ce. Such potential ...s be verified during ...d survey in a way ...g an application ...e use, again, is ...ed thus may not ...t be needed in ...)*	26										
...t Management Capacity											

To Be Completed

at the organization ite capacity to d monitor projects onor guidance or n.	77	Organization has an inadequate project management system. Organization does not have sufficiently qualified project management personnel.		Organization has a weak project management system for monitoring progress on projects. Organization's project management policies, procedures and practices are weak. Organization produces reasonably adequate project management reports. Organization has an incomplete project management manual that is seldom used. Organization has too few qualified project managers for its overall purposes.		Organization has an adequate project management system in place to monitor progress on projects on a regular basis. Organization's project management policies and procedures are generally followed. Organization produces adequate project management reports on a fairly regular basis. Organization has an adequate project management manual that is generally followed. Organization has an adequate number of qualified project managers.		Organization has a comprehensive and well documented project management system in place to monitor progress on projects on a regular basis. Organization consistently produces useful project management reports. Organization has a comprehensive project management manual that informs and guides actual performance. Organization has a sufficient number of qualified project managers to meet its needs and the capacity to obtain additional qualified personnel as needed.			
								Score			
Average Score for PROJECT PERFORMANCE MANAGEMENT											

ions: ORGANIZATIONAL SUSTAINABILITY											
low Management											
e organization has good discipline ng, monitoring ash flow budgets and in actually is cash and a responsible *rforming a few rformance the ial the ity of a for-profit on. For instance, be appropriate: as, acid test ratio, rtional or working*	28	Organization has no or little history of developing, monitoring and using cash flow budgets. Organization has inadequate capacity to develop, monitor, update and use comprehensive cash flow projections. Due to poor cash management practices and weak results of operation, payments to creditors and/or employee are often late and remain past due well beyond the terms of payment. There are material past due accounts, that are seriously delinquent. There are unliquidated advances over 1 yr		Organization has weak discipline in developing and monitoring and using cash flow budgets. Management is not adequately involved with finance personnel in daily or weekly cash flow management. Often, payments are not made on time due to fluctuations in cash inflow and outflow and weak cash management practices. There are no unliquidated advances over 90 days.		Organization has adequate discipline in developing and monitoring and using cash flow budgets. Management is adequately involved with finance personnel in daily or weekly cash flow management. Organization has a reasonably satisfactory history of making payments to creditors and employees on time. There are no material past due accounts (singly or in the aggregate). There are no unliquidated advances over 60 days.		Organization has good discipline in developing, monitoring and using cash flow budgets. Management is actively involved with finance personnel in daily cash flow management. Organization has a good history of making payments to creditors and employees on time. There are no material past due accounts (singly or in the aggregate), including long outstanding advances.			
								Score			
ptive Capacity											
at the organization ne absorptive e., can rise to the ort required to ae additional	29	Organization does not have capacity to absorb the level of effort required to implement an additional project/activity.		Organization's absorptive capacity is weak for purposes of the award (i.e., the organization may be hard pressed to rise to the level of effort required to take on an additional project/activity).		Organization's absorptive capacity is adequate. Given its resources and ability to obtain additional resources, organization has adequate capacity to absorb the level of effort required.		Organization's absorptive capacity is more than adequate. Given its resources, organization has the capacity to absorb the level of effort required to implement an additional project/activity.			
								Score			
Average Score for ORGANIZATIONAL SUSTAINABILITY											
TOTAL OVERALL AVERAGE SCORE											

at the organization ite capacity to d monitor projects onor guidance or n.	77	Organization has an inadequate project management system. Organization does not have sufficiently qualified project management personnel.		Organization has a weak project management system for monitoring progress on projects. Organization's project management policies, procedures and practices are weak. Organization produces reasonably adequate project management reports. Organization has an incomplete project management manual that is seldom used. Organization has too few qualified project managers for its overall purposes.		Organization has an adequate project management system in place to monitor progress on projects on a regular basis. Organization's project management policies and procedures are generally followed. Organization produces adequate project management reports on a fairly regular basis. Organization has an adequate project management manual that is generally followed. Organization has an adequate number of qualified project managers.		Organization has a comprehensive and well documented project management system in place to monitor progress on projects on a regular basis. Organization consistently produces useful project management reports. Organization has a comprehensive project management manual that informs and guides actual performance. Organization has a sufficient number of qualified project managers to meet its needs and the capacity to obtain additional qualified personnel as needed.			
								Score			
Average Score for PROJECT PERFORMANCE MANAGEMENT											

ion: ORGANIZATIONAL SUSTAINABILITY											
low Management											
e organization has good discipline ng, monitoring ash flow budgets and in actually is cash and a responsible *rforming a few rformance the ul the ity of a for-profit on. For instance, be appropriate: as, acid test ratio, rrent or working*	28	Organization has no or little history of developing, monitoring and using cash flow budgets. Organization has inadequate capacity to develop, monitor, update and use comprehensive cash flow projections. Due to poor cash management practices and weak results of operation, payments to creditors and/or employee are often late and remain past due well beyond the terms of payment. There are material past due accounts, that are seriously delinquent. There are unliquidated advances over 1 yr		Organization has weak discipline in developing and monitoring and using cash flow budgets. Management is not adequately involved with finance personnel in daily or weekly cash flow management. Often, payments are not made on time due to fluctuations in cash inflow and outflow and weak cash management practices. There are no unliquidated advances over 90 days.		Organization has adequate discipline in developing and monitoring and using cash flow budgets. Management is adequately involved with finance personnel in daily or weekly cash flow management. Organization has a reasonably satisfactory history of making payments to creditors and employees on time. There are no material past due accounts (singly or in the aggregate). There are no unliquidated advances over 60 days.		Organization has good discipline in developing, monitoring and using cash flow budgets. Management is actively involved with finance personnel in daily cash flow management. Organization has a good history of making payments to creditors and employees on time. There are no material past due accounts (singly or in the aggregate), including long outstanding advances.			
								Score			
ptive Capacity											
at the organization ne absorptive e., can rise to the ort required to ae additional	29	Organization does not have capacity to absorb the level of effort required to implement an additional project/activity.		Organization's absorptive capacity is weak for purposes of the award (i.e., the organization may be hard pressed to rise to the level of effort required to take on an additional project/activity).		Organization's absorptive capacity is adequate. Given its resources and ability to obtain additional resources, organization has adequate capacity to absorb the level of effort required.		Organization's absorptive capacity is more than adequate. Given its resources, organization has the capacity to absorb the level of effort required to implement an additional project/activity.			
								Score			
Average Score for ORGANIZATIONAL SUSTAINABILITY											
TOTAL OVERALL AVERAGE SCORE											

Appendix D – NUPAS Questions for Consideration

First Criterion: Legal Structure

1.1 Local Organization Definition

- Is this organization a Non-U.S. organization?
- If so, does the organization fit into the "local organization" definition? (Only for local limited competition.)
- Can the organization maintain its independent status or is it aware of potential "raiders"?

1.2 Legal Requirements

- Is the organization legally registered to operate in this country of service?
- Does this organization have the required licenses, permits or certifications (if needed) to operate in this country of service?
- Is the organization aware and in compliance of its obligations under those licenses, permits or certifications (i.e., taxes, labor, occupational health, safety, environment or other material laws and regulations)?

1.3 Organizational Structure

- Does the organization have a formal mission/vision?
- When was the organization established?
- Do the organization's articles of incorporation, or charter or by-laws support its mission?

1.4 Governance

- Does the organization have clearly defined roles and responsibilities for its board of directors and/or its governing board?
- Does the organization require integrity, ethical behavior and transparency of its board(s)?
- What is the composition of the board (i.e., gender, ethnic and age mix)?

1.5 Control Environment

- Does the board have clear terms of reference (TOR) and a clear understanding of its key functions?
- Are board limits clearly defined and reasonable?
- Are board members and officers elected/appointed/removed in accordance with applicable laws and approved, written procedures?
- Does the organization have fiduciary risk controls covering board members, officers and employees?
- Does the organization have effective mechanisms for enforcement of such policies?
- Are those controls in place?

Second Criterion: Financial Management and Internal Control Systems

2.1 Banking Relationship and Accounts

- In which commercial bank(s) does the organization have its account(s)?
- Are such accounts "free and clear" of personal funds of board members, officers or employees?
- How often (if ever) are bank accounts reconciled?

- Does the organization have credible financial records sufficient for internal and external audit trail purposes?
- What action does the organization take on outstanding items; when is this action taken?
- Are bank reconciliations reviewed and approved by a responsible official?

2.2 Accounting/Bookkeeping System

- Does the organization have a reliable double entry accounting system?
- Are financial transactions entered into the system on a daily basis? If not, how often?
- Does the accounting system have functionalities to automatically reconcile subsidiary ledgers to the main ledger?
- Does the organization keep appropriate supporting documentation for accounting entries (journal vouchers, payment vouchers, receipts, invoices, other applicable documents)?

2.3 Chart of Accounts, General Ledger and Financial Statements

- Does the organization have a chart of accounts and a corresponding general ledger?
- Does the general ledger numbering system follow (if any) statutory country requirements?
- Are material financial transactions consistently recorded according to accounting standards?
- Does the organization consistently conduct trail balances from the general ledger?

2.4 Variance Analysis (Budget to Actual Cost)

- Are financial reports accompanied by budget data and variance analysis?
- Does the organization prepare variance analysis of program and operating financial data?

2.5 Allowable and Unallowable Cost

- Do the individuals authorized to approve payments have a clear understanding of what costs are allowable, allocable and reasonable?
- Who authorizes payments?
- Who records payments?
- Does the organization have a procedure in place to avoid duplicate payments?
- Does the organization have clear lines of communication between finance and program staff relative to allowable and unallowable costs (from a donor restriction perspective)?

2.6 Direct and Indirect Cost

- Does the organization's accounting unit have a clear understanding of direct costs, indirect costs and cost allocation principles?
- Does this same unit understand the concept of "cost objectives" in relation to intermediate and final cost objectives?
- Does the organization have experience in accumulating direct and indirect costs by project?

2.7 Payments – Segregation of Duties

- Are there documented policies, procedures and practices that safeguard the payment process?
- Does the person receiving "cash" NOT have the authority to sign checks, reconcile bank accounts and no access to accounting records other than cash receipts?
- Are different employees responsible for purchases, receiving merchandise and services and approving vouchers?
- Do different people prepare checks, sign checks, reconcile bank accounts and record financial transactions?

2.8 Accounting Cycle – Segregation of Duties

- Does the organization have a well-documented delegation of authority system appropriate to its size?
- How many people are involved in the accounting cycle transaction?
- Is approval (from whom) obtained prior to disbursement of funds? Are these approvals documented?

2.9 Financial Records Management

- Where does the organization safeguard important documents including financial records?
- Does the organization have an effective and efficient filing and records management system?
- Does the organization have procedures in place for backup and recovery of important documents?
- Does the organization have a contingency plan in place for financial and operational continuity (in case of "sabotage" or a natural disaster)?

2.10 Sources of Funding

- How does the organization track its sources of funding?
- Do personnel have the skills needed for job cost accounting and fund accounting?
- What are the organization's sources of funding (fee for service, activities, donors, programs, other)?
- Does management articulate the importance of diversification of sources of funding?
- Is "business development" an active responsibility of a specific unit in the organization?
- How does the organization promote itself?
- What has the organization done to actively promote itself over the past three years?

2.11 Financial Reporting

- Does the organization have written procedures for producing monthly financial statements from the General Ledger?
- Are these reports sufficiently informative to highlight abnormalities?

2.12 Audit and Review of Financial Statements

- If there are monthly financial reports, are these reviewed by the organization's management?

- Does management take corrective actions based on its review of financial statements?
- Are financial statements reviewed on an annual basis by a third party based on the laws of the country?
- Does the organization have annual audits of their accounting records?
- Have audited reports received Qualified/Adverse/ or Disclaimer Opinions in the past three years?
- Has the organization ever received a Deficiency or Significant Deficiency in internal control?
- Does the organization have policies in place for closing audit findings and recommendations?

2.13 Financial Management Personnel

- What are the accounting qualifications of the accountant/bookkeeper?
- What level of understanding does that person seem to have of management and financial accounting standards, principles and practices?
- Does that person have the requisite ability to monitor operational and project budgets?
- Can that person prepare and monitor cash flow projections and statements?

Third Criterion: Procurement Systems

3.1 Procurement Policies, Procedures and Practices

- Does the organization have well-documented procurement policies that are appropriate to the country of service?
- Does the organization regularly apply those policies and procedures?
- Are these policies and procedures reviewed? (When? How often?)

3.2 Compliance with Policies and Procedures – Reasonableness of Price

- Does the organization have policies in place to require competitive procedures for procurement of goods and services?
- Who in the organization is responsible for purchases?
- Who in the organization is responsible for procurement policy compliance?

3.3 Procurement and Sub-awards

- Does the organization have written guidelines to avoid potential conflicts of interest?
- Do employees and management have a clear understanding of these guidelines?
- Does the organization conduct periodic "ethics" training for its employees?

Fourth Criterion: Human Resources Systems

4.1 Overall HR Policies and Procedures

- Does the organization have well-documented HR policies that meet their needs and reflect best practices?
- Does the organization maintain individual personnel files with original records of employment, rates and authorized deductions for every employee?
- Does the organization has an organizational chart?
- Do all key employees have written job descriptions?
- Is there a formal benefits/compensation plan in place?

- Do key personnel know their roles and responsibilities and delegations of authority?

4.2 Staff Time Management

- Does the organization have a well-documented staff time management system that captures, allocates and reports staff time, activities and costs?
- Do employees maintain timesheets/activity reports to reflect actual time worked?
- Are timesheets/activity reports signed and approved by supervisors?
- Does payment of salaries correspond to the information documented in the timesheets/activity reports?
- Do labor costs seem to be equitably distributed among projects?

4.3 Payroll System

- Are payroll taxes (if applicable) withheld and remitted according to local regulations?
- Is the payroll reconciled to the General ledger at least once a month?
- Does the organization have in place policies on compensation (salary scales and increases) for the different types and levels of employees?
- Are wages, salaries, overtime, etc. approved by management?

4.4 Travel Policies and Procedures

- Does the organization have well-documented travel policies?
- Does the organization enforce those policies?
- How are travel (cash) advances accounted for and monitored for compliance?

Fifth Criterion: Project Performance Management

5.1 Technical Evaluation Criteria

(Questions to be developed by the TEC)

5.2 Project Management Capacity

- Does the organization have a well-documented project management system?
- How regularly does the organization monitor progress on projects?
- How regularly, and how well does the organization produce project management reports?
- Does the organization have an internal project monitoring unit/team/group?
- Does the organization have the number of qualified project managers to meet its needs? If not, does it have the capacity to obtain additional qualified staff?

Sixth Criterion: Organizational Sustainability

6.1 Cash Flow Management

- What is the organization's experience (and results) of developing, monitoring and using cash flow budgets?
- Does the organization consistently make payments to creditors and employees when due?
- Does the organization have any material past due accounts? If so how does the organization plan to liquidate those debts?
- Does the organization have any unliquidated advances?

6.2 Absorptive Capacity

- Does the organization have the capacity to absorb the level of effort necessary to implement an additional project/activity?
- Is the organization's reputation such that it can hire qualified individuals to support implementation of additional projects and activities?
- Does the organization have the required systems in place for quality growth?

Final cross-check:

Using three years of financial statements (from the organization's annual balance sheets and income statements), perform the following ratios: current, acid test, monthly defensive interval, and working capital turnover, to confirm the organization's sustainability.

From: "Tammie O'Rourke" <torourke@metabiota.com>
Sent: Tue, 3 Mar 2020 09:25:08 -0800
Subject: Re: PREDICT EB Call - Tuesday March 3, 2020 @ 9:30AM
To: David J Wolking <djwolking@ucdavis.edu>
Cc: Amanda Fine <[redacted]>, Brian Bird <bhbird@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, "Churchill, Carolina" [redacted]>, Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>, Dawn Zimmerman <Zimmermand@si.edu>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Jon Epstein <epstein@ecohealthalliance.org>, Karen Saylors [redacted]>, Kevin Olival <Olival@ecohealthalliance.org>, Marc Valitutto <ValituttoM@si.edu>, "Murray, Suzan" <MurrayS@si.edu>, Peter Daszak <daszak@ecohealthalliance.org>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "Prof. Woutrina Smith" <wasmith@ucdavis.edu>, Sarah Olson [redacted]>, Simon Anthony <sja2127@columbia.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, "William B. Karesh" <karesh@ecohealthalliance.org>, Aleksei Chmura <chmura@ecohealthalliance.org>, Alison Andre <andre@ecohealthalliance.org>, Nicole Gardner <nrgardner@ucdavis.edu>, Ava Sullivan <sullivan@ecohealthalliance.org>, "predict@ucdavis.edu" <predict@ucdavis.edu>
GovtReportsOustanding_20200303.xlsx

Good morning,
Attached is the list of government reports that are either waiting for drafts to be approved (highlighted in yellow) or waiting for approval.
Tammie

On Fri, Feb 28, 2020 at 12:09 PM David J Wolking <djwolking@ucdavis.edu> wrote:

Hi there,
Just a reminder about our PREDICT EB call next week (Tuesday March 3, 2020 @ 9:30AM Pacific).

The agenda and Zoom details are below.

Enjoy the weekend!

David

PREDICT Executive Board Meeting Notes
Tuesday, March 3, 2020
9:30-10:30AM PST/12:30-1:30pm EST
Zoom link: https://onehealth.zoom [redacted]
Additional Zoom info below agenda

1. Brief recap from USAID Management Team call
Extension updates
March meeting updates and plans (March 17-19, 2020)

2. COVID-19 updates

3. Data updates

4. Close-out - standing item
On equipment...
On finances and subawards...
On government approvals and data...

5. Final Report
Vol 1 - Global report - teams and deadlines
- Capacity - draft received
- EHP - draft received
- Behavior - draft received with MB and EHA team input
- IM - in progress with planned user experience survey
- M&A - in progress
- Surveillance - February 24th
- Virus detection - in progress

Vol 2 - Country reports

6. Mission, partner communications & country roundup essentials

7. Consortium author list - P2 author list
- All updated? Here's a link to the Google Sheet....

8. Publication, media, and conference updates
- *On Publications*...Internal review of manuscripts in prep...
- 19th International Congress on Infectious Diseases, Kuala Lumpur - postponed due to COVID-19
- Consortium of Universities for Global Health: Global Health in a Time of Worldwide Political Change, Washington DC (April 17-20, 2020)
- World One Health Congress, Edinburgh, Scotland, NOTE: extra session on the 2019 Novel Coronavirus, abstract due May 1

Zoom Call-in info
Topic: PREDICT EB Call
Join Zoom Meeting: https://onehealth.zoom REDACTED

Meeting ID: REDACTED

One tap mobile
+16699006833,, REDACTED US (San Jose)
+16468769923,, US (New York)

Dial by your location
+1 669 900 6833 US (San Jose)
+1 646 876 9923 US (New York)
Meeting ID: REDACTED

--
Tammie O'Rourke
Metabiota
Senior Information Management Developer
Emerging Pandemic Threats - PREDICT Program
tel: +1-250-618-2460

PRODUCED IN NATIVE FORMAT

From: Tatiana Ronning <tronning@usaid.gov>
To: Paula Noble <pnoble@ucdavis.edu>
CC: Jonna Mazet <jkmazet@ucdavis.edu>;Andrew Clements <aclements@usaid.gov>;Patricia Bradley <pbradley@usaid.gov>;Jose Nunez Grullon <jnunezgrullon@usaid.gov>;Padmaja Shetty <pshetty@usaid.gov>;Hannah R Chale <hrchale@ucdavis.edu>;Cara Chrisman <cchrisman@usaid.gov>
Sent: 3/6/2020 7:45:14 PM
Subject: Re: AID-OAA-A-14-00102 Mod #20

Good Afternoon Paula,

When trying to process modification #20 , I received a Phoenix error in our Global Acquisition and Assistance System (GLAAS). This error, Vendor has debt subject to offset, is also linked to System for Award Management (SAM). When doing research on this, it appears that the Department of Treasury has a hold on UCD's account. In order for USAID to process any modifications, UCD would have to contact SAM to get this error resolved. I have attached a screenshot of the information in SAM.

Please contact me once this matter has been resolved or send me any documentation that this is being resolved. I am not sure if you were aware of this but I wanted to share this with you since we need to process this modification.

Thanks,

Tanya

Tatiana A. Ronning
Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA
1300 Pennsylvania Avenue, NW
Washington, D.C. 20523
Phone: +1 (202) 916 2710

On Fri, Mar 6, 2020 at 12:29 PM Paula Noble <pnoble@ucdavis.edu> wrote:

Dear Tanya,

Attached, please find a partially executed copy of Modification 20. Please return a fully executed copy for our files.

Thank you.

Paula Noble

Assistant Director, Negotiations & Subawards

Office of Research, Sponsored Programs University of California, Davis

(530) 754-8115

From: Tatiana Ronning <tronning@usaid.gov>
Sent: Thursday, March 5, 2020 2:33 PM
To: Jonna Mazet <jkmazet@ucdavis.edu>; Paula Noble <pnoble@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>; Patricia Bradley <pbradley@usaid.gov>; Jose Nunez Grullon <jnunezgrullon@usaid.gov>; Padmaja Shetty <pshetty@usaid.gov>
Subject: AID-OAA-A-14-00102 Mod #20

Dear Ms. Mazet and Ms. Noble:

Please find attached a modification #20 to the subject award for review, agreement, and signature by the authorized person. It is my understanding that you have been in discussions regarding the activities and budget with the ETD office. Please sign the modification and return to me so it could be fully executed.

Please also confirm the receipt of this message and the attachment and please let me know if you have any questions.

Sincerely,

Tanya

Tatiana A. Ronning

Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm 11.3.2D, UA

1300 Pennsylvania Avenue, NW
Washington, D.C. 20523

Phone: + 1 (202) 916 2710

View assistance for SAM.gov

SAM

A NEW WAY TO SIGN IN - If you already have a SAM account, use your **SAM email** for login.gov. Log In

Login.gov FAQs

ALERT: SAM.gov will be down for scheduled maintenance Saturday, 03/14/2020 from 8:00 AM to 3:00 PM

Search Results

Quick Search Results

Total results: 1

Save PDF | Export Results | Print

Result Page: 1

Sort by: Relevance | Order by: Descending

Your search returned the following results...

Entity | UNIVERSITY OF CALIFORNIA, DAVIS | Status: Active

DUNS: [redacted]
Has Active Exclusion? No
Expiration Date: 07/09/2020
Purpose of Registration:

CAGE Code: [redacted]
DoDAAC:
Debt Subject to Offset? Yes What is this?

View Details

Result Page: 1

Save PDF | Export Results | Print

GSA

Search Records | Disclaimers | FAPIIS.gov
Data Access | Accessibility | USA.gov/SAM
Check Status | Privacy Policy | USA.gov
About | USA.gov
Help

[illegible]

From: Tatiana Ronning <tronning@usaid.gov>
To: Paula Noble <pnoble@ucdavis.edu>
CC: Andrew Clements <aclements@usaid.gov>;Cara Chrisman <cchrisman@usaid.gov>;Hannah R Chale <hrchale@ucdavis.edu>;Jonna Mazet <jkmazet@ucdavis.edu>;Jose Nunez Grullon <jnunezgrullon@usaid.gov>;Padmaja Shetty <pshetty@usaid.gov>;Patricia Bradley <pbradley@usaid.gov>
Sent: 3/6/2020 9:38:53 PM
Subject: Re: AID-OAA-A-14-00102 Mod #20

Dear Paula:

In addition to my earlier email, please contact the Treasury Offset Program (TOP) Call Center 1-800-304-3107 with any questions regarding the reported debt and instructions for solution.

Thanks,
Tanya

On Fri, Mar 6, 2020 at 3:45 PM Tatiana Ronning <tronning@usaid.gov> wrote:
Good Afternoon Paula,

When trying to process modification #20 , I received a Phoenix error in our Global Acquisition and Assistance System (GLAAS). This error, Vendor has debt subject to offset, is also linked to System for Award Management (SAM). When doing research on this, it appears that the Department of Treasury has a hold on UCD's account. In order for USAID to process any modifications, UCD would have to contact SAM to get this error resolved. I have attached a screenshot of the information in SAM.

Please contact me once this matter has been resolved or send me any documentation that this is being resolved. I am not sure if you were aware of this but I wanted to share this with you since we need to process this modification.

Thanks,

Tanya

Tatiana A. Ronning
Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GIL Rm.11.3.2D, UA
1300 Pennsylvania Avenue, NW
Washington, D.C. 20523
Phone: +1 (202) 916 2710

On Fri, Mar 6, 2020 at 12:29 PM Paula Noble <pnoble@ucdavis.edu> wrote:

Dear Tanya,

Attached, please find a partially executed copy of Modification 20. Please return a fully executed copy for our files.

Thank you.

Paula Noble

Assistant Director, Negotiations & Subawards

Office of Research, Sponsored Programs University of California, Davis

(530) 754-8115

From: Tatiana Ronning <tronning@usaid.gov>
Sent: Thursday, March 5, 2020 2:33 PM
To: Jonna Mazet <jkmazet@ucdavis.edu>; Paula Noble <pnoble@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>; Patricia Bradley <pbradley@usaid.gov>; Jose Nunez Grullon <jnuezgrullon@usaid.gov>; Padmaja Shetty <pshetty@usaid.gov>
Subject: AID-OAA-A-14-00102 Mod #20

Dear Ms. Mazet and Ms. Noble:

Please find attached a modification #20 to the subject award for review, agreement, and signature by the authorized person. It is my understanding that you have been in discussions regarding the activities and budget with the ETD office. Please sign the modification and return to me so it could be fully executed.

Please also confirm the receipt of this message and the attachment and please let me know if you have any questions.

Sincerely,

Tanya

Tatiana A. Ronning

Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA

1300 Pennsylvania Avenue, NW
Washington, D.C. 20523

Phone: + 1 (202) 916 2710

--

Tatiana A. Ronning

Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA
1300 Pennsylvania Avenue, NW
Washington, D.C. 20523
Phone: + 1 (202) 916 2710

From: Paula Noble <pnoble@ucdavis.edu>
To: Tatiana Ronning <tronning@usaid.gov>
Cc: Andrew Clements <aclements@usaid.gov>, Cara Chrisman <cchrisman@usaid.gov>, Hannah R Chale <hrchale@UCDAVIS.EDU>, Jonna Mazet <jkmazet@ucdavis.edu>, Jose Nunez Grullon <jnunezgrullon@usaid.gov>, Padmaja Shetty <pshetty@usaid.gov>, Patricia Bradley <pbradley@usaid.gov>
Subject: RE: AID-OAA-A-14-00102 Mod #20
Sent: Mon, 9 Mar 2020 19:32:37 +0000
Attachment

Hi Tanya,

Please see the attached email stating that the issue has been resolved.

Thank you.

Paula Noble
Assistant Director, Negotiations & Subawards
Office of Research, Sponsored Programs | University of California, Davis
(530) 754-8115

From: Tatiana Ronning <tronning@usaid.gov>
Sent: Monday, March 9, 2020 10:47 AM
To: Paula Noble <pnoble@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>; Cara Chrisman <cchrisman@usaid.gov>; Hannah R Chale <hrchale@UCDAVIS.EDU>; Jonna Mazet <jkmazet@ucdavis.edu>; Jose Nunez Grullon <jnunezgrullon@usaid.gov>; Padmaja Shetty <pshetty@usaid.gov>; Patricia Bradley <pbradley@usaid.gov>
Subject: Re: AID-OAA-A-14-00102 Mod #20

Dear Paula:

I wanted to check in with you to see if you had a chance to call the Treasury and if you know how long/what it takes to resolve the issue? Also, could you please let us know as soon as this is resolved so we can process this Modification?

I look forward to hearing from you.

Thanks,
Tanya

--
Tatiana A. Ronning
Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA
1300 Pennsylvania Avenue, NW
Washington, D.C. 20523
Phone: +1 (202) 916 2710

On Fri, Mar 6, 2020 at 7:02 PM Tatiana Ronning <tronning@usaid.gov> wrote:
Hi Paula,

I saw the message "Contracting Officers can still make contract awards and payments...using Electronic Funds Transfer", as well. Unfortunately, the CO cannot make any payments/obligate the funds in the system until this is resolved with SAM and Treasury. I had to deal with this issue in the past and know from the experience that this message is incorrect or the system "doesn't agree with it" and will not allow the CO to approve this mod. Could you please try to contact the number I sent you and please do let me know if you have any questions.

Kind regards,

Tanya

On Fri, Mar 6, 2020 at 6:45 PM Paula Noble <pnoble@ucdavis.edu> wrote:

Hi Tanya,

We received the below email from the System for Awards Management (SAM). We are diligently trying to figure out why/how this occurred. However, I did notice that the email from SAM states that "Contracting Officers can still make contract awards and payments...using Electronic Funds Transfer". Based upon this, can we continue to move forward with Modification 20?

Thank you.

Paula Noble
Assistant Director, Negotiations & Subawards
Office of Research, Sponsored Programs | University of California, Davis
1850 Research Park Drive, Suite 300 | Davis, CA 95618
Phone: 530-754-8115 | Fax: 530-754-8367

-----Original Message-----
From: samadmin@sam.gov <samadmin@sam.gov>
Sent: Thursday, March 5, 2020 12:03 PM
To: Ahmad Hakim-Elahi <ahakimelahi@ucdavis.edu>; Christine Franco <cafranco@ucdavis.edu>
Cc: Ahmad Hakim-Elahi <ahakimelahi@ucdavis.edu>; Christine Franco <cafranco@ucdavis.edu>
Subject: Debt Subject to Offset Status for UNIVERSITY OF CALIFORNIA, DAVIS / REDACTED

This email was sent by an automated administrator. Please do not reply to this message.

Dear Ahmad Hakim-Elahi, Christine Franco,

This email serves as notice that the entity represented by DUNS REDACTED in the System for Award Management (SAM) has a delinquent debt with the Federal government subject to the Treasury Offset Program. As a result, this entity's SAM registration will now display a value of "Yes" for the Debt Subject to Offset indicator.

What does the Debt Subject to Offset indicator in SAM mean?
A value of "Yes" for Debt Subject to Offset? tells contracting officers they cannot use the governmentwide commercial purchase card to pay your entity for contracts/orders above the micro-purchase threshold as outlined in FAR 32.1108(b)(2). Contracting officers can still make contract awards and payments to your entity using Electronic Funds Transfer.

Where does the Debt Subject to Offset indicator value come from in SAM?
The Debt Subject to Offset indicator value comes from the U.S. Treasury's Bureau of the Fiscal Service through an automated interface. This notifies SAM when an entity represented by a specific DUNS number has a delinquent debt subject to the Treasury Offset Program.

Where do I find the Debt Subject to Offset indicator in SAM?
Navigate to https://www.sam.gov and search for your entity. In the search results, you will see the phrase Debt Subject to Offset? with either a Yes or a No answer. That is the indicator. If your entity has an affirmative response, you will also see a "Yes" for Debt Subject to Offset in the Core Data section of your entity's registration in SAM.

How do I change the Debt Subject to Offset status for my entity in SAM?
This is not a field you can update or change in SAM. Registrants must contact the Treasury Offset Program (TOP) Call Center at 1-800-304-3107 with any questions regarding the reported debt and instructions for resolution.

Why does SAM still show "Yes" for the Debt Subject to Offset status if Treasury told me it was resolved?
The delinquent debt information is updated twice a week through an automated process between SAM and Treasury's Bureau of the Fiscal Service's Debt Management Service in support of the Treasury Offset Program (TOP). Your update may not have been sent to SAM yet. If it has been more than one week since you received confirmation from Treasury that your delinquent debt was resolved, contact the Treasury Offset Program Call Center at 1-800-304-3107 to make sure it is reflected in the system they use to provide the updated values to SAM.

What is the difference between the Debt Subject to Offset indicator and my entity's response to Paragraph D of FAR 52.209-5 Certification of Responsibility Matters?
The delinquent debt indicator applies to all SAM registrants, and impacts the method of payment only (see FAR 32.1108). Registrants cannot change the Debt Subject to Offset information in SAM and must contact the Treasury Offset Program (TOP) Call Center at 1-800-304-3107 with any questions regarding the reported debt.

Representations & Certifications (Reps & Certs) only apply to registrants pursuing Federal contracts. A registrant's response in Paragraph D of FAR 52.209-5 (certifying to whether they have unsatisfied Federal tax liability over $3,500 in the past three years) is used as part of the contracting officer's responsibility determination. Paragraph D only relates to unsatisfied Federal tax liability. Registrants can update this information by updating their Reps & Certs in SAM.

For assistance with your SAM registration, please contact the Federal Service Desk at www.fsd.gov or by telephone at 866-606-8220 (toll free) or at 334-206-7828 (internationally).

Thank you,
The System for Award Management (SAM) Administrator
http://www.sam.gov/

Paula Noble
Assistant Director, Negotiations & Subawards
Office of Research, Sponsored Programs | University of California, Davis
(530) 754-8115

From: Tatiana Ronning <tronning@usaid.gov>
Sent: Friday, March 6, 2020 2:39 PM
To: Paula Noble <pnoble@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>; Cara Chrisman <cchrisman@usaid.gov>; Hannah R Chale <hrchale@UCDAVIS.EDU>; Jonna Mazet <jkmazet@ucdavis.edu>; Jose Nunez Grullon <jnunezgrullon@usaid.gov>; Padmaja Shetty <pshetty@usaid.gov>; Patricia Bradley <pbradley@usaid.gov>
Subject: Re: AID-OAA-A-14-00102 Mod #20

Dear Paula:

In addition to my earlier email, please contact the Treasury Offset Program (TOP) Call Center 1-800-304-3107 with any questions regarding the reported debt and instructions for solution.

Thanks,
Tanya

On Fri, Mar 6, 2020 at 3:45 PM Tatiana Ronning <tronning@usaid.gov> wrote:
Good Afternoon Paula,

When trying to process modification #20 , I received a Phoenix error in our Global Acquisition and Assistance System (GLAAS). This error, Vendor has debt subject to offset, is also linked to System for Award Management (SAM). When doing research on this, it appears that the Department of Treasury has a hold on UCD's account. In order for USAID to process any modifications, UCD would have to contact SAM to get this error resolved. I have attached a screenshot of the information in SAM.

Please contact me once this matter has been resolved or send me any documentation that this is being resolved. I am not sure if you were aware of this but I wanted to share this with you since we need to process this modification.

Thanks,

Tanya

Tatiana A. Ronning
Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA
1300 Pennsylvania Avenue, NW
Washington, D.C. 20523
Phone: +1 (202) 916 2710

On Fri, Mar 6, 2020 at 12:29 PM Paula Noble <pnoble@ucdavis.edu> wrote:

Dear Tanya,

Attached, please find a partially executed copy of Modification 20. Please return a fully executed copy for our files.

Thank you.

Paula Noble
Assistant Director, Negotiations & Subawards
Office of Research, Sponsored Programs | University of California, Davis
(530) 754-8115

From: Tatiana Ronning <tronning@usaid.gov>
Sent: Thursday, March 5, 2020 2:33 PM
To: Jonna Mazet <jkmazet@ucdavis.edu>; Paula Noble <pnoble@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>; Patricia Bradley <pbradley@usaid.gov>; Jose Nunez Grullon <jnunezgrullon@usaid.gov>; Padmaja Shetty <pshetty@usaid.gov>
Subject: AID-OAA-A-14-00102 Mod #20

Dear Ms. Mazet and Ms. Noble:

Please find attached a modification #20 to the subject award for review, agreement, and signature by the authorized person. It is my understanding that you have been in discussions regarding the activities and budget with the ETD office. Please sign the modification and return to me so it could be fully executed.

Please also confirm the receipt of this message and the attachment and please let me know if you have any questions.

Sincerely,
Tanya

Tatiana A. Ronning
Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA
1300 Pennsylvania Avenue, NW
Washington, D.C. 20523
Phone: +1 (202) 916 2710
--

Tatiana A. Ronning
Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA

1300 Pennsylvania Avenue, NW
Washington, D.C. 20523
Phone: +1 (202) 916 2710
--

Tatiana A. Ronning
Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA
1300 Pennsylvania Avenue, NW
Washington, D.C. 20523
Phone: +1 (202) 916 2710

From: "samadmin@sam.gov" <samadmin@sam.gov>
To: "Ahmad Hakim-Elahi" <ahakimelahi@ucdavis.edu>, "Christine Franco" <cafranco@ucdavis.edu>
Cc: "Ahmad Hakim-Elahi" <ahakimelahi@ucdavis.edu>, "Christine Franco" <cafranco@ucdavis.edu>
Subject: Debt Subject to Offset Status for UNIVERSITY OF CALIFORNIA, DAVIS / REDACTED REDACTED
Sent: Mon, 9 Mar 2020 19:03:00 +0000

This email was sent by an automated administrator. Please do not reply to this message.

Dear Ahmad Hakim-Elahi, Christine Franco

This email serves as notice that the entity represented by DUNS REDACTED in the System for Award Management (SAM) no longer has a delinquent debt with the Federal government. As a result, this entity's SAM registration will now display a value of "No" for the Debt Subject to Offset indicator.

Where do I find the Debt Subject to Offset indicator in SAM?
Navigate to https://www.sam.gov and search for your entity. In the search results, you will see the phrase Debt Subject to Offset? with either a Yes or a No answer. That is the indicator. If your entity has an affirmative response, you will also see a "Yes" for Debt Subject to Offset in the Core Data section of your entity's registration in SAM.

Where does the Debt Subject to Offset indicator value come from in SAM?
The Debt Subject to Offset indicator value comes from the U.S. Treasury's Bureau of the Fiscal Service through an automated interface. This notifies SAM when an entity represented by a specific DUNS number has a delinquent debt subject to the Treasury Offset Program. Registrants cannot change this value within the System for Award Management.

For any questions regarding delinquent debt information, please contact the Treasury Offset Program (TOP) Call Center at 1-800-304-3107. You may also go to the TOP Frequently Asked Questions page at https://fiscal.treasury.gov/fsservices/gov/debtColl/faqs/debt_questions_top_pub.htm.

For assistance with your SAM registration, please contact the Federal Service Desk at www.fsd.gov or by telephone at 866-606-8220 (toll free) or at 334-206-7828 (internationally).

Thank you,
The System for Award Management (SAM) Administrator
http://www.sam.gov/

From: Tatiana Ronning <tronning@usaid.gov>
Sent: Mon, 9 Mar 2020 15:47:07 -0400
Subject: Re: AID-OAA-A-14-00102 Mod #20
To: Paula Noble <pnoble@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>, Cara Chrisman <cchrisman@usaid.gov>, Hannah R Chale <hrchale@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, Jose Nunez Grullon <jnunezgrullon@usaid.gov>, Padmaja Shetty <pshetty@usaid.gov>, Patricia Bradley <pbradley@usaid.gov>

Great news! Thank you for letting me know.
We will process the mod as soon as our system receives the updated information from SAM and I will send you a fully executed copy. I just checked in our system and the error has not been cleared yet. It may take a few hours as I think the system updates overnight.

Please let me know if you have any questions.

Kind regards,
Tanya

Tatiana A. Ronning
Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA
1300 Pennsylvania Avenue, NW
Washington, D.C. 20523
Phone: +1 (202) 916 2710

On Mon, Mar 9, 2020 at 3:32 PM Paula Noble <pnoble@ucdavis.edu> wrote:

Hi Tanya,

Please see the attached email stating that the issue has been resolved.

Thank you.

Paula Noble

Assistant Director, Negotiations & Subawards

Office of Research, Sponsored Programs | University of California, Davis

(530) 754-8115

From: Tatiana Ronning <tronning@usaid.gov>
Sent: Monday, March 9, 2020 10:47 AM
To: Paula Noble <pnoble@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>; Cara Chrisman <cchrisman@usaid.gov>; Hannah R Chale <hrchale@UCDAVIS.EDU>; Jonna Mazet <jkmazet@ucdavis.edu>; Jose Nunez Grullon <jnunezgrullon@usaid.gov>; Padmaja Shetty <pshetty@usaid.gov>; Patricia Bradley <pbradley@usaid.gov>

Subject: Re: AID-OAA-A-14-00102 Mod #20

Dear Paula:

I wanted to check in with you to see if you had a chance to call the Treasury and if you know how long/what it takes to resolve the issue? Also, could you please let us know as soon as this is resolved so we can process this Modification?

I look forward to hearing from you.

Thanks,

Tanya

--

Tatiana A. Ronning

Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA

1300 Pennsylvania Avenue, NW
Washington, D.C. 20523

Phone: +1 (202) 916 2710

On Fri, Mar 6, 2020 at 7:02 PM Tatiana Ronning <tronning@usaid.gov> wrote:

Hi Paula,

I saw the message "Contracting Officers can still make contract awards and payments...using Electronic Funds Transfer", as well. Unfortunately, the CO cannot make any payments/obligate the funds in the system until this is resolved with SAM and Treasury. I had to deal with this issue in the past and know from the experience that this message is incorrect or the system "doesn't agree with it" and will not allow the CO to approve this mod. Could you please try to contact the number I sent you and please do let me know if you have any questions.

Kind regards,

Tanya

On Fri, Mar 6, 2020 at 6:45 PM Paula Noble <pnoble@ucdavis.edu> wrote:

Hi Tanya,

We received the below email from the System for Awards Management (SAM). We are diligently trying to figure out why/how this occurred. However, I did notice that the email from SAM states that "Contracting Officers can still make contract awards and payments...using Electronic Funds Transfer". Based upon this, can we continue to move forward with Modification 20?

Thank you.

Paula Noble

Assistant Director, Negotiations & Subawards

Office of Research, Sponsored Programs | University of California, Davis

1850 Research Park Drive, Suite 300 | Davis, CA 95618

Phone: 530-754-8115 | Fax: 530-754-8367

-----Original Message-----
From: samadmin@sam.gov <samadmin@sam.gov>
Sent: Thursday, March 5, 2020 12:03 PM
To: Ahmad Hakim-Elahi <ahakimelahi@ucdavis.edu>; Christine Franco <cafranco@ucdavis.edu>
Cc: Ahmad Hakim-Elahi <ahakimelahi@ucdavis.edu>; Christine Franco <cafranco@ucdavis.edu>
Subject: Debt Subject to Offset Status for UNIVERSITY OF CALIFORNIA, DAVIS REDACTED

This email was sent by an automated administrator. Please do not reply to this message.

Dear Ahmad Hakim-Elahi, Christine Franco,

This email serves as notice that the entity represented by DUNS REDACTED in the System for Award Management (SAM) has a delinquent debt with the Federal government subject to the Treasury Offset Program. As a result, this entity's SAM registration will now display a value of "Yes" for the Debt Subject to Offset indicator.

What does the Debt Subject to Offset indicator in SAM mean?

A value of "Yes" for Debt Subject to Offset? tells contracting officers they cannot use the governmentwide commercial purchase card to pay your entity for contracts/orders above the micro-purchase threshold as outlined in FAR 32.1108(b)(2). Contracting officers can still make contract awards and payments to your entity using Electronic Funds Transfer.

Where does the Debt Subject to Offset indicator value come from in SAM?

The Debt Subject to Offset indicator value comes from the U.S. Treasury's Bureau of the Fiscal Service through an automated interface. This notifies SAM when an entity represented by a specific DUNS number has a delinquent debt subject to the Treasury Offset Program.

Where do I find the Debt Subject to Offset indicator in SAM?

Navigate to https://www.sam.gov and search for your entity. In the search results, you will see the phrase Debt Subject to Offset? with either a Yes or a No answer. That is the indicator. If your entity has an affirmative response, you will also see a "Yes" for Debt Subject to Offset in the Core Data section of your entity's registration in SAM.

How do I change the Debt Subject to Offset status for my entity in SAM?

This is not a field you can update or change in SAM. Registrants must contact the Treasury Offset Program (TOP) Call Center at 1-800-304-3107 with any questions regarding the reported debt and instructions for resolution.

Why does SAM still show "Yes" for the Debt Subject to Offset status if Treasury told me it was resolved?

The delinquent debt information is updated twice a week through an automated process between SAM and Treasury's Bureau of the Fiscal Service's Debt Management Service in support of the Treasury Offset Program (TOP). Your update may not have been sent to SAM yet. If it has been more than one week since you received confirmation from Treasury that your delinquent debt was resolved, contact the Treasury Offset Program Call Center at 1-800-304-3107 to make sure it is reflected in the system they use to provide the updated values to SAM.

What is the difference between the Debt Subject to Offset indicator and my entity's response to Paragraph D of FAR 52.209-5 Certification of Responsibility Matters?

The delinquent debt indicator applies to all SAM registrants, and impacts the method of payment only (see FAR 32.1108). Registrants cannot change the Debt Subject to Offset information in SAM and must contact the Treasury Offset Program (TOP) Call Center at 1-800-304-3107 with any questions regarding the reported debt.

Representations & Certifications (Reps & Certs) only apply to registrants pursuing Federal contracts. A registrant's response in Paragraph D of FAR 52.209-5 (certifying to whether they have unsatisfied Federal tax liability over $3,500 in the past three years) is used as part of the contracting officer's responsibility determination. Paragraph D only relates to unsatisfied Federal tax liability. Registrants can update this information by updating their Reps & Certs in SAM.

For assistance with your SAM registration, please contact the Federal Service Desk at www.fsd.gov or by telephone at 866-606-8220 (toll free) or at 334-206-7828 (internationally).

Thank you,

The System for Award Management (SAM) Administrator

http://www.sam.gov/

Paula Noble

Assistant Director, Negotiations & Subawards

Office of Research, Sponsored Programs | University of California, Davis

(530) 754-8115

From: Tatiana Ronning <tronning@usaid.gov>
Sent: Friday, March 6, 2020 2:39 PM
To: Paula Noble <pnoble@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>; Cara Chrisman <cchrisman@usaid.gov>; Hannah R Chale <hrchale@UCDAVIS.EDU>; Jonna Mazet <jkmazet@ucdavis.edu>; Jose Nunez Grullon <jnunezgrullon@usaid.gov>; Padmaja Shetty <pshetty@usaid.gov>; Patricia Bradley <pbradley@usaid.gov>
Subject: Re: AID-OAA-A-14-00102 Mod #20

Dear Paula:

In addition to my earlier email, please contact the Treasury Offset Program (TOP) Call Center 1-800-304-3107 with any questions regarding the reported debt and instructions for solution.

Thanks,

Tanya

On Fri, Mar 6, 2020 at 3:45 PM Tatiana Ronning <tronning@usaid.gov> wrote:

Good Afternoon Paula,

When trying to process modification #20 , I received a Phoenix error in our Global Acquisition and Assistance System (GLAAS). This error, Vendor has debt subject to offset, is also linked to System for Award Management (SAM). When doing research on this, it appears that the Department of Treasury has a hold on UCD's account. In order for USAID to process any modifications, UCD would have to contact SAM to get this error resolved. I have attached a screenshot of the information in SAM.

Please contact me once this matter has been resolved or send me any documentation that this is being resolved. I am not sure if you were aware of this but I wanted to share this with you since we need to process this modification.

Thanks,

Tanya

Tatiana A. Ronning

Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA

1300 Pennsylvania Avenue, NW
Washington, D.C. 20523

Phone: +1 (202) 916 2710

On Fri, Mar 6, 2020 at 12:29 PM Paula Noble <pnoble@ucdavis.edu> wrote:

Dear Tanya,

Attached, please find a partially executed copy of Modification 20. Please return a fully executed copy for our files.

Thank you.

Paula Noble

Assistant Director, Negotiations & Subawards

Office of Research, Sponsored Programs | University of California, Davis

(530) 754-8123

From: Tatiana Ronning <tronning@usaid.gov>
Sent: Thursday, March 5, 2020 2:33 PM
To: Jonna Mazet <jkmazet@ucdavis.edu>; Paula Noble <pnoble@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>; Patricia Bradley <pbradley@usaid.gov>; Jose Nunez Grullon <jnunezgrullon@usaid.gov>; Padmaja Shetty <pshetty@usaid.gov>
Subject: AID-OAA-A-14-00102 Mod #20

Dear Ms. Mazet and Ms. Noble:

Please find attached a modification #20 to the subject award for review, agreement, and signature by the authorized person. It is my understanding that you have been in discussions regarding the activities and budget with the ETD office. Please sign the modification and return to me so it could be fully executed.

Please also confirm the receipt of this message and the attachment and please let me know if you have any questions.

Sincerely,

Tanya

Tatiana A. Ronning

Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA

1300 Pennsylvania Avenue, NW
Washington, D.C. 20523

Phone: +1 (202) 916 2710

--

Tatiana A. Ronning

Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA

1300 Pennsylvania Avenue, NW
Washington, D.C. 20523

Phone: +1 (202) 916 2710

--

Tatiana A. Ronning

Contract/Agreement Specialist

USAID Office of Acquisition & Assistance
M/OAA/GH, Rm.11.3.2D, UA

1300 Pennsylvania Avenue, NW
Washington, D.C. 20523

Phone: +1 (202) 916 2710

Sent: Mon, 16 Mar 2020 18:36:15 -0700
Subject: Re: URGENT: Draft slide deck for tomorrow's March 17th USAID briefing
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: David J Wolking <djwolking@ucdavis.edu>
Cc: Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Karen Saylors [redacted], Peter Daszak <daszak@ecohealthalliance.org>, Simon Anthony <sja2127@columbia.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, "William B. Karesh" <karesh@ecohealthalliance.org>, Amanda Fine [redacted], "Walzer, Christian" [redacted], "Murray, Suzan" <MurrayS@si.edu>, "Churchill, Carolina" [redacted], Alison Andre <andre@ecohealthalliance.org>, Aleksei Chmura <chmura@ecohealth.net>, Nicole R Gardner <nrgardner@ucdavis.edu>, predict Sympa List <predict@ucdavis.edu>, Marc Valitutto <ValituttoM@si.edu>

Thank you, David!!!
Jonna

On Mon, Mar 16, 2020 at 6:16 PM David J Wolking <djwolking@ucdavis.edu> wrote:

How many of these urgent messages are you going to get from me? It's getting old...

Here is a link to download the consolidated deck. We have 2 hours with USAID tomorrow (10AM-12PM Pacific) and since Zoom may be unreliable we will be sharing the final version of this deck ahead of time.

I've slightly reworked the order of presenters for a logical flow and hopefully compelling story, which is outlined below. In short, I think we have too many slides. That may be an understatement, we have 94 slides here in this version. If on review, you want to cut some content from your section, please let Chris and I know ASAP so we can make adjustments and trim back before sharing the final with USAID in advance of the call, again because it's feasible they will need to manually advance slides if Zoom isn't functioning properly.

Thanks for all the hard work on this!

David

Run of show (at least David's idea)

Aiming for 5-10min each as initially discussed to leave time for discussion...

1. Guiding light - modeling and analytics insights (PD)
2. Surveillance where it matters (CKJ)
3. Virus Discoveries (TG/SA) - what we found
4. Behavioral Risk & Community Engagement - moving from evidence to interventions (KS)
5. Policy and Partnerships for Health Security (BK) - evidence based advocacy to prevent pandemics at the national and global scale
6. Our legacy: PREDICT's Impact (JM) - strengthening the health security workforce

On Sun, Mar 15, 2020 at 8:53 PM David J Wolking <djwolking@ucdavis.edu> wrote:

Hi there,

Below is the agenda shared by Andrew today in advance of our tomorrow's discussion (March 16th @ 10AM Pacific). We will use this time to prepare for the March 17th USAID briefing, which Andrew is calling the "P2 management team meeting" so it's unclear to me if we are cancelling our regularly scheduled PREDICT senior management team meeting that same day.
All are welcome that can join tomorrow's call on short notice (Zoom details below the agenda).

As you'll notice, his agenda deviates in content and expectations from what we discussed last week Friday so please carefully think through the items below and come up with ideas, thoughts, etc. We can use the new WhatsApp group to connect internally during tomorrow's meeting as well, it will be a good dress rehearsal for the week.

Talk soon,

David

March 17th Prep Discussion with Andrew

March 16, 2020, 10AM Pacific

Zoom: https://onehealth.zoom [redacted]

1. Short summary of high-level accomplishments

A. Findings

B. Capacity strengthening

C. New/expanded partnerships

i. Donors

ii. USG

iii. Others

2. Lessons learned (what worked well and what needed improvement)

A. Project management (work plans, reporting, M&E, communications, etc.)

B. Data management/sharing

C. Working with in-country institutions/partners

3. What work within P2 was not finished (due to lack of time and/or funds), but should be followed up on

4. CoV Extension

A. Timing of outreach to countries and development of detailed work plan

B. Press/public engagement management related to the extension

Zoom Details
Topic: P2 Management Team Prep
Time: Mar 16, 2020 10:00 AM Pacific Time (US and Canada)

Join Zoom Meeting
https://onehealth.zoom [redacted]
Meeting ID: [redacted]
Password: [redacted]

One tap mobile
+16699006833 [redacted] US (San Jose)
+13462487799 US (Houston)

Dial by your location
+1 669 900 6833 US (San Jose)
+1 346 248 7799 US (Houston)
+1 646 876 9923 US (New York)
+1 253 215 8782 US

+1 301 715 8592 US
+1 312 626 6799 US (Chicago)
Meeting ID: REDACTED
Find your local number: https://onehealth.zoom.us/u/adNXEpXrr9

From: Jon Epstein <epstein@ecohealthalliance.org>
Sent: Tue, 14 Apr 2020 11:45:25 -0400
To: "Dr. Melinda Rostal" <rostal@ecohealthalliance.org>
Cc: David J Wolking <djwolking@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Alexandra Shaffer <aashaffer@ucdavis.edu>, Emily Hagan <hagan@ecohealthalliance.org>, "Dr. Billy Karesh" <karesh@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Nicole Gardner <nrgardner@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Subject: Re: [predict] Bangladesh govt request for PREDICT assistance

Hi Mindy,
I can update you - we discussed this on yesterday's EB call.
Cheers,
Jon

On Wed, Apr 8, 2020 at 1:54 PM Dr. Melinda Rostal <rostal@ecohealthalliance.org> wrote:

Hi again David:D
I was just wondering if there is any update at all on this request:)

Stay safe and healthy in CA!

Thank you,

Mindy

Melinda Rostal DVM, MPH, PhD
Principal Scientist, Vector-Borne Diseases

Rift Valley Fever Virus Project Manager

EcoHealth Alliance
460 West 34th Street, Suite 1701
New York, NY 10001

1.212.380.4489 (direct)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.
EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

On Apr 1, 2020, at 11:36 AM, David J Wolking <djwolking@ucdavis.edu> wrote:

Thanks Mindy, that's great intel. We'll work this into our tracking tool. Still no approved workplan or budget yet from USAID but hoping for quick turnaround this week or early next.
Stay tuned!

David

On Wed, Apr 1, 2020 at 8:24 AM Dr. Melinda Rostal <rostal@ecohealthalliance.org> wrote:

Good morning Chris and David,
I heard that in the meeting yesterday we are now allowed to use some funds from the PREDICT extension to support the salary of our team members who are helping with the SARS-CoV-2 response. Josefina was working on PREDICT at IEDCR and IEDCR has specifically requested that we fund her salary so that she can help now with the outbreak response. They only have 2 people at the lab to do the work so our support give them a 50% increase in their capacity!

Thanks very much!

Kind regards,
Mindy

Melinda Rostal DVM, MPH, PhD
Principal Scientist, Vector-Borne Diseases

Rift Valley Fever Virus Project Manager

EcoHealth Alliance
460 West 34th Street, Suite 1701
New York, NY 10001

1.212.380.4489 (direct)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.
EcoHealth Alliance
460 West 34th Street - 17th floor
New York, NY 10001

On Mar 27, 2020, at 1:37 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hi Mindy,
Thanks for keeping this on the front burner.

We are still moving through the process of getting the extension workpan approved with USAID and cannot aggressively push forward with spending until they sign off on that plan and budget. Philosophically USAID concurs that PREDICT is in position to support early detection of cases but that we do not have the resources or mandate for a large response operation. Tracey and her lab team are evaluating the requests from countries for technical assistance so I'm deferring to her council here on the Bangladesh wishlist.

We have another senior management team call next week Tuesday and hope to keep pushing ahead, we'll keep you posted.

David

On Fri, Mar 27, 2020 at 9:39 AM Dr. Melinda Rostal <rostal@ecohealthalliance.org> wrote:

Dear David,
I was just wondering what the outcome of your meeting earlier this week was?

We are still getting almost daily requests for updates from our partners and the USAID Mission in Bangladesh.

Thank you,

Mindy

Melinda Rostal DVM, MPH, PhD
Principal Scientist, Vector-Borne Diseases

Rift Valley Fever Virus Project Manager

EcoHealth Alliance
460 West 34th Street, Suite 1701
New York, NY 10001

1.212.380.4489 (direct)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.
EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

On Mar 24, 2020, at 10:16 AM, David J Wolking <djwolking@ucdavis.edu> wrote:

Thanks!

On Tue, Mar 24, 2020, 7:05 AM Dr. Melinda Rostal <rostal@ecohealthalliance.org> wrote:

Thanks David :)
I know you guys are doing everything you can to support the PREDICT country teams and we appreciate that. I went ahead and request a list of supplies to support COVID-19 testing in Bangladesh so you can get an idea of what that will be.

Best,
Mindy

Melinda Rostal DVM, MPH, PhD
Principal Scientist, Vector-Borne Diseases

Rift Valley Fever Virus Project Manager

EcoHealth Alliance
460 West 34th Street, Suite 1701
New York, NY 10001

1.212.380.4489 (direct)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.
EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

On Mar 23, 2020, at 4:07 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Thanks Mindy,
I'm hoping to connect with our team about this early this week (ASAP) really to get plans approved by Andrew for pandemic response and outline what we can do in this extension.

Please do keep the requests coming as that helps us learn the landscape and craft plans.

We'll be in touch and do acknowledge the gravity of the situation as we all sit on our laptops working in lockdown.

David

On Mon, Mar 23, 2020 at 1:02 PM Dr. Melinda Rostal <rostal@ecohealthalliance.org> wrote:

Dear David,
Just to pass on the message. The Mission in Bangladesh is very interested in any aid that can be provided to Bangladesh by PREDICT. He is calling Arif for an update every day. IEDCR is also calling him about aid. They are certainly grateful for the primers and probes that Tracey and Alex sent, but they are also asking for PCR reagents - extraction kits, etc. (I can get an exact list from Arif). While we wait to see if we can provide support for Josefina, can we provide the requested reagents?

Thanks very much!

Kind regards,
Mindy

Melinda Rostal DVM, MPH, PhD

Principal Scientist, Vector-Borne Diseases

Rift Valley Fever Virus Project Manager

EcoHealth Alliance
460 West 34th Street, Suite 1701
New York, NY 10001

1.212.380.4489 (direct)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.
EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

On Mar 17, 2020, at 3:52 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hey Jon,
We have limited personnel funded in this extension, the bulk of the budget is materials/reagents/supplies for COVID-19 testing and for reservoir testing (archive samples) in the "ring around China." We'll have to explore and get back to you as this is not an isolated request from the country teams.

Best,

David

On Tue, Mar 17, 2020 at 6:22 AM Jon Epstein <epstein@ecohealthalliance.org> wrote:

> Hi Chris,
> Our partners at IEDCR (MOH) in Bangladesh are asking us and the mission if we can support hiring back the PREDICT lab scientist to help with SARS COV2 testing. They're strapped for people.

Is this something we'd be able to do with the new funding being awarded?

Cheers,
Jon

Jonathan Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
New York

(e) epstein@ecohealthalliance.org
(o) 212.380.4467
(m) REDACTED
@epsteinjon

--

Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street, Ste. 1701
New York, NY 10001
1.212.380.4467 (direct)
REDACTED mobile)

web: ecohealthalliance.org

Twitter: @epsteinjon

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

From: Dennis Carroll [redacted]
Sent: Wed, 20 May 2020 15:49:44 -0400
Subject: Re: GVP BoD Next week
To: Samantha Maher <maher@ecohealthalliance.org>
Cc: Aleksei Chmura <chmura@ecohealthalliance.org>, Alison Andre <andre@ecohealthalliance.org>, Cara Chrisman <cchrisman@usaid.gov>, "Dr. Suzan Murray" <MurrayS@si.edu>, Eddy Rubin <erubin@metabiota.com>, Jennifer Gardy <Jennifer.Gardy@gatesfoundation.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "Oyewale Tomori [redacted] [redacted] Peter Daszak <daszak@ecohealthalliance.org> [redacted]

Samantha, thanks. A few items for the BOD meeting. I will provide documents for items 1and 2 in separate

INFORMATIONAL

1. Oxford University Grand Challenge - invitation for GVP to be a Founding Partner

2. David Cameron G20 proposal in suppert of GVP

3. Funding updates:
   - Rockefeller Foundation
   - FDA
   - DOE
   - etc

4. Media updates:
   - French documentary
   - Smithsonian Magazine
   - etc

ACTION

1. New Board members
   - criteria
   - names

On Tue, May 19, 2020 at 2:01 PM Samantha Maher <maher@ecohealthalliance.org> wrote:

Hi All,
We will be having our monthly GVP Board of Directors call next week on Thursday, May 28th at 1pm EST. The agenda items we discussed during the last meeting that we will be focusing on are:

1. Deep-dive on consortium memberships and requirements for participation
2. Follow up 3-5 big ticket funding targets
3. Review and discuss criteria for board member selection (see Eddy's email with selection criteria rubric)

For those who haven't gone through the documents that Zoe put together regarding item #1, I am re-attaching those documents here.

We also discussed looping Ariel into the next call. Provided it is ok with everyone, Dennis, would you mind linking him in?

The zoom meeting details remain the same:

Join Zoom Meeting [redacted] Meeting ID: [redacted]
Please let me know if there are any additional items.

Best,

Sam
--

Samantha Maher, MESc
Research Scientist, Conservation and Health

EcoHealth Alliance
460 West 34th Street Ste. 1701
New York, NY 10001

212.380.4464 (direct)
REDACTED (mobile)
212.380.4465 (fax)
www.ecohealthalliance.org

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation.

--
Dr Dennis Carroll
President, Global Virome Project
Senior Fellow, Scowcroft Institute of International Affairs at the Bush School of Government and Public Service, Texas A&M University
Counselor and Advisor to the Faculty of Tropical Medicine at Mahidol University, Bangkok, Thailand

mobile REDACTED
email:

From: Jon Epstein <epstein@ecohealthalliance.org>
Sent: Wed, 10 Jun 2020 13:10:31 -0400
To: Woutrina A Smith <wasmith@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>
Cc: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, onehealthnextgen Sympa List <onehealthnextgen@ucdavis.edu>
Subject: [onehealthnextgen] Re: ECHO and Q4 planning in OHW-NG

Yes, it seems like we need to do more outreach around the One Health Academy with both of the networks.
Let me know what you suggest as a new approach in getting buy-in and perhaps a sense of timing once you speak with Pat. We had a productive discussion today with folks from AFROHUN. They also want to discuss the Academy again with the Secretariat to get buy-in regarding the idea of the steering committee.

Cheers,
Jon

On Wed, Jun 10, 2020 at 1:00 PM Woutrina A Smith <wasmith@ucdavis.edu> wrote:

Agreed on regrouping, as I don't think Pat is on board yet. Jon stay tuned and we'll see if we can make headway when we talk with Pat this evening to get things back on track. Sheesh. Woutrina

---

From: Tracey Goldstein <tgoldstein@ucdavis.edu>
Date: Wednesday, June 10, 2020 at 9:54 AM
To: Jon Epstein <epstein@ecohealthalliance.org>
Cc: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, Woutrina A Smith <wasmith@ucdavis.edu>, onehealthnextgen Sympa List <onehealthnextgen@ucdavis.edu>
Subject: Re: ECHO and Q4 planning in OHW-NG

Hi Jon,

We will need to come up with a different strategy to engage with the country networks on this. Can we start by including Pat for SEAOHUN as a place to start and then we can see what is needed and how to include the networks?

Thanks Tracey

On Wed, Jun 10, 2020 at 9:47 AM Vipat Kuruchittham <vipat@seaohun.org> wrote:

Dear Jon,

Thank you for the draft email. I won't give OHUNs less than a week to respond as they have to coordinate with their member universities on who should represent their country network. We should be mindful that all faculty members have many other university responsibilities. If you were to request operational staff to get involved, the situation will be different. I would suggest you learn operating contexts of each regional and country networks to foster cooperation and collaboration.

Again, without the proposed meeting date and time, nominated faculty members may not be able to attend the initial meeting due to their teaching responsibility. Let's hope that this will not happen.

If you wish to proceed with the Monday timeline, you may proceed to contact OHUNs yourself. A push of this urgency

timeline will not come from the SEAOHUN Secretariat.

Best regards,

Pat

On Wed, Jun 10, 2020 at 8:52 PM Jon Epstein <epstein@ecohealthalliance.org> wrote:

Dear Pat,

Below is a draft email I had prepared to send to the OHUN coordinators, as you had recommended. However, if you would prefer to send the request for nominations, that's no problem. I would just like to confirm the participants by Monday, so that we may proceed with setting up the first steering committee meeting. If you'd prefer that I send this request, let me know. Many thanks for your help with this.

Cheers,

Jon

Dear Professors Hassan, Wiku, Monsoon, and Duc Phuc,

I hope that this email finds you well. I am reaching out to you, as SEAOHUN coordinators, to request your assistance in forming a steering committee for the online One Health Academy that we are developing under Objective 1 of our OHWNG project. The steering committee will provide technical input into the structure and help curate content for the Academy. This will be one of the main mechanisms through which we provide didactic training for participants from across the networks in Africa and Asia.

The steering committee will include 3-4 members from the global team, and 3-4 representatives from each of the OHW networks: AFROHUN and SEAOHUN. I would be grateful if you could each nominate one person from your country's OHUN who could commit to attending regular zoom meetings (frequency to be determined) and who is familiar enough with your country's one health programs, that they could provide meaningful input into content development and country-specific ideas that will ensure the Academy serves the needs of each of the network partners.

I would appreciate your nominations by ***Monday, June 15th***.

Please feel free to contact me if you have any questions.

Cheers,

Jon

On Tue, Jun 9, 2020 at 10:44 PM Vipat Kuruchittham <vipat@seaohun.org> wrote:

Dear Jon,

Our country networks (OHUNs) are not ware of the OHASC. There is no nominated representative to participate in the first call.

I will wait for your invitation to distribute to OHUNs to nominate at least one person who can attend the call. Without the timing of the regular meetings, a person attending the initial call may or may not be the same person attending subsequent calls. I thought if the time can be determined now, OHUNs will nominate a person who will make themselves available for the OHASC meeting.

Kindly give at least one week between the invitation and the call.

Best regards,

Pat

On Wed, Jun 10, 2020 at 1:45 AM Jon Epstein <epstein@ecohealthalliance.org> wrote:

Hi Pat,

Invitations for nominated folks to join the One Health Academy Steering Committee should go out soon. We're just waiting for confirmation of a few more folks, and then I will send out the invitations to the first meeting. During the initial meeting we'll discuss the objectives of the OHASC and also decide on the timing of the meetings. Thanks for your patience.

Cheers,

Jon

On Tue, Jun 9, 2020 at 11:47 AM Vipat Kuruchittham <vipat@seaohun.org> wrote:

Dear Woutrina,

For the regional speakers, I will ask OHUNs and let you know by Friday morning (Davis time).

For the One Health Workforce Academy Steering Committee, when do you plan for regular bi-weekly calls? May I assume that it will be at the same time (Wed in the US / Thu in SEA) and length (90 mins) like the COVID-19 OH updates? I would like to emphasize that their nominated person should be available every two weeks starting xx June to September for continuity.

Thanks,

Pat

On Tue, Jun 9, 2020 at 2:05 AM Woutrina A Smith <wasmith@ucdavis.edu> wrote:

Hi Pat, thanks for your updates and questions. For the One Health COVID ECHO next Thursday, would you like to recommend up to two speakers from the region who have been active in investigating emerging disease origins and spillover, COVID or otherwise, or would you like us to handle that planning? Brian or I can moderate this session and then in the future we can look to transition more of the ECHO tasks to your team. We will plan the e-learning pedagogy topics for July/August together.

For the One Health Workforce Academy Steering Committee, Dele and Jon can add in their thoughts but in short yes, having one person from each of the founding OHUNs nominated who can make time to participate in OHW Academy Steering Committee meetings every two weeks from June through September, and can bring in additional folks from their team to help complete specific tasks along the way, would be a very good way to move forward. The goal for September will be to have an internally facing OHW Academy website up that we can be trying out as part of a OHW-NG September Showcase three day mini e-conference (dates TBD) to highlight some of the OHW-NG Year 1 successes, etc. across the SEAOHUN and AFROHUN networks in place of a Year 1 face to face conference given the current travel limitations. Much to come on these ideas so we can plan together! Best wishes, Woutrina

---

From: Vipat Kuruchittham <vipat@seaohun.org>
Date: Friday, June 5, 2020 at 8:57 AM
To: Woutrina A Smith <wasmith@ucdavis.edu>
Cc: [redacted], Irene Naigaga <inaigaga@ohcea.org>, Ratsuda Poolsuk <ratsuda@seaohun.org>, Winnie Bikaako <wbikaako@ohcea.org>, Milly Nattimba <mnattimba@ohcea.org>, Agnes Yawe <ayawe@ohcea.org>, onehealthnextgen Sympa List <onehealthnextgen@ucdavis.edu>, OHW NG <ohw-ng@seaohun.org>, Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, Terra Kelly <trkelly@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Bruce B Struminger <BStruminger@salud.unm.edu>, Brian H Bird <bhbird@ucdavis.edu>, Jon Epstein <epstein@ecohealthalliance.org>, "Rabkin, Miriam" <mr84@cumc.columbia.edu>, alexandra zuber <alexandrazuber@atahealthstrategies.com>
Subject: Re: ECHO and Q4 planning in OHW-NG

Dear Woutrina,

Thank you for sharing a well-crafted plan. I agree with the plan overall to make a shift from the discussion to One Health Academy from COVID-19. As for the last COVID-19 session, I would prefer the general format that we have been doing. I am not ready to virtually moderate the large group with limited technical knowledge and limited ability to multitasking to listen and process information while reading the chatbox and screen questions. I wish I could do it in the future.

For OH academy, kindly share what OHUNs should expect. How many people OHUNs should nominate to serve on the steering committee? One each from the four founding countries? How about engaging in bi-weekly calls? I understand that the session will be a closed group working together rather than open like the COVID-19. After receiving your answers, I will contact the OHUNs and request their nominations.

Best regards,

Pat

On Thu, Jun 4, 2020 at 8:31 AM Woutrina A Smith <wasmith@ucdavis.edu> wrote:

Hello AFROHUN and SEAOHUN Secretariat teams,

I wanted to share ideas that we were talking about today amongst the global team, to get your input and so we can plan next steps together. I think this email will also help facilitate the discussion of One Health Academy roadmap and planning, and I look forward to ongoing feedback via email and on zoom.

Current situation: At this point in the year, we find ourselves with much accomplished and much still left to do in the coming months. Year 2 work planning will soon begin, and all our teams face daily challenges associated with COVID-19 to varying extents as countries and communities gradually reopen. Our One Health ECHO sessions focused on COVID-19 have been very successful and have given us good external visibility with the global community in being quick to engage with emerging One Health issues. The planned COVID-19 One Health ECHO sessions end in June.

Next steps: So as we think about the July-September window, I would like to suggest that we plan One Health ECHO sessions every two weeks, but instead of focusing on COVID-19 given the many online COVID resources that have emerged recently, I propose that we focus the ECHO sessions on e-learning best practices and supporting teams to develop effective online training materials, sharing successes and challenges, etc. in our OHW-NG One Health community of practice. I suggest this because it would help address one of the main challenges we have been hearing from many groups about uncertainty in how to go about making the most of online training opportunities, since traditionally we have focused on face to face trainings. We have experts ready to co-lead such ECHO sessions from the global team if paired with interest from regional faculty and students who want to actively engage over the next few months. We could be working towards a September Showcase as a three day online conference (a few hours each day based on best overlap of time zones) where we do a soft launch of the One Health Academy website, provide a forum to showcase country team successes, etc. in place of the Edinburgh or a regional face to face conference in Year 1. I think there are some interesting synergies and momentum that should be explored to achieve our Year 1 deliverables in OHW-NG.

Irene and others have expressed interest in now thinking through the roadmap and steps in developing the One Health Academy. Dele will more formally roll out an overview but as a quick summary to orient us, here is the current thinking:

- Now – steering committee is being formalized with representatives from SEAOHUN, AFROHUN, and the global team.
- Now – global team has been doing pre-work to provide high level structure and function ideas that the steering committee can discuss, decide on, and take forward for next steps in developing the One Health Academy website and plan. The name of the academy will be discussed.
- June – steering committee meetings; global team working group meetings; website development to be shared for feedback and refinement; OH Academy content development as a combination of existing AFROHUN/SEAOHUN training resources as well as global team contributions.
- July – presentation of initial website and OH Academy ideas to broader faculty, board, leadership, and usaid for feedback and planning next steps.
- August – refinement and building out of OH Academy content, website, and processes. This will be iterative over the next year.
- September – soft launch of the OH Academy website, likely paired with the September Showcase online forum I mentioned above.
- Year 2-3 – continuation of OH Academy development.

Please consider these ideas, discuss them internally, and share thoughts with this group over the coming days so we can make some progress and then perhaps discuss on calls next week as you see fit. This is your initiative and we

can take it in the directions that you think most useful for One Health University Networks around the world. We will be formally exploring collaborations and synergies with the other academies that are emerging from WHO, ASLM, etc. and we look forward to thinking through engagement strategies together.

Best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Professor of Infectious Disease Epidemiology
Associate Director, UCD One Health Institute
Technical Director, USAID One Health Workforce - Next Gen
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis
1089 Veterinary Medicine Dr
Davis, CA 95616
wasmith@ucdavis.edu
+1 530 219-1369 ¢

--

Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street, Ste. 1701

New York, NY 10001

1.212.380.4467 (direct)
REDACTED (mobile)

web: ecohealthalliance.org

Twitter: @epsteinjon

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

--

Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street, Ste. 1701

New York, NY 10001

1.212.380.4467 (direct)
REDACTED (mobile)

web: ecohealthalliance.org

Twitter: @epsteinjon

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

--

Tracey Goldstein, PhD

Associate Director, One Health Institute

Professor, Department of Pathology, Microbiology and Immunology

Director, One Health Institute Laboratory

One Health Institute
School of Veterinary Medicine
University of California
Davis, CA 95616
Phone: (530) 752-0412
Fax: (530) 752-3318
E-mail: tgoldstein@ucdavis.edu

--

Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street, Ste. 1701
New York, NY 10001
1.212.380.4467 (direct)
REDACTED (mobile)

web: ecohealthalliance.org

Twitter: @epsteinjon

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

From: Mah-Sere Keita | ASLM <sKeita@aslm.org>
To: Woutrina A Smith <wasmith@ucdavis.edu>
CC: Pascale Ondoa | ASLM <POndoa@aslm.org>;Mah-Sere Keita | ASLM <mkeita@aslm.org>;Oladele Oguseitan <oladele.oguseitan@uci.edu>;Jon Epstein <epstein@ecohealthalliance.org>;onehealthnextgen Sympa List <onehealthnextgen@ucdavis.edu>;Jonna Mazet <jkmazet@ucdavis.edu>;Bruce B Struminger <BStruminger@salud.unm.edu>;alexandra zuber <alexandrazuber@stahealthstrategies.com>
Sent: 6/16/2020 9:19:39 AM
Subject: Re: USAID One Health Workforce - Next Generation Project

Dear Woutrina,
Thank you for reaching out. It would be interesting to see if we can in fact collaborate via our Academies. We have not had discussions with WHO concerning the Academy yet. Please let us know when you are available for a call to discuss further.

Best regards,
Sere

On Jun 15, 2020, at 6:21 PM, Woutrina A Smith wrote:

Hi Pascale and Mah-Sere,

I'm reaching out now that we have gotten our feet under us in the new USAID One Health Workforce – Next Generation Project! I greatly enjoyed our brief interactions during the proposal development stage a year ago and my interest in finding ways to collaborate with ASLM has grown more as I have seen your ASLM Academy come to life in parallel to the One Health Workforce Academy that we had envisioned in our proposal to USAID and are just starting to co-create with AFROHUN (formerly OHCEA) and SEAOHUN as regional One Health university networks in Africa and Southeast Asia, respectively. Our OHW-NG Year 1 startup phase as well as the partial funding situation we find ourselves in with USAID, has precluded a formal partnership with ASLM to date but I'd like to explore changing that.

I think it could be both fun and strategic to find ways that the WHO Academy, ASLM Academy, and potentially the One Health Workforce Academy, as online training and networking resources, could be synergistic and connected to help address needs around the world. Are you already in touch with WHO or others about this type of collaborative effort? It would be timely to correspond by email or plan a zoom call to discuss this soon given that we are starting our USAID Year 2 work planning process that will fund activities from October 2020-September 2021, so if we want to work together on initiatives it would be good to sort what might be possible this month. Let me know if this is of interest to explore further.

Best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Professor of Infectious Disease Epidemiology
Associate Director, UCD One Health Institute
Technical Director, USAID One Health Workforce - Next Gen
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis
1089 Veterinary Medicine Dr
Davis, CA 95616
wasmith@ucdavis.edu
+1 530 219-1369 c

IMPORTANT NOTICE: This e-mail message is intended to be received only by persons entitled to receive the confidential information it may contain. E-mail messages to clients of ASLM may contain information that is confidential and legally privileged. Please do not read, copy, forward, or store this message unless you are an intended recipient of it. If you have received this message in error, please forward it to the sender and delete it completely from your computer system.

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
To: Andrew Clements <aclements@usaid.gov>
Cc: PREDICTMGT <predictmgt@usaid.gov>, Angela Wang <awang@usaid.gov>, Umesh Alavadi <ualavadi@usaid.gov>, David John Wolking <djwolking@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, predict Sympa List <predict@ucdavis.edu>
Sent: Tue, 29 Sep 2020 16:38:32 +0000
Subject: [predict] RE: Urgent Request

Hi Andrew, Total anticipated expenditures for India are $2,639,646.

Thanks,
Liz

Elizabeth Leasure
Financial Operations Manager
One Health Institute
REDACTED *(cell)*
530-754-9034 (office)
Skype: edleasure

From: Andrew Clements <aclements@usaid.gov>
Sent: Monday, September 28, 2020 9:54 AM
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Cc: PREDICTMGT <predictmgt@usaid.gov>; Angela Wang <awang@usaid.gov>; Umesh Alavadi <ualavadi@usaid.gov>; David John Wolking <djwolking@ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>
Subject: Re: Urgent Request

Hi Liz,

Can you provide a fully-loaded estimate for the total India expenditure under the PREDICT-2 cooperative agreement (between Oct 2014 and Sep 2020)? The Mission has requested this information.

Thanks!

Andrew

From: Andrew Clements <aclements@usaid.gov>
Sent: Fri, 10 Mar 2017 22:14:19 +0100
Subject: Re: monkey pox?
To: Jonna Mazet <jkmazet@ucdavis.edu>
Cc: PREDICTMGT <predictmgt@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>

I think I saw a coupe of days ago in CDC's daily update a ? ROC monkeypox ? mention but no link to any other information.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Mar 10, 2017, at 10:01 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

FYI
J

---------- Forwarded message ----------
From: **Karen Saylors** <ksaylors@metabiota.com>
Date: Friday, March 10, 2017
Subject: Fwd: monkey pox?
To: David John Wolking <djwolking@ucdavis.edu>
Cc: "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>

Hi David,
As I mentioned, yesterday I checked in with Prime and Dr. Shongo, the MOH point person for Monkeypox and Hemorrhagic Fevers, but no response from the latter.

Here I've translated what Prime said, so that you have it directly: " I just spoke to Ms. Elie who runs the Monkeypox lab at INRB. They received samples of suspected MPX from the territory of Opala in the north of DRC (which is near our PREDICT site of Buta). They have been having a problem with reagents and now they are testing the samples. Normally, an 'outbreak' is declared when there is a single case of Monkeypox, but it is an endemic disease here. Tomorrow I should have more information. Dr. Shongo is not responding by phone but I will continue to try to reach him."

"Je viens de parler avec Mme Elie qui s'occupe du labo MPX a l'INRB. Ils ont reçu des echantillons de cas suspects de MPX dans le territoire de Opala au nord de la RDC (dans les environs de notre site de Buta). Ils avaient un probleme de reactifs et maintenant ils sont en train de tester les échantillons. Normalement une epidemie est declaree des qu'on a un seul cas de MPX mais chez nous c'est une maladie endemique. Demain j'aurais plus de donnees sur cette situation. Dr Shongo ne repond pas au telephone mais je continue a insister."

Nothing unusual that we are seeing for the moment, but I will keep you posted if I have any other information.
Thanks,
Karen

From: David J Wolking <djwolking@ucdavis.edu>
Date: Friday, March 10, 2017 at 9:15 AM
To: Karen Saylors <ksaylors@metabiota.com>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Subject: Fwd: monkey pox?

Hi there,

So far not much to share about mpox this year in DRC from the GorillaDocs team.

David

——— Forwarded message ———
From: Kirsten Gilardi <kvgilardi@ucdavis.edu>
Date: Fri, Mar 10, 2017 at 01:37
Subject: Fwd: monkey pox?
To: David John Wolking <djwolking@ucdavis.edu>

Begin forwarded message:

From: "K.Syaluha Eddy" <[redacted]>
Subject: Re: monkey pox?
Date: March 10, 2017 at 11:20:42 AM GMT+2
To: Kirsten Gilardi <kvgilardi@ucdavis.edu>
Reply-To: [redacted]

I have not heard any news about Monkeypox this week, but I will ask the DPS epidemio-surveillance team. However, some cases were reported last year December in Bas Uele/Oriental province, seems like the disease is re-occuring.
Eddy

On 3/9/17, Kirsten Gilardi <kvgilardi@ucdavis.edu> wrote:

Eddy, heard anything about a current monkey pox outbreak somewhere in DRC? USAID is asking UCD - I haven't heard anything.... have you? -K

--
Eddy Kambale Syaluha, DVM,
Head Veterinarian/Gorilla Doctors
PREDICT-EPT2 Country Coordinator/Eastern DRC
T: [redacted]
Skype: [redacted]
www.gorilladoctors.org

--
Sent from Gmail Mobile

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to
predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit
https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/CAO5rDrFCmY1G_AMr0COoqvahrMUbhTotnck-aCjUqwbb9m9%3DGw%40mail.gmail.com.

Sent: Tue, 14 Mar 2017 12:19:20 -0700
Subject: Fwd: monkey pox?
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: PREDICTMGT <predictmgt@usaid.gov>
Cc: "predict@ucdavis.edu" <predict@ucdavis.edu>

Info per your request -- we are not currently involved,
Jonna

---------- Forwarded message ----------
From: **Karen Saylors** <ksaylors@metabiota.com>
Date: Tue, Mar 14, 2017 at 9:55 AM
Subject: Re: monkey pox?
To: David John Wolking <djwolking@ucdavis.edu>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Cc: Eddy Rubin <erubin@metabiota.com>, James Ayukekbong <jayukekbong@metabiota.com>

Hi again.
One additional detail I just received: MPX confirmation testing was conducted at INRB in Kinshasa.

Thanks,
Karen

From: Karen Saylors <ksaylors@metabiota.com>
Date: Tuesday, March 14, 2017 at 9:51 AM
To: David John Wolking <djwolking@ucdavis.edu>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Cc: Eddy Rubin <erubin@metabiota.com>, James Ayukekbong <jayukekbong@metabiota.com>
Subject: Re: monkey pox?

Good morning.
Upon hearing from David this weekend that in fact the Monkeypox concern relates to ROC and not DRC, I talked to the ROC Country Coordinator Monday morning and today got the following follow up:

Country Coordinator Bagamboula talked to the Department of Disease Control by phone and they have confirmed the outbreak, declared officially by Madame the Minister of Health. As of today, there are 20 cases, including 3 deaths, and there is a team from CDC that is planning to arrive to Brazzaville on the 22nd or 23rd March.

I will continue to follow this with the CC this week and communicate updates to you as I have them.
Thanks,
Karen

From: David J Wolking <djwolking@ucdavis.edu>
Date: Friday, March 10, 2017 at 9:49 AM
To: Karen Saylors <ksaylors@metabiota.com>
Cc: David John Wolking <djwolking@ucdavis.edu>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Subject: Re: monkey pox?

Thanks Karen, very much appreciated.
David

On Fri, Mar 10, 2017 at 9:32 AM, Karen Saylors <ksaylors@metabiota.com> wrote:

> Hi David.
> As I mentioned, yesterday I checked in with Prime and Dr. Shongo, the MOH point person for Monkeypox and Hemorrhagic Fevers, but no response from the latter.

Here I've translated what Prime said, so that you have it directly: " I just spoke to Ms. Elie who runs the Monkeypox lab at INRB. They received samples of suspected MPX from the territory of Opala in the north of DRC (which is near our PREDICT site of Buta). They have been having a problem with reagents and now they are testing the samples. Normally, an 'outbreak' is declared when there is a single case of Monkeypox, but it is an endemic disease here. Tomorrow I should have more information. Dr. Shongo is not responding by phone but I will continue to try to reach him."

"Je viens de parler avec Mme Elie qui s'occupe du labo MPX a l'INRB. Ils ont reçu des echantillons de cas suspects de MPX dans le territoire de Opala au nord de la RDC (dans les environs de notre site de Buta). Ils avaient un probleme de reactifs et maintenant ils sont en train de tester les échantillons. Normalement une epidemie est declarée des qu'on a un seul cas de MPX mais chez nous c'est une maladie endemique. Demain j'aurais plus de donnees sur cette situation. Dr Shongo ne repond pas au telephone mais je continue a insister."

Nothing unusual that we are seeing for the moment, but I will keep you posted if I have any other information.
Thanks,
Karen

From: David J Wolking <djwolking@ucdavis.edu>
Date: Friday, March 10, 2017 at 9:15 AM
To: Karen Saylors <ksaylors@metabiota.com>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Subject: Fwd: monkey pox?

Hi there,

So far not much to share about mpox this year in DRC from the GorillaDocs team.

David

——— Forwarded message ———
From: Kirsten Gilardi <kvgilardi@ucdavis.edu>
Date: Fri, Mar 10, 2017 at 01:37
Subject: Fwd: monkey pox?
To: David John Wolking <djwolking@ucdavis.edu>

Begin forwarded message:

From: "K.Syaluha Eddy" <[redacted]
Subject: Re: monkey pox?
Date: March 10, 2017 at 11:20:42 AM GMT+2
To: Kirsten Gilardi <kvgilardi@ucdavis.edu>
Reply-To: [redacted]

I have not heard any news about Monkeypox this week, but I will ask the DPS epidemio-surveillance team. However, some cases were reported last year December in Bas Uele/Oriental province, seems like the disease is re-occuring.
Eddy

On 3/9/17, Kirsten Gilardi <kvgilardi@ucdavis.edu> wrote:

Eddy, heard anything about a current monkey pox outbreak somewhere in DRC? USAID is asking UCD - I haven't heard anything.... have you? -K

--
Eddy Kambale Syaluha, DVM,
Head Veterinarian/Gorilla Doctors

PROJECT-EPT2 Country Coordinator/Eastern DRC
T REDACTED
Skype REDACTED
www.gorilladoctors.org

--

Sent from Gmail Mobile

From: Andrew Clements <aclements@usaid.gov>
Sent: Tue, 11 Apr 2017 12:44:09 +0200
Subject: Follow up on your talk with MB
To: Jonna Mazet <jkmazet@ucdavis.edu>
Cc: Alisa Pereira <apereira@usaid.gov>

Hi Jonna,

Can you provide us with an update (email or phone) on how the talk with MB went last week regarding their future arrangements in PREDICT countries through the end of EPT2?

I got a specific request regarding the status of Predict in ROC so that is the part that is most urgent, but I'd be interested in hearing about the overall plan as well.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From: Andrew Clements <aclements@usaid.gov>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: pmulembakani@metabiota.com <pmulembakani@metabiota.com>;Alisa Pereira <apereira@usaid.gov>
Sent: 5/14/2017 8:41:29 PM
Subject: Re: Heads up: another DRC outbreak

We'll assume FAO has it covered unless you or we hear otherwise.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On May 14, 2017, at 10:36 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Okay -- let us know when/how/if you'd like us to reach out,
J

On Sunday, May 14, 2017, Andrew Clements <aclements@usaid.gov> wrote:
Please do not share this information:

From FAO, we have heard about a duck die-off on a poultry farm on the shores of Lake Albert (Joo in the Blukwa group, Djugu Territory). FAO staff present to investigate and conduct necropsy. Rapid test on 1 bird positive for H5 influenza A. Since ducks have died, the virus is presumably HPAI. I believe FAO sent N8 primers to all countries in Africa earlier this year. I'm guessing the main veterinary lab in DRC will already have N1 primers.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

Sent: Thu, 25 May 2017 10:40:34 -0700
Subject: Re: CEPI & GVP idea
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Dennis Carroll <dcarroll@usaid.gov>

Great 530-754-9035 or 530-304-1231

On Thu, May 25, 2017 at 10:39 AM, Dennis Carroll <dcarroll@usaid.gov> wrote:

i can call you immediately after the call

On Thu, May 25, 2017 at 1:32 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Great -- if we finish early, I could chat.
Whatever works for you,
J

On Thu, May 25, 2017 at 10:31 AM, Dennis Carroll <dcarroll@usaid.gov> wrote:

i like the idea a lot lets talk separately from todays call

On Thu, May 25, 2017 at 12:06 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Hi Dennis,
Have you reached out & spoken to Richard Hatchett yet?
If yes, did he seem receptive to collaboration. If no, I may have a hook to explore with you.
I have a project scientist/postdoc who is doing the heavy lifting on the viral risk ranking. She's a PhD Disease Ecologist. She is from the UK, and I am supportive of her moving back there but continuing to work for us on the risk ranking application and other GVP/Predict forecasting projects remotely. If you think it might be of interest to Richard, I would be very interested in exploring placing/seconding her there with him as a GVP Liaison while he's developing the office. We would pay her; she would continue on our work, but be available to his team to bring the ecological perspective & animal sectors into conversations as appropriate. We would then have the chance to be a valuable resource for CEPI and real partner without any added cost to either project.
If you think this is an interesting idea, I could either get on a call with you or prepare a one pager and CV to help facilitate discussions.
Let me know,
Jonna

--
Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
Mobile: REDACTED

--
Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
Mobile: REDACTED

From: Andrew Clements <aclements@usaid.gov>
Sent: Mon, 3 Jul 2017 17:13:06 +0200
Subject: Additional H5N8 poultry outbreaks in DRC (Ituri)
To: [redacted] "Subhash Morzaria (FAORAP)" <[redacted], [redacted] [redacted] lparish@usaid.gov, Dennis Carroll <dcarroll@usaid.gov>, "Lisa Kramer (Nairobi/EA/RHH)" <lkramer@usaid.gov>, spiage@usaid.gov, rgreene@usaid.gov, alongwagar@usaid.gov, jnumbi@usaid.gov, Jonna Mazet <jkmazet@ucdavis.edu>, pmulembakani@metabiota.com, ksaylors@metabiota.com, Angela Wang <awang@usaid.gov>, akibria@usaid.gov, [redacted] "Priya Markanday (TCES)" [redacted]

FYI

http://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?reportid=24188

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From: gaof <gaof@im.ac.cn>
Sent: Wed, 12 Jul 2017 03:40:53 -0400
Subject: Re: National Academy of Medicine
To: Jonna Mazet <jkmazet@ucdavis.edu>

Jonna
Yes. introduce me.
I will write an email to each of them by copying yo you andbyou can reply to confirm your intro.
Best
G

发自我的 iPhone

在 2017年6月29日，下午10:34，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

> Hi again,
> I was all over India for a couple of different projects.
> There are definitely some good potential collaborators for you there.

You may want to check into our Predict-affiliated leadership:
Dr. Rajesh Bhatia REDACTED
Dr. Manish Kakkar <manish.kakkar@phfi.org>

Drs. Kakkar and Bhatia are based in Delhi, and are part of our senior management team. They bring a wealth of expertise related to zoonotic disease surveillance and research in India and have been instrumental in guiding us through the permitting and approval processes. Manish works at the Public Health Foundation, India, and Rajesh is previously from WHO and is currently a consultant working with us, as well as others developing and implementing India's antimicrobial resistance action plan. I'm happy to make introductions if you're interested.

In addition, during my trip, I met and discussed surveillance and interesting plans with Professor Sudhir Krishna at the National Centre for Biological Sciences <skrishna@ncbs.res.in>; https://www.ncbs.res.in/faculty/sudhir

Here's an example of discussions;
>
>> Dear Jonna,
>> Pleasure having you over for the talk at the NCBS campus and then
>> catching
>> up over dinner. I thought it might be useful to give you a few more
>> details on what I mentioned over dinner. The program is dengue vaccine
>> centric, but hopefully will function as both a broad enabler in
>> infectious
>> diseases and help facilitate partnerships. I should add that my role is
>> purely supportive.
>> The egovernance foundation of India
>> https://egovernments.org
>> will host the dengue density heat maps
>> Dr. Manoj Murhekar, Director, National Institute of Epidemiology, ICMR,
>> Chennai,
>> http://nie.gov.in
>> will be one of the key investigators on the grant along with other
>> colleagues that ICMR involves in the program
>> The involvement of egovernance foundation and the ICMR epidemiology
>> institute should enable objective 1 to visualize rapidly by digital
>> means
>> the patterns of Dengue cases in the country using ongoing record
>> keeping.
>> To build standard operating procedures (SOPs) for augmented dengue data
>> collection, we have roped in the Public health Institute, Bangalore
>> http://phiindia.org
>> Along with units that ICMR supports, this should take care of objective
>> 2.

>> which is figuring out how to estimate Dengue prevalence from the
>> community.
>> There are now several first generation Dengue vaccine products in
>> various
>> stages of development.
>> Vaccination roll-outs typically face challenges with diversity and
>> evolution of the viruses in the community, defining preferential target
>> groups (personalized vaccination) and predicting disease dynamics.
>> Typically, this then leads to the creation of the next generation of
>> vaccines, in the case of Influenza in fact every season, there are new
>> sub-units manufactured.
>> I think Satish Rao, Mary Diaz (Microbiology, St. Johnâ€™s) and the
>> collaborating ICMR team have a clear sense of the experiments they want
>> to
>> undertake to estimate viral diversity, understood immune profiles and
>> lay
>> the foundation for a bio-marker program.
>> Some of the Dengue vaccine products in development are with Serum
>> Institute
>> http://www.serumindia.com
>> and two other companies. Building synergy with them would be vital to
>> enable the Dengue vaccine rollout.
>> My sense is that the program should really be embedded within ICMR to
>> make
>> this a success. They are also significantly investing monetary resources
>> into the program. Might take a few more weeks while ICMR sorts out the
>> role of the various units and puts MOU's in place and so on.
>> Trust this helps and I assume you are having both fun and a productive
>> time on your trip to Wynad.
>> With regards,
>> Sudhir
>>

Let me know if you'd like an intro to anyone there that I might know,
Jonna

On Sat, Apr 29, 2017 at 9:40 AM, George GAO <gaof@im.ac.cn> wrote:

> Jonna. Where RU in India ? I also would like to visit India and start some collaborations there. Pls link me with some virologists/public health experts there.
> Best
> George

发自我的 iPhone George Gao

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

> Dear George,
> Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate.
> I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
> Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
> Hope you are well,
> Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Hope this emial finds you well. I wonder if you have some time to find any our friencds who is in Section 2 as we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

George

From: "William B. Karesh" <karesh@ecohealthalliance.org>
To: Brian Bird <bhbird@ucdavis.edu>, David Wolking <djwolking@ucdavis.edu>
Cc: "predict@ucdavis.edu" <predict@ucdavis.edu>, Elizabeth Leasure <ealeasure@ucdavis.edu>
Sent: Tue, 18 Jul 2017 20:57:19 +0000
Subject: [predict] Re: introduction and next steps on Sierra Leone + Cameroon office share

They don't waste any time. And, yes, exactly what date did you take over the lead ;) They were asking the same thing of us for CdI last week. I guess it's a fair question, but not an issue that was at the top of our list of things to focus on. They also asked if we wanted to share office space in Abidjan either for country or regional activities. That is the DAI regional office. Really nice folks though, and enthusiastic about working together.

BK

William B. Karesh, D.V.M
Executive Vice President for Health and Policy

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

On Jul 18, 2017, at 10:20 PM, Brian Bird <bhbird@ucdavis.edu> wrote:

Yes, I had heard there was some arrangement being put together for the office sharing. This is the first I've heard of anything worked out to this level. I talked with Susan Scribner of P&R when we were in Freetown together about cost sharing in the office space (if we chose to remain in the FT location). I was going to follow-up with her this week, but in light of this once you are back, let's discuss late this week before I do.

-b

From: David J Wolking <djwolking@ucdavis.edu>
Date: Tuesday, July 18, 2017 at 11:35 AM
To: Brian Bird <bhbird@ucdavis.edu>, "William B. Karesh, D.V.M" <karesh@ecohealthalliance.org>
Cc: "predict@ucdavis.edu" <predict@ucdavis.edu>, Elizabeth Leasure <ealeasure@ucdavis.edu>
Subject: Fwd: introduction and next steps on Sierra Leone + Cameroon office share

Brian,

Sharing this with you and Billy so you both are in the loop, I'd prefer to discuss when I'm back before we respond as I'm completely out of the loop on the P&R and PREDICT relationship in Sierra Leone. Feel free to send onto Karen but I'm assuming they turfed this to me so that might be a dead end.

[redacted]. Be back in the US late Weds so maybe we can connect on Thursday or Friday? I'll send a softball response now so Chethana knows I received the message.

D

-------- Forwarded message --------
From: **Chethana Billyar** <[redacted]
Date: Tue, Jul 18, 2017 at 6:50 PM
Subject: introduction and next steps on Sierra Leone + Cameroon office share
To: "djwolking@ucdavis.edu" <djwolking@ucdavis.edu>
Cc: David Whitfield <[redacted]>, Katie Taratus <[redacted]>, Leanne Polachek [redacted]

Hi David,
I hope this email finds you well. I am a Program Officer with DAI/Preparedness & Response, and have recently been in communication with Metabiota to put together an office sharing arrangement for two P&R staff members to work out of Metabiota's offices in Sierra Leone and Cameroon (one staff member per office). We had progressed to the point of establishing estimated costs for a purchase order to reimburse Metabiota, but have now learned that UC Davis has taken over implementation of PREDICT in these two countries.

It is our understanding that you are the point of contact for project management/operations questions related to this transition. If so, would you be able to confirm the effective date UC Davis began implementation in Sierra Leone and Cameroon (if the dates are different for each country, please let us know)? In addition, would you be able to confirm whether our two staff members would be able to share what is now UC Davis' office space?

Attached is a breakdown of estimated costs we had developed with Metabiota. If we are able to move forward with a new office sharing arrangement with UC Davis, please let us know what you think of this cost breakdown as a basis for a purchase order to reimburse you for office services provided.

Thanks!
Chethana

Chethana Billyar
Senior Program Officer
USAID | Preparedness & Response
skype: chethana.
[redacted] (Cisco Jabber)
(Mobile)
www.preparednessandresponse.org

One Health in Action.

---The DAI email disclaimer can be found at http://www.dai.com/disclaimer.---

From: David J Wolking <djwolking@ucdavis.edu>
Sent: Mon, 31 Jul 2017 12:14:56 -0700
Subject: Re: URGENT ACTION - Hotel Reservations
To: Alison Andre <andre@ecohealthalliance.org>, Amanda Fine [redacted], Amanda Fuchs <fuchs@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Brian Bird [redacted], Brooke Genovese <bgenovese@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Damien Joly <djoly@metabiota.com>, Dawn Zimmerman [redacted], Eddy Rubin <erubin@metabiota.com>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Emma Lane <lane@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Karen Saylors <ksaylors@metabiota.com>, Leilani Francisco <francisco@ecohealthalliance.org>, Megan Doyle <mmdoyle@ucdavis.edu>, Molly Turner <turner@ecohealthalliance.org>, "Murray, Suzan" <MurrayS@si.edu>, Peter Daszak <daszak@ecohealthalliance.org>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "Prof. Woutrina Smith" <wasmith@ucdavis.edu>, Sarah Olson [redacted], Simon Anthony <sja2127@columbia.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, William Karesh <karesh@ecohealthalliance.org>

Hi PREDICT EB,
We are in the process of planning our September semi-annual consortium meeting in New York (Sept. 11-13th). A draft agenda is in development and will be shared with you all for discussion on our next call (Wednesday August 9, 2017).

The EHA team is hosting and Amanda Andre kindly worked with Hotel Edison to set aside a block of rooms at a discounted rate but **hotel reservations need to be made by August 11th** (details below). For participation, please plan on having the same individuals that joined us at the Pacifica meeting in attendance, and please follow our usual practice to involve only critical support staff necessary for discussions. For example, when on the West Coast, UCD and MB teams typically involve a larger group of staff but restrict attendance to our key personnel when traveling East. We expect the EHA and WCS teams to involve their broader teams in appropriate sessions at the September meeting given the location.

If you have any questions on attendance please let me know, otherwise feel free to proceed with reservations using the link below. We will also have 1-2 days after the EB call on the 9th to finalize plans and address any questions/concerns based on the draft agenda.

Best,

David

On Wed, Jul 19, 2017 at 10:54 AM, Amanda Andre <amanda.andre@ecohealthalliance.org> wrote:

Dear David and Liz,

Hope you are doing well! I'm reaching out to update you on the progress of the Semi-Annual meeting in NYC Sept 11-13th. The same conference space as the Data Meeting last fall, AMA, located at 1601 Broadway, New York, NY 10019, has been reserved.

There is a contract in place for a block of rooms at the same hotel as the Data Meeting last year as well, Hotel Edison, located at 228 W 47th St, New York, NY 10036 (https://www.edisonhotelnyc.com/).

All room reservations must be made by August 11th in order to get the discounted group rate. Reservations can be made online using the specialized link:

https://pc.synxis.com/rez.aspx?Hotel=66316&Chain=16087&arrive=9/10/2017&depart=9/11/2017&adult=1&child=0&group=EHASE17
Participants can also call and mention the group EcoHealth Alliance, or speak with Kim Cofresi, Senior Group Sales Coordinator who is handling logistics for our group. It's important to get this information to those attending as soon as possible, as we have a little under 30 days for everyone to make reservations. Would you like to share this information with those who will be attending?

If there is any way that I can further assist in this, please let me know as I will be glad to help. Any questions let me know. Thank you!!

Best,

Amanda Andre
Administrative Assistant to the Executive Vice President for Health &Policy

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4470 (direct)
1.212.380.4465 (fax)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: Cara Chrisman <cchrisman@usaid.gov>
Sent: Fri, 25 Aug 2017 10:49:10 -0400
Subject: Upcoming GVP Meeting Schedule
To: Peter Daszak <daszak@ecohealthalliance.org>, Eddy Rubin <erubin@metabiota.com>, Brooke Watson <watson@ecohealthalliance.org>, Nathan Wolfe <nwolfe@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>, REDACTED
REDACTED
Cc: Dennis Carroll <dcarroll@usaid.gov>

Hi Team,
We had a chance to discuss the regular GVP meeting schedule over the next month and wanted to provide an update to everyone:

- Aug. 31: Canceled
- Sept. 7: Canceled
- Sept. 14: TBD (please plan to participate, barring any conflicts with the West Coast mtgs)
- Sept. 21: It's on!
- Sept. 28: Canceled

While the August 31 and Sept. 7th meetings are canceled, as per yesterday's call, we would like to find a time during the next few weeks to have a call (or two) and discuss the two outstanding technical topics, likely with a larger group. The goal is to speak regarding those topics prior to the Sept. 15th BioHub meeting.

Eddy & Peter will decide if that needs to be 1 or 2 calls and the desired length. We can then work with the various schedulers to find blocks of time for that/those meeting(s) to occur. Please let me know as soon as possible in order to find a time in the (packed) next several weeks.

Thanks,
Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: (202) 712-1161
Cell: REDACTED
E-mail: cchrisman@usaid.gov

From: George F GAO <gaof@im.ac.cn>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: baiyu <baiyu@im.ac.cn>
Sent: 9/17/2017 9:53:42 PM
Subject: Re: Re: Re: National Academy of Medicine

Dear Jonna,

Here are the tentative filled form and my updated publication list.

Many thanks and do let me know if you need anything more.

All the best

George

-----原始邮件-----
发件人:"Jonna Mazet"
发送时间:2017-09-11 23:59:08 (星期一)
收件人: "George F GAO"
抄送:
主题: Re: Re: National Academy of Medicine

Great news -- I'll contact him.
It would be good if I could get the materials by end of October. Will that work for you?
Have a good day,
Jonna

On Sat, Sep 9, 2017 at 7:39 AM, George F GAO <gaof@im.ac.cn> wrote:

Jonna,

David Ho is a good seconder in Section 2. He knows me very well.

Director and Chief Executive Officer
The Aaron Diamond AIDS Research Center
The Rockefeller University

Regular, 2c

Elected 1997

Male

New York

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-06-30 10:07:32 (星期五)

收件人: gaof <gaof@im.ac.cn>
抄送:
主题: Re: National Academy of Medicine

Hi George,
How are you? Hope all is well there. Attached, you will find the current listing of all of the Section 2 members. Please have a look and let me know which of them you think might be willing to be a co-nominator(s) for your submission. As I said, I am happy to nominate you for Section 10 with a cross-listing in Section 2, if we can find a good Section 2 member who will agree to co-nominate with me.

We will also need to submit all of the following information with the materials taking the following into consideration, in that the application must:
1. Convey this clearly: WHY SHOULD THE CANDIDATE BE AN NAM MEMBER?
a. The sections on sponsor statement, contributions (past/future), and citation are critical.
b. Identify candidate's impact in terms that are understandable to those less familiar with the field.
c. For international candidates: i. Place the candidate's accomplishments into the context of the national/regional/international sphere; ii. Note the level of prestige associated with institutions or prizes in the candidate's background that may be unfamiliar to others; iii. Where appropriate, use phrases such as: 1. …is the leader of Organization X, the most prestigious organization in this field in the nation/region 2. …is distinguished professor at X university, one of the top institutions in the nation/region 3. …is an internationally recognized leader in this field
2. Avoid these common errors in the candidate's personal information:
a. Missing or excessive contact information
b. Missing demographic information
c. Incorrect date of birth, citizenship information
3. Avoid these common errors in nomination details:
a. Wrong section or subsection
b. Missing bridging section where applicable
c. Institutional affiliation of both sponsors is the same as the candidate (at least one must be from an entirely separate institution)
d. >10 (maximum allowed) bibliographic citations

In addition to a co-nominator, I will need the following information in a Word document:

CANDIDATE: Name, Credentials, Institution

Type of Nomination: Regular/66+ Intl Section/Subsection: (#)/(x) Bridging Section(s): (#)

Demographics: ☒ Female ☒ Racial & Ethnic Diversity

Geographic Location: [state/country] Age: [effective October 1]

Subject Emphasis: ☒ This info is not yet available for this year's nominations, but I will get it to you as soon as it comes out.

SPONSORS: Name, Institution
Name, Institution

PAST AND POTENTIAL CONTRIBUTIONS TO NAM:
[~6 lines]

CITATION OF ACCOMPLISHMENT: (50 words)
PROPOSERS' STATEMENT:
[~13 lines]

PRIMARY FIELD & AREA OF SPECIALIZATION OR EXPERTISE:
[3 lines]

CURRENT EMPLOYMENT:
[up to 3]

PRINCIPAL PREVIOUS EMPLOYMENT:
[up to 3]

RESIDENCIES OR FELLOWSHIPS:
[up to 5]

EDUCATION:
[up to 3, highest first]

PRINCIPAL HONORS, AWARDS:
[~6 lines]

CURRENT MAJOR GRANT(s):
[~2 lines]

MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
[~5 lines]

SELECTED BIBLIOGRAPHY
[up to 10 items]

Please let me know if you can provide the name and contact of a co-nominator and the information above, then we can move forward. We should aim to have the co-nominator on board and the materials all pulled together by November.

Hope to see you soon,
Jonna

On Mon, Jun 12, 2017 at 9:10 AM, gaof <gaof@im.ac.cn> wrote:
Jonna
Still have not got any news from you about the section classifications
Best
George

发自我的 iPhone

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Dear George,
Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate. I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
Hope you are well,
Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Hope this emial finds you well. I wonder if you have some time to find any our frieneds who is in Section 2 as we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

Publications List

(Bibliography, George F. Gao, 高福)

(* Correspondence author)

1. Dudas, G., Carvalho, L. M., Bedford, T., Tatem, A. J., Baele, G., Faria, N. R., Park, D. J., Ladner, J., Arias, A., Asogun, D., Bielejec, F., Caddy, S., Cotten, M., MAJ Dumbrozio, J., Dellicour, S., Di Caro, A., Diclaro II, J. W., Duraffour, S., Elmore, M., Fakoli, L., CPT Gilbert, M., Gevao, S. M., Gire, S., Gladden-Young, A., Geisbe, A., Goba, A., Grant, D. S., Haagmans, B., Hiscox, J. A., Jah, U., Kargbo, B., CPT Kugelman, J. R., Liu, D., Lu, J., Malboeuf, C. M., CPT Mate, S., Matthews, D. A., Matranga, C. B., Meredith, L., Qu, J., Quick, J., Pas, S. D., Phan, M. V. T., Pollakis, G., Poliakis, G., Rousken, C., Sanchez-Lockhart, M., Schaffner, S. F., Schieffelin, J. S., Scalfon, R. S., Simon-Loriere, E., Smits, S. L., Stoecker, K., Thorne, L., Tobin, E. A., Vandi, M. A., Watson, S. J., West, K., Whitmer, S., Wiley, M. R., Winnicki, S. M., Wohl, S., Wölfel, R., Yozwiak, N. L., Andersen, K. G., Blyden, S., Bolay, F., Carroll, M., Dahn, B., Diallo, B., Formenty, P., Fraser, C., **Gao, G. F.**, Garry, R. F., Goodfellow, I., Günther, S., Happi, C., Holmes, E. C., Kargbo, B., Kellam, P., Koopmans, M. P. G., Kuhn, J. H., Lomax, N. J., N'Faly Magassouba, Naidoo, D., Nichol, S. T., Nyenswah, T., Palacios, G., Pybus, O. G., Sabeti, P., Sakoba, K., Sall, A., Ströher, U., Wurie, I., Suchard, M. A., Lemey, P. and Rambaut, A., 2017, Virus genomes reveal factors that spread and sustained the Ebola epidemic, ***Nature***, 544 (7650): 309-315. doi: 10.1038/nature22040.

2. Wu, Y., Zhu, Y., Gao*, F., Jiao, Y., Oladejo, B. O., Chai, Y., Bi, Y., Lu, S., Dong, M., Zhang, C., Huang, G., Wong, G., Li, N., Zhang, Y., Li, Y., Feng, W., Shi, Y., Liang, M., Zhang, R., Qi, J. and **Gao*, G. F.**, 2017, Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope, ***Proceedings of the National Academy of Sciences of the United States of America (PNAS)***, (In press)

3. Peng, R., Zhang, S., Cui, Y., Shi, Y., **Gao*, G. F.** and Qi*, J., 2017, Structures of human-infecting *thogotovirus* fusogens support a common ancestor with insect baculovirus, ***Proceedings of the National Academy of Sciences of the United States of America (PNAS)***, (Accepted)

4. Tan, S., Zhang, H., Chai, Y., Song, H., Tong, Z., Wang, Q., Qi, J., Wong, G., Zhu, X., Liu, J., Gao, S., Wang, Z., Shi, Y., Yang, F., **Gao*, G. F.** and Yan*, J., 2017, An unexpected N-terminal loop in PD-1 dominates the binding by nivolumab, ***Nature Communications***, 8: 14369. doi: 10.1038/ncomms14369.

UCDUSR0004175

5. Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu, Y., Yan, J., Shi*, Y., Zhang*, X. and **Gao*, G. F.**, 2017, Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor-binding domains. ***Nature Communications***, 8: 15092. doi: 10.1038/ncomms15092.

6. Wang, J., Ge, P., Qiang, L., Tian, F., Zhao, D., Chai, Q., Zhu, M., Zhou, R., Meng, G., Iwakura, Y., **Gao, G. F.** and Liu*, C. H., 2017, The mycobacterial phosphatase PtpA regulates the expression of host genes and promotes cell proliferation. ***Nature Communications***, 8 (1): 244. doi:10.1038/s41467-017-00279-z.

7. Wang, X., Jiang, H., Wu, P., Uyeki, T. M., Feng, L., Lai, S., Wang, L., Huo, X., Xu, K., Chen, E., Wang, X., He, J., Kang, M., Zhang, R., Zhang, J., Wu, J., Hu, S., Zhang, H., Liu, X., Fu, W., Qu, J., Wu, S., Qin, Y., Zhang, Z., Shi, Y., Zhang, J., Artois, J., Fang, V. J., Zhu, H., Guan, Y., Gilbert, M., Horby, P. W., Leung, G. M., **Gao, G. F.**, Cowling, B. J. and Yu, H., 2017, Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series. ***Lancet Infectious Diseases***, 17 (8): 822-832.

8. Li, A., Lu, G., Qi, J., Wu, L., Tian, K., Luo, T., Shi, Y., Yan*, J. and **Gao*, G. F.**, 2017, Structural basis of nectin-1 recognition by pseudorabies virus glycoprotein D. ***PLoS Pathogens***, 13 (5): e1006314.

9. Sheng, X., You, Q., Zhu, H., Chang, N., Li, Q., Wang, H., Wang, C., Wang, H., Hui, L., Du, C., Xie, X., Zeng, R., Yao, Y., Lin, A., Shi, D., Ruan, K., Yan, J., **Gao, G. F.**, Shao, F. and Hu, R.-g., 2017, Bacterial effector NleL promotes enterohemorrhagic *E. coli*-induced attaching and effacing lesions by ubiquitylating and inactivating JNK. ***PLoS Pathogens***, 13 (7): e1006534.

10. Duan, W., Song, H., Wang, H., Chai, Y., Su, C., Qi, J., Shi*, Y. and **Gao*, G. F.**, 2017, The crystal structure of Zika virus NS5 reveals conserved drug targets. ***EMBO Journal***, 36 (7): 919-933.

11. Shi*, Y. and **Gao*, G. F.**, 2017, Structural biology of the Zika virus. (Invited review) ***Trends in Biochemical Sciences***, 42 (6): 443-456.

12. Liu, G., Wong, G., Su, S., Bi, Y., **Gao, G. F.**, Kobinger, G. and Qiu, X., 2017, Clinical evaluation of Ebola virus disease therapeutics. ***Trends in Molecular Medicine***, (In press).

13. Su, S., Gu, M., Liu, D., Cui, J., **Gao, G. F.**, Zhou*, J. and Liu*, X., 2017, Epidemiology, evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China. ***Trends in Microbiology***, 25 (9): 713-728.

UCDUSR0004176

14. Song, H., Qi, J., Xiao, H., Bi, Y., Zhang, W., Xu, Y., Wang, F., Shi, Y. and **Gao*, G. F.**, 2017, Avian-to-human receptor-binding adaptation by influenza A virus hemagglutinin H4. ***Cell Reports***, 20 (5): 1201-1214.

15. Zhang*, F., Bi, Y., Wang, J., Wong, G., Shi, W., Hu, F., Yang, Y., Yang, L., Deng, X., Jiang, S., He, X., Liu, Y., Yin, C., Zhong, N. and **Gao*, G. F.**, 2017, Human infections with recently-emerging highly pathogenic H7N9 avian influenza in China. ***Journal of Infection***, 75 (1): 71-75. doi: 10.1016/j.jinf.2017.04.001.

16. Sun, J., Wu, D., Zhong, H., Guan, D., Zhang, H., Tan, Q., Zhou, H., Zhang, M., Ning, D., Zhang, B., Ke*, C., Song, T., Lin, J., Zhang, Y., Koopmans, M. and **Gao, G. F.**, 2017, Returning ex-patriot Chinese to Guangdong, China, increase the risk for local transmission of Zika virus. ***Journal of Infection***, pii: S0163-4453(17)30231-1. doi: 10.1016/j.jinf.2017.07.001.

17. Li, Y., Zeng, X., Liu, J., Liu, Y., Liu, S., Yin, P., Qi, J., Zhao, Z., Yu, S., Hu, Y., He, G., Lopez, A. D., **Gao, G. F.**, Wang, L. and Zhou*, M., 2017, Can China achieve a one-third reduction in premature mortality from non-communicable diseases by 2030? ***BMC Medicine***, 15: 132. doi: 10.1186/s12916-017-0894-5.

18. Liu, K., Tan, S., Chai, Y., Chen, D., Song, H., Zhang, C. W.-H., Shi, Y., Liu, J., Tan, W., Lv, J., Gao, S., Yan, J., Qi*, J. and **Gao*, G. F.**, 2017, Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. ***Cell Research***, 27 (1): 151-153.

19. Peng, R., Xu, Y., Zhu, T., Li, N., Qi, J., Chai, Y., Wu, M., Zhang, X., Shi, Y., Wang, P., Wang*, J., Gao*, N. and ***Gao*, G. F.***, 2017, Alternate binding modes of anti-CRISPR viral suppressors AcrF1/F2 to Csy surveillance complex revealed by cryo-EM structures. ***Cell Research***, 27 (7): 853-864.

20. Wong*, G. and **Gao, G. F.**, 2017, An mRNA-based vaccine strategy against Zika. (Invited Research Highlight). ***Cell Research***, doi: 10.1038/cr.2017.53.

21. Liu, W. J., Lan, J., Liu, K., Deng, Y., Yao, Y., Wu, S., Chen, H., Bao, L., Zhang, H., Zhao, M., Wang, Q., Han, L., Chai, Y., Qi, J., Zhao, J., Meng, S., Qin, C., **Gao*, G. F.** and Tan*, W., 2017, Protective T-cell responses featured by concordant recognition of Middle East respiratory syndrome-derived CD8^{+} T-cell epitopes and host MHC. ***The Journal of Immunology***, 198 (2): 873-882.

22. Shi, Y., Kawana-Tachikawa, A., Gao, F., Qi, J., Liu, C., Gao, J., Cheng, H., Ueno, T., Iwamoto, A. and **Gao*, G. F.**, 2017, Conserved Vδ1 binding geometry in a setting of locus-disparate

UCDUSR0004177

pHLA recognition by δ/αβ TCRs: insight into recognition of HIV peptides by TCR. ***Journal of Virology***, (In press)

23. Zhu, T., Song, H., Peng, R., Shi, Y., Qi, J. and **Gao*, G. F.**, 2017, Crystal structure of the Marburg virus nucleoprotein core domain chaperoned by a VP35 peptide reveals a conserved drug target for filovirus. ***Journal of Virology***, (In press)

24. Wang*, Q., Yan, J. and **Gao, G. F.**, 2017, Monoclonal antibodies against Zika virus: Therapeutics and their implications for vaccine design. ***Journal of Virology***, (Accepted)

25. Huang, H., Li, S., Zhang, Y., Han, X., Jia, B., Liu, H., Liu, D., Tan, S., Wang, Q., Bi, Y., Liu, W. J., Hou, B., **Gao*, G. F.** and Zhang*, F., 2017, CD8$^+$ T cell immune response in immunocompetent mice during Zika virus infection. ***Journal of Virology***, (In press)

26. Zheng, W., Cao, S., Chen, C., Li, J., Zhang, S., Jiang, J., Niu, Y., Fan, W., Li, Y., Bi, Y., **Gao, G. F.**, Sun, L. and Liu*, W., 2017, Threonine 80 Phosphorylation of Non-Structural Protein 1 Regulates the Replication of Influenza A Virus by Reducing the Binding Affinity with RIG-I. ***Cellular Microbiology***, 19 (2). doi: 10.1111/cmi.12643.

27. Li, J., Zheng, W., Hou, L., Chen, C., Fan, W., Qu, H., Jiang, J., Liu, J., **Gao, G. F.**, Zhou, J., Sun, L. and Liu*, W., 2017, Differential nucleocytoplasmic shuttling of the nucleoprotein of influenza A viruses and association with host tropism. ***Cellular Microbiology***, 19 (5). doi: 10.1111/cmi.12692.

28. Li, W., Liu, H., Bi, Y., Sun, J., Wong, G., Liu, D., Li, L., Liu, J., Chen, Q., Wang, H., He, Y., Shi, W., **Gao, G. F.** and Chen*, J., 2017, Highly pathogenic avian influenza A (H5N8) virus in wild migratory birds, Qinghai Lake, China. ***Emerging Infectious Diseases***, 23 (4): 637-641. doi: 10.3201/eid2304.161866.

29. Lan, J., Yao, Y., Deng, Y., Hu, Y., Bao, L., Hu, B., Yan, J., **Gao, G. F.**, Qin, C. and Tan, W., 2017, The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. ***Vaccine***, 35 (1): 10-18.

30. Liu*, W. J., Zhao, M., Liu, K., Xu, K., Tan W. and **Gao*, G. F.**, 2017, T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. ***Antiviral Research***, 137: 82-92.

31. Liu, J., Sun, Y., Shi, W., Tan, S., Pan, Y., Cui, S., Zhang, Q., Dou, X., Lv, Y., Li, X., Li, X., Chen, L., Quan, C., Wang, Q., Zhao, Y., Lv, Q., Hua, W., Zeng, H., Chen, Z., Xiong, H., Jiang, C., Pang, X., Zhang, F., Liang, M., Wu, G., **Gao, G. F.**, Liu, W. J., Li, A. and Wang, Q., 2017,

UCDUSR0004178

The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages. ***Emerging Microbes and Infections***, 6 (1): e4. doi: 10.1038/emi.2016.136.

32. Wu, Z., Hu, J., Zeng, T., Zhang, Z., Chen, J., Wong, G., Qiu, X., Liu, W., **Gao, G. F.**, Bi*, Y. and Pang*, D., 2017, Ultrasensitive Ebola virus detection based on electroluminescent nanospheres and immunomagnetic separation. ***Analytical Chemistry***, 89 (3): 2039-2048.

33. Zheng, L., Wei, J., Lv, X., Bi, Y., Wu, P., Zhang, Z., Wang, P., Liu, R., Jiang, J., Cong, H., Liang, J., Chen, W., Cao, H., Liu, W., **Gao, G. F.**, Du, Y., Jiang, X. and Li X., 2017, Detection and differentiation of influenza viruses with glycan-functionalized gold nanoparticles. ***Biosensors and Bioelectronics***, 91: 46-52.

34. Jiang, H., Wu, P., Uyeki, T. M., He, J., Deng, Z., Xu, W., Lv, Q., Zhang, J., Wu, Y., Tsang, T. K., Kang, M., Zheng, J., Wang, L., Yang, B., Qin, Y., Feng, L., Fang, V. J., **Gao, G. F.**, Leung, G. M., Yu, H. and Cowling, B. J., 2017, Preliminary epidemiological assessment of human infections with highly pathogenic avian influenza A(H5N6) virus, China. ***Clinical Infectious Diseases***, (In press). doi: 10.1093/cid/cix334.

35. Han, X., Qi, J., Song, H., Wang, Q., Zhang, Y., Wu, Y., Lu, G., K.-Y., Yuen, Shi*, Y. and **Gao*, G. F.**, 2017, Structure of the S1 subunit C-terminal domain from bat-derived coronavirus HKU-5 spike protein. ***Virology***, 507: 101-109.

36. Tan, S., Zhang, S., Wu, B., Zhao, Y., Zhang, W., Han, M., Wu, Y., Shi, G., Liu, Y., Yan, J., Wu, G., Wang, H., **Gao, G. F.**, Zhu*, F. and Liu*, W. J., 2017, Hemagglutinin-specific $CD4^+$ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. ***Vaccine***, (Accepted).

37. He, M., Chai, Y., Qi, J., Zhang, C. W.-H., Tong, Z., Shi, Y., Yan, J., Tan*, S. and **Gao*, G. F.**, 2017, Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. ***Oncotarget***, doi: 10.18632/oncotarget.18004.

38. Tan, S., Liu, K., Chai, Y., Zhang, C. W.-H., Gao, S., **Gao*, G. F.** & Qi*, J., 2017, Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. ***Protein & Cell***, (In press).

39. Yang, Y., Wong, G., Ye, B., Li, S., Li, S., Zheng, H., Wang, Q., Liang, M., **Gao, G. F.**, Liu, L., Liu, Y. and Bi*, Y., 2017, Development of a reverse transcription quantitative polymerase chain reaction-based assay for broad coverage detection of African and Asian Zika virus lineages. ***Virologica Sinica***, 32 (3): 199-206.

40. Hu*, Y., **Gao, G. F.** and Zhu*, B., 2017, The antibiotic resistome: gene flow in environments,

UCDUSR0004179

animals and human beings. ***Frontiers of Medicine***, 11 (2): 161-168.

41. Tan, S., Lin, N., Huang, M., Wang, Q., Tan, Y., Li, B., Zhang, N., Gao, T., Cui, Y., Chen, X., Wang, D., Wang, J., Xiao, H., Liu, W. J., Yan, J., Zhang, C. W.-H., Liu, C., Wan*, K. and **Gao*, G. F.**, 2017, CTL Immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for *Mycobacterium tuberculosis* infection. ***Tuberculosis***, (In press)

42. Vavricka, C. J., Muto, C., Hasunuma, T., Kimura, Y., Araki, M., Wu, Y., **Gao, G.F.**, Ohrui, H. and Kiyota, H., 2017, Synthesis of sulfo-sialic acid analogues: potent neuraminidase inhibitors in regards to anomeric functionality. ***Scientific Reports***, 7 (1): 8239.

43. Li*, X., Ma, W., Wong, G., Ma, S., Li, S., Bi, Y. and **Gao*, G. F.**, 2017, A new threat to human reproduction system posted by Zika virus (ZIKV): from clinical investigations to experimental studies. ***Virus Research***, (In press).

44. Wang, H., Shi, Y., Song, J., Qi, J., Lu, G., Yan, J. and **Gao*, G. F.**, 2016, Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. ***Cell***, 164: 258-268.

45. Gong, X., Qian, H., Zhou, X., Wu, J., Wan, T., Cao, P. Huang, W., Zhao, X., Wang, X., Wang, P., Shi, Y., **Gao, G. F.**, Zhou*, Q. and Yan*, N., 2016, Structural insights into the Niemann-Pick C1 (NPC1)-mediated cholesterol transfer and Ebola infection. ***Cell***, 165 (6): 1467-1478.

46. Ma, W., Li, S., Ma, S., Jia, L., Zhang, F., Zhang, Y., Zhang, J., Wong, G., Zhang, S., Lu, X., Zhang, H., Yan, J., Li, W., Qin, C., Han, D., Qin, C., Wang, N., Li*, X. and **Gao*, G. F.**, 2016, Zika virus causes testis damage and leads to male infertility in mice, ***Cell***, 167 (6): 1511-1524.

47. Dai, L., Song, J., Lu, X., Deng, Y., Musyoki, A. M., Cheng, H., Zhang, Y., Yuan, Y., Song, H., Haywood, J., Xiao, H., Yan, J., Shi, Y., Qin*, C., Qi*, J. and **Gao*, G. F.**, 2016, Structures of the Zika virus envelope protein and its complex with a flavivirus broadly-protective antibody. ***Cell Host and Microbe***, 19 (5): 696-704.

48. Bi, Y., Chen, Q., Wang, Q., Chen, J., Jin, T., Wong, G., Quan, C., Liu, J., Wu, J., Yin, R., Zhao, L., Li, M., Ding, Z., Zou, R., Xu, W., Li, H., Wang, H., Tian, K., Fu, G., Huang, Y., Shestopalov, A. M., Li, S., Xu, B., Yu, H., Luo, T., Lu, L., Xu, X., Luo, Y., Liu*, Y., Shi*, W., Liu*, D. and **Gao*, G. F.**, 2016, Genesis, evolution and prevalence of H5N6 avian influenza viruses causing sporadic human infections. ***Cell Host and Microbe***, 20 (6): 810-821. (Cover story)

49. Song, H., Qi, J., Haywood, J., Shi*, Y. and **Gao*, G. F.**, 2016, Zika virus NS1 structure reveals

UCDUSR0004180

a diversified electrostatic surface among flavivirus. ***Nature Structural and Molecular Biology***, 23 (5): 456-458.

50. Qiu*, X., Audet, J., Lv, M., He, S., Wong, G., Wei, H., Luo, L., Fernando, L., Bovendo, H. F., Bello, A., Li, F., Ye, P., Jacobs, M., Ippolito, G., Saphire, E. O., Bi, S., Shen, B., **Gao, G. F.**, Zeitlin, L., Feng, J., Zhang, B. and Kobinger*, G. P., 2016, Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. ***Science Translational Medicine***, 8 (329): 329-333.

51. Wang, Q., Yang, H., Liu, X., Dai, L., Ma, T., Qi, J., Wong, G., Peng, R., Liu, S., Li, J., Li, S., Song, J., Liu, J., He, J., Yuan H., Xiong, Y., Liao, Y., Li, J., Yang, J., Tong, Z., Griffin, B. D., Bi, Y., Liang, M., Xu, X., Qin, C., Cheng, G., Zhang, X., Wang, P., Qiu, X., Kobinger, G., Shi, Y., Yan*, J. and **Gao*, G. F.**, 2016, Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. ***Science Translational Medicine***, 8 (369): 369ra179. (Cover story)

52. Ni, M., Chen, C., Qian, J., Xiao, H.-X., Shi, W.-F., Luo, Y., Wang H.-Y., Li, Z., Wu, J., Xu, P.-S., Chen, S.-H., Wong, G., Bi, Y., Xia, Z.-P., Li, W., Lu, H.-J., Tong, Y.-G., Ma, J., Zeng, H., Wang*, S.-Q., **Gao*, G. F.**, Bo*, X.-C. and Liu*, D., 2016, Intra-host variations of Ebola virus during 2014. ***Nature Microbiology***, 1 (11): 16151. doi: 10.1038/nmicrobiol.2016.151. (cover story)

53. Haywood, J., Qi, J., Chen, C.-C., Lu, G., Liu, Y., Yan, J., Shi, Y. and **Gao*, G. F.**, 2016, Structural basis of collagen recognition by human osteoclast associated receptor: design of osteoclastogenesis inhibitors. ***Proceedings of the National Academy of Sciences of the United States of America (PNAS)***, 113 (4): 1038-1043.

54. Mouyoki A. M., Shi, Z., Xuan, C., Lu, G., Qi, J., Gao, F., Zheng, B., Zhang, Q., Li, Y., Haywood, J., Liu, C., Yan, J., Shi, Y. and **Gao*, G. F.**, 2016, Structural and functional analysis of an anchorless fibronectin-binding protein FBPS from Gram positive bacterium *Streptococcus suis*. ***Proceedings of the National Academy of Sciences of the United States of America (PNAS)***, 113 (48): 13869-13874.

55. Xu, X., Song, H., Qi, J., Liu, Y., Wang, H., Su, C., Shi*, Y. and **Gao*, G. F.**, 2016, Contribution of intertwined loop to membrane association revealed by Zika virus full-length NS1 structure. ***EMBO Journal***, 35 (20): 2170-2178. (Cover story)

56. Song, H., Qi, J., Khedri, Z., Diaz, S. L., Yu, H., Chen, X., Varki, A., Shi, Y. and **Gao*, G. F.**, 2016, An open receptor-binding cavity of hemagglutinin-esterase-fusion glycoprotein from newly-identified influenza D virus: basis for its broad cell tropism. ***PLoS Pathogens***, 12 (1):

UCDUSR0004181

e1005411.

57. Huang, C., Liu, J., Xu, W., Jin, T., Zhao, Y., Song, J., Shi, Y., Ji, W., Jia, H., Zhou, Y., Wen, H., Zhao, H., Liu, H., Li, H., Wang, Q., Wu, Y., Wang, L., Liu, D., Liu, G., Yu, H., Holmes, E. C., Lu*, L. and **Gao*, G. F.**, 2016, A bat-derived putative cross-family recombinant coronavirus with a reovirus gene. ***PLoS Pathogens***, 12 (9): e1005883. doi: 10.1371/journal.ppat.1005883.

58. Hu, Y., Li u, F., Lin, I. Y.-C., **Gao, G. F.** and Zhu*, B., 2016, Dissemination of the MCR-1 colistin resistance gene. ***Lancet Infectious Diseases***, 16 (2): 146-147.

59. Lai, S., Qin, Y., Cowling, B. J., Ren, X., Wardrop, N. A., Gilbert, M., Tsang, T. K., Wu, P., Feng, L., Jiang, H., Peng, Z., Zheng, J., Liao, Q., Li, S., Horby, P. W., Farrar, J. J., **Gao, G. F.**, Tatem, A. J. and Yu*, H., 2016, Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: a systematic review of individual case data. ***Lancet Infectious Diseases***, 16 (7): e108-118.

60. Sun, X., Shi, Y., Akahoshi, T., Fujiwara, M., Gatanaga, H., Schonbach, C., Kuse, N., Appay, V., **Gao, G. F.**, Oka, S. and Takiguchi*, M., 2016, Effects of a single escape mutation on T cell and HIV-1 co-adaptation. ***Cell Reports***, 15 (10): 2279-2291. doi: 10.1016/j.celrep.2016.05.017.

61. Su*, S., Wong, G., Shi, W., Liu, J., Lai, A. C. K., Zhou, J., Liu, W., Bi*, Y. and **Gao*, G. F.**, 2016, Epidemiology, genetic recombination, and pathogenesis of coronaviruses. ***Trends in Microbiology***, 24 (6): 490-502.

62. Shi*, W., Zhang, Z., Ling, C., Carr, M., Tong, Y. and **Gao, G. F.**, 2016, Increasing genetic diversity of Zika virus in the Latin American outbreak. ***Emerging Microbes and Infections***, 5 (7): e68. doi: 10.1038/emi.2016.68.

63. Chen, Q., Wang, H., Zhao, L., Ma, L., Wang, R., Lei, Y., Yang, G., Chen, J., Chen, G., Li, L., Jin, T., Li, J., Liu, X., Xu, X., Wong, G., Liu, L., Liu, Y., Shi, W., Bi, Y. and **Gao, G. F.**, 2016, First documented case of avian influenza (H5N1) virus infection in a lion. ***Emerging Microbes and Infections***, 5 (12): e125. doi: 10.1038/emi.2016.

64. Wong, G., Qiu, X., Bi, Y., Formenty, P., Sprecher, A., Jacobs, M., **Gao, G. F.** and Kobinger*, G., 2016, More challenges from Ebola: the infection of the central nervous system. ***The Journal of Infectious Diseases***, 214 (suppl 3): S294-S296.

65. Wong, G., Qiu, X., de La Vega, M.-A., Fernando, L., Wei, H., Bello, A., Fausther-Bovendo, H., Audet, J., Kroeker, A., Kozak, R., Tran, K., He, S., Tierney, K., Soule, G., Moffat, E., Günther, S., **Gao, G. F.**, Strong, J., Embury-Hyatt, C. and Kobinger, G., 2016, Pathogenicity

UCDUSR0004182

comparison between the Kikwit and Makona Ebola variants in rhesus macaques. ***The Journal of Infectious Diseases***, 214 (suppl 3): S281-S289.

66. Liu, W. J., Tan, S., Zhao, M., Quan, C., Bi, Y., Wu, Y., Zhang, S., Zhang, H., Xiao, H., Qi, J., Yan, J., Liu, W., Yu, H., Shu, Y., Wu, G. and **Gao*, G. F.**, 2016, Cross-immunities against avian influenza H7N9 virus in the healthy population affected by antigenicity-deficient substitutions. ***The Journal of Infectious Diseases***, 214 (12): 1937-1946.

67. Bai, C.-Q., Mu, J.-S., Kargbo, D., Song, Y.-B., Niu, W.-K., Nie, W.-M., Kanu, A., Liu, W.-W., Wang, Y.-P., Dafae, F., Yan, T., Hu, Y., Deng, Y.-Q., Lu, H.-J., Yang, F., Zhang, X.-G., Sun, Y., Cao, Y.-X., Su, H.-X., Sun, Y., Liu, W.-S., Wang, C.-Y., Qian, J., Liu, L., Wang, H., Tong, Y.-G., Liu, Z.-Y., Chen, Y.-S., Wang, H.-Q., Kargbo, B., **Gao, G. F.** and J.-F., Jiang*, 2016, Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705), Sierra Leone, 2014. ***Clinical Infectious Diseases***, 63 (10): 1288-1294.

68. Zhou, K., Wang, J., Li, A., Zhao, W., Wang, D., Zhang, W., Yan, J., **Gao, G. F.**, Liu, W. and Fang, M., 2016, Swift and strong NK cell responses protect 129 mice against high-dose influenza virus infection. ***The Journal of Immunology***, 196 (4): 1842-1854.

69. Yao, S., Liu, J., Qi, J., Chen, R., Zhang, N., Liu, Y., Wang, J., Wu, Y., **Gao, G. F.** and Xia*, C., 2016, Structural illumination of equine MHC class I molecules highlights unconventional epitope presentation manner that is evolved in equine leukocyte antigen alleles. ***The Journal of Immunology***, 196 (4): 1943-1954.

70. Xiao, J., Xiang, W., Chai, Y., Haywood, J., Qi, J., Ba, L., Qi, P., Wang, M., Liu*, J. and **Gao*, G. F.**, 2016, Diversified anchoring features the peptide presentation of DLA-88*50801: first structural insight into domestic dog MHC class I. ***The Journal of Immunology***, 197 (6): 2306-2315.

71. Jiang, J., Li, J., Fan, W., Zheng, W., Yu, M., Chen, C., Sun, L., Bi, Y., Ding, C., **Gao, G. F.** and Liu*, W., 2016, Robust Lys63-linked ubiquitination of RIG-I promotes cytokine eruption in early influenza B virus infection. ***Journal of Virology***, 90 (14): 6263-6275.

72. Wang, H.-J., Li, X.-F., Liu, L., Xu, Y.-P., Ye, Q., Deng, Y.-Q., Huang, X.-Y., Zhao, H., Qin, E-D., Shi, P.-Y., **Gao, G. F.** and Qin*, C.-F., 2016, The emerging duck flavivirus is not pathogenic for primates and is highly sensitive to mammalian interferon antiviral signaling. ***Journal of Virology***, 90 (14): 6538-6548.

73. Chan, C.-M., Chu, H., Wang, Y., Wong, B. H.-Y., Zhao, X., Zhou, J., Yang, D., Leung, S. P., Chan, J. F.-W., Yeung, M.-L., Yan, J., Lu, G., **Gao, G. F.** and Yuen*, K.-Y., 2016,

UCDUSR0004183

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is an important surface attachment factor facilitating the entry of the Middle East respiratory syndrome coronavirus (MERS-CoV). ***Journal of Virology***, 90 (20): 9114-9127.

74. Wu, Y., Gao, F., Qi, J., Bi, Y., Fu, L., Mohan, S., Chen, Y., Li, X., Pinto, B. M., Vavricka, C. J., Tien*, P. & **Gao*, G. F.**, 2016, Resistance to mutant group-2 influenza virus neuraminidases of an oseltamivir-zanamivir hybrid inhibitor. ***Journal of Virology***, 90 (23): 10693-10700.

75. Zhao, X., Tefsen, B., Li, Y., Qi, J., Lu, G., Shi, Y., Yan, J., Xiao, H. and **Gao*, G. F.**, 2016, The NS1 gene from bat-derived influenza-like virus H17N10 can be rescued in influenza A PR8 backbone. ***Journal of General Virology***, 97 (8): 1797-1806.

76. Sun, H., Pu, J., Liu, L., Xu, G., **Gao, G. F.**, Liu, X. and Liu*, J., 2016, Characterization of clade 2.3.4.4 highly pathogenic H5 avian influenza viruses in ducks and chickens. ***Veterinary Microbiology***, 182: 116-122.

77. Huang, C., Qi, J., Lu, G., Wang, Q., Yuan, Y., Wu, Y., Zhang, Y., Yan, J. and **Gao*, G. F.**, 2016, Putative receptor-binding domain of bat-derived coronavirus HKU9 spike protein: evolution of betacoronavirus receptor binding motifs. ***Biochemistry***, 55 (43): 5977-5988.

78. Wong, G., **Gao, G. F.** and Qiu, X., 2016, Can Ebola virus become endemic in the human populations? ***Protein & Cell***, 7 (1): 4-6.

79. Zhang, Y., Chen, W., Wong, G., Bi, Y., Yan, J., Sun, Y., Chen, E., Yan, H., Lou, X., Mao, H., Xia, S., **Gao, G. F.**, Shi*, W. and Chen*, Z., 2016, Highly diversified Zika viruses imported to China, 2016. ***Protein & Cell***, 7 (6): 461-464.

80. Bi, Y., Wong, G., Liu, Y., Liu, L., **Gao, G. F.** and Shi*, Y., 2016, Ribavirin is effective against drug-resistant H7N9 influenza virus infections. ***Protein & Cell***, 7 (8): 611-614.

81. Peng, R., Zhu, T., Oladejo, B. O., Musyoki, A. M., Cui, Y., Shi, Y., Wang*, P. and **Gao*, G. F.**, 2016, *In vitro* assembly of Ebola virus nucleocapsid-like complex expressed in *E. coli*. ***Protein & Cell***, 7 (12): 888-898.

82. Tan, S., Chen, D., Liu, K., He, M., Song, H., Shi, Y., Liu, J., Zhang, C. W.-H., Qi, J., Yan, J., Gao*, S. and **Gao*, G. F.**, 2016, Crystal clear: visualizing the intervention mechanism of the PD1/PDL1 interaction by two by two cancer therapeutic monoclonal antibodies. ***Protein & Cell***, 7 (12): 866-877.

83. Qin, Y., Li, H., Jia, L., Yan, J., **Gao*, G. F.** and Li*, X., 2016, Targeted disruption of Noc4l leads to peri-implantation embryonic lethality in mice, ***Protein & Cell***, 8 (3): 230–235. doi: 10.1007/s13238-016-0335-9.

UCDUSR0004184

84. Zhang, Y., Li, X., Grailer, J. J., Wang, N., Wang, M., Yao, J., Zhong, R., **Gao, G. F.**, Ward, P. A., Tan, D. X. and Li*, X., D., 2016, Melatonin alleviates acute lung injury through inhibiting NLRP3 inflammasome. ***Journal of Pineal Research***, 60 (4): 405-414.

85. Ye, H., Li, Y., Li, Z., Gao, R., Zhang, H., Wen, R., **Gao, G. F.**, Hu, Q. and Feng*, Y., 2016, Diversified mcr-1-harbouring plasmid reservoirs confer resistance to colistin in human gut microbiota. ***mBio***, 7 (2): e00177. doi: 10.1128/mBio.00177-16.

86. Chen, H., Liu, S., Liu, J., Chai, C., Mao, H., Yu, Z., Tang, Y., Zhu, G., Chen, H. X., Zhu, C., Shao, H., Tan, S., Wang, Q., Bi, Y., Zou, Z., Liu, G., Jin, T., Jiang, C., **Gao, G. F.**, Peiris, M., Yu, H. and Chen, E., 2016, Nosocomial co-transmission of avian influenza A(H7N9) and A(H1N1)pdm09 viruses between 2 patients with hematologic disorders. ***Emerging Infectious Diseases***, 22 (4): 598-607.

87. Wu, D., Sun, J., Zhong, H., Guan, D., Zhang, H., Tan, Q., Zhou, H., Ning, D., Ke, C., Song, T., Lin, J., Zhang, Y., Koopmans, M. and **Gao G. F.**, 2016, A family cluster of imported ZIKV cases: viremia period may be longer than previously reported. ***Journal of Infection***, 73 (3): 300-303.

88. Hu, Y., Yang, X., Li, J., Lv, N., Liu, F., Wu, J., Lin, I., Wu, N., Weimer, B., **Gao, G. F.**, Liu, Y. and Zhu, B., 2016, The transfer network of bacterial mobile resistome connecting animal and human microbiome. ***Applied and Environmental Microbiology***, 82 (22): 6672-6681.

89. Wang*, Q., Wong, G., Lu, G., Yan, J. and **Gao*, G. F.**, 2016, MERS-CoV spike protein: targets for vaccines and therapeutics. ***Antiviral Research***, 133: 165-177.

90. Fu, L., Bi, Y., Wu, Y., Zhang, S., Qi, J., Li, Y., Lu, X., Zhang, Z., Lv, X., Yan, J., **Gao, G. F.** and Li*, X., 2016, Structure-based tetravalent Zanamivir with potent inhibitory activity against drug-resistant influenza viruses. ***Journal of Medicinal Chemistry***, 59 (13): 6303-12.

91. Cheng, S., Wang, Y., Zhang, Z., Lv, X., **Gao, G. F.**, Shao, Y., Ma, L. and Li*, X., 2016, Enfuvirtide-PEG conjugate: a potent HIV fusion inhibitor with improved pharmacokinetic properties. ***European Journal of Medicinal Chemistry***, 121: 232-237.

92. Liu, Y., Sun, J., Zhang, H., Wang, M., **Gao, G. F.** and Li*, X., 2016, Ebola virus encodes a miR-155 analogue to regulate importin-α5 expression. ***Cellular and Molecular Life Sciences***, 73 (19): 3733-3744.

93. Cao, L., Fu, S., Gao, X., Li, M., Cui, S., Li, X., Cao, Y., Lei, W., Lu, Z., He, Y., Wang, H., Yan, J., **Gao, G. F.** and Liang*, G., 2016, Low protective efficacy of the current Japanese

UCDUSR0004185

encephalitis vaccine against the emerging Genotype 5 Japanese encephalitis virus. ***PLoS Neglected Tropical Diseases***, 10 (5): e0004686. doi: 10.1371/journal.pntd.0004686.

94. Li, X. F., Dong, H. L., Huang, X. Y., Qiu, Y. F., Wang, H. J., Deng, Y. Q., Zhang, N. N., Ye, Q., Zhao, H., Liu, Z. Y., Fan, H., An, X. P., Sun, S. H., Gao, B., Fa, Y. Z., Tong, Y. G., Zhang, F. C., **Gao, G. F.**, Cao, W. C., Shi, P. Y., and Qin, C. F., 2016, Characterization of a 2016 clinical isolate of Zika virus in non-human primates. ***EBioMedicine***, 12: 170-177. doi: 10.1016/j.ebiom.2016.09.022.

95. Katoh, I., Kawana-Tachikawa, A., Shimizu, A., Zhu, D., Han, C., Nakamura, H., Koga, M., Kikuchi, T., Adachi, E., Koibuchi, T., **Gao, G. F.**, Brumme, Z. L. and Iwamoto*, A., 2016, Rapid HIV-1 disease progression in individuals infected with a virus adapted to its host population. ***PLoS ONE***, 11 (3): e0150397.

96. Li, J., Chen, C., Wong, G., Dong, W., Zheng, W., Li, Y., Sun, L., Zhang, L., **Gao, G. F.**, Bi, Y. and Liu*, W., 2016, Cyclophilin A protects mice against infection by influenza A virus. ***Scientific Reports***, 6: 28978. doi: 10.1038/srep28978.

97. Zhang, Q., Gui, M., Niu, X., He, S., Wang, R., Feng, Y., Kroeker, A., Zuo, Y., Wang, H., Wang, Y., Li, J., Li, C., Shi, Y., Shi, X., **Gao, G. F.**, Xiang, Y., Qiu*, X., Chen*, L. and Zhang*, L., 2016, Potent neutralizing monoclonal antibodies against Ebola virus infection. ***Scientific Reports***, 6: 25856. doi: 10.1038/srep25856.

98. Zheng, X., Wong, G., Zhao, Y., Wang, H., He, S., Bi, Y., Chen, W., Jin, H., Gai, W., Chu, D., Cao, Z., Wang, C., Fan, Q., Chi, H., Gao, Y., Wang, T., Feng, N., Yan, F., Huang, G., Zheng, Y., Li, N., Li, Y., Qian, J., Zou, Y., Kobinger, G., **Gao, G. F.**, Qiu, X., Yang, S. and Xia*, X., 2016, Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. ***Scientific Reports***, 6: 24179. doi: 10.1038/srep24179.

99. Bi, Y., Liu, J., Xiong, H., Zhang, Y., Liu, D., Liu, Y., **Gao, G. F.** and Wang, B., 2016, A new reassortment of influenza A (H7N9) virus causing human infection in Beijing, 2014. ***Scientific Reports***, 6: 26624. doi: 10.1038/srep26624.

100. Bi*, Y., Liu, H., Xiong, C., Liu, D., Shi, W., Li, M., Liu, S., Chen, J., Chen, G., Li, Y., Yang, G., Lei, Y., Xiong, Y., Lei, F., Wang, H., Chen*, Q., Chen*, J. and **Gao, G. F.**, 2016, Novel avian influenza A (H5N6) viruses isolated in migratory waterfowl before the first human case reported in China, 2014. ***Scientific Reports***, 6: 29888. doi: 10.1038/srep29888.

101. Jia, H., Du, P., Yang, H., Zhang, Y., Wang, J., Zhang, W., Han, G., Han, N., Yao, Z., Wang, H.,

UCDUSR0004186

Zhang, J., Wang, Z., Ding, Q., Qiang, Y., Barbut, F., **Gao, G. F.**, Cao, Y., Cheng, Y. and Chen, C., 2016, Nosocomial transmission of *Clostridium difficile* in a Chinese hospital, 2012-2014, traced by whole genome sequencing. ***BMC Genomics***, 17 (1): 405. doi: 10.1186/s12864-016-2708-0

102. Bi*, Y., Chen, J., Zhang, Z., Li, M., Cai, T., Sharshov, K., Susloparov, I., Shestopalov, A., Wong, G., He, Y., Xing, Z., Sun, J., Liu, D., Liu, Y., Liu, L., Liu, W., Lei, F., Shi, W. and **Gao, G. F.**, 2016, Highly pathogenic avian influenza H5N1 Clade 2.3.2.1c virus in migratory birds, 2014-2015. ***Virologica Sinica***, 31 (4): 300-305.

103. Dai*, L., Wang, Q., Qi, J., Shi, Y., Yan J. and **Gao*, G. F.**, 2016, Molecular basis of antibody-mediated neutralization and protection against flavivirus. ***IUBMB Life***, 68 (10): 783-791. (Invited review) (Cover story).

104. Tong, Y.-G., Shi, W.-F., Liu, D., Bo, X.-C., Liang, L., Qian, J., Liu, J., Ren, H.-G., Fan, H., Ni, M., Sun, Y., Jin, Y., Teng, Y., Li, Z., Kargbo, D., Dafae, F., Kanu, A., Chen, C.-C., Lan, Z.-H., Jiang, H., Luo, Y., Lu, H.-J., Zhang, X.-G., Yang, F., Hu, Y., Cao, Y.-X., Deng, Y.-Q., Su, H.-X., Sun, Y., Liu, W.-S., Wang, Z., Wang, C.-Y., Bu, Z.-Y., Guo, Z.-D., Zhang, L.-B., Nie, W.-M., Bai, C.-Q., Sun, C.-H., An, X.-P., Xu, P.-S., Zhang, X.-L.-L., Huang, Y., Mi, Z.-Q., Yu, D., Yao, H.-W., Feng, Y., Xia, Z.-P., Zheng, X.-X., Yang, S.-T., Lu, B., Jiang, J.-F., Kargbo, B., He*, F.-C., **Gao*, G. F.**, Cao*, W.-C. and The China Mobile Laboratory Testing Team in Sierra Leone, 2015, Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. ***Nature***, 524 (7563): 93-96.

105. Wang, J., Li, B.-X., Ge, P.-P., Li, J., Wang, Q., **Gao*, G. F.**, Qiu*, X.-B. and Liu*, C. H., 2015, *Mycobacterium tuberculosis* suppresses innate immunity by coopting the host ubiquitin system. ***Nature Immunology***, 16 (3): 237-245. (Cover story).

106. Su, S., Wong, G., Liu, Y., **Gao, G. F.**, Li*, S. and Bi*, Y., 2015, MERS in South Korea and China: a potential outbreak threat? (Correspondence). ***The Lancet***, 385 (9985): 2349-2350.

107. Li, N., Ren, A., Wang, X., Fan, X., Zhao, Y., **Gao, G. F.**, Cleary, P. and Wang*, B., 2015, Influenza viral neuraminidase primes bacterial co-infection through TGF-beta-mediated expression of host cell receptors. ***Proceedings of the National Academy of Sciences of the United States of America (PNAS)***, 112 (1): 238-243.

108. Wang, F., Qi, J., Bi, Y., Zhang, W., Wang, M., Zhang, B., Wang, M., Liu, J., Yan, J., Shi, Y. and **Gao*, G. F.**, 2015, Adaptation of avian influenza A (H6N1) virus from avian to human receptor binding preference. ***EMBO Journal***, 3(12): 1661-1673.

UCDUSR0004187

109. Wang, M., Zhang, W., Qi, J., Wang, F., Zhou, J., Bi, Y., Wu, Y., Sun, H., Liu, J., Huang, C., Li, X., Yan, J., Shu, Y., Shi, Y. and **Gao*, G. F.**, 2015, Structural basis for preferential avian receptor binding by the human-infecting H10N8 avian influenza virus. ***Nature Communications***, 6: 5600. doi: 10.1038/ncomms6600.

110. Wu, Y., Cho, M.-S., Shore, D., Song, M., Choi, J.-A., Jiang, T., Deng, Y.-Q., Bourgeois, M., Almli, L., Yang, H., Chen, L.-M., Shi, Y., Qi, J., Li, A., Yi, K. S., Chang, M.-S., Bae, J. S., Lee, H.-J., Shin, J.-Y., Stevens, J., Hong, S.-S., Qin*, C.-F., **Gao*, G. F.**, Chang*, S. J. and Donis*, R. O., 2015, A potent broad-spectrum protective human monoclonal antibody crosslinking two monomers of influenza A virus haemagglutinin. ***Nature Communications***, 6: 7708. doi: 10.1038/ncomms8708.

111. Lu*, G., Wang, Q. and **Gao*, G. F.**, 2015, Bat-to-human: spike features determining "host jump" of coronaviruses SARS-CoV, MERS-CoV, and beyond. ***Trends in Microbiology***, 23 (8): 468-478.

112. Wong, G., Liu, W., Liu, Y., Zhou, B., Bi*, Y. and **Gao*, G. F.**, 2015, MERS, SARS and Ebola: the role of super-spreaders in infectious diseases. (Forum). ***Cell Host and Microbe***, 18 (4): 398-401.

113. Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., Wang, Q., Lu, X., Wu, Y., Liu, W., Yuen, K.-Y., Perlman, S., **Gao*, G. F.** and Yan*, J., 2015, A humanized neutralizing monoclonal antibody against MERS-CoV targeting the receptor binding domain of the spike protein. ***Cell Research***, 25 (11): 1237-1249.

114. Wang, Y., Liu, D., Shi, W., Lu, R., Wang, W., Zhao, Y., Deng, Y., Zhou, W., Ren, H., Wu, J., Wang, Y., Wu, G., **Gao*, G. F.** and Tan*, W., 2015, Origin and possible genetic recombination of the Middle East respiratory syndrome Coronavirus from the first imported case in China: phylogenetics and coalescence analysis. ***mBio***, 6 (5): e01280-15.

115. Lan, J., Yao, Y., Deng, Y., Chen, H., Lu, G., Wang, W., Bao, L., Deng, W., Wei, Q., **Gao, G. F.**, Qin, C. and Tan, W., 2015, Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. ***EBioMedicine***, 2 (10): 1438-1446.

116. Li, F., Chen, Y., Zhang, Z., Ouyang, J., Wang, Y., Yan, R., Huang, S., **Gao, G. F.**, Guo, G. and Chen, J. L., 2015, Robust expression of vault RNAs induced by influenza A virus plays a critical role in suppression of PKR-mediated innate immunity, ***Nucleic Acids Research***, 43 (21): 10321-10337.

UCDUSR0004188

117. Bi, Y., Xie, Q., Zhang, S., Li, Y., Xiao, H., Jin, T., Zheng, W., Li, J., Jia, X., Sun, L., Liu, J., Qin*, C., **Gao*, G. F.** and Liu*, W., 2015, Assessment of the internal genes of influenza A (H7N9) virus contributing to high pathogenicity in mice. ***Journal of Virology***, 89 (1): 2-13.

118. Bi*, Y., Xiao H., Chen, Q., Wu, Y., Fu, L., Quan, C., Wong, G., Liu, J., Haywood, J., Liu, Y., Zhou, B., Yan, J., Liu, W. and **Gao*, G. F.**, 2015, Changes in the length of the neuraminidase stalk region impacts H7N9 virulence in mice. ***Journal of Virology***, 90 (4): 2142-2149.

119. Zheng, W., Li, J., Wang, S., Cao, S., Jiang, J.-W., Chen, C., Ding, C., Qin, C., Ye, X., **Gao, G. F.** and Liu*, W., 2015, Phosphorylation controls the nuclear-cytoplasmic shuttling of influenza A virus nucleoprotein. ***Journal of Virology***, 89 (11): 5822-5834.

120. Su, S., Bi, Y., Wong, G., Gray, G., **Gao, G. F.** and Li*, S., 2015, Epidemiology, evolution and recent outbreak of avian influenza virus in China: a review. ***Journal of Virology***, 89 (17): 8671-8676.

121. Yu, Y., Wang, X., Jin, T., Wang, H., Si, W., Yang, H., Wu, J., Yan, Y., Liu, G., Sang, X.-Y., Wu, X., Gao, Y. W., Xia, X., Yu, X., Pan, J., **Gao, G. F.** and Zhou*, J., 2015, Newly emergent highly pathogenic H5N9 subtype avian influenza A virus. ***Journal of Virology***, 89 (17): 8806-8815.

122. Yang, X., Liu, D., Lv, N., Zhao, F., Liu, F., Zou, J., Chen, Y., Xiao, X., Wu, J., Liu, P., Gao, J., Hu, Y., Shi, Y., Liu, J., Zhang, R., Chen, C., Ma, J., **Gao, G. F.** and Zhu*, B., 2015, TCRklass: a new K-string-based algorithms for human and mouse TCR repertoire characterization. ***The Journal of Immunology***, 194 (1): 446-454.

123. Qin, Y., Horby, P. W., Tsang, T. K., Chen, E., Gao, L., Ou, J., Nguyen, T. H., Duong, T. N., Gasimov, V., Feng, L., Wu, P., Jiang, H., Ren, X., Peng, Z., Li, S., Li, M., Zheng, J., Liu, S., Hu, S., Hong, R., Farrar, J. J., Leung, G. M., **Gao, G. F.**, Cowling, B. J. and Yu*, H., 2015, Differences in the epidemiology of human cases of avian influenza A (H7N9) and A (H5N1) viruses infection. ***Clinical Infectious Diseases***, 61 (4): 563-571.

124. Lu, H. J., Qian, J., Kargbo, D., Zhang, X. G., Yang, F., Hu, Y., Sun, Y., Cao, Y. X., Deng, Y. Q., Su, H. X., Dafae, F., Sun, Y., Wang, C.Y., Nie, W. M., Bai, C. Q., Xia, Z. P., Liu, K., Kargbo, B., **Gao, G. F.** and Jiang, J. F., 2015, Ebola virus outbreak investigation, Sierra Leone, September 28-November 11, 2014, ***Emerging Infectious Diseases***, 21 (11): 1921-1927.

125. Wu, D., Zou, S., Bai, T., Li, J., Zhao, X., Yang, L., Liu, H., Li, X., Yang, X., Xin, L., Xu, S., Zou, X., Li, X., Wang, A., Guo, J., Sun, B., Huang, W., Zhang, Y., Li, X., Gao, R., Shen, B., Chen, T., Dong, J., Wei, H., Wang, S., Li, Q., Li, D., Wu, G., Feng, Z., **Gao, G. F.**, Wang, Y.,

UCDUSR0004189

Wang, D., Fan, M. and Shu*, Y., 2015, Poultry farms as a source of avian influenza A (H7N9) virus reassortment and human infection. ***Scientific Reports***, 5: 7630. doi: 10.1038/srep07630.

126. Gao, J., Huang, F., Liu, J., Chen, Y., Wang, W., Cao, B., Zou, Z., Liu, S., Pan, J., Bao, C., Zeng, M., Xiao, H., Gao, H., Yang, S., Zhao, Y., Liu, Q., Zhou, H., Zhu, J., Liu, X., Liang, W., Yang, Y., Zheng, S., Yang, J., Diao, H., Su, K., Shao, L., Cao, H., Wu, Y., Zhao, M., Tan, S., Li, H., Xu, X., Wang, C., Zhang, J., Wang, L., Wang, J., Xu, J., Li, D., Zhong, N., Cao, X., **Gao*, G. F.**, Li*, L. and Jiang*, C., 2015, The serum profile of hypercytokinemia factors identified in H7N9-infected patients can predict fatal outcome. ***Scientific Reports***, 5: 10942. doi: 10.1038/srep10942.

127. Bi, Y., Zhang, Z., Liu, W., Yin, Y., Hong, J., Li, X., Wang, H., Wong, G., Chen, J., Li, Y., Ru, W., Gao, R., Liu, D., Liu, Y., Zhou, B., **Gao, G. F.**, Shi, W. and Lei, F., 2015, Highly pathogenic avian influenza A(H5N1) virus struck migratory birds in China in 2015. ***Scientific Reports***, 5: 12986. doi: 10.1038/srep12986.

128. Li, J., Rao, Y., Sun, Q., Wu, X., Jin, J., Bi, Y., Chen, J., Lei, F., Liu, Q., Duan, Z., Ma, J., **Gao, G. F.**, Liu, D. and Liu*, W., 2015, Identification of climate factors related to human infection with avian influenza A H7N9 and H5N1 viruses in China. ***Scientific Reports***, 5: 18094. doi: 10.1038/srep18094.

129. Zou, R., Zhang, G., Li, S., Wang, W., Yuan, J., Li, J., Wang, Y., Lin, Y., Deng, Y., Zhou B., **Gao, G. F.** and Liu*, Y., 2015, A functional polymorphism in INFAR1 gene is associated with susceptibility and severity of HFMD with EV71 infection. ***Scientific Reports***, 5: 18541. Doi: 10.1038/srep18541.

130. Xu, Y., Cao, H., Liu, H., Sun, H., Martin, B., Zhao, Y., Wang, Q., Deng, G., Xue, J., Zong, Y., Zhu, J., Wen, F., Long, L., Wong, S., Zhao, N., Fu, X., Liao, M., Hu, G., Webby, R., **Gao, G. F.** and Wan*, X., 2015, Identification of the source of influenza A (H10N8) virus causing human infection. ***Infection, Genetics and Evolution***, 30: 159-163.

131. Duan, D., Fan, K., Zhang, D., Tan, S., Liang, M., Liu, Y., Zhang, J., Zhang, P., Liu, W., Qiu, X., Kobinger, G. P., **Gao, G. F.** and Yan*, X., 2015, Nanozyme-strip for rapid local diagnosis of Ebola. ***Biosensors and Bioelectronics***, 74: 134-141.

132. Zhang, B. and **Gao, G. F.**, 2015, A new chapter for China's public health security-aids offered to Africa to combat Ebola. ***Science China Life Sciences***, 58 (1): 114-116.

133. Cheng, S., Chang, X., Wang, Y., **Gao, G. F.**, Shao, Y., Ma, L. and Li*, X., 2015, Glycosylated Enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity. ***Journal of Medicinal***

UCDUSR0004190

Chemistry, 58 (3): 1372-1379.

134. Bi, Y., Mei, K., Shi, W., Liu, D., Yu, X., Gao, Z., Zhao, L., **Gao, G. F.**, Chen*, J., Chen*, Q., 2015, Two novel reassortants of avian influenza A (H5N6) virus in China. ***Journal of General Virology***, 96 (Pt 5): 975-981.

135. Duan, X., Lu, J., Zhou, K., Wang, J., Wu, J., **Gao, G. F.** and Fang*, M., 2015, NK-cells are involved in thymic atrophy induced by influenza A virus infection. ***Journal of General Virology***, 96 (11): 3223-3235.

136. Gohda, J., Ma, Y., Huang, Y., Zhang, Y., Gu, L., Han, Y., Li, T., Gao, B., **Gao, G. F.**, Inoue, J., Iwamoto, A. and Ishida, T., 2015, HIV-1 replicates in human osteoclasts and enhances their differentiation *in vitro*. ***Retrovirology***, 12 (1): 12.

137. Li, Y., Xiao, H., Huang, C., Sun, H., Li, L., Su, J., Ma, J., Liu, D., Wang, H., Liu, W., **Gao, G. F.**, Li*, X. and Yan*, J., 2015. Distribution of sialic acid receptors and experimental infections with different subtypes of influenza A viruses in Qinghai-Tibet plateau wild pika. ***Virology Journal***, 12 (1): 63.

138. Pan, M., Gao, R., Lu, Q., Huang, S., Zhou, Z., Yang, L., Li, X., Zhao, X., Zou, X., Tong, W., Mao, S., Zou, S., Bo, H., Zhu, X., Liu, L., Yuan, H., Zhang, M., Wang, D., Li, Z., Zhao, W., Ma, M., Li, Y., Li, T., Yang, H., Xu, J., Zhou, L., Zhou, X., Tang, W., Song, Y., Chen, T., Bai, T., Zhou, J., Wang, D., Wu, G., Li, D., Feng, Z., **Gao, G. F.**, Wang, Y., He, S. and Shu*, Y., 2015, Human infection with a novel highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings. ***Journal of Infection***, 72 (1): 52-59. doi: 10.1016/j.jinf.2015.06.009.

139. Qi*, X., Wang, Y., Li, Y., Meng, Y., Chen, Q., Ma, J. and **Gao*, G. F.**, 2015, The effects of socioeconomic and environmental factors on the incidence of Dengue fever in the Pearl River Delta, China, 2013, ***PLoS Neglected Tropical Diseases***, 9 (10): e0004159.

140. Gu, L., Han, Y., Li, Y., Zhu, T., Song, X., Huang, Y., Yang, F., Guan, S., Xie, J., Gohda, J., Hosoya, N., Kawana-Tachikawa, A., Liu, W., **Gao, G. F.**, Iwamoto, A., Li*, T. and Ishida*, T., 2015, Emergence of lamivudine-resistant HBV during antiretroviral therapy including lamivudine for patients coinfected with HIV and HIV in China. ***PLoS ONE***, 10 (8): e0134539. DOI: 10.1371/journal. PONE.0134539.

141. Wu, Y., Vavricka, C. J., Wu, Y., Li, Q., Rudrawar, S., Thomson, R. J., von Itzstein, M., **Gao, G. F.** and Qi*, J., 2015, Atypical group 1 neuraminidase pH1N1-N1 bound to a group 1 inhibitor, ***Protein & Cell***, 6 (10): 771-773.

UCDUSR0004191

142. Liu*, D., Shi, W. and **Gao*, G. F.**, 2014, Poultry carrying H9N2 act as incubators for novel human-infecting avian influenza viruses, (Correspondence). ***The Lancet***, 383 (9920): 869.

143. **Gao*, G. F.**, 2014, Influenza and the live poultry trade, (Editorial). ***Science***, 344: 235.

144. **Gao*, G. F.** and Feng, Y., 2014, On the ground in Sierra Leone, (Working Life). ***Science***, 346 (6209): 666.

145. Lu, Q., Lu, G., Qi, J., Wang, H., Xuan, Y., Wang, Q., Li, Y., Zhang, Y., Zheng, C., Fan, Z., Yan, J. and **Gao*, G. F.**, 2014, PILRα and PILAβ have a siglec fold and provide the basis of binding to sialic acid. ***Proceedings of the National Academy of Sciences of the United States of America (PNAS)***, 111 (22): 8221-8226.

146. Chen, H., Yuan, H., Gao, R., Zhang, J., Wang, D., Xiong, Y., Fan, G., Yang, F., Li, X., Zhou, J., Zou, S., Yang, L., Chen, T., Dong, L., Bo, H., Zhao, X., Zhang, Y., Lan, Y., Bai, T., Dong, J., Li, Q., Wang, S., Zhang, Y., Li, H., Gong, T., Shi, Y., Ni, X., Li, J., Zhou, J., Fan, J., Wu, J., Zhou, X., Hu, M., Wan, J., Yang, W., Li, D., Wu, G., Feng, Z., **Gao, G. F.**, Wang, Y., Jin*, Q., Liu*, M. and Shu*, Y., 2014, Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. ***The Lancet***, 383 (9918): 714-721.

147. Wu*, Y., Wu, Y., Tefsen, B., Shi, Y. and **Gao*, G. F.**, 2014, Bat-derived influenza-like viruses H17N10 and H18N11. ***Trends in Microbiology***, 22 (4): 183-191.

148. Shi*, Y., Wu, Y., Zhang, W., Qi, J. and **Gao*, G. F.**, 2014, Enabling the 'host jump': structural determinants of receptor-binding specificity in influenza A viruses, ***Nature Reviews Microbiology***, 12 (12): 822-831.

149. Wang, Q., Qi, J., Yuan, Y., Xuan, Y., Han, P., Wan, Y., Ji, W., Li, Y., Wu, Y., Wang, J., Iwamoto, A., Woo, P. C. Y., Yuen, K.-Y., Yan, J., Lu, G. and **Gao*, G. F.**, 2014, Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26, ***Cell Host and Microbe***, 16 (3): 328-337.

150. Ouyang, J., Zhu, X., Chen, Y., Wei, H., Chen, Q., Chi, X., Qi, B., Zhang, L., Zhao, Y., **Gao, G. F.**, Wang, G. and Chen, J., 2014, NRAV, a long noncoding RNA, modulates antiviral responses through suppression of interferon-stimulated gene transcription, ***Cell Host and Microbe***, 16 (5): 616-626.

151. Cui#, L., Liu#, D., Shi#, W., Pan#, J., Qi#, X., Li, X., Guo, X., Zhou, M., Li, W., Li, J., Xiao, H., Yu, X., Pu, X., Wu, Y., Yu, H., Zhao, K., Zhu, Y., Wu, B., Jin, T., Shi, Z., Tang, F., Zhu, F., Sun, Q., Wu, L., Yang, R., Yan, J., Lei, F., Zhu, B., Liu, W., Ma, J., Wang, H. and **Gao*, G. F.**, 2014, Dynamic reassortments and genetic heterogeneity of the human-infecting influenza A (H7N9)

UCDUSR0004192

virus. ***Nature Communications***, 5: 3142 (doi: 10.1038/ncomms4142).

152. Huang[#], F., Guo[#], J., Zou[#], Z., Liu[#], J., Cao[#], B., Zhang[#], S., Li, H.,Wang, W., Sheng, M., Liu, S., Pan, J., Bao, C., Zeng, M., Xiao, H., Qian, G., Hu, X., Chen, Y., Chen, Y., Zhao, Y., Liu, Q., Zhou, H., Zhu, J., Gao, H., Yang, S., Liu, X., Zheng, S., Ya J ng, J., Diao, H., Cao, H., Wu, Y., Zhao, M., Tan, S., Guo, D., Zhao, X., Ye, Y., Wu, W., Xu, Y., Penninger, J., Li, D., **Gao*, G. F.**, Jiang*, C. and Li*, L., 2014, Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. ***Nature Communications***, 5: 3595. doi: 10.1038/ncomms4595.

153. Wei, H., Wang, S., Chen, Q., Chen, Y., Zhang, L., Huang S., **Gao, G. F.** and Chen*, J., 2014, Suppression of interferon lambda signaling by SOCS-1 results in their excessive production during influenza virus infection. ***PLoS Pathogens***, 10 (1): e1003845.

154. Yu, W., Zheng, H., Lin, W., Tijima, A., Zhang, Y., Zhang, X., Zhang, H., Wu, J., Han, D., Rahman, N., Korach, K., **Gao*, G. F.**, Inoue, I. and Li*, X., 2014, Estrogen promotes Leydig cell engulfment by macrophages in male infertility. ***Journal of Clinical Investigation (JCI)***, 124 (6): 2709-2721.

155. Deng, M., Lu, Z., Zheng, J., Wan, X., Chen, X., Hirayasu, K., Sun, H., Lam, Y., Chen, L., Wang, Q., Song, C., Huang, N., **Gao, G. F.**, Jiang, Y., Arase, H. and Zhang, C. C., 2014, A motif in LILRB2 critical for angptl2 binding and activation. ***Blood***, 124 (6): 924-935.

156. Wu, P., Jiang, H., Wu, J. T., Chen, E., He, J., Zhou, H., Wei, L., Yang, J., Yang, B., Qin, Y., Fang, V.J., Li, M., Tsang, T. K., Zheng, J., Lau, E. H., Cao, Y., Chai, C., Zhong, H., Li, Z., Leung, G. M., Feng, L., **Gao, G. F.**, Cowling, B. J. and Yu*, H. 2014, Poultry market closures and human infection with influenza A(H7N9) viruses, China, 2013-14, ***Emerging Infectious Diseases (EID)***, 20 (11): 1891-1894.

157. Li, J., Kou, Y., Yu, X., Sun, Y., Zhou, Y., Pu, X., Jin, T., Pan*, J. and **Gao, G. F.**, 2014, Human co-infection with avian and seasonal influenza viruses, China, ***Emerging Infectious Diseases (EID)***, 20 (11): 1953-1955.

158. Zhang, T., Bi, Y., Tian, H., Li, X., Liu, D., Wu, Y., Jin, T., Wang, Y., Chen, Q., Chen, Z., Chang, J., **Gao, G. F.** and Xu*, B., 2014, Human infection with influenza virus A(H10N8) from live poultry markets, China, 2014. ***Emerging Infectious Diseases (EID)***, 20 (12): 2076-2079.

159. Qi*, X., Jiang, D., Wang, H., Zhuang, D., Ma, J., Fu, J., Qu, J., Sun, Y., Yu, S., Meng, Y., Huang, Y., Xia, L., Li, Y., Wang, Y., Wang, G., Xu, K., Zhang, Q., Wan, M., Su, X., Fu, G. and **Gao*, G. F.**, 2014, Calculating the burden of disease of avian-origin H7N9 infections in China.

UCDUSR0004193

BMJ Open, 4 (1): e004189. doi: 10.1136/bmjopen-2013-004189.

160. Wei, J., Zheng, L., Lv, X., Bi, Y., Chen, W., Zhang, W., Shi, Y., Zhao, L., Sun, X., Wang, F., Cheng, S., Yan, J., Liu, W., Jiang, X., **Gao, G. F.** and Li*, X., 2014, Analysis of influenza virus receptor specificity using glycan-functionalized gold nanoparticles, ***ACS Nano***, 8 (5): 4600-4607.

161. Li, T., Zhu, S., Yin, S., Shuai, L., Xu, Y., Bian, Y., Wang, Y., Zuo, B., Wang, W., Zhao, S., Zhang, L., Zhang, J., **Gao, G. F.**, Allain, J.-P. and Li, C., 2014, Infection of common marmosets with hepatitis C virus/GB virus-B chimeras. ***Hepatology***, 59 (3): 789-802.

162. Sun, M., Liu, J., Qi, J., Tefsen, B., Shi, Y. and **Gao*, G. F.**, 2014, N$^{\alpha}$-terminal acetylation for T cell recognition: molecular basis of MHC class I-restricted N$^{\alpha}$-acetylpeptide presentation, ***The Journal of Immunology***, 192 (12): 5509-5519.

163. Sun, X., Fujiwara, M., Shi, Y., Kuse, N., Gatanaga, H., Appay, V., **Gao, G. F.**, Oka, S. and Takiguchi, M., 2014, Superimposed epitopes restricted by the same HLA molecule drive distinct HIV-specific CD8+ T cell repertoires. ***The Journal of Immunology***, 193: 77-84.

164. Tefsen*, B., Lu, G., Zhu, Y., Haywood, J., Zhao, L., Deng, T., Qi, J. and **Gao*, G. F.**, 2014, The N-terminal domain of PA from bat-derived influenza-like virus H17N10 has endonuclease activity. ***Journal of Virology***, 88 (4): 1935-1941.

165. Sun, X., Li, Q., Wu, Y., Wang M., Liu, Y., Qi, J., Vavricka, C. J. and **Gao*, G. F.**, 2014, Structure of influenza virus N7: the last piece of the neuraminidase "jigsaw" puzzle. ***Journal of Virology***, 88 (16): 9197-9207. (Cover story).

166. Yu, X., Jin, T., Cui, Y., Pu, X., Li, J., Xu, J., Liu, G., Jia, H., Liu, D., Song, S., Yu, Y., Xie, L., Huang, R., Ding, H., Kou, Y., Zhou, Y., Wang, Y., Xu, X., Yin, Y., Wang, J., Gao, C., Yang, X., Hu, L., Wu, X., Wang, H., Liu, J., Zhao, G., Zhou, J., Pan, J., **Gao, G. F.**, Yang, R. and Wang, J., 2014, Influenza H7N9 and H9N2 viruses: coexistence in poultry linked to human H7N9 infection and genome characteristics. ***Journal of Virology***, 88 (6): 3423-3431.

167. Gao, S., Wang, S., Cao, S., Sun, L., Li, J., Bi, Y., **Gao, G. F.** and Liu, W., 2014, Characteristics of nucleocytoplasmic transport of H1N1 influenza A viruses nuclear export protein (NEP). ***Journal of Virology***, 88 (13): 7455-7463.

168. Cao, S., Jiang, J.-W., Li, J., Li, Y., Yang, L., Wang, S., Yan, J., **Gao, G. F.** and Liu*, W., 2014, Characterization of the nucleocytoplasmic shuttle of the matrix protein of influenza B virus. ***Journal of Virology***, 88 (13): 7464-7473.

169. Lu, G., Zhang, N., Qi, J., Li, Y., Chen, Z., Zhong[2], C., **Gao, G. F.** and Yan*, J., 2014, Crystal

UCDUSR0004194

structure of Herpes Simplex Virus 2 gD bound to nectin-1 reveals a conserved mode of receptor recognition. ***Journal of Virology***, 88 (23): 13678-13688.

170. Yan*, J. and **Gao, G. F.**, 2014, MicroRNAs: the novel targets for Ebola drugs, 2014, ***Science China Life Sciences***, 57 (10): 985-986.

171. Ping, Z., Qi, J., Lu, G., Shi, Y., Sun, Y., Wang, X., **Gao*, G. F.** and Wang*, M., 2014, Crystal structure of the interferon gamma receptor alpha chain from chicken reveals an undetected extra helix compared with the human counterparts. ***Journal of Interferon and Cytokine Research***, 34 (1): 41-51 (Cover story; A figure illustration was used as a cover in the following issue).

172. Bi, Y., Li, J., Yang, L., Zhang, S., Li, Y., Jia, X., Sun, L., Yin, Y., Qin, C., Wang, B., **Gao, G. F.** and Liu*, W., 2014, Assessment of the pathogenesis of *Streptococcus suis* type 2 infection in piglets for understanding streptococcal toxic shock-like syndrome, meningitis, and sequelae. ***Veterinary Microbiology***, 173 (3-4): 299-309.

173. **Gao*, G. F.**, 2014, Implementing immunization program efficiently, and establishing national database of adverse reactions. ***Science China Life Sciences***, 57: 553-554.

174. Liu, D. and **Gao*, G. F.**, 2014, The new emerging H7N9 influenza virus indicates poultry as a new mixing vessel, ***Science China Life Sciences***, 57 (7): 731-732.

175. Shi, W., Li, W., Li, X., Haywood, J., Ma, J., **Gao, G. F.** and Liu*, D., 2014, Phylogenetics of varied subtypes of avian influenza viruses in China: potential threat to humans. ***Protein & Cell***, 5 (4): 253-257.

176. Sun, L., Zhang, Y., Zhao, B., Deng, M., Liu, J., Li, X., Hou, J., Gui, M., Zhang, S., Li, X., **Gao*, G. F.** and Meng*, S., 2014, A new unconventional HLA-A2-restricted epitope from HBV core protein elicits antiviral cytotoxic T lymphocytes, ***Protein & Cell***, 5 (4): 317-327.

177. Li, C., Hu, J., Hao, J., Zhao, B., Wu, B., Sun, L., Peng, S., **Gao, G. F.** and Meng*, S., 2014, Competitive virus and host RNAs: the interplay of a hidden virus and host interaction. ***Protein & Cell***, 5 (5): 348-356.

178. Liu, P., Liu, D., Yang, X., Gao, J., Chen, Y., Xiao, X., Liu, F., Zou, J., Wu, J., Ma, J., Zhao, F., Zhou*, X., **Gao*, G. F.**, Zhu*, B., 2014, Characterization of human αβTCR repertoire and discovery of D-D fusion in TCR β chains. ***Protein & Cell***, 5 (8): 603-615.

179. Shi, Z., Xuan, C., Han, H., Cheng, X., Wang, J., Feng, Y., Srinivas, S., Lu, G. and **Gao*, G. F.**, 2014, Gluconate 5-dehydrogenase (Ga5DH) participates in *Streptococcus suis* cell division.

UCDUSR0004195

Protein & Cell, 5 (10): 761-769.

180. Abdel-Mageed, W. M., Bayoumi, S. A., Chen, C., Vavricka, C. J., Li, L., Malik, A., Dai, H., Song, F, Wang, L., Zhang, J., **Gao, G. F.**, Lv, Y., Liu, L., Liu, X., Sayed, H. M. and Zhang*, L., 2014, Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity, ***Bioorganic and Medicinal Chemistry***, 22 (7): 2236-2243.

181. Ju, Y., Fan, H., Liu, J., Hu, J., Li, X., Li, C., Chen, L., Gao, Q., **Gao, G. F.** and Meng*, S., 2014, Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine, ***Vaccine***, 32 (23): 2703-2711.

182. Segura, M., Zheng, H., Greeff, Ad., **Gao, G. F.**, Grenier, D., Jiang, Y., Lu, C., Maskell, D., Oishi, K., Okura, M., Osawa, R., Schultsz, C., Schwerk, C., Sekizaki, T., Smith, H., Srimanote, P., Takamatsu, D., Tang, J., Tenenbaum, T., Tharavichitkul, P., Hoa, N. T., Valentin-Weigand, P., Wells, J. M., Wertheim, H., Zhu, B., Gottschalk, M. and Xu, J., 2014, Latest development on *Streptococcus suis*: an emerging zoonotic pathogen: Part 1. ***Future Microbiology***, 9 (4): 441-444.

183. Segura, M., Zheng, H., Greeff, Ad., **Gao, G. F.**, Grenier, D., Jiang, Y., Lu, C., Maskell, D., Oishi, K., Okura, M., Osawa, R., Schultsz, C., Schwerk, C., Sekizaki, T., Smith, H., Srimanote, P., Takamatsu, D., Tang, J., Tenenbaum, T., Tharavichitkul, P., Hoa, N. T., Valentin-Weigand, P., Wells, J. M., Wertheim, H., Zhu, B., Xu, J. and Gottschalk, M., 2014, Latest development on *Streptococcus suis*: an emerging zoonotic pathogen: Part 2. ***Future Microbiology***, 9 (5): 587-591.

184. Sharshov, K., Sivay, M., Liu, D., Pantin-Jackwood, M., Marchenko, V., Durymanov, A., Alekseev, A, Damdindorj, T, **Gao, G. F.**, Swayne, D. E. and Shestopalov, A., 2014, Molecular characterization and phylogenetics of a reassortant H13N8 influenza virus isolated from gulls in Mongolia, ***Virus Genes***, 49 (2): 237-249.

185. Wang, D., Yang, L., Gao, R., Zhang, X., Tan, Y., Wu, A., Zhu, W., Zhou, J., Zou, S., Li, X., Sun, Y., Zhang, Y., Liu, Y., Liu, T., Xiong, Y., Xu, J., Chen, L., Weng, Y., Qi, X., Guo, J., Li, X., Dong, J., Huang, W., Zhang, Y., Dong, L., Zhao, X., Liu, L., Lu, J., Lan, Y., Wei, H., Xin, L., Chen, Y., Xu, C., Chen, T., Zhu, Y., Jiang, T., Feng, Z., Yang, W., Wang, Y., Zhu, H., Guan, Y., **Gao, G. F.**, Li, D., Han, J., Wang, S., Wu, G. and Shu, Y., 2014, Genetic tuning of the novel avian influenza A(H7N9) virus during interspecies transmission, China, 2013, ***Eurosurveillance***, 19 (25). pii: 20836.

186. Feng, L., Wu, J., Liu, X., Yang, P., Tsang, T., Jiang, H., Wu, P., Yang, J., Fang, V., Qin, Y., Lau, E., Li, M., Zheng, J., Peng, Z., Xie, Y., Wang, Q., Li, Z., Leung, G., **Gao, G. F.**, Yu, H. and

UCDUSR0004196

Cowling, B., 2014, Clinical severity of human infections with avian influenza A (H7N9) virus, China, 2013/14, ***Eurosurveillance***, 19 (49). pii: 20984.

187. Han, C., Kawana-Tachikawa, A., Shimizu, A., Zhu, D., Nakamura, H., Adachi, E., Kikuchi, T., Koga, M., Koibuchi, T., **Gao, G. F.**, Sato, Y., Yamagata, A., Martin, E., Fukai, S., Brumme, Z. L., Iwamoto, A., 2014, Switching and emergence of CTL epitopes in HIV-1 infection, ***Retrovirology***, 11: 38.

188. Yanaka, S., Ueno, T., Shi, Y., Qi, J., **Gao, G. F.**, Tsumoto, K. and Sugase, K., 2014, Peptide-dependent conformational fluctuation determines the stability of the human leukocyte antigen class I complex. ***Journal of Biological Chemistry***, 289 (35): 24680-24690.

189. Xu, G., Wang, J., **Gao*, G. F.** and Liu*, C., 2014, Insights into battles between *Mycobacterium tuberculosis* and macrophages, ***Protein & Cell***, 5 (10): 728-736.

190. Qi, W., Shi, W., Li, W., Huang, L., Li, H., Wu, Y., Yan, J., Jiao, P., Zhu, B., Ma, J., **Gao, G. F.**, Liao, M. and Liu, D., 2014, Continuous reassortments with local chicken H9N2 virus underlie the human-infecting influenza A (H7N9) virus in the new influenza season, Guangdong, China. ***Protein & Cell*** 5 (11): 878-882.

191. Liu, F., Hu, Y., Wang, Q., Li, H. M., **Gao, G. F.**, Liu, C. H. and Zhu, B., 2014, Comparative genomic analysis of *Mycobacterium tuberculosis* clinical isolates, ***BMC Genomics***, 15: 469. doi: 10.1186/1471-2164-15-469.

192. Li, J., Liu, F., Wang, Q., Ge, P., Woo, P. C. W., Zhao, Y., Yan, J., **Gao, G. F.**, Liu, C. H. and Liu*, C., 2014, Genomic and transcriptomic analysis of NDM-1 *Klebsiella pneumonia* in spaceflight reveal mechanisms underlying environmental adaptability, ***Scientific Reports***, 4: 6216.

193. Audet, J., Wong, G., Wang, H., Lu, G., **Gao, G. F.**, Kobinger, G. and Qiu, X., 2014, Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus, ***Scientific Reports***, 4: 6881.

194. Gu, L., Kawana-Tachikawa, A., Shiino, T, Nakamura, H., Koga, M., Kikuchi, T., Adachi, E., Koibuchi, T., Ishida, T., **Gao, G. F.**, Matsushita, M., Sugiura, W., Iwamoto, A. and Hosoya, N., 2014, Development and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptase, ***PLoS ONE***, 9 (10): e109823.

195. Lan, J., Deng, Y., Chen, H., Lu, G., Wang, W., Guo, X., Lu, Z., **Gao, G. F.** and Tan*, W., 2014, Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen,

UCDUSR0004197

PLoS ONE, 9 (11): e112602.

196. Yang, Y., Deng, Y., Wen, B., Wang, H., Meng, X., Lan, J., **Gao*, G. F.** and Tan*, W., 2014, The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents, ***Viral Immunology*** 27 (10): 1-8.

197. Liu*, J., Xiao, H., Wu, Y., Liu, D., Qi, X., Shi, Y. and **Gao*, G. F.**, 2014, H7N9: a low-pathogenic avian influenza A virus infecting humans. ***Current Opinion in Virology***, 5C: 91-97.

198. Shi[#], Y., Zhang[#], W., Wang[#], F., Qi[#], J., Wu[#], Y., Song, H., Gao, F., Bi, Y., Zhang, Y., Fan, Z., Qin, C., Sun, H., Liu, J., Haywood, J., Liu, W., Gong, W., Wang, D., Shu, Y., Wang, Y., Yan, J. and **Gao*, G. F.**, 2013, Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. ***Science***, 342 (6155): 243-247.

199. Lu[#], G., Hu[#], Y., Wang[#], Q., Qi[#], J., Gao[#], F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J., Zhang, B., Shi, Y., Yan, J. and **Gao*, G. F.**, 2013, Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. ***Nature***, 500 (7461): 227-231.

200. Zhang[#], W., Shi[#], Y., Lu, X., Shu, Y., Qi, J. and **Gao*, G. F.**, 2013, An airborne transmissible avian influenza H5 hemagglutinin seen at the atomic level. ***Science***, 340 (6139): 1463-1467.

201. Liu[#], D., Shi[#], W., Shi, Y., Wang D., Xiao, H., Li, W., Bi, Y., Wu, Y., Li, X., Yan, J., Liu, W., Zhao, G., Yang, W., Wang, Y., Ma, J., Shu*, Y., Lei*, F. and **Gao*, G. F.**, 2013, Origin and diversity of novel avian influenza A H7N9 viruses causing human infections: phylogenetic, structural, and coalescent analyses. ***The Lancet***, 381 (9881): 1926-1932.

202. Zhang, X., Lu, G., Qi, J., Li, Y., He, Y., Xu, X., Shi, J., Zhang, C. W-H., Yan, J. and **Gao*, G. F.**, 2013, Structure of measles virus hemagglutinin bound to its epithelial receptor nectin-4. ***Nature Structural and Molecular Biology***, 20 (1): 67-72.

203. Vavricka, C. J., Liu, Y., Kiyota, H., Sriwilaijaroen, N., Qi, J., Tanaka, K., Wu, Y., Li, Q., Li, Y., Yan, J., Suzuki, Y. and **Gao*, G. F.**, 2013, Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. ***Nature Communications***, 4: 1491 (DOI: 10.1038/ncomms2487).

204. Sun, X., Shi, Y., Lu, X., He, J., Gao, F., Yan, J., Qi, J. and **Gao*, G. F.**, 2013, Bat-derived influenza hemagglutinin H17 does not bind canonical avian or human receptors and most likely uses a unique entry mechanism. ***Cell Reports***, 3: 769-778.

UCDUSR0004198

205. Wu#, Y., Bi#, Y., Vavricka#, C. J., Sun, X., Zhang, Y., Gao, F., Zhao, M., Xiao, H., Qin, C., He, J., Liu, W., Yan, J., Qi, J., **Gao*, G. F.**, 2013, Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. ***Cell Research***, 23 (12): 1347-1355. (Cover story).

206. Zhang, S., Lu, G., Qi, J., Li, Y., Zhang, Z., Zhang B., Yan, J. and **Gao*, G. F.**, 2013, Competition of cell adhesion and immune recognition: insights into the interaction between CRTAM and Nectin-like 2. ***Structure***, 21 (8): 1430-1439.

207. Chen, Y., Hwang, S., Chan, V., Chung, N., Wang, S., Li, Z., Ma, J., Lin, C., Hsieh, Y., Chang, K., Kung, S., Wu, Y., Chu, C., Tai, H., **Gao, G. F.**, Zheng, B., Yokoyama, K., Austyn*, J. and Lin*, C., 2013, Binding of HIV-1 gp120 to DC-SIGN promotes ASK-1-dependent activation-induced apoptosis of human dendritic cells. ***PLoS Pathogens***, 9 (1): e1003100.

208. Zhou, J., Wang, D., Gao, R., Zhao, B., Song, J., Qi, X., Zhang, Y., Shi, Y., Yang, L., Zhu, W., Bai, T., Qin, K., Lan, Y., Zou, S., Guo, J., Dong, J, Dong, L., Zhang, Y., Wei, H, Li, X., Lu, J., Liu, L., Zhao, X., Li, X., Huang, W., Wen, L., Bo, H., Xin, L., Chen, Y., Xu, G., Pei, Y., Yang, Y., Zhang, X., Wang, S., Feng, Z., Han, J., Yang, W., **Gao, G. F.**, Wu, G., Li, D., Wang, Y. and Shu*, Y. 2013, Biological features of novel avian influenza A (H7N9) virus. ***Nature***, 499: 500-503.

209. Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H., Xu, K., Xu,X., Lu, H., Zhu, W., Gao, Z., Xiang, N., Shen, Y., He, Z., Gu, Y., Zhang, Z., Yang, Y., Zhao, X., Zhou, L., Li, X., Zou, X., Zhang, Y., Li, X., Yang, L., Guo, J., Dong, J., Li, Q., Dong, L., Zhu, Y., Bai, T., Wang, S., Hao, P., Yang, W., Zhang, Y., Han, J., Yu, H., Li, D., **Gao, G. F.**, Wu, G., Wang, Y., Yuan*, Z. and Shu*, Y., 2013, Human infection with a novel avian-origin influenza A (H7N9) virus. ***The New England Journal of Medicine***, 368: 1888-1897.

210. Bao, C., Cui, L., Zhou, M., Hong, L., **Gao, G. F.** and Wang*, H., 2013, Live-animal markets and influenza A (H7N9) virus infection. ***The New England Journal of Medicine***, 368: 2337-2339.

211. Yang, G., Wang, Y., Zeng, Y., **Gao, G. F.**, Liang, X., Zhou, M., Wan, X., Yu, S., Jiang, Y., Naghavi, M., Vos, T., Wang, H., Lopez, A. D. and Murray, C. J. L., 2013, Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. ***The Lancet***, 381: 1987-2015.

212. Wu#, A., Su#, C., Wang#, D., Peng, Y., Liu, M., Hua, S., Li, T., **Gao, G. F.**, Tang, H., Chen, J., Liu, X., Shu, Y., Peng*, D. and Jiang*, T., 2013, Sequential reassortments underlie diverse influenza H7N9 genotypes in China. ***Cell Host and Microbe***, 14 (4): 446-452.

UCDUSR0004199

213. Hu, Y., Yang, X., Qin, J., Lu, N., Cheng, G., Wu, N., Pan, Y., Li, J., Zhu, L., Wang, X., Meng, Z., Zhao, F., Liu, D., Ma, J., Qin, N., Xiang, C., Xiao, Y., Li, L., Yang, H., Wang, J., Yang, R., **Gao, G. F.**, Wang, J. and Zhu*, B., 2013, Metagenome-wide analysis of antibiotic resistance genes in large cohort of human gut microbiota. ***Nature Communications***, 4 (2151). doi: 10.1038/ncomms3151.

214. Wu, Y., Qin, G., Gao, F., Liu, Y., Vavricka, C. J., Qi, J., Jiang, H., Yu, K. and **Gao*, G. F.**, 2013, Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. ***Scientific Reports***, 3: 1551. doi: 10.1038/srep01551.

215. Zhang, W., Shi, Y., Qi, J., Gao, F., Li, Q., Fan, Z., Yan, J. and **Gao*, G.F.**, 2013, Molecular basis of the receptor binding specificity switch of the hemagglutinins from both the 1918 and 2009 pandemic influenza A viruses by a D225G substitution. ***Journal of Virology***, 87 (10): 5949-5958.

216. Lu, X., Qi, J., Shi, Y., Wang, M., Smith, D., Heimburg-Molinaro, J., Zhang, Y., Paulson, J. C., Xiao, H. and **Gao*, G. F.**, 2013, Structure and receptor binding specificity of the hemagglutinin H13 from avian influenza A virus H13N6. ***Journal of Virology***, 87 (16): 9077-9085.

217. Li, Q., Qi, J., Wu, Y., Kiyota, H., Tanaka, K., Suhara, Y., Obuni, H., Suzuki, Y., Vavricka, C. J. and **Gao*, G. F.**, 2013, Functional and structural analysis of influenza neuraminidase N3 offers further insight into the mechanisms of oseltamivir-resistance. ***Journal of Virology***, 87 (18): 10016-10024.

218. Gao, J., Lu, G., Qi, J., Li, Y., Wu, Y., Deng, Y., Geng, H., Li, H., Xiao, H., Tan, W., Yan, J. and **Gao*, G. F.**, 2013, Structure of the fusion core and inhibition of fusion by a heptad-repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. ***Journal of Virology***, 87 (24): 13134-13140.

219. Zhang, Y., Ren, Y., Wu, Y., Zhao, B., Qiu, L., Li, X., Xu, D., Liu, J., **Gao*, G. F.** and Meng*, S., 2013, The L60V variation in hepatitis B virus core protein elicits new epitope-specific cytotoxic T lymphocytes and enhances viral replication. ***Journal of Virology***, 87 (14): 8075-8084.

220. Sun, Y., Tan, Y., Wei, K., Sun, H., Shi, Y., Pu, J., Yang, H., **Gao, G. F.**, Yin, Y., Feng, W., Perez, D. R. and Liu, J., 2013, Amino acid 316 of hemagglutinin and the neuraminidase stalk length influence virulence of H9N2 influenza virus in chickens and mice. ***Journal of Virology***, 87 (5): 2963-2968.

UCDUSR0004200

221. Tan, S., Liu, J., Tan, X., Sun, X., Lu, G., Chen, C.-c., Yan, J., Xu*, W. and **Gao*, G. F.**, 2013, VP2 dominated CD4$^+$ T-cell responses against enterovirus 71 and cross-reactivity against Coxsackievirus A16 and polioviruses in a healthy population. ***The Journal of Immunology***, 191 (4): 1637-1647.

222. Li, G., Fox III, J., Liu, Z., Liu, J., **Gao, G. F.**, Jin, Y., Gao*, H. and Wu*, M., 2013, Lyn mitigates mouse airway remodeling by down-regulating the TGF-β3 isoform in house dust mite model. ***The Journal of Immunology***, 191 (11): 5359-5370.

223. Liu, J., Wu, B., Zhang, S., Tan, S., Sun, Y., Chen, Z., Qin, Y., Sun, M., Shi, G., Wu, Y., Sun, M., Liu, N., Ning, K., Ma, Y., Gao, B., Yan, J., Zhu, F., Wang, H. and **Gao,* G. F.**, 2013, Conserved epitopes dominate cross-CD8$^+$ T-cell responses against influenza A H1N1 virus among Asian populations. ***European Journal of Immunology***, 43 (8): 2055-2069.

224. Niu, L., Cheng, H., Zhang, S., Tan, S., Zhang, Y., Qi, J., Liu, J. and **Gao*, G. F.**, 2013, Structural basis for the differential classification of HLA-A*6802 and HLA-A*6801 into the A2 and A3 supertypes. ***Molecular Immunology***, 55 (3-4): 381-392.

225. Shimizu, A., Kawana-Tachikawa, A., Yamagata, A., Han, C. Y., Zhu, D., Sato, Y., Nakamura, H., Koibuchi, T., Carlson, J., Martin, E., Brumme, C., Shi, Y., **Gao, G. F.**, Brumme, Z. L., Fukai, S. and Iwamoto, A., 2013, Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection. ***Scientific Reports***, 3: 3097. Doi: 10.1038/srep03097.

226. Qu, M., Boruah, B. M., Zhang, W., Li, Y., Liu, W., Bi, Y., **Gao, G. F.**, Yang, R., Liu, D. and Gao*, B., 2013, A rat basophilic leukaemia cell sensor for the detection of pathogenic viruses. ***Biosensor and Bioelectronics***, 43: 412-418.

227. Zhang, H., Liu, Y., Wang, L., Li, Z., Zhang, H., Wu, J., Rahman, N., Guo, Y., Li, D., Li, N., Hahtaniemi, I., Tsang, S.Y., **Gao, G. F.** and Li, X., 2013, Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat. ***Journal of Lipid Research***, 54(2): 345-357.

228. Wu, N., Yang, X., Zhang, R., Li, J., Xiao, X., Hu, Y., Chen, Y., Yang, F., Lu, N., Wang, Z., Luan, C., Liu, Y., Wang, B., Xiang, C., Wang, Y., Zhao, F., **Gao, G. F.**, Wang, S., Li, L., Zhang*, H. and Zhu*, B. 2013, Dysbiosis signature of fecal microbiota in colorectal cancer patients. ***Microbial Ecology***, 66: 462-470.

229. Chen, C., Zhang, W., Zheng, H., Lan, R., Wang, H., Du, P., Bai, X., Ji, S., Meng, Q., Jin, D., Liu, K., Jing, H., Ye, C., **Gao, G. F.**, Wang, L., Gottschalk, M. and Xu, J., 2013, Minimum

UCDUSR0004201

core genome sequence typing of bacterial pathogens: a unified approach for clinical and public health microbiology. ***Journal of Clinical Microbiology,*** 51 (8): 2582-2591

230. Hekele, A., Bertholet, S., Archer, J., Gibson, D. G., Palladino, G., Brito, L. A., Otten, G. R., Brazzoli, M., Buccato, S., Bonci, A., Casini, D., Maione, D., **Gao, G. F.**, Shu, Y., De Gregorio, E., Mason, P. W., Settembre, E., Ulmer, J. B., Venter, J. C., Donnitzer, P. R., Rappuoli, R., and Geall*, A. J., 2013, Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. ***Emerging Microbes and Infections***, 2: e52; doi:10.1038/emi.2013.54.

231. Wu*, Y. and **Gao*, G. F.**, 2013, Lessons learnt from the human infections of avian-origin influenza A H7N9 virus: Live free markets and human health. ***Science China Life Sciences,*** 56 (6): 493–494.

232. Wu*, Y. and **Gao*, G. F.**, 2013, Severe fever with thrombocytopenia syndrome virus expands its borders. ***Emerging Microbes and Infections***, 2: e36; doi:10.1038/emi.2013.36.

233. Lu, X., Shi, Y., Zhang, W., Zhang, Y., Qi, J., **Gao*, G. F.**, 2013, Structure and receptor-binding properties of an air-borne transmissible avian influenza A virus hemagglutinin H5 (VN1203mut). ***Protein & Cell***, 4: 502-511. (Cover story).

234. Xiao, H., Liu, L., Zhu, Q., Tan, Z., Yu, W., Tang, X., Zhan, D., Du, Y., Wang, H., Liu, D., Li, Z., Yuen, K. Y., Ho, D. D., **Gao*, G. F.** and Chen*, Z., 2013, A replicating modified vaccinia Tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. ***PLoS ONE***, 8 (12): e83274.

235. Liu, P., Lu, H., Li S., Wu, Y., **Gao*, G. F.** and Su*, J., 2013, Duck egg drop syndrome virus: an emerging Tembusu-related flavivirus in China. ***Science China Life Sciences***, 56: 701-710.

236. **Gao*, G. F.** and Wu*, Y., 2013, Haunted with and hunting for viruses. ***Science China Life Sciences***, (Editorials), 56: 675-677.

237. Zhang, W., Yu, W. W., Liu, D., Li, M., Du, P. C., Wu, Y. L., **Gao, G. F.** and Chen*, C., 2013, T4SP: A novel tool and database for Type IV secretion system in bacterial genomes. ***Biomedical and Environmental Sciences***, 26: 614-617.

238. Lu, K., Chen, T., Chen, Y. and **Gao, G. F.**, 2013, Transcontinental translational medicine collaboration: a successful Sino-Cuban joint B-to-B program. ***Biomedical and Environmental Sciences***, 26: 517-519. (Perspective).

239. Lu, K., Qin, Y., He, G. and **Gao, G. F.**, 2013, The impact of haze weather on health: a view to

UCDUSR0004202

future. ***Biomedical and Environmental Sciences***, 26 (12): 945-946. (Perspective).

240. Nam, G., Shi, Y., Ryu, M., Wang, Q., Song, H., Yan, J., Qi, J. and **Gao*, G. F.**, 2013, Crystal structures of the two membrane-proximal Ig-like domains (D3D4) of LILRB1/B2: alternative models for their involvement in peptide-HLA binding. ***Protein & Cell***, 4 (10): 761-770. (Cover story).

241. Wu*, Y. and **Gao*, G. F.**, 2013, Compiling of comprehensive data of human infections with novel influenza A (H7N9) virus. ***Frontiers of Medicine***, 7 (3): 275-276. (Editorials).

242. Li, X., Liu, Z., Yan, X., Zhang, X., Li, Y., Zhao, B., Wang, S., Zhou, X., **Gao, G. F.** and Meng*, S., 2013, Induction of regulatory T cells by high-dose gp96 suppresses murine liver immune hyperactivation. ***PLoS ONE***, 8: e68997.

243. Teeranaipong, P., Hosoya, N., Kawana-Tachikawa, A., Fuji, T., Koibuchi, T., Nakamura, H., Koga, M., Kondo, N., **Gao, G. F.**, Hoshino, H., Matsuda, Z. and Iwamoto, A., 2013, Development of a rapid cell-fusion-based phenotypic HIV-1 tropism assay. ***Journal of the International AIDS Society***, 16 (1): 18723.

244. Shi, W., Shi, Y., Wu, Y., Liu*, D. and **Gao, G. F.**, 2013, Origin and molecular characterization of the human-infecting H6N1 influenza virus in Taiwan, ***Protein & Cell***, 4 (11): 846-853.

245. Limberis, M., Racine, T., Kobasa, D., Li, Y., **Gao, G. F.**, Kobinger, G. and Wilson, J., 2013, Vectored expression of a broadly neutralizing antibody (FI6) in mouse airway provides partial protection against a new avian influenza A (H7N9) virus, ***Clinical and Vaccine Immunology***, 20 (12): 1836-1837.

246. Li, Q., Sun, X., Li Z., Liu, Y., Vavricka, C. J., Qi, J. and **Gao*, G. F.**, 2012, Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus. ***Proceedings of the National Academy of Sciences of the United States of America (PNAS)***, 109 (46): 18897-18902.

247. Liu, C., Li, H., Lu, N., Wang, Q., Hu, Y., Yang, X., Hu, Y., Woo, C. Y., **Gao*, G. F.** and Zhu*, B., 2012, Genomic sequence based scanning for drug resistance-associated mutations and evolutionary analysis of multidrug-resistant and extensively drug-resistant *Mycobacterium tuberculosis*. ***Journal of Infection***, 65 (5): 412-422.

248. Zhang, J., Chen Y., Qi, J., Gao, F., Liu, Y., Liu, J., Zhou, X., Kaufman, J., Xia*, C. and **Gao*, G. F.**, 2012. Narrow groove and restricted anchors of MHC class I molecule BF2*0401 plus peptide transporter restriction can explain disease susceptibility of B4 chickens. ***The Journal of Immunology***, 189 (9): 4478-4487.

UCDUSR0004203

249. Liu, J., Qian, X., Chen, Z., Xu, X., Gao, F., Zhang, S., Zhang, R., Qi, J., Yan*, J. and **Gao*, G. F.**, 2012, Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226. ***The Journal of Immunology***, 188 (11): 5511-5520.

250. Liu, J., Zhang, S., Tan, S., Yi, Y., Wu, B., Cao, B., Zhu, F., Wang, C., Wang, H., Qi, J. and **Gao*, G. F.**, 2012, Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. ***Journal of Virology***, 86 (24): 13281-13294.

251. Lu, X., Shi, Y., Gao, F., Xiao, H., Wang, M., Qi, J. and **Gao*, G. F.**, 2012, Insights into avian influenza virus pathogenicity: the hemagglutinin precursor HA0 of subtype H16 has an α-helix structure in its cleavage site with an inefficient HA1/HA2 cleavage. ***Journal of Virology***, 86 (23): 12861-12870.

252. Cao, S., Shi, Y., Tan, S., Song, H., **Gao*, G. F.** and Liu*, W., 2012, Reply to "Nuclear export signal and immunodominant CD8+ T cell epitope in influenza A virus matrix protein 1"--Sequence sharing between viral nuclear export signals (NES) and CD8+ T cell epitopes. ***Journal of Virology***, 86 (18): 10259-10260.

253. Jiang, T., Liu, J., Deng, Y., Su, J., Xu, L., Liu Z., Li X., Yu, X., Zhu, S., **Gao, G. F.**, Qin, E. D. and Qin*, C., 2012, Development of RT-LAMP and real-time RT-PCR assays for the rapid detection of the new duck Tembusu-like BYD virus. ***Archives of Virology***, 157 (12): 2273-2280.

254. Cao, S., Liu, X., Yu, M., Li, J., Jia, X., Bi, Y., Sun, L., **Gao, G. F.** and Liu*, W., 2012, A nuclear export signal in the matrix protein of influenza A virus is required for the efficient virus replication. ***Journal of Virology***, 86 (9): 4883-4891.

255. Yu, M., Liu, X., Cao, S., Zhao, Z., Zhang, K., Xie, Q., Chen, C., Gao, S., Bi, Y., Sun, L., Ye, X., **Gao, G. F.** and Liu*, W., 2012, Identification and characterization of three novel nuclear export signals in influenza A virus nucleoprotein. ***Journal of Virology***, 86 (9): 4970-4980.

256. Zhang, Y., Sun, Y., Sun, H., Pu, J., Bi, Y., Shi, Y., Lu, X., Li, J., Zhu, Q., **Gao, G. F.**, Yang, H. and Liu*, J., 2012, A single amino acid at the hemagglutinin cleavage site contributes to the pathogenicity and neurovirulence of H5N1 influenza virus in mice. ***Journal of Virology***, 86 (12): 6924-6931.

257. Wang, S., Qiu, L., Yan, X., Jin, W., Wang, Y., Chen, L., Wu, E., Ye, X., **Gao, G. F.**, Wang, F., Chen, Y., Duan*, Z. and Meng*, S., 2012, Loss of MiR-122 expression in patients with hepatitis B enhances hepatitis B virus replication through Cyclin G1 modulated P53 activity.

UCDUSR0004204

Hepatology, 55 (3): 730-741.

258. Klionsky, D. J., ..., **Gao, G. F.** (342nd author), ... (1272 authors in total), 2012, Guidelines for the use and interpretation of assays for monitoring autophagy. ***Autophagy***, 8 (4): 445-544.

259. Hu, H., Hu, Y., Pan, Y., Liang, H., Wang, H., Wang, X., Hao, Q., Yang, X., Yang, X., Xiao, X., Luan, C., Yang, Y., Cui, Y., Yang, R., **Gao, G. F.**, Song*, Y., Zhu*, B., 2012, Novel plasmid and its variant harboring both a bla_{VEB-1} gene and type IV secretion system in clinical isolates of *Acinetobacter lwoffii*. ***Antimicrobial Agents and Chemotherapy***, 65 (4): 1698-1702.

260. Wang, S., Li, H., Chen, Y., Wei, H., **Gao, G. F.**, Liu, H., Huang, S. and Chen*, J., 2012, Transport of influenza virus neuraminidase (NA) to host cell surface is regulated by ARHGAP21 and Cdc42 proteins. ***Journal of Biological Chemistry***, 287 (13): 9804-9816.

261. Zhang, W., Rong, C., Chen*, C and **Gao*, G. F.**, 2012, Type-IVC Secretion system: A novel subclass of type IV secretion system (T4SS) common existing in gram-positive genus *Streptococcus*. ***PLoS ONE***, 7 (10): e46390.

262. Li, B., Yi, Y., Wang, Q., Woo, P. C., Tan, L., Jing, H., **Gao*, G. F.** and Liu*, C., 2012, Analysis of drug resistance determinants in *Klebsiella pneumoniae* isolates from a tertiary-care hospital in Beijing, China. ***PLoS ONE***, 7 (7): e42280.

263. Qiu, J., Wang, W., Wu, J., Zhang, H., Wang, Y., Qiao, J., Chen, C., **Gao, G. F.**, Allain, J. P. and Li*, C., 2012, Characterization of periplasmic protein BP26 epitopes of *Brucella melitensis* reacting with murine monoclonal and sheep antibodies. ***PLoS ONE***, 7 (3): e34246.

264. Li, G., Hu, F.,Yang, X., Cui, Y., Yang, J., Qu, F., **Gao, G. F.** and Zhang*, J., 2012, Complete genome sequence of *Streptococcus pneumoniae* strain ST556, a multi-drug resistant isolate from an otitis media patient. ***Journal of Bacteriology***, 194 (2): 3294-3295.

265. Li*, D., Hong, A, Lu, Q., **Gao, G. F.**, Jin, B., Screaton, G. R. and Xu, X., 2012, A novel role of CD1c in regulating CD1d-mediated NKT cell recognition by competitive binding to Ig-like transcript 4. ***International Immunology***, 24 (11): 729-737.

266. Liu, P., Lu, H., Li, S., Moureau, G., Deng, Y. Q., Wang, Y., Zhang, L., Jiang, T., de Lamballerie, X., Qin, C., Gould, E. A., Su*, J. and **Gao*, G. F.**, 2012, Genomic and antigenic characterization of the newly-emerging Chinese duck egg-drop syndrome flavivirus: genomic comparison with Tembusu and Sitiawan viruses. ***Journal of General Virology***, 93 (10): 2158-2170.

267. Lu, Q., Lu, H., Qi, J., Lu, G. and **Gao*, G. F.**, 2012, An octamer of enolase from *Streptococcus suis*. ***Protein & Cell***, 3(10): 769-780. (Cover story)

UCDUSR0004205

268. Han, H., Liu, C., Wang, Q., Xuan, C., Zheng, B., Tang, J., Yan, J., Zhang, J., Li, M., Cheng, H., Lu, G. and **Gao*, G. F.**, 2012, The two-component system Ihk/Irr contributes to the virulence of *Streptococcus suis* serotype 2 strain 05ZYH33 through alteration of the bacterial cell metabolism. ***Microbiology***, 158:1852-1866.

269. Rohde, H., Qin J., Cui, Y., Li, D., Loman, N. J., Hentschke, M., Chen, W., Pu, F., Peng, Y., Li, J., Xi, F., Li, S., Li, Y., Zhang, Z., Yang, X., Zhao, M., Wang, P., Guan, Y., Cen, Z., Zhao, X., Christner, M., Kobbe, R., Loos, S., Oh, J., Yang, L., Danchin, A., **Gao, G. F.**, Song, Y., Li, Y., Yang, H., Wang, J., Xu, J., Pallen*, M. J., Wang*, J., Aepfelbacher*, M. and Yang*, R., 2011, Open-source genomic analysis of shiga-toxin-producing *E. coli* O104:H4. ***The New England Journal of Medicine***, 365:718-724.

270. Vavricka, C. J., Li, Q., Wu, Y., Qi, J., Wang, M., Liu, Y., Gao, F., Liu, J., Feng, E., Wang, J., Liu, H., Jiang, H. and **Gao*, G. F.**, 2011, Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. ***PLoS Pathogens***, 7 (10): e1002249.

271. Zhang, N., Yan, J., Lu, G., Guo, Z., Fan, Z., Wang, J., Shi, Y., Qi, J. and **Gao*, G. F.**, 2011, Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesion. ***Nature Communications***, 2: 557.

272. Wu, Y., Gao, F., Liu, J., Qi, J., Gostick, E., Price, A. D. and **Gao*, G. F.**, 2011, Structural basis of diverse peptide accommodation by the Rhesus Macaque MHC class I molecule Mamu-B*17: insights into immune protection from simian immunodeficiency virus. ***The Journal of Immunology***, 187 (12): 6382-6392. (With a front cover illustration (Cover story), be featured in the "In This Issue" section of ***The Journal of Immunology***)

273. Cheng, H., Mohammed, F., Nam, G., Chen, Y., Qi, J., Garner, L. I., Allen, R. L., Yan, J., Willcox, B. E. and **Gao*, G. F.**, 2011, Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance. ***Journal of Biological Chemistry (JBC)***, 286: 18013-18025.

274. Li*, X., Wu, P., **Gao, G. F.** and Cheng, S., 2011, Carbohydrate-functionalized chitosan fiber for influenza virus capture. ***Biomacromolecules***, 12 (11): 3962-3969.

275. Li, X., Liu, J., Qi, J., Gao, F., Li, Q., Li, X., Zhang, N., Xia*, C. and **Gao*, G. F.**, 2011, Two distinct conformations of a rinderpest virus epitope presented by bovine major histocompatibility complex class I N*01801: a host strategy to present featured peptides. ***Journal of Virology***, 85 (12): 6038-6048.

UCDUSR0004206

276. Liu, J., Dai, L., Qi, J., Gao, F., Feng, Y., Liu, W., Yan[*], J. and **Gao, G. F.**, 2011, Diverse peptide presentation of rhesus macaque major histocompatibility complex class I Mamu-A*02 revealed by two peptide complex structures and insights into immune escape of simian immunodeficiency virus. ***Journal of Virology***, 85 (14): 7372-7383.

277. Wang, M., Qi, J., Liu, Y., Vavricka, C., Wu, Y., Li, Q. and **Gao*, G. F.**, 2011, Influenza A virus neuraminidase N5 has an extended 150-cavity. ***Journal of Virology***, 85 (16): 8431-8435.

278. Lu, G., Qi, J., Chen, Z., Xu, X., Gao, F., Lin, D., Qian, W., Liu, H., Jiang, H., Yan*, J. and **Gao*, G. F.**, 2011, Enterovirus 71 and Coxsackievirus A16 3C proteases: binding to Rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. ***Journal of Virology***, 85 (19): 10319-10331.

279. Zhang, N., Qi, J., Feng, S., Gao, F., Liu, J., Pan, X., Chen, R., Li, Q., Chen, Z., Li, X., Xia*, C. and **Gao*, G. F.**, 2011, Crystal structure of swine major histocompatibility complex class I SLA-1*0401 and identification of 2009 pandemic swine-origin influenza A H1N1 virus cytotoxic T lymphocyte epitope peptides. ***Journal of Virology***, 85 (22): 11709-11724.

280. Li, M., Shen, X., Yan, J., Han, H., Zheng, B., Liu, D., Cheng, H., Zhao, Y., Rao, X., Wang, C., Tang*, J., Hu*, F. and **Gao*, G. F.**, 2011, GI-type T4SS mediated horizontal transfer of the 89K pathogenicity island in epidemic *Streptococcus suis* serotype 2. ***Molecular Microbiology***, 79 (6): 1670-1683.

281. Hu, X., Liu, D., Wang, M., Yang, L., Wang, M., Zhu, Q., Li L. and **Gao*, G. F.**, 2011, Clade 2.3.2 avian influenza virus (H5N1), Qinghai Lake region, China, 2009–2010. ***Emerging Infectious Diseases***, 17 (3): 560-562.

282. Su[*], J., Li, S., Hu, X., Yu, X., Wang, Y., Liu, P., Lu, X., Zhang, G., Hu, X., Liu, D., Li, X., Su, W., Lu, H., Mok, N. S., Wang, P., Wang, M., Tian[*], K. and **Gao*, G. F.**, 2011, Duck egg-drop syndrome caused by BYD virus, a new Tembusu-related flavivirus. ***PLoS ONE***, 6 (3): e18106.

283. Ryu, M., Chen, Y., Qi, J., Liu, J., Fan, Z., Nam, G., Shi, Y., Cheng, H. and **Gao*, G. F.**, 2011, LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1/LILRB2: structural evidence. ***PLoS ONE***, 6 (4): e19245.

284. Zheng, B., Zhang, Q., Gao, J., Han, H., Li, M., Zhang, J., Qi, J., Yan, J. and **Gao*, G. F.**, 2011, Insight into the interaction of metal ions with TroA from *Streptococcus suis*. ***PLoS ONE***, 6 (5): e19510.

285. Wang, Z., Liu, X., Zhao, Z., Xu, C., Zhang, K., Chen, C., Sun, L., **Gao, G.F.**, Ye X. and Liu*,

UCDUSR0004207

W., 2011, Cyclophilin E functions as a negative regulator to influenza virus replication by impairing the formation of the viral ribonucleoprotein complex. ***PLoS ONE***, 6 (8): e22625.

286. Zhao, Y., Zhang, Y., Cao, Y., Qi, J., Mao, L., Xue, Y., Gao, F., Hao, P., Wang, X., **Gao, G. F.** and Ma*, Y., 2011, Structural analysis of alkaline β-mannanase from alkaliphilic *Bacillus* sp. N16-5: implications for adaptation to alkaline conditions. ***PLoS ONE***, 6 (1): e14608.

287. Wang, S., Qiu, L., Liu, G., Li, Y., Zhang, X., Jin, W., **Gao, G. F.**, Kong, X. and Meng*, S., 2011, Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice. ***Vaccine***, 29 (37): 6342-6351.

288. Shi, Y., Qi, J., Iwamoto, A. and **Gao*, G. F.**, 2011, Plasticity of human CD8αα binding to peptide-HLA-A*2402. ***Molecular Immunology***, 48 (15-16): 2198-2202.

289. Zhang, S., Liu, J., Cheng, H., Tan, S., Qi, J., Yan, J. and **Gao*, G. F.**, 2011, Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes. ***Molecular Immunology***, 49 (1-2): 395-401.

290. Lu, G., Qi, J., Gao, F., Yan, J., Tang, J. and **Gao*, G. F.**, 2011, A novel "open-form" structure of sortaseC from *Streptococcus suis*. ***Proteins: Structure, Function, and Bioinformatics***, 79 (9): 2764-2769.

291. Wu, Z., Li, M., Wang, C., Li, J., Lu, N., Zhang, R., Jiang, Y., Yang, R., Liu, C., Liao, H., **Gao*, G. F.**, Tang*, J. and Zhu*, B., 2011, Probing genomic diversity and evolution of *Streptococcus suis* serotype 2 by NimbleGen tiling arrays. ***BMC Genomics***, 12: 219.

292. Du[#], P., Yang[#], Y., Wang, H., Liu, D., **Gao*, G. F.** and Chen*, C., 2011, A large scale comparative genomic analysis reveals insertion sites for newly acquired genomic islands in bacterial genomes. ***BMC Microbiology***, 11: 135.

293. Liu, J., Zhang, S., Tan, S., Zheng, B. and **Gao*, G. F.**, 2011, Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development. ***Experimental Biology and Medicine***, 236: 253-267.

294. Hu, Y., Zhang, W., Liang, H., Liu, L., Peng, G., Pan, Y., Yang, X., Zheng, B., **Gao, G. F.**, Zhu, B. and Hu*, H., 2011, Whole-genome sequence of a multidrug resistant clinical isolate of *Acinetobacter baylyi*. ***Journal of Bacteriology***, 193 (19): 5549-5550.

295. Li, Z., Liu, Z., Ma, C., Zhang, L., Su, Y., **Gao, G. F.**, Li, Z., Cui, L. and He*, W., 2011, Identification of amino acids in highly pathogenic avian influenza H5N1 virus hemagglutinin that determine avian influenza species specificity. ***Archives of Virology***, 156 (10): 1803-1812.

UCDUSR0004208

296. Vavricka*, C. J., Liu, Y., Li, Q., Shi, Y., Wu, Y., Sun, Y., Qi, J. and **Gao*, G. F.**, 2011, Special features of the 2009 pandemic swine-origin influenza A H1N1 hemagglutinin and neuraminidase (invited review). ***Chinese Science Bulletin***, 56 (17): 1747-11752. (Cover story)

297. Feng, C., Liu, Y., Yan, J. and **Gao*, G. F.**, 2011, An infectious clone of the highly pathogenic porcine reproductive and respiratory syndrome virus: topology of glycoprotein 3 (GP3) addressing the intrachain disulfide bonds. ***Chinese Science Bulletin***, 56 (1): 2785-2793.

298. Feng, C., Gao, F., Liu, Y., Wang G., Peng, H., Ma Y., Yan, J. and **Gao*, G. F.**, 2011, Crystal structure of histidine-containing phosphocarrier protein from *Thermoanaerobacter tengcongensis* MB4 and the implications for thermostability. ***Science China Life Sciences***, 54 (6): 513-519.

299. Lu, G., Zhang, J., Li, Y., Li, Z., Zhang, N., Xu, X., Wang, T., Guan, Z., **Gao, G. F.** and Yan*, J., 2011, hNUDT16: a universal decapping enzyme for small nucleolar RNA and cytoplasmic mRNA. ***Protein & Cell***, 2 (1): 64-73.

300. Zheng, B., Tan, S., Gao, J., Han, H., Liu, J., Lu, G., Liu, D., Yi, Y., Zhu, B. and **Gao*, G. F.**, 2011, An unexpected similarity between antibiotic-resistant NDM-1 and β-lactamase II from *Erythrobacter litoralis*. ***Protein & Cell***, 2 (3): 250-258.

301. Xuan, C., Shi, Y., Qi, J., Zhang, W., Xiao, H. and **Gao*, G. F.**, 2011, Structural vaccinology: structure-based design of influenza A virus hemagglutinin subtype-specific subunit vaccines. ***Protein & Cell***, 2(12): 997-1005. (With a back cover illustration)

302. Zhang, Y., Cao, S., Meng, S. and **Gao*, G. F.**, 2011, A strategy to produce monoclonal antibodies against gp96 by prime-boost regimen using endogenous protein and *E. coli* heterologously-expressed fragment. ***Journal of Central South University of Technology***, 18: 1857−1864.

303. Shi, G., Yagyu, F., Shimizu, K., Oshima, M., Iwamoto, A., Gao, B., Liu, W., **Gao, G. F.** and Kitamura, Y., 2011, Flow cytometric assay using two fluorescent proteins for the function of the internal ribosome entry site of hepatitis C virus. ***Cytometry A***, 79 (8): 653-660.

304. Li, Q., Qi, J., Zhang, W., Vavricka, C. J., Shi, Y., Wei, J., Feng, E., Shen, J., Chen, J., Liu, D., He, J., Yan, J., Liu, H., Jiang, H., Teng, M., Li, X. and **Gao*, G. F.**, 2010, The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. ***Nature Structural and Molecular Biology***, 17 (10): 1266-1268. (With a short title in the front cover: Swine flu NA)

305. Liu, J., Sun, Y., Qi, J., Chu, F., Wu, H., Gao, F., Li, T., Yan, J. and **Gao*, G. F.**, 2010, The membrane protein of SARS-CoV acts as a dominant immunogen revealed by a clustering

UCDUSR0004209

region of novel functional and structural defined CTL epitopes. ***The Journal of Infectious Diseases (JID)***, 202 (8): 1171-1180. (With a front cover illustration)

306. Neumann, G., Chen, H., **Gao, G. F.**, Shu, Y. and Kawaoka*, Y., 2010, H5N1 influenza viruses: outbreaks and biological properties. ***Cell Research***, 20 (1): 51-61.

307. Feng*, Y., Zhang, H., Ma, Y. and **Gao*, G. F.**, 2010, Uncovering newly emerging variants of *Streptococcus suis*, an important zoonotic agent. ***Trends in Microbiology***, 18 (3): 124-131.

308. Yin, Y., Lei, F., Zhu, L., Li, S., Wu, Z., Zhang, R., **Gao, G. F.**, Zhu*, B. and Wang*, X., 2010, Exposure of different bacterial inocula to newborn chicken affects gut microbiota development and ileum gene expression. ***ISME Journal***, 4 (3): 367-376.

309. Chen, W., Jia, Z., Zhang, T., Zhang, N., Lin, C., Gao, F., Wang, L., Li, X., Jiang, Y., Li, X., **Gao, G. F.** and Xia*, C., 2010, MHC class I presentation and regulation by IFN in bony fish determined by molecular analysis of the class I locus in grass carp. ***The Journal of Immunology***, 185: 2209-2221.

310. Qi, C., Tian, X., Chen, S., Yan, J., Cao, Z., Tian, K., **Gao*, G. F.** and Jin*, G., 2010, Detection of avian influenza virus subtype H5 using a biosensor based on imaging ellipsometry. ***Biosensors and Bioelectronics***, 25 (6): 1530-1534.

311. Chen, W., Gao, F., Chu, F., Zhang, J., **Gao, G. F.** and Xia*, C., 2010, Crystal structure of a bony fish β2-microglobulin: insights into the evolutionary origin of IGSF constant molecules. ***Journal of Biological Chemistry (JBC)***, 285: 22505-22512.

312. Liu, J., Wu, P., Gao, F., Qi, J., Tachikawa, A. K., Xie, J., Vavricka, C. J., Iwamoto, A., Li*, T. and **Gao*, G. F.**, 2010, Novel immunodominant peptide presentation strategy: a featured HLA-A*2402 restricted CTL-epitope stabilized by intra-chain hydrogen-bonds from SARS-CoV N protein. ***Journal of Virology***, 84 (22): 11849-11857.

313. Xu, Y., Fan, H., Lu, C., **Gao, G. F.** and Li*, X., 2010, Synthesis of galabiose-chitosan conjugate as potent inhibitor of *Streptococcus suis* adhesion. ***Biomacromolecules***, 11 (7): 1701-1704.

314. Yi, Y., Ma, Y., Gao, F., Mao, X., Peng, H., Feng, Y., Fan, Z., Wang, G., Guo, G., Yan, J., Zeng, H., Zou*, Q. and **Gao*, G. F.**, 2010, Crystal structure of EHEC intimin: insights into the complementarity between EPEC and EHEC. ***PLoS ONE***, 5 (12): e15285.

315. Cui, J., Chen, Q., Yue, X., Jiang, X., **Gao*, G. F.**, Yu*, L. and Zhang*, Y., 2010, Galanin protects against intracellular amyloid toxicity in human primary neurons. ***Journal of Alzheimer's Disease***, 19 (2): 529-544.

UCDUSR0004210

316. Sun, Y., Liu, J., Yang, M., Gao, F., Zhou, J., Kitamura, Y., Gao, B., Tien, P., Shu, Y., Iwamoto, A., Chen, Z. and **Gao*, G. F.**, 2010, Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from H5N1 subtype of influenza A viruses. ***Journal of General Virology***, 91: 919-930.

317. Lu, L., Yin, Y., Sun, Z., Gao, L., **Gao, G. F.**, Sun*, L. and Liu*, W., 2010, Genetic correlation between current circulating H1N1 swine and human influenza viruses. ***Journal of Clinical Virology***, 49 (3): 186-191.

318. Gao, N., Chen, W., Zheng, Q., Fan, D., Zhang, J., Chen, H., **Gao, G. F.**, Zhou*, D. and An*, J., 2010, Co-expression of Japanese encephalitis virus prM–E–NS1 antigen with granulocyte-macrophage colony-stimulating factor enhances humoral and anti-virus immunity after DNA vaccination. ***Immunology Letters***, 129 (1): 23-31.

319. Yu, M., Liu, X., Sun, L., Chen, C., Ma, G., Kitamura, Y., **Gao, G. F.** and Liu*, W., 2010, Subcellular localization and topology of porcine reproductive and respiratory syndrome virus E protein. ***Virus Research***, 152 (1-2): 104-114.

320. Yu, L., Aoki, C., Shimizu, Y., Shimizu, K., Hou, W., Yagyu, F., Wen, X., Oshima, M., Iwamoto, A., Gao, B., Liu, W., **Gao, G. F.** and Kitamura*, Y., 2010, Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication. ***Journal of Virological Methods***, 169 (2): 380-384.

321. Song, X., Xiao, H., Huang, Y., Fu, G., Jiang, B., Kitamura, Y., Liu, W., Liu, D. and **Gao*, G. F.**, 2010, Serological surveillance of influenza A virus infection in swine populations in Fujian Province, China: no evidence of naturally occurring H5N1 infection in pigs. ***Zoonoses and Public Health***, 57 (4): 291-298.

322. Sun, Y., Shi, Y., Zhang, W., Li, Q., Liu, D., Vavricka, C. J., Yan, J. and **Gao*, G. F.**, 2010, *In-silicon* characterization of the functional and structural modules of the haemagglutinin protein from the swine-origin influenza virus A (H1N1)-2009. ***Science China Life Sciences***, 53 (6): 633-642. (With a front cover illustration)

323. Mi, S., Li Y., Yan, J. and **Gao*, G. F.**, 2010, Na^+/K^+-ATPase β1 subunit interacts with M2 proteins of influenza A and B viruses and affects the virus replication. ***Science China Life Sciences***, 53 (9): 1098-1105.

324. **Gao*, G. F.** and Sun, Y., 2010, It is not just AIV: From avian to swine-origin influenza virus. ***Science China Life Sciences***, 53 (1): 1-3. (Perspective)

UCDUSR0004211

325. Zhang, W., Qi, J., Shi, Y., Li, Q., Gao, F., Sun, Y., Lu, X., Lu, Q., Vavricka, C. J., Liu, D., Yan, J. and **Gao*, G. F.**, 2010, Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. ***Protein & Cell***, 1 (5): 459-467. (Cover story)

326. Chen, Y., Liu, P., Gao, F., Cheng, H., Qi, J. and **Gao*, G. F.**, 2010, A dimeric structure of PD-L1: functional units or evolutionary relics? ***Protein & Cell***, 1 (2): 153-160. (Cover story)

327. Zhang, X. and **Gao*, G. F.**, 2010, Revival of gene therapy. ***Protein & Cell***, 1 (2): 107-108. (News & Views)

328. Guan, Z., Liu, D., Mi, S., Zhang, J., Ye, Q., Wang, M., **Gao, G. F.** and Yan*, J., 2010, Interaction of Hsp40 with influenza virus M2 protein: implication for PKR signaling pathway. ***Protein & Cell***, 1 (10): 944-955. (With a back cover illustration)

329. Cole, D. K., Yuan, F., Rizkallah, P. J., Miles, J. J., Gostick, E., Price, D. A., **Gao, G. F.**, Jakobsen, B. K. and Sewell*, A. K., 2009, Germline-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. ***Journal of Biological Chemistry (JBC)***, 284 (40): 27281-27289.

330. Miyazaki, E., Kawana-Tachikawa, A., Tomizawa, M., Nunoya, J., Odawara, T., Fujii,T., Shi, Y., **Gao, G. F.** and Iwamoto*, A., 2009, Highly restricted T-cell receptor repertoire in the CD8+ T-cell response against an HIV-1 epitope with a stereotypic amino acid substitution. ***AIDS***, 23 (6): 651-660.

331. Song, X., Huang, Y., Xiao, H., Liu, D. and **Gao*, G. F.**, 2009, Stable non-synonymous substitutions on NS gene (NS1 and NS2 proteins) of Qinghai Lake H5N1 influenza virus (Clade 2.2) after successive passages in Muscovy ducks. ***Science China Series C: Life Science***, 52 (9): 847-853.

332. Feng, Y., Pan, X., Sun, W., Wang, C., Zhang, H., Li, X., Ma, Y., Shao, Z., Ge, J., Zheng, F., **Gao, G. F.** and Tang*, J., 2009, *Streptococcus suis* enolase functions as a protective antigen displayed on the bacterial cell surface. ***The Journal of Infectious Diseases (JID)***, 200: 1583-1592.

333. Ma, Y., Feng, Y., Liu D. and **Gao*, G. F.**, 2009, Avian influenza virus, *Streptococcus suis* serotype 2, SARS-coronavirus and beyond: molecular epidemiology, ecology and the situation in China. ***Philosophical Transactions of the Royal Society B (Biological Sciences)***, 364 (1530): 2725-2737.

334. Tian, X., Lu, G., Gao, F., Peng, H., Feng, Y., Ma, G., Bartlam, M., Tian, K., Yan, J., Hilgenfeld,

UCDUSR0004212

R. and **Gao*, G. F.**, 2009, Structure and cleavage-specificity of the chymotrypsin-like serine protease (3CLSP/nsp4) of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). ***Journal of Molecular Biology***, 392 (4): 977-993.

335. Zhang, Q., Gao, F., Peng, H., Cheng, H., Liu, Y., Tang, J., Thompson, J., Wei, G., Zhang, J., Du, Y., Yan, J. and **Gao*, G. F.**, 2009, Crystal structures of *Streptococcus suis* mannonate dehydratase (ManD) and its complex with substrate: genetic and biochemical evidence for a catalytic mechanism. ***Journal of Bacteriology***, 191 (18): 5832-5837.

336. **Gao*, G. F.** and Shaw*, P., 2009, The challenges of avian influenza virus: mechanism, epidemiology and control. ***Science China Life Sciences***, 52 (5): 405-406.

337. Liu, D., Liu, X., Yan, J., Liu W. and **Gao*, G. F.**, 2009, Interspecies transmission and host restriction of avian H5N1 influenza virus. ***Science China Life Sciences***, 52 (5): 428-438. (Cover story)

338. Liu, D., Liu, Q., Wu, L., Liu, B., Wu, J., Lao, Y., Li, X., **Gao, G. F.** and Ma*, J., 2009, Website for avian flu information and bioinformatics. ***Science China Life Sciences***, 52 (5): 470-473.

339. Chen, Y., Shi, Y., Cheng, H., An, Y. and **Gao*, G. F.**, 2009, Structural immunology and crystallography help immunologists see the immune system in action: How T and NK cells touch their ligands. ***IUBMB Life***, 61 (6): 579-590.

340. Gao, Y., Rumschlag-Booms, E., Wang, J., Xiao, H., Yu, J., Wang, J., Guo, L., **Gao, G. F.**, Cao, Y., Caffrey, M. and Rong*, L., 2009, Analysis of hemagglutinin-mediated entry tropism of H5N1 avian influenza. ***Virology Journal***, 6: e39.

341. Zhu, X., Chang, S., Fang, K., Cui, S., Liu, J., Wu, Z., Yu, X., **Gao, G. F.**, Yang, H., Zhu*, B. and Wang*, J., 2009, MyBASE: a database for genome polymorphism and gene function studies of Mycobacterium. ***BMC Microbiology***, 9 (1): e40.

342. Chen, Y., Gao, F., Chu, F., Peng, H., Zong, Li., Liu, Y., Tien, P. and **Gao*, G. F.**, 2009, Crystal structure of myeloid cell activating receptor leukocyte Ig-like receptor A2 (LILRA2/ILT1/LIR-7) domain swapped dimer: molecular basis for its non-binding to MHC complexes. ***Journal of Molecular Biology***, 386 (3): 841-853.

343. Zhou, Z., Jiang, X., Liu, D., Fan, Z., Hu, X., Yan, J., Wang, M. and **Gao*, G. F.**, 2009, Autophagy is involved in influenza A virus replication. ***Autophagy***, 5 (3): 321-328.

344. Zhang, Q., Peng, H., Gao, F., Liu, Y., Cheng, H., Thompson, J. and **Gao*, G. F.**, 2009, Structural insight into the catalytic mechanism of gluconate 5-dehydrogenase from *Streptococcus suis*: crystal structures of the substrate-free and quaternary complex enzymes.

UCDUSR0004213

Protein Science, 18 (2): 294-303.

345. Feng, Y., Shi, X., Zhang, H., Zhang, S., Ma, Y., Zheng, B., Han, H., Lan, Q., Tang, J., Cheng, J., **Gao, G. F.** and Hu*, Q., 2009, Recurrence of human *Streptococcus suis* infections in 2007: three cases of meningitis and implications that heterogeneous *S. suis* 2 circulates in China. ***Zoonoses and Public Health***, 56 (2009): 506-514.

346. Zong, L., Chen, Y., Peng, H., Gao, F., Iwamoto, A. and **Gao*, G. F.**, 2009, Rhesus macaque: a tight homodimeric CD8αα. ***Proteins: Structure, Function, and Bioinformatics***, 75 (1): 241-244. (Cover story).

347. Hou, W., Aoki, C., Yu, L., Wen, X., Xue , Y., Gao, B., Liu, W., **Gao, G. F.**, Iwamoto, A. and Kitamura*, Y., 2008, A recombinant replication-competent hepatitis C virus expressing Azami-Green, a bright green-emitting fluorescent protein, suitable for visualization of infected cells. ***Biochemical and Biophysical Research Communications (BBRC)***, 377: 7-11.

348. Leung, A. S., Tran, V., Wu, Z., Yu, X., Alexander, D. C., **Gao, G. F.**, Zhu*, B. and Liu*, J., 2008, Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. ***BMC Genomics***, 9: e413.

349. Zhang, Q., Gao, F., Qi, J., Cheng, H., Liu, Y. and **Gao*, G. F.**, 2008, Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of 2-keto-3-deoxy-6-phosphogluconate (KDPG) aldolase from *Streptococcus suis* serotype 2. ***Acta Crystallographica Section F Structural Biology and Crystallization Communications***, 64: 997-999.

350. Zhang, Y., Ju, J., Peng, H., Gao, F., Zhou, C., Zeng, Y., Xue, Y., Li, Y., Henrissat, B., **Gao, G. F.** and Ma*, Y., 2008, Biochemical and structural characterization of the intracellular mannanase AaManA of alicyclobacillus acidocaldarius reveals a novel glycoside hydrolase family belonging to clan GH-A. ***The Journal of Biological Chemistry (JBC)***, 283 (46): 31551-31558.

351. Liu, J., Liu, B., Cao, Z., Inoue, S., Morita, K., Tian, K., Zhu, Q. and **Gao*, G. F.**, 2008, Characterization and application of monoclonal antibodies specific to West Nile virus envelope protein. ***Journal of Virological Methods***, 154 (2008): 20-26.

352. Feng, Y., Li, M., Zhang, H., Zheng, B., Han, H., Wang, C., Yan, J., Tang J. and **Gao*, G. F.**, 2008, Functional definition and global regulation of Zur, a zinc uptake regulator in a *Streptococcus suis* serotype 2 strain causing streptococcal toxic shock syndrome. ***Journal of Bacteriology***, 190 (20): 7567-7578.

UCDUSR0004214

353. Chen, H., Ma, Y., Yang, J., O'Brien, C. J., Lee, S. L., Mazurkiewicz, J. E., Hautaja, S., Yan, J., **Gao, G. F.** and Zhang*, J., 2008, Genetic requirement for pneumococcal ear infection. ***PLoS ONE***, 3 (8): e2950.

354. Khan, A. H., Chu, F., Feng, Y., Zhang, Q., Qi, J. and **Gao*, G. F.**, 2008, Crystallization and preliminary crystallographic analysis of recombinant immunoglobulin G-binding protein from *Streptococcus suis*. ***Acta Crystallography Section F Structure Biology and Crystallization Communications***, 64: 757-759.

355. Feng, Y., Zhao, T., Nguyen, T., Inui, K., Ma, Y., Nguyen, T., H., Nguyen, V. C., Liu, D., Bui, Q. A., To, L. T., Tian*, K. and **Gao, G. F.**, 2008, Porcine respiratory and reproductive syndrome virus variants, Vietnam and China, 2007. ***Emerging Infectious Diseases (EID)***, 14 (11): 1774-1776.

356. Li, M., Wang, C., Feng, Y., Pan, X., Cheng, G., Wang, J., Ge, J., Zheng, F., Cao, M., Dong, Y., Liu, D., Wang, J., Lin, Y., Du, H., **Gao, G. F.**, Wang*, X., Hu*, F. and Tang*, J., 2008, SalK/SalR, a two-component signal transduction system, is essential for full virulence of highly invasive *Streptococcus suis* serotype 2. ***PLoS ONE***, 3 (5): e2080.

357. Wang, G., Zhan, D., Li, L., Lei, F., Liu, B., Liu, D., Xiao, H., Feng, Y., Li, J., Yang, B., Yin, Z., Song, X., Zhu, X., Cong, Y., Pu, J., Wang, J., Liu*, J., **Gao*, G. F.** and Zhu*, Q., 2008, H5N1 avian influenza re-emergence of Lake Qinghai: phylogenetic and antigenic analyses of the newly isolated viruses and roles of migratory birds in virus circulation. ***Journal of General Virology***, 89: 697-702.

358. Li, M., Jiang, X., Liu, D., Na, Y., **Gao*, G. F.** and Xi*, Z., 2008, Autophagy protects LNCaP cells under androgen deprivation conditions. ***Autophagy***, 4 (1): 54-60.

359. Chen, Y., Chu, F., Gao, F., Zhou, B. and **Gao*, G. F.**, 2007, Stability engineering, biophysical, and biological characterization of the myeloid activating receptor immunoglobulin-like transcript 1 (ILT1/LIR-7/LILRA2). ***Protein Expression and Purification***, 56 (2): 253-260.

360. Feng, Y., Zheng, F., Pan, X., Sun, W., Wan, C., Dou, Y., Ju, A., Ge, J., Liu, D., Liu, C., Yan, J., Tang J. and **Gao*, G. F.**, 2007, Existence and characterization of allelic variants of Sao, a newly identified surface protein from *Streptococcus suis*. ***FEMS Microbiology Letters***, 275 (1): 80-88.

361. Yuan, F., Georgiou, T., Hillon, T., Gostick, E., Price, D. A., Sewell, A. K., Meyscy, R., Gavarret, J., Vuidepot, A., Sami, M., Bell, J. I., **Gao, G. F.**, Rizkallah, P. J. and Jakobsen*, B. K., 2007, Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR

UCDUSR0004215

complex. ***Acta Crystallographica Section F Structural Biology and Crystallization Communications***, 63: 758-760.

362. Tian*, K., Yu, X., Zhao, T., Feng, Y., Cao, Z., Wang, C., Hu, Y., Chen, X., Hu, D., Tian, X., Liu, D., Zhang, S., Deng, X., Ding, Y., Yang, L., Zhang, Y., Xiao, H., Qiao, M., Wang, B., Hou, L., Wang, X., Yang, X., Kang, L., Sun, M., Jin, P., Wang, S., Kitamura, Y., Yan, J. and **Gao*, G. F.**, 2007, Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. ***PLoS ONE***, 2: e526.

363. Chen, C., Tang, J., Dong, W., Wang, C., Feng, Y., Wang, J., Zheng, F., Pan, X., Liu, D., Li, M., Song, Y., Zhu, X., Sun, H., Feng, T., Guo, Z., Ju, A., Ge, J., Dong, Y. , Sun, W., Jiang, Y., Wang, J., Yan, J., Yang, H. M., Wang*, X., **Gao*, G. F.**, Yang*, R., Wang*, J. and Yu*, J., 2007, A glimpse of streptococcal toxic shock syndrome from comparative genomics of *S. suis* 2 Chinese isolates. ***PLoS ONE***, 2: e315.

364. Feng, Y. and **Gao*, G. F.**, 2007, Towards our understanding of SARS-CoV, an emerging and devastating but quickly-conquered virus. ***Comparative Immunology, Microbiology and Infectious Diseases***, 30 (5-6): 309-327.

365. Cole, D. K., Pumphrey, N. J., Boulter, J. M., Sami, M., Bell, J. I., Gostick, E., Price, D. A., **Gao, G. F.**, Sewell, A. K. and Jakobsen*, B. K., 2007, Human TCR-binding affinity is governed by MHC class restriction. ***The Journal of Immunology***, 178 (9): 5727-5734.

366. Cole, D. K., Rizkallah, P. J., Boulter, J. M., Sami, M., Vuidepot, A. L., Glick, M., Gao, F., Bell, J. I., Jakobsen*, B. K. and **Gao*, G. F.**, 2007, Computational design and crystal structure of an enhanced affinity mutant human CD8αα coreceptor. ***Proteins: Structure, Function, and Bioinformatics***, 67 (1): 65-74. (Cover story).

367. Chu, F., Lou, Z., Chen, Y., Liu, Y., Gao, B., Zong, L., Khan, A. H., Bell, J. I., Rao, Z. and **Gao*, G. F.**, 2007, First glimpse of the peptide presentation by rhesus macaque MHC class I: crystal structures of Mamu-A*01 complexed with two immunogenic SIV epitopes and insights into CTL escape. ***The Journal of Immunology***, 178 (2): 944-952.

368. Huang, B. J., Liu, R. Y., Huang, J. L., Liang, Z. H., **Gao, G. F.**, Wu, J. X. and Huang*, W., 2007, Long-term toxicity studies in canine of E10A, an adenoviral vector for human Endostatin gene. ***Human Gene Therapy***, 18 (3): 207-221.

369. Chang, S., Zhang, J., Liao, X., Zhu, X., Wang, D., Zhu, J., Feng, T., Zhu, B., **Gao, G. F.**, Wang, J., Yang, H. M., Yu*, J. and Wang*, J., 2007, Influenza Virus Database (IVDB): an integrated information resource and analysis platform for influenza virus research. ***Nucleic Acids***

UCDUSR0004216

Research, 35: 376-380. (Database issue).

370. Zhang, J. Y., Zhang, Z., Wang, X., Fu, J. L., Yao, J., Jiao, Y., Chen, L., Zhang, H., Wei, J., Jin, L., Shi, M., **Gao, G. F.**, Wu, H. and Wang*, F. S., 2007, PD-1 upregulation is correlated with HIV-specific memory $CD8^+$ T-cell exhaustion in typical progressors, but not in long-term non-progressors. ***Blood***, 109 (11): 4671-4678.

371. Fan, Z., Zhao, Y., Tan, X., Zhou, Z., Yuan, J., Qiang, B., Yan, J., Peng, X. and **Gao*, G. F.**, 2006, SARS-CoV nucleocapsid protein binds to hUbc9, a ubiquitin conjugating enzyme of the sumoylation system. ***Journal of Medical Virology***, 78 (11): 1365-1373.

372. Lou, Z., Xu, Y., Xiang, K., Su, N., Qin, L., Li, X., **Gao, G. F.**, Bartlam, M. and Rao*, Z., 2006, Crystal structures of Nipah and Hendra virus fusion core proteins. ***FEBS Journal***, 273 (19): 4538-4547.

373. Liu, Y., Xu, Y., Lou, Z., Zhu, J., Hu, X., **Gao, G. F.**, Qiu*, B. S., Rao*, Z. and Tien*, P., 2006, Structural characterization of Mumps virus fusion protein core. ***Biochemical and Biophysical Research Communications (BBRC)***, 348 (3): 916-922.

374. Zhou, M., Xu, D., Li, X., Li, H., Shan, M., Tang, J. R., Wang, M., Wang, F. S., Zhu, X., Tao, H., He, W., Tien*, P. and **Gao*, G. F.**, 2006, Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. ***The Journal of Immunology***, 177 (4): 2138-2145.

375. Kannan, S., Audet, A., Knittel, J., Mullegama, S., **Gao, G. F.** and Wu*, M., 2006, Src kinase Lyn is crucial for Pseudomonas aeruginosa internalization into lung cells. ***European Journal of Immunology***, 36 (7): 1739-1752.

376. Zhang, Y., Zan, Y., Shan, M., Liu, C., Shi, M., Li, W., Zhang, Z., Liu, N., Wang, F., Zhong, W., Liao, F., **Gao*, G. F.** and Tien*, P., 2006, Effects of heat shock protein gp96 on human dendritic cell maturation and CTL expansion. ***Biochemical and Biophysical Research Communications (BBRC)***, 344 (2): 581–587.

377. Tang*[#], J., Wang[#], C., Feng[#], Y., Yang[#], W., Song[#], H., Chen[#], Z., Yu[#], H., Pan, X., Zhou, X., Wang, H., Wu, B., Wang, H., Zhao, H., Lin, Y., Yue, J., Wu, Z., He, X., Gao, F., Khan, A. H., Wang, J., Zhao, G. P., Wang*, Y., Wang*, X., Chen, Z. and **Gao*, G. F.**, 2006, Streptococcal toxic shock syndrome caused by *Streptococcus suis* serotype 2. ***PLoS Medicine***, 3 (5): 668-676. (With a short title in the front cover: *Streptococcus suis* outbreak in China)

378. Li, X., Liu, X., Sun, F., Gao, J., Zhou, H., **Gao, G. F.**, Bartlam, M. and Rao*, Z., 2006, Crystal structure of the N-terminal SH3 domain of mouse βPIX, p21-activated kinase-interacting

UCDUSR0004217

exchange factor. ***Biochemical and Biophysical Research Communications (BBRC)***, 339 (1): 407-414.

379. Cole, D. K., Rizkallah, P. J., Gao, F., Watson, N. L, Beuher, J. M., Bell, J. L, Sami, M., **Gao*, G. F.** and Jakobsen*, B. K., 2006, Crystal structure of HLA-A*2402 complexed with a telomerase peptide. ***European Journal of Immunology***, 36 (1): 170-179.

380. Liu[6,*], J., Xiao[6], H., Lei[6], F., Zhu, Q., Qin, K., Zhang, X. W., Zhang, X. L., Zhao, D., Wang, G., Feng, Y., Ma, J., Liu, W., Wang, J. and **Gao*, G. F.**, 2005, Highly pathogenic H5N1 influenza virus infection in migratory birds. ***Science***, 309 (5738): 1206.

381. Gao, G. F., 2005, Avian Flu: Is Taiwan or Not? (Letters to the Editor). ***Science***, 310 (5746): 235-236.

382. Ni, L., Zhao, L., Qian, Y., Zhu, J., Jin, Z., Chen, Y. W., Tien*, P. and **Gao*, G. F.**, 2005, Design and characterization of human respiratory syncytial virus entry inhibitors. ***Antiviral Therapy***, 10 (7): 833-840.

383. Zhu, J., Jiang, X., Liu, Y., Tien*, P. and **Gao*, G. F.**, 2005, Design and characterization of viral polypeptide inhibitors targeting Newcastle disease virus fusion. ***Journal of Molecular Biology***, 354 (3): 601-613.

384. Ni, L., Zhao, L., **Gao, G. F.**, Qian*, Y. and Tien*, P., 2005, The antibodies directed against N-terminal heptad-repeat peptide of hRSV fusion protein and its analog-5-Helix inhibit virus infection in vitro. ***Biochemical and Biophysical Research Communications (BBRC)***, 331 (4): 1358-1364.

385. Ni, L., **Gao*, G. F.** and Tien*, P., 2005, Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics. ***Biochemical and Biophysical Research Communications (BBRC)***, 332 (3): 831-836.

386. Zhang, Z., Xu, D., Li, Y., Jin, L., Shi, M., Wang, M., Zhou, X., Wu, H., **Gao, G. F.** and Wang*, F. S., 2005, Longitudinal alteration of circulating dendritic cell subsets and its correlation with steroid treatment in patients with severe acute respiratory syndrome. ***Clinical Immunology***, 116 (3): 225-235.

387. Chu, F., Lou, Z., Gao, B., Bell, J. L, Rao, Z. and **Gao*, G. F.**, 2005, Complex assembly, crystallization and preliminary X-ray crystallographic studies of rhesus macaque MHC Mamu-A*01 complexed with an immunodominant SIV-Gag nonapeptide. ***Acta Crystallographica Section F Structural Biology and Crystallization Communications***, 61 (Pt 6): 614-616.

UCDUSR0004218

388. Zhao, X., Li, M., Xu, Y., Lou, Z., Meng, Z., Li, S., Tian, B., **Gao, G. F.** and Rao*, Z., 2005, Cloning, expression, purification, crystallization, and preliminary crystallographic study of the protein module (BIV-Helix) in the fusion core of bovine immunodeficiency-like virus (BIV) gp40. ***Acta Crystallographica Section F Structural Biology and Crystallization Communications***, 61 (Pt 2): 249-251.

389. Li, H., Zhou, M., Han, J., Zhu, X., Dong, T., **Gao*, G. F.** and Tien*, P., 2005, Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. ***The Journal of Immunology***, 174 (1): 195-204.

390. **Gao, G. F.**, 2005, Filling the hole: evidence of a small molecule binding to the fusion core pocket in human respiratory syncytial virus. ***Expert Opinion on Investigational Drugs***, 14 (2): 195-197.

391. Yuan, F., Lou, Z., Li, X., Chen, Y., Bell, J. I., Rao, Z. and **Gao*, G. F.**, 2005, Refolding, crystallization and preliminary X-ray structural studies of the West Nile virus envelope (E) protein domain III. ***Acta Crystallographica Section F Structural Biology and Crystallization Communications***, 61 (Pt 4): 421-423.

392. Li, S., Zhu, J., Peng, Y., Cui, S., Wang, C., **Gao*, G. F.** and Tien*, P., 2005, Characterization of BIV Env core: implication for mechanism of BIV-mediated cell fusion. ***Biochemical and Biophysical Research Communications (BBRC)***, 329 (2): 603-609.

393. Cole, D. K., Rizkallah*, P. J., Sami, M., Lissin, N. M., Gao, F., Bell, J. I., Boulter, J. M., Glick, M., Vuidepot, A. L., Jakobsen*, B. K. and **Gao, G. F.**, 2005, Crystallization and preliminary X-ray structural studies of a high-affinity CD8ααco-receptor to pMHC. ***Acta Crystallographica Section F Structural Biology and Crystallization Communications***, 61: 285-287.

394. Ni, L., Zhu, J., Zhang, J., Yan, M., **Gao*, G. F.** and Tien*, P., 2005, Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain. ***Biochemical and Biophysical Research Communications (BBRC)***, 330 (1): 39-45.

395. Wang, X., Bai, Y., Zhang, G., Zhao, J., Wang*, M. and **Gao*, G. F.**, 2005, Structure and function study of paramyxovirus fusion protein heptad repeat peptides. ***Archives of Biochemistry and Biophysics (ABB)***, 436 (2): 316-322.

396. Xu, D., Zhang, Z., Jin, L., Chu, F., Mao, Y., Wang, H., Liu, M., Wang, M., Zhang, L., **Gao, G.**

UCDUSR0004219

F. and Wang*, F. S., 2005, Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. ***European Journal of Clinical Microbiology & Infectious Diseases***, 24 (3): 165-171.

397. Liu, Y., Xu, Y., Zhu, J., Qin, B., Rao, Z., **Gao, G. F.** and Tien* P., 2005, Crystallization and preliminary X-ray diffraction analysis of central structure domains from mumps virus F protein. ***Acta Crystallographica Section F Structural Biology and Crystallization Communications***, 61 (Pt9): 855-857.

398. Xu, Y., Lou, Z., Liu, Y., Pang, H., Tien, P., **Gao, G. F.** and Rao*, Z., 2004, Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. ***Journal of Biological Chemistry (JBC)***, 279 (47): 49414-49419.

399. Xu, Y., Liu, Y., Lou, Z., Qin, L., Li, X., Bai, Z., Tien, P., **Gao*, G. F.** and Rao*, Z., 2004, Structural basis for coronavirus-mediated virus membrane fusion: crystal structure of mouse hepatitis virus spike protein fusion core. ***Journal of Biological Chemistry (JBC)***, 279 (29): 30514-30522.

400. Cole, D. K. and **Gao*, G. F.**, 2004, CD8: Adhesion molecule, co-receptor and immuno-modulator. ***Cellular and Molecular Immunology***, 1 (2): 81-88.

401. Pang, H., Bartlam, M., Zeng, Q., Miyatake, H., Hisano, T., Miki, K., Wong, L. L., **Gao, G. F.** and Rao*, Z., 2004, Crystal structure of human pirin: an iron binding nuclear protein and transcription cofactor. ***Journal of Biological Chemistry (JBC)***, 279 (2): 1491-1498.

402. Xu, D., Zhang, Z., Chu, F., Li, Y., Jin, L., Zhang, L., **Gao, G. F.** and Wang, F. S., 2004, Genetic variation of SARS coronavirus in Beijing Hospital. ***Emerging Infectious Diseases***, 10 (5): 789-794.

403. **Gao, G. F.**, 2004, Just holding back: convergence of viral fusion mechanisms (Monitor). ***Drug Discovery Today***, 9: 288. (Comments)

404. Xu, Y., Zhu, J., Liu, Y., Lou, Z., Yuan, F., Liu, Y., Cole, D. K., Ni, L., Su, N., Qin, L., Li, X., Bai, Z., Bell, J. I., Pang, H., Tien, P., **Gao*, G. F.** and Rao*, Z., 2004, Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. ***Biochemistry***, 43 (44): 14064-14071.

405. Zhu, X., Li, C., Lang, Z., **Gao*, G. F.** and Tien*, P., 2004, Significant correlation between expression level of HSP gp96 and the progression of hepatitis B virus induced diseases. ***World Journal of Gastroenterology***, 10 (8): 1141-1145.

UCDUSR0004220

406. Xu, Y., Cole, D. K., Lou, Z., Liu, Y., Qin, L., Li, X., Bai, Z., Yuan, F., Rao*, Z. and **Gao*, G. F.**, 2004. Construct design, biophysical, and biochemical characterization of the fusion core from mouse hepatitis virus (a coronavirus) spike protein. ***Protein Expression and Purification***, 38 (1): 116-22.

407. Xu, Y., Gao, S., Cole, D. K., Zhu, J., Su, N., Wang, H., **Gao*, G. F.** and Rao*, Z., 2004, Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses. ***Biochemical and Biophysical Research Communications (BBRC)***, 315 (3): 664-670.

408. Xia*, C., Xu*, G. X., Lin, C. Y., Hu, T. J., Yan, R. Q. and **Gao, G. F.**, 2004, Molecular cloning and polymorphism of major histocompatibility complex class I genes from grass carp (*Ctenopharyngodon idellus*). ***Progress in Natural Science***, 14 (5): 403-410.

409. Zhu, J., Xiao, G., Xu, Y., Yuan, F., Zheng, C., Liu, Y., Cole, D. K., Yan, H., Bell, J. I., Rao, Z., Tien*, P. and **Gao*, G. F.**, 2004, Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and identification of potent peptide inhibitors. ***Biochemical and Biophysical Research Communications (BBRC)***, 319 (1): 283-288.

410. Liu, Y., Zhu, J., Feng, M., Tien, P. and **Gao*, G. F.**, 2004, Six-helix bundle assembly and analysis of the central core of mumps virus fusion protein. ***Archives of Biochemistry and Biophysics (ABB)***, 421 (1): 143-148.

411. Yan, H., Xiao, G., Zhang, J., Hu, Y., Yuan, F., Cole, D. K., Zheng*, C. and **Gao*, G. F.**, 2004, SARS coronavirus induces apoptosis in Vero E6 cells. ***Journal of Medical Virology***, 73 (3): 323-331.

412. Xu, Y., Lou, Z., Liu, Y., Cole, D. K., Su, N., Qin, L., Li, X., Bai, Z., Rao*, Z. and **Gao*, G. F.**, 2004, Crystallization and preliminary crystallographic analysis of the fusion core from two new zoonotic paramyxoviruses, Nipah virus and Hendra virus. ***Acta Crystallographica Section D Biological Crystallography***, 60 (Pt 6): 1161-1164.

413. Zhou, M., Xu, Y., Lou, Z., Cole, D. K., Li, X., Liu Y., Tien, P., Rao*, Z. and **Gao*, G. F.**, 2004, Complex assembly, crystallization and preliminary X-ray crystallographic studies of MHC H-2K^d complexed with an HBV core nonapeptide. ***Acta Crystallographica Section D Biological Crystallography***, 60 (Pt 8): 1473-1475.

414. Wang, X., Xu, Y., Cole, D. K., Lou, Z., Liu, Y., Rao, Z., Wang*, M. and **Gao*, G. F.**, 2004, Biochemical, biophysical and preliminary X-ray crystallographic analyses of the fusion core

UCDUSR0004221

of Sendai virus F protein. ***Acta Crystallographica Section D Biological Crystallography***, 60 (Pt 9): 1632-1635.

415. Xu, Y., Bai, Z., Qin, L., Li, X., **Gao, G. F.** and Rao*, Z., 2004, Crystallization and preliminary crystallographic analysis of the fusion core of the spike protein of the murine coronavirus mouse hepatitis virus (MHV). ***Acta Crystallographica Section D Biological Crystallography***, 60 (Pt 11): 2013-2015.

416. Xu, Y., Su, N., Qin, L., Bai, Z., **Gao, G. F.** and Rao*, Z., 2004, Crystallization and preliminary crystallographic analysis of the heptad-repeat complex of SARS coronavirus spike protein. ***Acta Crystallographica Section D Biological Crystallography***, 60: 2377-2379.

417. Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., **Gao, G. F.**, Anand, K., Bartlam, M., Hilgenfeld, R. and Rao*, Z., 2003, The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. ***Proceedings of National Academy of Sciences USA (PNAS)***, 100 (23): 13190-13195.

418. Ding, Y., Xu, G., Yang, M., Yao, M., **Gao, G. F.**, Wang, L., Zhang*, W. and Rao, Z., 2003, Crystal structure of the ectodomain of human FcεRI. ***Journal of Biological Chemistry (JBC)***, 278 (30): 27966-27970. (Cover story).

419. Wang, E., Sun, X., Qian Y., Zhao, L., Tien*, P. and **Gao*, G. F.**, 2003, Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion. ***Biochemical and Biophysical Research Communication (BBRC)***, 302 (3): 469-475.

420. Zhu, J., Ding, Y., Gao, F., Wu, T., Zhang, C. W. H., Tien, P., Rao, Z. and **Gao*, G. F.**, 2003, Crystallization and preliminary X-ray crystallographic analysis of the trimer core from measles virus fusion protein. ***Acta Crystallographica Section D Biological Crystallography***, 59 (3): 587-590.

421. Li, P., Zhu, J., Wu, B., Gao, F., Tien, P., Rao, Z. and **Gao*, G. F.**, 2003, Crystallization and preliminary X-ray diffraction analysis of post-fusion 6-helix bundle core structure from Newcastle disease virus F protein. ***Acta Crystallographica Section D Biological Crystallography***, 59 (7): 1296-1298.

422. Zhu, J., Li, P., Wu, T., Gao, F., Ding Y., Zhang, C. W. H., Rao, Z., **Gao*, G. F.** and Tien*, P., 2003, Design and analysis of post-fusion 6-helix bundle of heptad repeat regions from Newcastle disease virus F protein. ***Protein Engineering***, 16 (5): 373-379.

423. Zhu, J., Zhang, C. W. H., Rao, Z., Tien, P. and **Gao, G. F*.**, 2003, Biochemical and biophysical analysis of heptad repeat regions from the fusion protein of Menangle virus, a

UCDUSR0004222

newly emergent paramyxovirus. ***Archives of Virology***, 148 (7): 1301-1316.

424. **Gao*, G. F.**, Rao, Z. and Bell, J. I., 2002, Molecular coordination of αβ T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands. ***Trends in Immunology***, 23: 408-413. (Review)

425. **Gao, G. F.**, 2002, CD8αα and CD8 αβ: truly different? ***Trends in Immunology***, 23 (4): 177. (Comments)

426. **Gao, G. F.** and Rao, Z., 2002, Seeing the change: TCR binds pMHC with an 'induced-fit'. ***Trends in Immunology***, 23 (6): 281. (Comments)

427. Rao, Z. and **Gao, G. F.**, 2002, Lipid-antigen presentation by CD1 is crystal clear. ***Trends in Immunology***, 23 (10): 473. (Comments)

428. Jiang, S., Borthwick, N. J., Morrison, P., **Gao, G. F.** and Steward*, M. W., 2002, Virus-specific CTL responses induced by an H-2Kd-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. ***Journal of General Virology***, 83: 429-438.

429. Yu, M., Wang, E., Liu, Y., Cao, D., Jin, N., Zhang, C. W. H., Bartlam, M., Rao, Z., Tien, P. and **Gao*, G. F.**, 2002, Six-helix bundle assembly and characterization of heptad repeat regions from the F protein of Newcastle disease virus. ***Journal of General Virology***, 83: 623-629.

430. Zhu, J., Zhang, C. W. H., Qi, Y., Tien, P. and **Gao*, G. F.**, 2002, The fusion protein core of measles virus forms stable coiled coil trimer. ***Biochemical and Biophysical Research Communications (BBRC)***, 299 (5): 897-902.

431. Meng, S. D., Song, J., Rao, Z., Tien, P. and **Gao*, G. F.**, 2002, Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides. ***Journal of Immunological Methods***, 264 (1-2): 29-35.

432. Meng, S. D., Gao, T., **Gao, G. F.** and Tien*, P., 2001, HBV-specific peptide associated with heat-shock protein gp96. ***The Lancet***, 357 (9255): 528-529.

433. Lin, C. L., Sewell, A. K., **Gao, G. F.**, Whelan, K., Phillips, R. E. and Austyn, J. M., 2000, Macrophage-tropic HIV induces and exploits dendritic cell chemotaxis. ***Journal of Experimental Medicine***, 192 (4): 587-593.

434. **Gao, G. F.**, Willcox, B. E., Wyer, J. R., Boulter, J. M., O'Callaghan, C. A., Maenaka, K., Stuart, D. I., Jones, E. Y., van der Merwe, P. A., Bell, J. I. and Jakobsen, B. K., 2000,

UCDUSR0004223

Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8αα. ***Journal of Biological Chemistry (JBC)***, 275: 15232-15238.

435. Gao*, G. F. and Jakobsen, B. K., 2000, Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. ***Immunology Today***, 21 (12): 630-636.

436. Sewell, A. K., Gerth, U. C., Price, D. A., Purbhoo, M. A., Boulter, J. M., **Gao, G. F.**, Bell, J. I., Phillips, R. E. and Jakobsen, B. K., 1999, Antagonism of cytotoxic T-lymphocyte activation by soluble CD8. ***Nature Medicine***, 5 (4): 399-404.

437. Wyer*, J. R., Willcox*, B. E., **Gao*, G. F.**, Gerth, U. C., Davis, S. J., Bell, J. I., van der Merwe, P. A. and Jakobsen, B. K., 1999, T cell receptor and coreceptor CD8 αα bind peptide-MHC independently and with distinct kinetics. ***Immunity***, 10 (2): 219-225. (Shared first author).

438. Maenaka, K., Juji, T., Nakayama, T., Wyer, J. R., **Gao, G. F.**, Maenaka, T., Zaccai, N. R., Kikuchi, A., Yabe, T., Tokunaga, K., Tadokoro, K., Stuart, D. I., Jones, E. Y. and van der Merwe, P. A., 1999, Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histocompatibility complex class I with distinct thermodynamic and kinetic properties. ***Journal of Biological Chemistry (JBC)***, 274: 28329-28334.

439. Willcox, B. E., **Gao, G. F.**, Wyer, J. R., O'Callaghan, C. A., Jones, E. Y., van der Merwe, P. A., Bell, J. I. and Jakobsen, B. K., 1999, Production of soluble αβ T-cell receptor heterodimers suitable for biophysical analysis of ligand binding. ***Protein Science***, 8 (11): 2418-2423.

440. Willcox*, B. E., **Gao*, G. F.**, Wyer, J. R., Ladbury, J. E., Bell, J. I., Jakobsen, B. K. and van der Merwe, P. A., 1999, TCR binding to peptide-MHC stabilizes a flexible recognition interface. ***Immunity***, 10 (3): 357-365. (Shared first author).

441. McGuire, K., Holmes, E. C., **Gao, G. F.**, Reid, H. W. and Gould, E. A., 1998, Tracing the origins of louping ill virus by molecular phylogenetic analysis. ***Journal of General Virology***, 79 (Pt5): 981-988.

442. Gao, G. F., Gerth, U. C., Wyer, J. R., Willcox, B. E., O'Callaghan, C. A., Zhang, Z. H., Jones, E. Y., Bell, J. I. and Jakobsen, B. K., 1998, Assembly and crystallization of the complex between the human T cell coreceptor CD8α homodimer and HLA-A2. ***Protein Science***, 7: 1245-1249.

443. Gao, G. F., Tormo, J., Gerth, U. C., Wyer, J. R., McMichael, A. J., Stuart, D. I., Bell, J. I., Jones, E. Y. and Jakobsen, B. K., 1997, Crystal structure of the complex between human

UCDUSR0004224

CD8αα and HLA-A2. ***Nature***, 387: 630-634. (With a front cover illustration (Cover story) and a short title in the front cover page: CD8 comes to grips with MHC).

444. **Gao, G. F.**, Zanotto, P. M. A., Holmes, E. C., Reid, H. W. and Gould, E. A., 1997, Molecular variation, evolution and geographical distribution of louping ill virus. ***Acta Virologica***, 41 (2): 259-268.

445. Zanotto, P. M. A., Gould, E. A., **Gao, G. F.**, Harvey, P. H. and Holmes, E. C., 1996, Population dynamics of flaviviruses revealed by molecular phylogenies. ***Proceedings of the National Academy of Sciences USA (PNAS)***, 93 (2): 548-553.

446. Zanotto, P. M. A., **Gao, G. F.**, Gritsun, T. S., Marin, S., Jiang, W. R., Venugopal, K., Reid, H. W. and Gould, E. A., 1995, An arbovirus cline across the Northern Hemisphere. ***Virology***, 210 (1): 152-159.

447. Marin, M. S., McKenzie, J., **Gao, G. F.**, Reid, H. W., Antoniadis, A. and Gould, E. A., 1995, The virus causing encephalomyelitis in sheep in Spain: a new member of the tick-borne encephalitis group. ***Research in Veterinary Science***, 58 (1): 11-13.

448. **Gao, G. F.**, Hussain, M. H., Reid, H. W. and Gould, E. A., 1994, Identification of naturally occurring monoclonal antibody escape variants of louping ill virus. ***Journal of General Virology***, 75 (Pt 3): 609-614.

449. **Gao, G. F.**, Hussain, M. H., Reid, H. W. and Gould, E. A., 1993, Classification of a new member of the TBE flavivirus subgroup by its immunological, pathogenetic and molecular characteristics: identification of subgroup-specific pentapeptides. ***Virus Research***, 30 (2): 129-144.

450. **Gao, G. F.**, Jiang, W. R., Hussain, M. H., Venugopal, K., Gritsun, T. S., Reid, H. W. and Gould, E. A., 1993, Sequencing and antigenic studies of a Norwegian virus isolated from encephalomyelitic sheep confirm the existence of louping ill virus outside Great Britain and Ireland. ***Journal of General Virology***, 74 (Pt 1): 109-114.

中文文章 **(Publications in Chinese):**

451. 庞立丽，靳森，王慧娟，王莹，陈爱珺，李慧颖，章青，**高福**，段招军， 2016，鼠诺如病毒MNV-CW1感染C57BL/6小鼠的特点. ***中华实验和临床病毒学杂志***, 30 (3): 263-265.

452. **高福**, 2016, 踏上新征程，奔向新辉煌. ***科学通报***, 61 (1): 1.

453. 王琴，齐建勋，刘宁宁，李燕，高俊，张廷虹，柴莲，高峰，张浩，李向东，叶昕，严景华，

UCDUSR0004225

逯光文, **高福**, 2015, 埃博拉病毒入侵:人TIM分子的结构与结合PS的分子基础. ***科学通报***, 60 (35): 3438-3453. (封面文章)

454. **高福**，2014，打赢埃博拉“比赛”的下半场. ***科学通报***，59 (36): 3570-3571.

455. 赖圣杰，Miniota, J.，王丽萍，任翔，张洪龙，李中杰，**高福**，Khan, K.，余宏杰*，2014，西非埃博拉病毒病传入中国的可能航线和风险估计. ***科学通报***，59 (36): 3572-3580.

456. 李昱，任翔，刘翟，程颖，**高福**，余宏杰*，2014，埃博拉病毒病：流行病学、生态学、诊断、治疗与控制. ***科技导报***, 32 (24): 15-24. (封面文章)

457. 程颖，刘军，李昱，刘翟，任翔，施一，**高福**，余宏杰*，2014，埃博拉病毒病：病原学、致病机制、治疗与疫苗研究进展. ***科学通报***，59: 2889-2899.

458. 闫章才，薛丽香，李国才，**高福***，董尔丹*，2014，流行性感冒防控基础研究状况及关键科学问题分析. ***中国科学：生命科学***， 44（1）：101-106.

459. 逯光文，**高福***，严景华*，2013，麻疹病毒受体与病毒侵入. ***生物工程学报***，29 (1): 1-9. (特邀综述) （封面文章）

460. 刘军，齐建勋，高峰，严景华，**高福***，2011，T细胞功能学与结构免疫学结合方法鉴定HLA－A2限制性的细胞毒性T淋巴细胞表位富集区. ***科技导报***, 29 (27): 19-26. (封面文章)

461. 孙明伟，路希山，**高福***，2011，合成病毒：对流感病毒研究的贡献. ***生命科学***, 23 (9): 921-930.

462. 胡旭东，路浩，刘培培，逯秀玲，李爽，王秀月，莫毅诚，张国中，田克恭，**高福**，苏敬良*，2011，我国发现的一种引起鸭产蛋下降综合征的新型黄病毒. ***中国兽医杂志***, 47 (7): 43-47.

463. 孙明伟，**高福***，2011，小议2010国内外生命科学重要进展. ***遗传***, 33 (2): 97-99.

464. 李青，冯思光，柳红，**高福***，2010，基于结构的抗流感病毒神经氨酸酶抑制剂的设计和研发. ***生物产业技术***, (6): 42-48.

465. 孙明伟，邓培文，**高福**，朱宝利*，2010，人类与病原菌的军备竞赛：NDM-1耐药基因与超级细菌. ***生物工程学报***, 26 (11): 1461-1472. (《新华文摘》2011年第1期转载)

466. 孙明伟，李寅，**高福***，2010，从人类基因组到人造生命：克雷格文特尔领路生命科学. ***生***

UCDUSR0004226

物工程学报, 25 (6): 697-706. (《新华文摘》2010年第17期转载)

467. 孙业平，**高福***, 2010, 天然免疫抗病毒效应分子Mx 蛋白的结构与功能研究进展. *生物化学与生物物理进展*, 37 (7): 699-706. (综述)

468. 宋晓晖，胡旭东，马素芳，王明晗，张蔚，马颖，陈越，马广鹏，汪明，杨希才，刘文军，刘金华，田波，刘翟，严景华，**高福***, 2009, 动物源性流感病毒与人流感流行. *科技导报*, 27 (9): 19-24. (封面论文，《新华文摘》2009年第14期转载)

469. 戴连擎，周斌，齐建勋，马颖，**高福***，杨希才*, 2009, 恒河猴MHC-I类分子Mamu-A*02与SIV抗原表位复合物的纯化和晶体学研究. *生物工程学报*, 25 (7): 1028-1034.

470. 张建华，高峰，彭浩，夏春*，**高福***, 2009, 鸡β_2-微球蛋白及其硒代衍生物的制备和晶体学研究. *科技导报*, 27 (1): 38-41.

471. 尹捷，刘一苇，李洁，马延和，向华，严景华，**高福***, 2008, 腾冲嗜热厌氧杆菌6-磷酸-β-葡萄糖苷酶的表达与结晶及其功能鉴定. *中国生物化学与分子生物学报*, 24 (10): 916-924.

472. 校海霞，严景华，王贵华，刘翟，孙业平，**高福***, 2007, 禽流感研究进展：迁徙鸟的作用与反向遗传技术的贡献. *前沿科学*, 1: 62-73. (综述)

473. 王晓佳，张卫红，汪明*，**高福***, 2004, 囊膜病毒膜融合的分子机制. *生物化学与生物物理进展*, 31 (6): 482-491. (综述)

Book Chapters:

1. Edited by Paul F. Torrence, ***Combating the Threat of Pandemic Influenza: Drug Discovery Approaches***, John Wiley & Sons Inc., 2007, USA, ISBN 987-0-470-11879-5. Chapter 10: Peptide Inhibitors Targeting Virus-Cell Fusion in Class I Enveloped Viruses, **George Fu Gao**.
2. ***Major Histocompatibility Complex: Interaction with Peptides***, In: eLS. John Wiley & Sons, Ltd, 2011, Chichester. DOI: 10.1002/9780470015902.a0000922.pub2. Jun Liu, **George Fu Gao**.
3. Edited by Pier Andrea Serra, ***Biosensors for Health, Environment and Biosecurity***, InTech, 2011, Croatia, ISBN 978-953-307-443-6. Chapter 7: Label-free Biosensors for Health Applications, Cai Qi, **George Fu Gao** and Gang Jin.

UCDUSR0004227

4. Edited by Shuiping Jiang, ***Regulatory T Cells and Clinical Application***, Springer, 2008, New York, ISBN 978-0-387-77908-9. Chapter 21: Regulatory T Cells in Hepatitis and Hepatocellular Carcinoma, Fu-Sheng Wang and **George Fu Gao**.

5. Edited by Qinghua Wang, ***Influenza: Current Research***, Horizon Scientific Press and Caister Academic Press, 2015, USA. Avian Influenza H7N9 Virus, Ying Wu, Yi Shi, Jun Liu, Yan Wu and **George F Gao**.

中文书籍 (Book chapters in Chinese):

6. 曹雪涛主编, ***免疫学前沿进展(第一版)***, 人民卫生出版社, 2009, ISBN 987-7-117-12311-2. 第六章: 结构免疫学研究进展: 主要组织相容性复合物的分子识别, 施一, 刘军, **高福**。

   曹雪涛主编, ***免疫学前沿进展 (第二版)***, 人民卫生出版社, 2011, ISBN 978-7-117-14763-7. 第七章: 结构免疫学研究进展: 主要组织相容性复合物的分子识别, 施一, 刘军, **高福**。

7. U. 克拉格 (U. Kragl) [德]主编, 曹竹安 主译, **高福** 主校, ***生物技术产业化—从实验室到工厂到产品***, 应用生物技术大系, 科学出版社, 2008, ISBN 978-7-03-021732-5。

8. 谢克特 (M. Schaechter) 编, **高福**, 黄力, 谭华荣 主编译, ***微生物学案头百科 (The Desk Encyclopedia of Microbiology)***, 英文原版名著中文导读系列, 科学出版社, 2006, ISBN 7-03-016711-2。

9. A. D. 莱曼 (A. D. Leman) 主编, 刘文军, 张仲秋, 狄伯雄, 陈德威, 唐桂运, **高福**, 贾人雄等 主译校, ***猪病学 (第六版)***, 北京农业大学出版社, 1990, 北京。

10. B. W. 卡尔尼科 (B. W. Calnek) 主编, **高福**, 刘文军 主译, 郭玉璞, 狄伯雄 主校, ***禽病学 (第九版)***, 北京农业大学出版社, 1991.11, 北京。

    第 10 和 11 版的翻译:

    B. W. 卡尔尼科 (B. W. Calnek) 主编, **高福**, 苏敬良主译, 郭玉璞, 狄伯雄 主校, ***禽病学 (第十版)***, 中国农业出版社, 1999.10, 北京。

    Y. M. 赛弗 (Y. M. Saif) 主编, 苏敬良, **高福**, 索勋主译, 郭玉璞 主校, ***禽病学 (第十一版)*** (世界兽医经典著作译丛), 中国农业出版社, 2005.1, ISBN 7-109-09486-3, 北京。

11. 郭德明, **高福** 编, ***病毒学家---田波院士***, 武汉大学出版社, 2011, 武汉。

UCDUSR0004228

12. 彼得•杜赫提 (Peter Doherty) 著，与颖，孙业平译，高福，徐小宁审校，***通往诺贝尔奖之路***，科学出版社，2013，北京。

13. 余宏杰 主编，**高福** 主审，***埃博拉出血热公众防护问答***，科学普及出版社，2014，北京。

14. 余宏杰 主编，**高福** 主审，***中东呼吸综合征公众防护问答***，科学普及出版社，2015，北京。

15. 余宏杰 主编，**高福** 主审，***寨卡病毒病公众防护问答***，科学普及出版社，2016，北京。

UCDUSR0004229

NATIONAL ACADEMY OF MEDICINE
Proposal for Nomination

Candidate's Name	George Fu Gao
Primary Affiliation:	Institute of Microbiology, Chinese Academy of Sciences; Chinese Center for Disease Control and Prevention (China CDC), China
Demographics:	REDACTED
Geographic Location:	
Age:	
Subject Emphasis	This info is not yet available for this year's nominations, but I will get it to you as soon as it comes out.
Sponsors:	Jonna Mazet, University of California, Davis; David Ho, Aaron Diamond AIDS Research Center, Rockefeller University
Professional Title:	Professor and General, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences; Director-General, China CDC
Address:	REDACTED
Phone:	REDACTED Fax: REDACTED
E-mail:	gaof@im.ac.cn
Type of Nomination:	√Regular/66+/Intl Section/Subsection: (#)/(x) Bridging Section(s): (#)

PAST AND POTENTIAL CONTRIBUTIONS TO NAM: [~6 lines]

Gao has been an excellent coordinator for the scientific research between the US and China scientists, for which has already organized the collaborative work on avian influenza, new bunyavirus and Ebola virus with institutions from US-CDC, NIH and etc. As a leading scientist in public health in China, he has been playing a key role in the joint efforts for the disease control. Gao has been involved in many scientific activities organized by NAM/NAS, e.g., financing global pandemic response (Aug 25-28, 2015, DC); Gain of function (GOF) research (Mar 10-11, 2016 DC). Gao will continuously be an important figure for the NAM interests.

CITATION OF ACCOMPLISHMENT: (50-WORDS):

Using interdisciplinary methods, including virology, immunology and structural biology, Gao has made remarkable contributions to the study of pathogen infection, and interspecies transmission and pathogen-host interaction. His work revealed the origin and interspecies transmission mechanism of important pathogens including avian influenza virus, MERS-CoV, Zika and Ebola virus, etc. He is a leading figure for the control of infectious diseases in China and a world advocate of global public health strategy.

PROPOSERS' STATEMENT: [~13 lines]

Gao has pioneered the research work of origins, interspecies transmission and pathogenesis mechanisms of emerging pathogens- influenza and coronavirus in particular-molecular basis of pathogen "host jump", virus entry/release and host T-cell molecular recognition by using interdisciplinary methods, inc., phylogeny, virology, immunology and structural biology and has made remarkable contributions. His related work includes: **Molecular basis of host "jump"** of zoonotic pathogens, including influenza, MERS-CoV, Ebola and Zika virus etc., providing insights into vaccine and therapeutic agent development. **Discovery of emerging pathogens**, new pathogen-infected hosts and new disease forms of infectious diseases and molecular epidemiology and virus evolution, etc. **Molecular basis of T/NK cell immune recognition**, which leads to new therapeutic ideas to be

developed. A new ELISPOT-based TB diagnostic kit, now widely used in China. Most recently, his group has made a great contribution for our understanding of **Zika disease**, inc., mouse testis damage and infertility, human monoclonal antibodies and virus protein structures. He is always in the frontline on war against emerging pathogens and a leading figure for the control of infectious diseases in China and a world advocate of global public health strategy. His heroic work in leading China Mobile Laboratory Testing Team to fight against Ebola in Sierra Leone in 2014 was highly appreciated worldwide.

PRIMARY FIELD & AREA OF SPECIALIZATION OR EXPERTISE: [~3 lines]

Mechanisms of interspecies transmission ("host jump") of pathogens, especially interaction between the enveloped viruses and host cells, and molecular immune recognition, and public health policy and global public health strategy.

CURRENT EMPLOYMENT: [up to 3]

REDACTED

PRINCIPAL PREVIOUS EMPLOYMENT: [up to 3]

REDACTED

RESIDENCIES OR FELLOWSHIPS: [up to 5]

REDACTED

EDUCATION: [up to 3, highest first]

REDACTED

PRINCIPAL HONORS, AWARDS: (~6 lines)

Thompson Reuters Research Front Award, 2008
Visiting Professor, Oxford University, 2010-now
TWAS Prize in Medical Sciences, 2012 (TWAS, The Third World Academy of Sciences)
(Japan) Nikkei Asia Prize (19th), 2014
Honorary Professor, The University of Hong Kong, 2016-
Wu Jieping-Paul Janssen Medical & Pharmaceutical Awards, 2015

CURRENT MAJOR GRANT(s): (~2 lines)

Mega-project for Ebola, avain flu, The National Natural Science Foundation of China (NSFC)
The China Ministry of Science and Technology National 973 Project

MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:

[~5 lines]

President, Chinese Society of Biotechnology (CSBT)
President, Asian Federation of Biotechnology (AFOB)
Vice President, Chinese Medical Association (CMA)
Immediate Past-President, Chinese Society of Virology
Board of Directors, Pasteur Institut Shanghai

SELECTED BIBLIOGRAPHY (10 entries)

Year	Details of Publication
1997	**Gao, G.F.**, Tormo, J., Gerth, U. C., Wyer, J. R., McMichael, A. J., Stuart, D. I., Bell, J. I., Jones, E. Y. and Jakobsen, B. K., 1997, Crystal structure of the complex between human CD8αα and HLA-A2. ***Nature***, 387: 630-634. (With a front cover illustration and a short title in the front cover page: CD8 comes to grips with MHC) (Gao as first author)
2001	Meng, S. D., Gao, T., **Gao, G. F.** and Tien, P., 2001, HBV-specific peptide associated with heat-shock protein gp96. ***The Lancet***, 357 (9255): 528-529. (Gao supervised the project and wrote the paper)
2005	Liu*, J., Xiao, H., Lei, F., Zhu, Q., Qin, K., Zhang, X. W., Zhang, X. L., Zhao, D., Wang, G., Feng, Y., Ma, J., Liu, W., Wang, J. and **Gao*, G. F.**, 2005, Highly pathogenic H5N1 influenza virus infection in migratory birds. ***Science***, 309 (5738): 1206. (Gao as one the two correspondence authors)
2013	Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H., Xu, K., Xu,X., Lu, H., Zhu, W., Gao, Z., Xiang, N., Shen, Y., He, Z., Gu, Y., Zhang, Z., Yang, Y., Zhao, X., Zhou, L., Li, X., Zou, X., Zhang, Y., Li, X., Yang, L., Guo, J., Dong, J., Li, Q., Dong, L., Zhu, Y., Bai, T., Wang, S., Hao, P., Yang, W., Zhang, Y., Han, J., Yu, H., Li, D., **Gao, G. F .**, Wu, G., Wang, Y., Yuan*, Z. and Shu*, Y., 2013, Human infection with a novel avian-origin influenza A (H7N9) virus. ***The New England Journal of Medicine***, 368: 1888-1897. (As deputy director-general of China CDC in charge of communicable diseases, Gao coordinated the investigation and co-wrote the paper)
2013	Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J., Zhang, B., Shi, Y., Yan, J. and **Gao*, G. F.**, 2013, Molecular basis of novel human coronavirus MERS-CoV bound to its receptor CD26. ***Nature***, 500 (7461): 227-231. (Gao as correspondence author)
2013	Zhang, W., Shi, Y., Lu, X., Shu, Y., Qi, J. and **Gao*, G. F.**, 2013, An airborne transmissible avian influenza H5 hemagglutinin seen at the atomic level. ***Science***, 340 (6139): 1463-1467. (Gao as correspondence author)
2013	Liu, D., Shi, W., Shi, Y., Wang D., Xiao, H., Li, W., Bi, Y., Wu, Y., Li, X., Yan, J., Liu, W., Zhao, G., Yang, W., Wang, Y., Ma, J., Shu*, Y., Lei*, F. and **Gao*, G. F.**, 2013, Origin and diversity of novel H7N9 avian influenza viruses causing human infections: phylogenetic, structural, and coalescent analyses. ***The Lancet***, 381 (9881): 1926-1932. (Gao as one of the three correspondence authors)
2015	Tong, Y.-G., Shi, W.-F., Liu, D., Bo, X.-C., Liang, L., Qian, J., Liu, J., Ren, H.-G., Fan, H., Ni, M., Sun, Y., Jin, Y., Teng, Y., Li, Z., Kargbo, D., Dafae, F., Kanu, A., Chen, C.-C., Lan, Z.-H., Jiang, H., Luo, Y., Lu, H.-J., Zhang, X.-G., Yang, F., Hu, Y., Cao, Y.-X., Deng, Y.-Q., Su, H.-X., Sun, Y., Liu, W.-S., Wang, Z., Wang, C.-Y., Bu, Z.-Y., Guo, Z.-D., Zhang, L.-B., Nie, W.-M., Bai, C.-Q., Sun, C.-H., An, X.-P., Xu, P.-S., Zhang, X.-L.-L., Huang, Y., Mi, Z.-Q., Yu, D., Yao, H.-W., Feng, Y., Xia, Z.-P., Zheng, X.-X., Yang, S.-T., Lu, B., Jiang, J.-F., Kargbo, B., He*, F.-C., **Gao*, G. F.**, Cao*, W.-C. and The China Mobile Laboratory Testing Team in Sierra Leone, 2015, Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. ***Nature***, 524 (7563): 93-96. (Gao as one of the three correspondence authors)

2016 Wang, H., Shi, Y., Song, J., Qi, J., Lu, G., Yan, J. and **Gao*, G. F.**, 2016, Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. ***Cell***, 164: 258-268. (Gao as correspondence author)

2016 Ma, W., Li, S., Ma, S., Jia, L., Zhang, F., Zhang, Y., Zhang, J., Wong, G., Zhang, S., Lu, X., Zhang, H., Yan, J., Li, W., Qin, C., Han, D., Qin, C., Wang, N., Li*, X. and **Gao*, G. F.**, 2016, Zika virus causes testis damage and leads to male infertility in mice, ***Cell***, 167 (6): 1511-1524. (Gao as one of the two co-correspondence authors)

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: George F GAO <gaof@im.ac.cn>
CC: baiyu <baiyu@im.ac.cn>
Sent: 10/9/2017 8:16:13 PM
Subject: Re: Re: Re: Re: National Academy of Medicine

Thanks, George.
I'm headed to Washington DC this weekend to the National Academy meeting, where I will propose your nomination to the head of the section for political support.
All is going well -- hope you are doing great,
Jonna

On Mon, Oct 2, 2017 at 12:41 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Here is another document related to your nomination.

All the best

George

-----原始邮件-----
发件人:"George F GAO" <gaof@im.ac.cn>
发送时间:2017-09-18 05:53:42 (星期一)
收件人: "Jonna Mazet" <jkmazet@ucdavis.edu>
抄送: baiyu <baiyu@im.ac.cn>
主题: Re: Re: Re: National Academy of Medicine

Dear Jonna,

Here are the tentative filled form and my updated publication list.

Many thanks and do let me know if you need anything more.

All the best

George

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-09-11 23:59:08 (星期一)
收件人: "George F GAO" <gaof@im.ac.cn>
抄送:
主题: Re: Re: National Academy of Medicine

Great news -- I'll contact him.
It would be good if I could get the materials by end of October. Will that work for you?

Have a good day,
Jonna

On Sat, Sep 9, 2017 at 7:39 AM, George F GAO <gaof@im.ac.cn> wrote:

Jonna,

David Ho is a good seconder in Section 2. He knows me very well.

Director and Chief Executive Officer
The Aaron Diamond AIDS Research Center
The Rockefeller University

Regular, 2c

Elected 1997

Male

New York

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-06-30 10:07:32 (星期五)
收件人: gaof <gaof@im.ac.cn>
抄送:
主题: Re: National Academy of Medicine

Hi George,
How are you? Hope all is well there. Attached, you will find the current listing of all of the Section 2 members. Please have a look and let me know which of them you think might be willing to be a co-nominator(s) for your submission. As I said, I am happy to nominate you for Section 10 with a cross-listing in Section 2, if we can find a good Section 2 member who will agree to co-nominate with me.

We will also need to submit all of the following information with the materials taking the following into consideration, in that the application must:
1. Convey this clearly: WHY SHOULD THE CANDIDATE BE AN NAM MEMBER?
a. The sections on sponsor statement, contributions (past/future), and citation are critical.
b. Identify candidate's impact in terms that are understandable to those less familiar with the field.
c. For international candidates: i. Place the candidate's accomplishments into the context of the national/regional/international sphere; ii. Note the level of prestige associated with institutions or prizes in the candidate's background that may be unfamiliar to others; iii. Where appropriate, use phrases such as: 1. …is the leader of Organization X, the most prestigious organization in this field in the nation/region 2. …is distinguished professor at X university, one of the top institutions in the nation/region 3. …is an internationally recognized leader in this field
2. Avoid these common errors in the candidate's personal information:
a. Missing or excessive contact information
b. Missing demographic information
c. Incorrect date of birth, citizenship information
3. Avoid these common errors in nomination details:
a. Wrong section or subsection
b. Missing bridging section where applicable
c. Institutional affiliation of both sponsors is the same as the candidate (at least one must be from an entirely separate institution)

& >10 (maximum allowed) bibliographic citations

In addition to a co-nominator, I will need the following information in a Word document:

CANDIDATE: Name, Credentials, Institution

Type of Nomination: Regular/66+/Intl Section/Subsection: (#)(s) Bridging Section(s): (#)

Demographics: ① Female ② Racial & Ethnic Diversity

Geographic Location: [state/country] Age: [effective October 1]

Subject Emphasis ③ This info is not yet available for this year's nominations, but I will get it to you as soon as it comes out.

SPONSORS: Name, Institution
Name, Institution

PAST AND POTENTIAL CONTRIBUTIONS TO NAM:
[~6 lines]

CITATION OF ACCOMPLISHMENT: (50 words)
PROPOSERS' STATEMENT:
[~13 lines]

PRIMARY FIELD & AREA OF SPECIALIZATION OR EXPERTISE:
[3 lines]

CURRENT EMPLOYMENT:
[up to 3]

PRINCIPAL PREVIOUS EMPLOYMENT:
[up to 3]

RESIDENCIES OR FELLOWSHIPS:
[up to 5]

EDUCATION:
[up to 3, highest first]

PRINCIPAL HONORS, AWARDS:
[~6 lines]

CURRENT MAJOR GRANT(s):
[~2 lines]

MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
[~5 lines]

SELECTED BIBLIOGRAPHY:
[up to 10 items]

Please let me know if you can provide the name and contact of a co-nominator and the information above, then we can move forward. We should aim to have the co-nominator on board and the materials all pulled together by November.

Hope to see you soon,
Joanna

On Mon, Jun 12, 2017 at 9:10 AM, gaof <gaof@im.ac.cn> wrote:
Joanna
Still have not got any news from you about the section classifications
Best
George

发自我的 iPhone

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Dear George,
Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate. I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
Hope you are well,
Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Hope this emial finds you well. I wonder if you have some time to find any our friends who is in Section 2 as we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: gaof <gaof@im.ac.cn>
CC: baiyu <baiyu@im.ac.cn>
Sent: 10/11/2017 2:26:42 AM
Subject: Re: National Academy of Medicine

Will do on Victor & deadline is usually Feb 1, but it is important to be ready for the meeting this weekend for discussion, which we are!
More soon,
Jonna

On Tue, Oct 10, 2017 at 2:36 AM, gaof <gaof@im.ac.cn> wrote:
Jonna
When is the nomination deadline this year ?
G

发自我的 iPhone George Gao

在 2017年10月10日，上午4:16，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Thanks, George,
I'm headed to Washington DC this weekend to the National Academy meeting, where I will propose your nomination to the head of the section for political support.
All is going well -- hope you are doing great,
Jonna

On Mon, Oct 2, 2017 at 12:41 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Here is another document related to your nomination.

All the best

George

-----原始邮件-----
发件人:"George F GAO" <gaof@im.ac.cn>
发送时间:2017-09-18 05:53:42 (星期一)
收件人: "Jonna Mazet" <jkmazet@ucdavis.edu>
抄送: baiyu <baiyu@im.ac.cn>
主题: Re: Re: Re: National Academy of Medicine

Dear Jonna,

Here are the tentative filled form and my updated publication list.

Many thanks and do let me know if you need anything more.

All the best

George

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-09-11 23:59:08 (星期一)
收件人: "George F GAO" <gaof@im.ac.cn>
抄送:
主题: Re: Re: National Academy of Medicine

Great news -- I'll contact him.
It would be good if I could get the materials by end of October. Will that work for you?
Have a good day,
Jonna

On Sat, Sep 9, 2017 at 7:39 AM, George F GAO <gaof@im.ac.cn> wrote:

Jonna,

David Ho is a good seconder in Section 2. He knows me very well.

Director and Chief Executive Officer
The Aaron Diamond AIDS Research Center
The Rockefeller University

Regular, 2c

Elected 1997

Male

New York

-----原始邮件-----
发件人:"Jonna Mazet" <jkmazet@ucdavis.edu>
发送时间:2017-06-30 10:07:32 (星期五)
收件人: gaof <gaof@im.ac.cn>
抄送:
主题: Re: National Academy of Medicine

Hi George,
How are you? Hope all is well there. Attached, you will find the current listing of all of the Section 2 members. Please have a look and let me know which of them you think might be willing to be a co-nominator(s) for your submission. As I said, I am happy to nominate you for Section 10 with a cross-listing in Section 2, if we can find a good Section 2 member who will agree to co-nominate with me.

We will also need to submit all of the following information with the materials taking the following into consideration, in that the application must:
1. Convey this clearly: WHY SHOULD THE CANDIDATE BE AN NAM MEMBER?
a. The sections on sponsor statement, contributions (past/future), and citation are critical.
b. Identify candidate's impact in terms that are understandable to those less familiar with the field.
c. For international candidates: i. Place the candidate's accomplishments into the context of the national/regional/international sphere; ii. Note the level of prestige associated with institutions or prizes in the candidate's background that may be unfamiliar to others; iii. Where appropriate, use phrases such as: 1. …is the leader of Organization X, the most prestigious organization in this field in the nation/region 2. …is

distinguished professor at X university, one of the top institutions in the nation/region 3. …is an internationally recognized leader in this field
2. Avoid these common errors in the candidate's personal information:
a. Missing or excessive contact information
b. Missing demographic information
c. Incorrect date of birth, citizenship information
3. Avoid these common errors in nomination details:
a. Wrong section or subsection
b. Missing bridging section where applicable
c. Institutional affiliation of both sponsors is the same as the candidate (at least one must be from an entirely separate institution)
d. >10 (maximum allowed) bibliographic citations

In addition to a co-nominator, I will need the following information in a Word document:

CANDIDATE: Name, Credentials, Institution

Type of Nomination: Regular/66+/3rd Section/Subsection: (#)/(c) Bridging Section(s): (#)

Demographics: ☒ Female ☒ Racial & Ethnic Diversity

Geographic Location: [state/country] Age: [effective October 1]

Subject Emphasis ☒ This info is not yet available for this year's nominations, but I will get it to you as soon as it comes out.

SPONSORS: Name, Institution
Name, Institution

PAST AND POTENTIAL CONTRIBUTIONS TO NAM:
[~6 lines]

CITATION OF ACCOMPLISHMENT: (50 words)
PROPOSERS' STATEMENT:
[~13 lines]

PRIMARY FIELD & AREA OF SPECIALIZATION OR EXPERTISE:
[3 lines]

CURRENT EMPLOYMENT:
[up to 3]

PRINCIPAL PREVIOUS EMPLOYMENT:
[up to 3]

RESIDENCIES OR FELLOWSHIPS:
[up to 5]

EDUCATION:
[up to 3, highest first]

PRINCIPAL HONORS, AWARDS:
[~6 lines]

CURRENT MAJOR GRANT(s):
[~2 lines]

MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
[~5 lines]

SELECTED BIBLIOGRAPHY:
[up to 10 items]

Please let me know if you can provide the name and contact of a co-nominator and the information above, then we can move forward. We should aim to have the co-nominator on board and the materials all pulled together by November.

Hope to see you soon,
Jonna

On Mon, Jun 12, 2017 at 9:10 AM, gaof <gaof@im.ac.cn> wrote:
Jonna
Still have not got any news from you about the section classifications
Best
George

发自我的 iPhone

在 2017年4月26日，下午2:41，Jonna Mazet <jkmazet@ucdavis.edu> 写道：

Dear George,
Sorry, I am in India now. As I mentioned when we were together, I am happy to nominate you in Section 10 with a cross listing in Section 2 if we can find someone in that section to co-nominate. When I am back in California, I can share some names in Section 2 for your consideration of who might be best to co-nominate. I can't nominate you in Section 2, only cross list you in Section 2. If that is acceptable, we can proceed. I do think that is the best plan, as I understand that primary Section 2 nominations are very conservatively applied and difficult to find success.
Let me know if this all sounds good to you, and I will send the list of some names when I return in a couple of weeks.
Hope you are well,
Jonna

On Tue, Apr 25, 2017 at 10:18 PM, George F GAO <gaof@im.ac.cn> wrote:

Dear Jonna,

Hope this emial finds you well. I wonder if you have some time to find any our friends who is in Section 2 as we discussed when you are in China. In addition to your nomination we might want to have someone from Section 2. Can you give me any furhter info?

All the best

From: David J Wolking <djwolking@ucdavis.edu>
To: Andrew Clements <aclements@usaid.gov>
CC: Jonna Mazet <jkmazet@ucdavis.edu>;Wolking David <djwolking@ucdavis.edu>;Karen L Wood <klwood@ucdavis.edu>;Alisa Pereira <apereira@usaid.gov>;Shana Gillette <sgillette@usaid.gov>
Sent: 11/14/2017 8:45:13 PM
Subject: Re: Brussels is a go!

Well that's exciting news!

On Tue, Nov 14, 2017 at 12:31 PM, Andrew Clements <aclements@usaid.gov> wrote:
Got a read from the people who wrote the conference language. There is an exception for "grants" which under their definition includes cooperative agreements. So you are good to go forward. Sorry for the unnecessary drama!

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From: Andrew Clements <aclements@usaid.gov>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: David J Wolking <djwolking@ucdavis.edu>;Amalhin Shek <ashek@usaid.gov>;Pereira, Alisa (GH/HIDN) <apereira@usaid.gov>;Shana Gillette <sgillette@usaid.gov>;predict@ucdavis.edu <predict@ucdavis.edu>;Brooke Genovese <bgenovese@ucdavis.edu>
Sent: 12/8/2017 6:36:53 AM
Subject: Re: Ebola funds

I asked Richard and Robbin to confirm that they are okay with the possible consequences of the shift. Let's wait to see how they respond.

On Fri, Dec 8, 2017 at 12:59 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:
I could do a quick call at 7:30 am my time (4:30 pm Geneva) or 11 am my time (8 pm Geneva) tomorrow.
Today was swamped, just getting back to email now.
Thanks,
J

On Thu, Dec 7, 2017 at 1:48 AM, Andrew Clements <aclements@usaid.gov> wrote:
Hi Jonna,

Sounds good. Let me know when you're available today (would have to be between 10:00 AM to 12:00 PM your time) or tomorrow.

Richard said several times yesterday that the country caps have been removed. I did not discuss it with him to verify that it means what I think it means. I will try to get him to put in writing exactly what he means about the caps being removed.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Dec 7, 2017, at 12:13 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

We'll need a call to discuss the potential consequences for other countries of this kind of planning, especially with the imposed country caps. With the constraints your system has contrived, there are complex planning and accounting pieces involved with those kind of swaps that leave other countries out of funds and under their caps if promises for the future are not kept.
Jonna

On Wed, Dec 6, 2017 at 8:50 AM, Andrew Clements <aclements@usaid.gov> wrote:
Hi Jonna,

Just had a phone call with Richard asking if you wanted to redistribute your existing Ebola pipeline among countries so that you do not run out of funds in Guinea, Liberia, and Sierra Leone while other countries still have funds. I think in his ideal world, most/all countries would be a similar position in terms of the percentage of their obligated funds that have been expended.

He indicated that new Ebola funding would not be considered for obligation until the previously-obligated Ebola funds have reached about a 75% expenditure rate. (We wouldn't need to wait until you hit 75% expenditures to start the process of requesting the new obligation; in theory, with advanced information from PREDICT on when that threshold will be met, USAID could be ready to do the obligation when that date arrives.)

Your thoughts?

1-571-345-4251
a.clements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see http://www.usaid.gov/ept2/

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4251
E-mail: a.clements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see http://www.usaid.gov/ept2/

From: Andrew Clements <aclements@usaid.gov>
Sent: Wed, 24 Jan 2018 11:56:33 +0100
Subject: Re: PREDICT International Travel Requests
To: Katherine Leasure <kaleasure@ucdavis.edu>
Cc: PREDICTMGT <predictmgt@usaid.gov>, Predict inbox <predict@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>

Approved, subject to mission concurrence.

On Wed, Jan 24, 2018 at 2:27 AM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

Please find below international travel requests for your review and approval. Please let me know if you have any questions. Thanks!

1. Belkhiria (Guinea): $650 airfare/$327 (Conakry) max daily per diem

2. Karesh, Laudisoit, Gutierrez-Jimenez (RoC): $2,500 Economy, $7,500 Business **required for Dr. Karesh due to* REDACTED $392 (Brazzaville) max daily per diem

3. Francisco, Hagan, Epstein, Watson (Bangladesh): $1700 airfare each/$290 (Dhaka), $144 (Other) max daily per diems

4. Dawson (Jordan): $1100 airfare/$390 (Amman) max daily per diem

Travel Requests –

1. UC Davis would like to request travel approval for Dr. Jaber Belkhiria to travel from Tunis, Tunisia to Conakry, Guinea from February 12-26, 2018 to coordinate a laboratory training and field sampling.

Trip Purpose: In Conakry, Dr. Belkhiria will assist and coordinate the laboratory training at the Viral Hemorrhagic Fever Laboratory which will include staff from UC Davis [Dr. Alexandrew Tremeau-Bravard], staff from the Laboratoire Central de diagnostique Vétérinaire and Laboratory of National Institute of Public Health. In Nzerekore, Dr. Belkhiria will assist and coordinate the field sampling.

2. EcoHealth Alliance would like to request travel approval for William Karesh, Anne Laudisoit and Leticia Gutierrez-Jimenez to travel from New York City, NY, USA to Brazzaville, Republic of Congo from February 24 to March 2, 2018 to meet with PREDICT Republic of Congo project collaborators and local ministry officials.

Trip purpose: Drs. Karesh, Laudisoit and Gutierrez-Jimenez will be attending meetings with collaborators now that subawards have been approved to discuss plans for animal sampling and evaluate the laboratory by testing equipment for quality assurance. There will also be meetings with the ministries of Health and Agriculture to finalize working agreements.

3. EcoHealth Alliance would like to request travel approval for Dr. Leilani Francisco, Emily Hagan, Dr. Jon Epstein, and Brooke Watson to travel from New York City, NY, USA to Dhaka, Bangladesh, from March 8-16, 2018, to conduct human surveillance site visits with the local PREDICT human surveillance team and other implementing partners.

Trip Purpose: In their roles as Global Director of Behavioral Risk Surveillance for PREDICT-2, Behavioral Risk Research Coordinator, Country Lead for Bangladesh for PREDICT-2, and Research Scientist, respectively, Dr. Francisco, Ms. Hagan, Dr. Epstein, and Ms. Watson will be meeting with implementing partners, key stakeholders, and surveillance team members in community and hospital sampling sites in Bangladesh to review current practices and to provide guidance and support in ensuring robust adherence to the data collection protocol. Dr. Francisco, Ms. Hagan, Dr. Epstein, and Ms. Watson will be meeting extensively with the members of the country team involved in human surveillance to identify topics or areas of concern with regard to data collection and analysis, and to provide refresher trainings accordingly.

4. EcoHealth Alliance would like to request travel approval for Patrick Dawson to travel from New York City, NY, USA to Amman, Jordan from March 8-14, 2018 to train the PREDICT Jordan human community surveillance team on two new modules being implemented for Year 4.

Trip Purpose: Mr. Dawson will train the PREDICT Jordan human community surveillance team in administering two new modules (camel exposure module & camel work module) which are planned for immediate implementation following IRB approval. These new modules are developed specifically for Jordan to provide key epidemiological data to address hypotheses about the risk of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) from different exposure types to camels, as well as inform the Jordanian health community about which biosafety measures would be easiest to implement for those who work with camels to reduce their risk of viral infections from camels. Mr. Dawson developed the new modules and will need to train the Jordan team on how to integrate the new modules into their work flow, how to properly follow the skip patterns in the questionnaire, how to perform data quality checks, and how to store the data.

Katherine Leasure

HR/Payroll/Financial Assistant

One Health Institute

University of California, Davis

530-752-7526

530-752-3318 FAX

kaleasure@ucdavis.edu

—
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit
https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/055a01d394b2%247b174b10%247145e130%24%40ucdavis.edu

--

Andrew Cunningham, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: acunningham@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see: http://www.usaid.gov/ept2

From: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
To: David John Wolking <djwolking@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>
Subject: RESPONSE FOR ANDREW: ADS 253- TraiNet?
Sent: Mon, 14 May 2018 16:00:53 +0000

Response for Andrew:

Hi Andrew. ADS 253 states that individuals who USAID sponsors for "Participant Training" **must not** be working under a competitively awarded USAID cooperative agreement or sub-agreement, grant or sub-grant. Seeing as how PREDICT-2 is funded via a cooperative agreement (and numerous subawards under that agreement), training of project staff and affiliates conducted under the P2 CoAg would not be considered "Participant Training" and would not require TraiNet entry.

Elizabeth Leasure
Financial Operations Manager
One Health Institute
REDACTED *(cell)*
530-754-9034 (office)
Skype: ealeasure

From: Andrew Clements [mailto:aclements@usaid.gov]
Sent: Monday, May 14, 2018 6:46 AM
To: Elizabeth Leasure; David John Wolking
Cc: Jonna Mazet
Subject: Fwd: ADS 253- TraiNet?

I think you've answered before that this doesn't apply to cooperative agreements (or something like that). Is that correct?

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov
Begin forwarded message:

From: Angela Wang <awang@usaid.gov>
Date: May 14, 2018 at 10:17:06 AM GMT+2
To: Andrew Clements <aclements@usaid.gov>, Marilyn Crane <mcrane@usaid.gov>, Nadira Kabir <nkabir@usaid.gov>, Ricardo Echalar <rechalar@usaid.gov>
Cc: Amalhin Shek <ashek@usaid.gov>, Alisa Pereira <apereira@usaid.gov>
Subject: ADS 253- TraiNet?

Hi AORs,

Do you know if your projects are in compliance with ADS 253 (required learning activities have been correctly inputted into TraiNet/VCS systems)? I'm not sure if projects go through you to do this, so if you don't know, can you please ask?

It is one of the questions we need to answer for the RDMA portfolio review sheets I'm helping them with this week.

Thanks!
Angela

--
Angela Wang, MMPH
Public Health Advisor
Emerging Threats Division, Office of Infectious Disease
Bureau for Global Health, USAID/Washington

Phone: 571-531-7832 (O) [redacted] (C)
Email: [redacted]

From: Peter Daszak <daszak@ecohealthalliance.org>
To: Jaber Belkhiria <jabelkhiria@ucdavis.edu>, Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, "David John Wolking" <djwolking@ucdavis.edu>, Predict inbox <predict@ucdavis.edu>, "Noam Ross" REDACTED Aleksei Chmura <chmura@ecohealthalliance.org>, Anna Willoughby <willoughby@ecohealthalliance.org>, Noam Ross <ross@ecohealthalliance.org>
Subject: RE: FW: PREDICT Emerging Disease Insights - 2 pagers
Sent: Wed, 30 May 2018 21:52:07 +0000

Hi Jaber - Thanks for spotting these errors. I'm really surprised, because we used our translator from Cote d'Ivoire – who's great conversationally in meetings, but maybe he's not so good with the written docs that are heavy on the science!! It's good to know now because we were planning to use him for the bat book also...

I'll have Anne Laudisoit or Alice Latinne look them over and correct all the grammar/spelling etc and then re-circulate in a week or so. Both are francophone (Belgian) and in the office, so it'll be easy to do.

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
www.ecohealthalliance.org
@PeterDaszak
@EcoHealthNYC

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From: Peter Daszak <daszak@ecohealthalliance.org>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: William B. Karesh <karesh@ecohealthalliance.org>;Amanda Andre <amanda.andre@ecohealthalliance.org>;Alison Andre <andre@ecohealthalliance.org>;predict@ucdavis.edu <predict@ucdavis.edu>
Sent: 6/5/2018 6:59:44 PM
Subject: Brown bag at USAID end July/early August w Andrew C and USAID

Hi Jonna

I just realized that Billy and I will be in DC for a Blue Ribbon Panel meeting on Tuesday, July 31st. I don't know what dates we're going to settle on for meetings w/ Andrew Clements, but maybe Monday July 30th or Wed August 1st would work for a brown bag on EID modeling/mapping?

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
www.ecohealthalliance.org
@PeterDaszak
@EcoHealthNYC

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From: Oyewale Tomori [redacted]
Sent: Mon, 2 Jul 2018 21:28:43 +0100
Subject: Re: Time Sensitive - Response to recent Commentary in Nature on the GVP
To: Peter Daszak <daszak@ecohealthalliance.org>
Cc: Cara Chrisman <cchrisman@usaid.gov>, "Morzaria, Subhash (TCE)" [redacted], Jonna Mazet <jkmazet@ucdavis.edu>, "George F Gao (gaof@im.ac.cn)" <gaof@im.ac.cn>, Carlos Morel [redacted] "Subhash P Morzaria [redacted], Ariel Pablos-Mendez [redacted] "ap39@cumc.columbia.edu" <ap39@cumc.columbia.edu>, Nathan Wolfe <nwolfe@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, "Dennis Carroll (DCarroll@usaid.gov)" <DCarroll@usaid.gov>, Brooke Watson <watson@ecohealthalliance.org> [redacted], Hongying Li <li@ecohealthalliance.org>

Thanks Peter
Regards
Oyewale

Oyewale TOMORI
Tel: [redacted]

On Sun, Jul 1, 2018 at 11:26 PM, Peter Daszak <daszak@ecohealthalliance.org> wrote:

Dear All,

Just to let you know that I did submit the response to Holmes *et al*. I checked in with *Nature* and they only allow 300 words, normally 3 authors for a response to a comment, and usually no figures. I included all of your comments then edited back to 435 words, and included a figure and all of us as authors – let's see how it goes. Note that I've toned down some of the rhetoric to try and take the 'high road' and keep this as a scientific debate rather than a snarky exchange…I've attached the as-submitted text above.

Also – you should know that I gave a talk at the Pasteur Institute, Paris last week at a 1918 flu centenary event. Eddie Holmes spoke after me on the topic "The Fallacy of Predicting Emerging Diseases". I've known Eddie for many years, and he'd submitted that talk a few months earlier, so it wasn't necessarily a direct swipe at the GVP. He also sent me a polite email the day before apologizing for the aggressive title and commenting that he would only show one slide critiquing the GVP.

All that said, I spoke first and gave a solid rebuttal to his critique, including pointing out that he inflated the GVP costs 42 times. I also listed out a series of ways the GVP will target sampling to increase likelihood of finding important viruses, and a series of direct benefits we can expect to public and livestock health. It went down well, and although I'm sure Eddie Holmes was less critical because I was in the room, his response was amicable and polite …

Let's see what the response is from *Nature*, and if they aren't willing to publish our response, I'll get ready to maybe expand our arguments and submit as a commentary to another journal.

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

Tel. +1 212-380-4474

www.ecohealthalliance.org

@PeterDaszak

@EcoHealthNYC

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From: Cara Chrisman [mailto:cchrisman@usaid.gov]
Sent: Tuesday, June 19, 2018 9:44 AM
To: Morzaria, Subhash (TCE)
Cc: Jonna Mazet; Peter Daszak; George F Gao (gaof@im.ac.cn); Carlos Morel; Subhash P Morzaria [redacted] Ariel Pabios-Mendez; Oyewale Tomori; ap39@cumc.columbia.edu; Nathan Wolfe; Eddy Rubin; Dennis Carroll (DCarroll@usaid.gov); Brooke Watson [redacted] Hongying Li
Subject: Re: Time Sensitive -Response to recent Commentary in Nature on the GVP

Hi Peter,

This is past the deadline, but if you're still compiling edits, I've attached another draft with additional edits building off of what Subhash shared on Saturday.

Best,

Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health

U.S. Agency for International Development (USAID)

Desk: (571) 551-7413
Cell: REDACTED
E-mail: cchrisman@usaid.gov

On Sat, Jun 16, 2018 at 11:42 AM, Morzaria, Subhash (TCF) REDACTED wrote:

Dear Peter,

I have inserted my comments in track changes mode in the same the document (see attached) that Jonna has used. Excellent work and hope that this time the response will be published.

I think that the key message that is clearly coming through is that GVP does not preclude the various ongoing surveillance programs. The GVP actually will enhance these efforts through availability of better, and more improved diagnostics enabling early detection of spill over events of a whole range of new and existing viruses, that has not been possible before. This will also result in dramatically more cost effective early response capabilities of emerging and re-emerging infectious diseases.

With best regards,

Subhash

From: REDACTED **On Behalf Of** Jonna Mazet
Sent: Friday, June 15, 2018 9:16 PM
To: Peter Daszak <daszak@ecohealthalliance.org>
Cc: George F Gao (gacf@im.ac.cn) <gacf@im.ac.cn>; Carlos Morel REDACTED; Morzaria, Subhash (TCF) REDACTED; Subhash P Morzaria REDACTED; Ariel Pablos-Mendez REDACTED; Oyewale Tomori REDACTED; ap3@cumc.columbia.edu; Nathan Wolfe <nwolfe@metabiota.com>; Eddy Rubin <erubin@metabiota.com>; Dennis Carroll (DCarroll@usaid.gov) <DCarroll@usaid.gov>; Brooke Watson <watson@ecohealthalliance.org>; Cara Chrisman <cchrisman@usaid.gov> REDACTED Hongying Li <li@ecohealthalliance.org>
Subject: Re: Time Sensitive -Response to recent Commentary in Nature on the GVP

Very nicely done!

Thank you and Brooke for the heavy-lifting.

I have suggested some insertions and added a comment that I think we might want to address.

Funnily, I was having a chat with Julie Segre (NIH), who didn't know I was involved with the GVP, at the Forum. She asked me if I had seen the Holmes et al. article. I said that I had. She said, didn't you think that was a silly (inferred pathetic) foot stomping from one research group just jealous of another. I laughed & told her that I was from the conceptual other. We had a good giggle. Her general tenor was that NIH, including NIAID, think the GVP is a good idea, and then she offered collaboration for sequencing.

Really appreciate the good work,

Jonna

On Mon, Jun 11, 2018 at 8:54 AM, Peter Daszak <daszak@ecohealthalliance.org> wrote:

Dear Co-authors,

Some of you have already seen a critique of predictive approaches to pandemic prevention that cites our GVP paper and was published in *Nature* last week:

https://www.nature.com/articles/d41586-018-05373-w

I feel that it is important to respond, given the high profile nature of the journal, and the inaccuracies of assumptions and analysis this article contains. Brooke, Dennis and I have therefore drafted a response that we'd like you to look at. There are three key issues we highlight:

1. That the surveillance vs. prevention argument is a false dichotomy

2. Inaccurate comparison of GVP vs. other budgets (and please look at the PDF file that re-creates the Figure from the *Nature* Comment).

3. Direct value of GVP data for mitigating outbreaks

Please read the response, make very brief edits, and let us know if you will join as an author. I'm hoping to respond rapidly, **so if you can get any comments back by Friday 15th June (This Friday), that would be much appreciated!!**

We will then circulate further to the SC of the GVP to see if others will also sign on to this.

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

Tel. +1 212-380-4474

www.ecohealthalliance.org

@PeterDaszak

@EcoHealthNYC

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From: Peter Daszak
Sent: Thursday, March 22, 2018 12:37 PM
To: 'George F Gao (gaof@im.ac.cn)'; 'Carlos Morel'; 'Subhash (FAO/RAP) Morzaria [REDACTED]'; 'Subhash P Morzaria [REDACTED]'; 'Ariel Pablos-Mendez'; 'Oyewale Tomori'; 'ap39@cumc.columbia.edu'; 'Dennis Carroll (DCarroll@usaid.gov)'; 'Nathan Wolfe'
Cc: 'Jonna Mazet'; Brooke Watson; 'Cara Chrisman'; [REDACTED] Hongying Li
Subject: Time Sensitive - another letter to Science about the GVP - Needs your response
Importance: High

Dear Co-authors,

We've now received a 'letter' about our Science paper (see attachment 'aat5918_Other_seq1_vq.doc'). As you'll see, this is from the same authors as the 'Technical Comment' that we already responded to. I checked with Science, and they have asked us to respond, so I drafted a response (attached) which Jonna has helped with. I now need all of you to read the response, then either agree to be an author of that response and send me any edits or comments, or decline to be listed as an author.

Note that we are allowed 600 words maximum and 10 references. We're currently at ~560 words, so please don't add a lot of text!

Also, like the Technical Comment, Science editors often will choose not to publish the correspondence, but in this case, if they do it will appear in the journal in print. I've therefore argued back strongly against the points raised by these authors, and made sure to focus the response back onto the GVP (and away from PREDICT), so we get value if it is published.

Please can I ask all of you to respond by email ASAP, and certainly by **5pm Monday March 26th**.

At that point, I'll insert edits, confirm authorship and send this back to Science for them to decide on the merits of the discussion, ahead of the deadline.

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

Tel. +1 212-380-4474

www.ecohealthalliance.org

@PeterDaszak

@EcoHealthNYC

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From: Andrew Clements <aclements@usaid.gov>
Sent: Thu, 2 Aug 2018 08:40:51 -0700
Subject: Re: Re-Allocating GHSA Country Levels
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Amalhin Shek <ashek@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, David John Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>, Hannah R Chale <hrchale@ucdavis.edu>, Alisa Pereira <apereira@usaid.gov>

Hi Liz
Can we walk through this later today (before 4:00 EDT) to make sure we are all on the same page?

Thanks

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Aug 1, 2018, at 4:55 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Andrew. I spoke with Jonna, and we are supportive of the arguments you presented for the obligation of the last $3M. With our proposed reallocations, all Ebola-funded countries are on track to spend out by Sept 2019, and no single country has a pipeline that exceeds the number of months remaining in the PREDICT-2 performance period. These changes were determined through an extensive and carefully thought out exercise using actual and projected Y4 costs and requested Y5 budgets, and substantial amounts of funds were moved from several non-EHP countries, including Cameroon, Ethiopia, Tanzania, and Uganda. As it is, we have had to go back to partners and ask them to cut their budgets for Y5 in order to stay within the $56.3M overall cap on Ebola funds.

As of the LOP expenditure report through June 2018, we have already spent the full $12M obligated for EHP to date, as well as approximately half of the last $3M that is pending obligation. Furthermore, our projections indicate that the full $15M for EHP (which includes funds obligated to date plus the pending $3M) will be spent out by the end of September 2018.

To clarify, are you are proposing to move $2M from non-EHP to EHP countries instead of the $4.149M we proposed as an interim measure while you work on the obligation of the last $3M or in place of our requested reallocations? Given that the EHP cap is a minimum spending cap, I don't see any major issues with your proposal as long as this course of action won't result in new country-specific caps, meaning we will have some flexibility with regard to shifts among the Ebola-funded countries as previously specified.

As always, thank you for your continued support and efforts to get the funding we need to complete the project. If there is anything I can do or further information I can provide to assist with this, please let me know.

Thanks,

Liz

From: Andrew Clements <aclements@usaid.gov>
Sent: Tuesday, July 31, 2018 10:10:17 AM
To: Jonna Mazet
Cc: Elizabeth Leasure; Amalhin Shek; predict@ucdavis.edu; PREDICTMGT; David John Wolking; Cara Chrisman; Hannah R Chale; Alisa Pereira
Subject: Re: Re-Allocating GHSA Country Levels

Thanks, Jonna. I appreciate the additional input.
Our strongest argument for getting the additional 3M is:

1) if all of the countries have 17 months of pipeline or less (which means they are on track to spend all funds by 9/30/18).

AND

2) the 3 EHP countries currently have 12 months of pipeline or less (so that adding the 3M won't cause any of them to exceed 17 months of pipeline).

I believe #2 is no problem, but Ethiopia and Uganda both have pipelines of 20 or more months which looks like they will not be able to spend down completely. (If this is incorrect, please let us know.) I'm not sure we can avoid "moving" funds from these countries to others while still trying to make an argument for the new 3M.

To me, the least disruptive fix (in terms of number of countries with budget/agreements to be adjusted) is to move 500,000 from Ethiopia and 1,500,000 from Uganda (which would effectively reduce both of their pipelines to 15 months) and combine it with the new 3,000,000 for distribution to the 3 EHP countries as follows: country totals for Guinea and Liberia each increase by 1,500,000 and Sierra Leone increases by 2,000,000.

Overall, all countries would now have pipelines less than 17 months (less than 11 months for the 3 EHP countries) and budgets/agreements would only have to be adjusted for 5 countries. I would be happy to grant an extension for submitting work plans for those 5 countries.

Let me know how this sounds.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infections Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jul 31, 2018, at 9:28 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Hi Andrew,
> You can, of course, do that, but it will potentially rock our whole workplanning effort and schedule, since we have been aligning country workplans with these levels, as instructed when we started the workplanning process. Additionally, we were given explicit instructions that those country caps are no longer in play, except for the Ghana & DRC combined maximum.

If you think it best for you to try the exercise and see what we can do with your projections, fine, but I don't want to go back to the drawing board on the workplans and with Missions unless absolutely necessary. The numbers we provided to you represent bare bones budgets for actual plans in all of the other Ebola-funded countries.
As discussed previously, if those funds, that allow us to achieve our intended scope, are not forthcoming, we will need time to do layoffs according to specific country rules, etc. And as you promised, we will expect that USAID will assume the responsibility of informing the Missions and partners that we will end early and will take responsibility and deal with the fall-out.
From my perspective, the EHP countries and that part of the project were the ones that were told that P-2 may not be able to continue, because the yet-to-be received funds were targeted for them. In addition, despite funding level ambiguity, we have been trying to accommodate shifting goals for these three countries as USAID plans change and in response to GHSA targets. Therefore, while devastating for progress there, the three most Ebola affected countries are the ones that should either be funded or not this year in my opinion, which is informed by our instructions and planning and incremental funding distribution for EHP.
Appreciate your allowing me to provide my input to inform your discussion.
We, of course, defer to your collective wisdom on the way forward,
Jonna

On Mon, Jul 30, 2018 at 2:00 PM, Andrew Clements <aclements@usaid.gov> wrote:

Hi Liz,
We were discussing this among the management team and thought it would be confusing to the GHSA team to include the additional 3M.

So I propose that Alisa, Amalhin, and I sit down tomorrow and come up with some suggested country totals by shifting from countries that have expended a lower percentage of their funds to those that have expended a higher percentage. We'll share that with you to either get your blessing or for you to tweak if there are reasons our suggestions are not good. To minimize confusion, we're going to use the format that the GHSA team uses to track funding by country so that it's in their "language".

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jul 24, 2018, at 12:16 PM, Elizabeth Leasure <calcasure@ucdavis.edu> wrote:

Hi Amalhin and Andrew. After reviewing Y5 budgets received from partners and evaluating funding needs for each Ebola-funded country through the end of the project in 2019, we propose increasing the combined cap for the EHP countries by $4.149M to $19.149M (inclusive of the last $3M obligation that is currently pending) and increasing the combined cap for the Phase II countries by $335K to $9.335M. As a result of these increases, the combined cap for the non-EHP, Phase I Ebola-funded countries would decrease by $4.484M to $27.816M. Since we have been advised that only the combined caps for the EHP and Phase II countries are still in effect, we have not broken the requested changes down by country in an effort to avoid possible confusion and the erroneous application of these caps in the future.

A quick comparison of the revised EHP cap and the updated LOP expenditure figures for the EHP countries through June 2018 (comprehensive updated LOP expenditure by country report is forthcoming) shows that we have spent approximately 70% of the proposed revised EHP combined cap (inclusive of the last $3M obligation as noted above), which is in line with guidance received on our last SMT call. With regard to the small requested increase to the combined Phase II country cap, please note that the cap must be increased by the requested amount in order to continue activities through Y5 and wrap up the project by September 2019. Without the requested increase, activities in both countries would cease at the end of Y4.

Thank you for your consideration, and please let me know if you have any questions.

Thank you!

Liz

Elizabeth Leasure

Financial Operations Manager

One Health Institute

REDACTED *(cell)*

530-754-9054 (office)

Skype: ealeasure

From: Amalhin Shek <ashek@usaid.gov>
Sent: Thursday, June 21, 2018 11:12 AM
To: PREDICTMGT <predictmgt@usaid.gov>; Jonna Mazet <jkmazet@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Andrew <aclements@usaid.gov>; David John Wolking <djwolking@ucdavis.edu>; Cara Chrisman <cchrisman@usaid.gov>
Subject: Re-Allocating GHSA Country Levels

Hi team,

Per our last MT call, please see attached the tracker currently in use to document country level GHSA expenditures against obligation and planning levels. I have modified it to include a column for a new re-distribution of country levels, which should be updated based on planned implementation.

The GHSA team would like to receive the new distribution of budgets prior to receiving the

June 30 expenditure report, as this will prevent any concerns with those countries above 90% expended (column H).

As a heads up, I will be out of the country Starting next Monday through July 13, but Andrew, Alisa, or Cara will be able to answer or relay any questions related to country levels. Please let us know if you have any questions as you prepare this for submission before the as of June 30 LOP report!

Thanks in advance,

Amalhin Shah | **Budget & Communications Analyst**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
Phone: 571-551-7102(o)| REDACTED (c) | CP3 8092
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

USAID **Contractor**
GHSD-IIF - Social Solutions International, Inc.

From: Andrew Clements <aclements@usaid.gov>
Sent: Wed, 17 Oct 2018 12:42:14 -0700
Subject: Re: New article in Nature Biotechnology
To: Tracey Goldstein <tgoldstein@ucdavis.edu>
Cc: Dennis Carroll <DCarroll@usaid.gov>, Alisa Pereira <apereira@usaid.gov>, Cara Chrisman <cchrisman@usaid.gov>, Amalhin Shek <ashek@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <PREDICT@ucdavis.edu>

Thanks, Tracey.

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Oct 17, 2018, at 7:28 PM, Tracey Goldstein <tgoldstein@ucdavis.edu> wrote:

Dear Dennine, Andrew, Alisa, Cara and Amahlin,

Please find attached a new piece published in Nature Biotechnology this month featuring PREDICT and GVP among other things. Overall I think it nicely features and highlights our work, although they have some of the terminology a bit wrong.

https://www.nature.com/articles/nbt.4268#ref5

Best Tracey

--
Tracey Goldstein, PhD
One Health Institute
School of Veterinary Medicine
University of California
Davis, CA 95616
Phone: (530) 752-0422
Fax: (530) 752-3318
E-mail: tgoldstein@ucdavis.edu

From: Cara Chrisman <cchrisman@usaid.gov>
Sent: Mon, 4 Feb 2019 16:18:37 -0500
Subject: Re: Update: EHP Findings "to date" presentation -- Feb 7th
To: Alisa Pereira <apereira@usaid.gov>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Brian Bird <bhbird@ucdavis.edu>, Jon Epstein <epstein@ecohealthalliance.org>, Predict inbox <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Amalhin Shek <ashek@usaid.gov>, Cassandra Louis Duthil <clouisduthil@usaid.gov>
Directions to Global Health in Crystal City (1) (1).docx

Hi All,
Looking forward to seeing you then! My phone numbers are below and attached are directions, if needed (please note that the Au Bon Pain referenced is now closed, but it's across from the library).

Best,
Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
U.S. Agency for International Development (USAID) Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-8091A, Arlington, VA 22202
Desk: (571) 551-7413
Cell: REDACTED
E-mail: cchrisman@usaid.gov

GHSI-III - Social Solutions International, Inc. prime contractor

On Mon, Feb 4, 2019 at 4:15 PM Alisa Pereira <apereira@usaid.gov> wrote:

We needed to adjust the time so Senior Representatives from the Bureau could attend. The new start time for the presentation is 3:30. Please plan on arriving per the instructions below, except, ask the security guard to contact Cara Chrisman instead of texting me.
Please confirm this new time works for both Brian and Jon.

Thanks
Alisa
Sent from my iPhone

On Feb 4, 2019, at 9:48 AM, Alisa Pereira <apereira@usaid.gov> wrote:

We have secured a conference room, and Dennis' time (for the intro) for the meeting on Feb 7th at 1pm for the presentation on EHP findings. Brian and Jon, thank you so much for making yourselves available at such short notice.

We would greatly appreciate your help in preparing a very short intro blurb that we can circulate with the invitation.

I am copying Cassandra and Amalhin on this message too because they will be critical in the communication/logistical arrangements (including projecting the presentation, etc).

The presentation will be held in our Crystal City offices (2100 Crystal Drive, Arlington, Va 22202) at 1pm. You should plan to arrive earlier than that so get through security. When you arrive, please go to the 9th floor to the security office. Text me before you get in the elevator (202-997-9966), and I will meet you there to get you checked in.

Thank you again!!
Alisa

Alisa Pereira, Senior Public Health Advisor
USAID, Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-0001, Arlington, VA 22202
Phone:202-997-9966
Email: apereira@usaid.gov

GHSI-III - Social Solutions International, Inc. prime contractor

--

You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit
https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/CALRuqj8kafBDEH5JRDRxKUeYmMWhZtNMEoeO6-x4Bu3LFPz5pQ%40mail.gmail.com.

Directions to Global Health in Crystal City (CP3)

Driving

USAID's Global Health Bureau is located in Arlington, VA and the address is:

2100 Crystal Drive
Arlington, VA 22202

From Washington: As you enter Arlington, traveling South on Route 1 (Richmond Highway), turn left onto 20th Street S.

From Virginia: As you enter Arlington, traveling North on Route 1 (Richmond Highway), turn right onto 20th Street S.

Continue straight and once you reach Crystal Drive, turn right. 2100 Crystal Drive will be on your right side of the street. The glass doors you will enter are for the Crystal City Shops, and on the right side of these doors is the pizza restaurant, "We The Pizza". Walk straight through the glass doors at 2100 Crystal Drive and walk straight until you see several elevators on your right side. Take these up to the lobby level (PBS is on the level you'll get off on.) When stepping off the elevators, you will see PBS in front of you. Walk about 12 feet and turn to the left. You'll see more elevators. You'll take this up to the floor you need to go to if USAID staff. Make sure you scan your badge on the right side of the elevator once inside and then press your floor. If you're a visitor, you don't need a badge to scan. You can only go to the 9th floor where there is a guard who can help you check in. They are at the end of the hall, near the glass doors. They can then call the USAID staff you are here to see and the GH staff will come to get you.

Metro

Using either the Yellow or Blue line, get off at the Crystal City station. As you come off the metro and go upstairs and go through the turnstiles to exit, you'll have three options to get to the USAID space. Two are above ground, one is underground.

Below ground: As you come through the metro's turnstiles, go up the first set of escalators. You'll now see glass doors on your left and your right for the Crystal City Shops. Turn to your left and go in the glass doors. You'll walk on the main corridor and pass through 4 sections of hallway. The last two segments of hallway are a white color. Once you reach the end of the second white hallway, you'll see various stores etc. Come out and turn right. You'll pass an Au Bon Pan on your right and a men's clothing store on the left. Once you pass this store, turn left about 12 feet and you should see elevators on your left. Take these up to the lobby level (PBS is on the level you'll get off on.) When stepping off the elevators, you will see PBS in front of you. Walk about 12 feet and turn to the left. You'll see more elevators. You'll take

this up to the floor you need (8-12) to go to if USAID staff. Make sure you scan your badge on the right side of the elevator once inside and then press your floor. If you're a visitor, you don't need a badge to scan. You can only go to the 9th floor where there is a guard who can help you check in. They are at the end of the hall, near the glass doors. They can then call the USAID staff you are here to see and the GH staff will come to get you.

Above Ground: As you come through the metro's turnstiles, go up the first set of escalators. Continue straight and take the second set up escalators up to the outside entrance.

Option 1 - Coming off, take a left and walk across the street. This is S. Bell St. Once you reach the end, you will have 20th street in front of you. Cross this street and walk towards the large white circular bench in the park. A large dark apartment building will be on your left side as you pass it. As you pass the large white Circular park bench, you'll see the PBS building in front of you. The front entrance says 2200 and with PBS on the front. Walk in the glass doors, pass the interior entrance for PBS on your left until you reach the six elevators that are in the left corner of the building in front of you.

You'll take this up to the floor you need (8-12) to go to if USAID staff. Make sure you scan your badge on the right side of the elevator once inside and then press your floor. If you're a visitor, you don't need a badge to scan. You can only go to the 9th floor where there is a guard who can help you check in. They are at the end of the hall, near the glass doors. They can then call the USAID staff you are here to see and the GH staff will come to get you.

Option 2 - As you are coming off the escalator, turn left and you'll be facing 18th street. S. Bell Street is in front of you if going straight. But you'll turn left onto 18th Street. Walk about 2 blocks until you reach Crystal Drive in front of you. Take a right onto Crystal Drive and then walk past the large building with the overhang on your right. Cross the street and walk about half a block until you see 2100 Crystal Drive on your right. Go in the glass doors, pass the "We The Pizza" on your left, and keep going. You'll take the elevators on your right side up to the lobby level (PBS is on the level you'll get off on.) When stepping off the elevators, you will see PBS in front of you. Walk about 12 feet and turn to the left. You'll see more elevators. You'll take this up to the floor you need to go to if USAID staff. Make sure you scan your badge on the right side of the elevator once inside and then press your floor. If you're a visitor, you don't need a badge to scan. You can only go to the 9th floor where there is a guard who can help you check in. They are at the end of the hall, near the glass doors. They can then call the USAID staff you are here to see and the GH staff will come to get you.

Shuttle from RRB (14th Street)

The shuttle coming from the 14th street at the RRB leaves every 30 minutes (7:20, 7:50, 8:20, 8:50, 9:20, 9:50 etc.). The shuttle is a large white vehicle that says "Chariots for Hire". There may be a sign taped to the door saying "CP3 - Crystal City". Ask the driver as well if they are going to Crystal City. Once you get off the shuttle, you'll be on 20th Street S. On your right side of the vehicle, (as you get off) you'll see a glass door that goes into the Crystal

City Shops. Go in this door and you'll see a long hallway in front of you. Walk all the way down until you see the Au Bon Pan on your right and a men's clothing store on the left. Once you pass the men's clothing store, turn left about 12 feet and you should see elevators on your left. Take these up to the lobby level (PBS is on the level you'll get off on.) When stepping off the elevators, you will see PBS in front of you. Walk about 12 feet and turn to the left. You'll see more elevators. You'll take this up to the floor you need (8-12) to go to if USAID staff. Make sure you scan your badge on the right side of the elevator once inside and then press your floor. If you're a visitor, you don't need a badge to scan. You can only go to the 9th floor where there is a guard who can help you check in. They are at the end of the hall, near the glass doors. They can then call the USAID staff you are here to see and the GH staff will come to get you.

From: Brian Bird <bhbird@ucdavis.edu>
To: Jon Epstein <epstein@ecohealthalliance.org>, Alisa Pereira <apereira@usaid.gov>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Predict inbox <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Amalhin Shek <ashek@usaid.gov>, Cassandra Louis Duthil <clouisduthil@usaid.gov>
Subject: Re: EHP Findings "to date" presentation -- Feb 7th
Sent: Mon, 4 Feb 2019 21:57:12 +0000

Works for me too. See you Thursday.

-b

Brian H. Bird DVM, MSPH, PhD
Global Lead Sierra Leone – PREDICT Ebola Host Project
Co-PI PREEMPT Lassa fever ecology study
One Health Institute
University of California, Davis
School of Veterinary Medicine
Skype: BrianHBird1

From: "epstein@ecohealthalliance.org" <epstein@ecohealthalliance.org>
Date: Monday, February 4, 2019 at 1:30 PM
To: Alisa Pereira <apereira@usaid.gov>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Brian Bird <bhbird@ucdavis.edu>, Predict inbox <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Amalhin Shek <ashek@usaid.gov>, Cassandra Louis Duthil <clouisduthil@usaid.gov>
Subject: Re: Update: EHP Findings "to date" presentation -- Feb 7th

It's OK for me.
-Jon

On Mon, Feb 4, 2019 at 4:15 PM Alisa Pereira <apereira@usaid.gov> wrote:
We needed to adjust the time so Senior Representatives from the Bureau could attend. The new start time for the presentation is 3:30. Please plan on arriving per the instructions below, except, ask the security guard to contact Cara Chrisman instead of texting me.
Please confirm this new time works for both Brian and Jon.

Thanks
Alisa
Sent from my iPhone
On Feb 4, 2019, at 9:48 AM, Alisa Pereira <apereira@usaid.gov> wrote:

We have secured a conference room, and Dennis' time (for the intro) for the meeting on Feb 7th at 1pm for the presentation on EHP findings. Brian and Jon, thank you so much for making yourselves available at such short notice.

We would greatly appreciate your help in preparing a very short intro blurb that we can circulate with the invitation.

I am copying Cassandra and Amalhin on this message too because they will be critical in the communication/logistical arrangements (including projecting the presentation, etc).

The presentation will be held in our Crystal City offices (2100 Crystal Drive, Arlington, Va 22202) at 1pm.

You should plan to arrive earlier than that so get through security. When you arrive, please go to the 9th floor to the security office. Text me before you get in the elevator (202-997-9966), and I will meet you there to get you checked in.

Thank you again!!
Alisa

Alisa Pereira, Senior Public Health Advisor
USAID, Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-0001, Arlington, VA 22202
Phone:202-997-9966
Email: apereira@usaid.gov

GHSI-III - Social Solutions International, Inc. prime contractor

--

Jonathan H. Epstein DVM, MPH, PhD
Vice President for Science and Outreach
EcoHealth Alliance
460 West 34th Street, Ste. 1701
New York, NY 10001
1.212.380.4467 (direct)
REDACTED (mobile)

web: ecohealthalliance.org
Twitter: @epsteinjon
EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.

Sent: Fri, 15 Mar 2019 10:49:25 -0700
Subject: Re: [Response Requested] P2 Budget
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
Cc: Andrew Clements <aclements@usaid.gov>, David John Wolking <djwolking@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, predict Sympa List <predict@ucdavis.edu>

Definitely -- huge thank you to you, Dennis, Alisa, Richard & the rest of the team working to make the bridge as seamless as possible, especially for the countries involved.
Have a nice weekend,
Jonna

On Fri, Mar 15, 2019 at 8:53 AM Elizabeth Leasure <calcasure@ucdavis.edu> wrote:

Thanks, Andrew! This is fantastic news. I'll setup a separate account internally for the "borrowed" Ebola funds to ensure there is no confusion when "returning" the funds or in a potential audit.

Please extend our thanks to Richard for his flexibility, and thank you to the P2 Management team for making it happen.

Have a great weekend!

Liz

Elizabeth Leasure

Financial Operations Manager

One Health Institute

REDACTED *(cell)*

530-754-9034 (office)

Skype: calcasure

From: Andrew Clements <aclements@usaid.gov>
Sent: Friday, March 15, 2019 8:21 AM
To: Jonna Mazet <jkmazet@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; David John Wolking <djwolking@ucdavis.edu>
Cc: PREDICTMGT <predictmgt@usaid.gov>
Subject: Fwd: [Response Requested] P2 Budget

Hi Jonna, Liz, and David,

I'm forwarding an email showing Richard Greene concurring with the temporary borrowing of $2,200,000 of Ebola funds already obligated to PREDICT-2 to cover year 5 core-funded activities until new FY2018 core funds are obligated for year 5 activities.

Please ensure that you track this temporary usage of Ebola funds and document in a way that will be sufficient for an audit (if there is one).

Please let me know if you have any questions.

Andrew

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health

U.S. Agency for International Development

Mobile phone: 1-571-345-4253
E-mail: [redacted]

For more information on USAID's Emerging Pandemic Threats program, see http://www.usaid.gov/ept2

---------- Forwarded message ---------
From: **Richard Greene** <rgreene@usaid.gov>
Date: Thu, Mar 14, 2019 at 6:47 PM
Subject: Re: [Response Requested] P2 Budget
To: Cara Chrisman <cchrisman@usaid.gov>
Cc: Andrew Clements <aclements@usaid.gov>, Dennis Carroll <dcarroll@usaid.gov>, PREDICTMGT <predictmgt@usaid.gov>, Robbin Boyer <rboyer@usaid.gov>, Jane Pyon <jpyon@usaid.gov>

Hi Cara

Thanks for summarizing our discussion. I concur in this email.

Best

Richard

On Thu, Mar 14, 2019 at 12:38 PM Cara Chrisman <cchrisman@usaid.gov> wrote:

Hi Richard,

As per our earlier conversation, on behalf of the PREDICT-2 (P2) management team, I'd like to confirm that you are okay with our proposed plan and subsequent communications to the partner.

Given that P2 will be running out of core funding at the end of this month and that we are in a very unique situation in which it is mid-March 2019 and ETD has not yet received core (GH-C-AI) FY18 funding, the proposal is that Andrew (as the AOR) will communicate to UC Davis (prime for the P2 project) that they can immediately use $2.2M of GH-C-XEB funding previously obligated to the project to allow them to continue core-funded programs uninterrupted.

The hope is that this utilization of GH-C-XEB funds will enable the project to continue activities until the ETD core funding is received. At that time, the aforementioned utilization of funding will be reconciled within the project. Throughout this process, the partner will be directed to keep track of this usage of funds and appropriately document.

Please confirm your approval of this proposed plan.

Thanks,
Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
U.S. Agency for International Development (USAID) Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-8091A, Arlington, VA 22202

Desk: (571) 551-7413
Cell: REDACTED
E-mail: cchrisman@usaid.gov

GHSI-III - Social Solutions International, Inc. prime contractor

--

Richard S. Greene
Senior Infectious Disease Strategy Advisor

Office of Health, Infectious Diseases, and Nutrition

Bureau for Global Health

USAID
Tel: (571) 551-7364

E-mail: rgreene@usaid.gov

From: [redacted]
To: Dennis Carroll [redacted]
Cc: Cara Chrisman <cchrisman@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>
Subject: FW: letters for the Board
Sent: Mon, 21 Oct 2019 15:51:35 +0000

Letter Bogner.3.29.19.pdf
Letter Daszak.3.29.19.pdf
Letter Mazet.3.29.19.pdf
Letter Brechot.3.29.19.pdf
Letter Gardy.3.29.19.pdf
Letter Murray.3.29.19.pdf
Letter Cyrwale.3.29.19.pdf
Letter Rubin.3.29.19.pdf

For your records – Letters to BOD from March.

[redacted]

From: Dennis Carroll [mailto:dcarroll@usaid.gov]
Sent: Friday, March 29, 2019 11:26 AM
To: [redacted] Cara Chrisman <cchrisman@usaid.gov>
Subject: letters for the Board

[redacted] the letters are attached. I presume you have all the emails, with the possible exception of Christian Brechot - cbrechot@gvn.org

let me know if you have any issues or questions

Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 571-551-7109
Mobile: [redacted]

March 29, 2019

Christian Brechot
President
Global Virus Network

Dear Christian,

I am very pleased to welcome you as a member of the Board of Directors for the Global Virome Project (GVP). The transition of the GVP into a legal and operational reality is both exciting and daunting. The Board of Directors will be critical to ensuring the GVP's long term success. This transition has been a long time in the making. Over the past two years, a network of international partners has been actively guiding the evolution of the GVP from a "scientific" proposal towards an operational reality. This "Steering Committee" has provided a strong 10 year vision that frames the GVP's way forward in three phases – an initial "incubation period", a longer term "steady state", and the "post GVP" period.

The Incubation Period is the critical first phase that is intended to "validate the operational and scientific scalability" of the GVP; mobilize initial funding; and, build out the GVP organization. The incorporation of the GVP and the establishment of the Board of Directors are vital first steps towards building out the GVP's organizational structure. In parallel, the first steps have been taken to launch the "validation" phase in Thailand and China. Both countries are in the process of establishing their respective national Virome projects (the Thai Virome Project and the China Virome Project). Further, a series of scientific and operational working groups, overseen by the Steering Committee and composed of international scientific and legal experts, have provided a sound technical, scientific, and operational framework for the GVP's field activities. Together the Steering Committee and the Working Groups have well positioned the GVP for this next, exciting step.

With the legal launch of the GVP, the Board of Directors will be responsible for setting the GVP's overarching direction, championing stakeholder engagement, and providing financial oversight. In the coming months, the Board of Directors will be specifically responsible for approving membership to a Scientific Advisory Group and for providing oversight of the operational work of the GVP's secretariat or "Hub". I will provide you with a more detailed

UCDUSR0004275

introduction to the current organizational and strategic plan for the GVP in a separate communication.

As some of you may be aware, I will be retiring from my current position at USAID later this summer. I intend to use my time, as a voluntary member of the Board of Directors, to help accelerate the transition of the GVP into a fully-functioning organization. I strongly believe the GVP has the potential to transform how the global community understands, prepares for, and responds to future viral threats – and in the end will make the world a far safer place. I look forward to working with you to make this vision a reality.

In the coming weeks each of you will receive an email and packet drafted by the law offices of Tarter Krinsky & Drogin LLP including resolutions and bylaws for the new 501 (c) 3. You will be asked to sign and return the resolutions to formally accept your appointment to the Board.

At your convenience I can arrange a phone conversation to provide you additional information and answer any questions you might have.

All the best,

Dennis Carroll
GVP Core Team

UCDUSR0004276

GLOBAL VIROME PROJECT

March 29, 2019

Suzan Murray
Program Director
Smithsonian Wildlife Health Program

Dear Suzan,

I am very pleased to welcome you as a member of the Board of Directors for the Global Virome Project (GVP). The transition of the GVP into a legal and operational reality is both exciting and daunting. The Board of Directors will be critical to ensuring the GVP's long term success. This transition has been a long time in the making. Over the past two years, a network of international partners has been actively guiding the evolution of the GVP from a "scientific" proposal towards an operational reality. This "Steering Committee" has provided a strong 10 year vision that frames the GVP's way forward in three phases – an initial "incubation period", a longer term "steady state", and the "post GVP" period.

The Incubation Period is the critical first phase that is intended to "validate the operational and scientific scalability" of the GVP; mobilize initial funding; and, build out the GVP organization. The incorporation of the GVP and the establishment of the Board of Directors are vital first steps towards building out the GVP's organizational structure. In parallel, the first steps have been taken to launch the "validation" phase in Thailand and China. Both countries are in the process of establishing their respective national Virome projects (the Thai Virome Project and the China Virome Project). Further, a series of scientific and operational working groups, overseen by the Steering Committee and composed of international scientific and legal experts, have provided a sound technical, scientific, and operational framework for the GVP's field activities. Together the Steering Committee and the Working Groups have well positioned the GVP for this next, exciting step.

With the legal launch of the GVP, the Board of Directors will be responsible for setting the GVP's overarching direction, championing stakeholder engagement, and providing financial oversight. In the coming months, the Board of Directors will be specifically responsible for approving membership to a Scientific Advisory Group and for providing oversight of the operational work of the GVP's secretariat or "Hub". I will provide you with a more detailed

UCDUSR0004277

introduction to the current organizational and strategic plan for the GVP in a separate communication.

As some of you may be aware, I will be retiring from my current position at USAID later this summer. I intend to use my time, as a voluntary member of the Board of Directors, to help accelerate the transition of the GVP into a fully-functioning organization. I strongly believe the GVP has the potential to transform how the global community understands, prepares for, and responds to future viral threats – and in the end will make the world a far safer place. I look forward to working with you to make this vision a reality.

In the coming weeks each of you will receive an email and packet drafted by the law offices of Tarter Krinsky & Drogin LLP including resolutions and bylaws for the new 501 (c) 3. You will be asked to sign and return the resolutions to formally accept your appointment to the Board.

At your convenience I can arrange a phone conversation to provide you additional information and answer any questions you might have.

All the best,

Dennis Carroll
GVP Core Team

P.S. Great feedback from the Zero Point Zero people on the dinner. You were a big hit

UCDUSR0004278

GLOBAL VIROME PROJECT

March 29, 2019

Professor Oyewale Tomori

REDACTED

Dear Oyewale,

I am very pleased to welcome you as a member of the Board of Directors for the Global Virome Project (GVP). The transition of the GVP into a legal and operational reality is both exciting and daunting. The Board of Directors will be critical to ensuring the GVP's long term success. This transition has been a long time in the making. Over the past two years, a network of international partners has been actively guiding the evolution of the GVP from a "scientific" proposal towards an operational reality. This "Steering Committee" has provided a strong 10 year vision that frames the GVP's way forward in three phases – an initial "incubation period", a longer term "steady state", and the "post GVP" period.

The Incubation Period is the critical first phase that is intended to "validate the operational and scientific scalability" of the GVP; mobilize initial funding; and, build out the GVP organization. The incorporation of the GVP and the establishment of the Board of Directors are vital first steps towards building out the GVP's organizational structure. In parallel, the first steps have been taken to launch the "validation" phase in Thailand and China. Both countries are in the process of establishing their respective national Virome projects (the Thai Virome Project and the China Virome Project). Further, a series of scientific and operational working groups, overseen by the Steering Committee and composed of international scientific and legal experts, have provided a sound technical, scientific, and operational framework for the GVP's field activities. Together the Steering Committee and the Working Groups have well positioned the GVP for this next, exciting step.

With the legal launch of the GVP, the Board of Directors will be responsible for setting the GVP's overarching direction, championing stakeholder engagement, and providing financial oversight. In the coming months, the Board of Directors will be specifically responsible for approving membership to a Scientific Advisory Group and for providing oversight of the

UCDUSR0004279

operational work of the GVP's secretariat or "Hub". I will provide you with a more detailed introduction to the current organizational and strategic plan for the GVP in a separate communication.

As some of you may be aware, I will be retiring from my current position at USAID later this summer. I intend to use my time, as a voluntary member of the Board of Directors, to help accelerate the transition of the GVP into a fully-functioning organization. I strongly believe the GVP has the potential to transform how the global community understands, prepares for, and responds to future viral threats – and in the end will make the world a far safer place. I look forward to working with you to make this vision a reality.

In the coming weeks each of you will receive an email and packet drafted by the law offices of Tarter Krinsky & Drogin LLP including resolutions and bylaws for the new 501 (c) 3. You will be asked to sign and return the resolutions to formally accept your appointment to the Board.

At your convenience I can arrange a phone conversation to provide you additional information and answer any questions you might have.

All the best,

Dennis

Dennis Carroll
GVP Core Team

UCDUSR0004280

March 29, 2019

Jennifer Gardy
Deputy Director
Surveillance, Data, & Epidemiology
Gates Foundation

Dear Jennifer,

I am very pleased to welcome you as a member of the Board of Directors for the Global Virome Project (GVP). The transition of the GVP into a legal and operational reality is both exciting and daunting. The Board of Directors will be critical to ensuring the GVP's long term success. This transition has been a long time in the making. Over the past two years, a network of international partners has been actively guiding the evolution of the GVP from a "scientific" proposal towards an operational reality. This "Steering Committee" has provided a strong 10 year vision that frames the GVP's way forward in three phases – an initial "incubation period", a longer term "steady state", and the "post GVP" period.

The Incubation Period is the critical first phase that is intended to "validate the operational and scientific scalability" of the GVP; mobilize initial funding; and, build out the GVP organization. The incorporation of the GVP and the establishment of the Board of Directors are vital first steps towards building out the GVP's organizational structure. In parallel, the first steps have been taken to launch the "validation" phase in Thailand and China. Both countries are in the process of establishing their respective national Virome projects (the Thai Virome Project and the China Virome Project). Further, a series of scientific and operational working groups, overseen by the Steering Committee and composed of international scientific and legal experts, have provided a sound technical, scientific, and operational framework for the GVP's field activities. Together the Steering Committee and the Working Groups have well positioned the GVP for this next, exciting step.

With the legal launch of the GVP, the Board of Directors will be responsible for setting the GVP's overarching direction, championing stakeholder engagement, and providing financial oversight. In the coming months, the Board of Directors will be specifically responsible for approving membership to a Scientific Advisory Group and for providing oversight of the operational work of the GVP's secretariat or "Hub". I will provide you with a more detailed

UCDUSR0004281

introduction to the current organizational and strategic plan for the GVP in a separate communication.

As some of you may be aware, I will be retiring from my current position at USAID later this summer. I intend to use my time, as a voluntary member of the Board of Directors, to help accelerate the transition of the GVP into a fully-functioning organization. I strongly believe the GVP has the potential to transform how the global community understands, prepares for, and responds to future viral threats – and in the end will make the world a far safer place. I look forward to working with you to make this vision a reality.

In the coming weeks each of you will receive an email and packet drafted by the law offices of Tarter Krinsky & Drogin LLP including resolutions and bylaws for the new 501 (c) 3. You will be asked to sign and return the resolutions to formally accept your appointment to the Board.

At your convenience I can arrange a phone conversation to provide you additional information and answer any questions you might have.

All the best,

Dennis Carroll
GVP Core Team

UCDUSR0004282

GLOBAL VIROME PROJECT

March 29, 2019

Peter Bogner
Director
GISAID

Dear Peter,

I am very pleased to welcome you as a member of the Board of Directors for the Global Virome Project (GVP). The transition of the GVP into a legal and operational reality is both exciting and daunting. The Board of Directors will be critical to ensuring the GVP's long term success. This transition has been a long time in the making. Over the past two years, a network of international partners has been actively guiding the evolution of the GVP from a "scientific" proposal towards an operational reality. This "Steering Committee" has provided a strong 10 year vision that frames the GVP's way forward in three phases – an initial "incubation period", a longer term "steady state", and the "post GVP" period.

The Incubation Period is the critical first phase that is intended to "validate the operational and scientific scalability" of the GVP; mobilize initial funding; and, build out the GVP organization. The incorporation of the GVP and the establishment of the Board of Directors are vital first steps towards building out the GVP's organizational structure. In parallel, the first steps have been taken to launch the "validation" phase in Thailand and China. Both countries are in the process of establishing their respective national Virome projects (the Thai Virome Project and the China Virome Project). Further, a series of scientific and operational working groups, overseen by the Steering Committee and composed of international scientific and legal experts, have provided a sound technical, scientific, and operational framework for the GVP's field activities. Together the Steering Committee and the Working Groups have well positioned the GVP for this next, exciting step.

With the legal launch of the GVP, the Board of Directors will be responsible for setting the GVP's overarching direction, championing stakeholder engagement, and providing financial oversight. In the coming months, the Board of Directors will be specifically responsible for approving membership to a Scientific Advisory Group and for providing oversight of the operational work of the GVP's secretariat or "Hub". I will provide you with a more detailed

UCDUSR0004283

introduction to the current organizational and strategic plan for the GVP in a separate communication.

As some of you may be aware, I will be retiring from my current position at USAID later this summer. I intend to use my time, as a voluntary member of the Board of Directors, to help accelerate the transition of the GVP into a fully-functioning organization. I strongly believe the GVP has the potential to transform how the global community understands, prepares for, and responds to future viral threats – and in the end will make the world a far safer place. I look forward to working with you to make this vision a reality.

In the coming weeks each of you will receive an email and packet drafted by the law offices of Tarter Krinsky & Drogin LLP including resolutions and bylaws for the new 501 (c) 3. You will be asked to sign and return the resolutions to formally accept your appointment to the Board.

At your convenience I can arrange a phone conversation to provide you additional information and answer any questions you might have.

All the best,

Dennis Carroll
GVP Core Team

UCDUSR0004284

GLOBAL VIROME PROJECT

March 29, 2019

Peter Daszak
President
EcoHealth Alliance

Dear Peter,

I am very pleased to welcome you as a member of the Board of Directors for the Global Virome Project (GVP). The transition of the GVP into a legal and operational reality is both exciting and daunting. The Board of Directors will be critical to ensuring the GVP's long term success. This transition has been a long time in the making. Over the past two years, a network of international partners has been actively guiding the evolution of the GVP from a "scientific" proposal towards an operational reality. This "Steering Committee" has provided a strong 10 year vision that frames the GVP's way forward in three phases – an initial "incubation period", a longer term "steady state", and the "post GVP" period.

The Incubation Period is the critical first phase that is intended to "validate the operational and scientific scalability" of the GVP; mobilize initial funding; and, build out the GVP organization. The incorporation of the GVP and the establishment of the Board of Directors are vital first steps towards building out the GVP's organizational structure. In parallel, the first steps have been taken to launch the "validation" phase in Thailand and China. Both countries are in the process of establishing their respective national Virome projects (the Thai Virome Project and the China Virome Project). Further, a series of scientific and operational working groups, overseen by the Steering Committee and composed of international scientific and legal experts, have provided a sound technical, scientific, and operational framework for the GVP's field activities. Together the Steering Committee and the Working Groups have well positioned the GVP for this next, exciting step.

With the legal launch of the GVP, the Board of Directors will be responsible for setting the GVP's overarching direction, championing stakeholder engagement, and providing financial oversight. In the coming months, the Board of Directors will be specifically responsible for approving membership to a Scientific Advisory Group and for providing oversight of the operational work of the GVP's secretariat or "Hub". I will provide you with a more detailed

UCDUSR0004285

introduction to the current organizational and strategic plan for the GVP in a separate communication.

As some of you may be aware, I will be retiring from my current position at USAID later this summer. I intend to use my time, as a voluntary member of the Board of Directors, to help accelerate the transition of the GVP into a fully-functioning organization. I strongly believe the GVP has the potential to transform how the global community understands, prepares for, and responds to future viral threats – and in the end will make the world a far safer place. I look forward to working with you to make this vision a reality.

In the coming weeks each of you will receive an email and packet drafted by the law offices of Tarter Krinsky & Drogin LLP including resolutions and bylaws for the new 501 (c) 3. You will be asked to sign and return the resolutions to formally accept your appointment to the Board.

At your convenience I can arrange a phone conversation to provide you additional information and answer any questions you might have.

All the best,

Dennis Carroll
GVP Core Team

UCDUSR0004286

March 29, 2019

Jonna Mazet
Executive Director
One Health Institute
University of California, Davis

Dear Jonna,

I am very pleased to welcome you as a member of the Board of Directors for the Global Virome Project (GVP). The transition of the GVP into a legal and operational reality is both exciting and daunting. The Board of Directors will be critical to ensuring the GVP's long term success. This transition has been a long time in the making. Over the past two years, a network of international partners has been actively guiding the evolution of the GVP from a "scientific" proposal towards an operational reality. This "Steering Committee" has provided a strong 10 year vision that frames the GVP's way forward in three phases – an initial "incubation period", a longer term "steady state", and the "post GVP" period.

The Incubation Period is the critical first phase that is intended to "validate the operational and scientific scalability" of the GVP; mobilize initial funding; and, build out the GVP organization. The incorporation of the GVP and the establishment of the Board of Directors are vital first steps towards building out the GVP's organizational structure. In parallel, the first steps have been taken to launch the "validation" phase in Thailand and China. Both countries are in the process of establishing their respective national Virome projects (the Thai Virome Project and the China Virome Project). Further, a series of scientific and operational working groups, overseen by the Steering Committee and composed of international scientific and legal experts, have provided a sound technical, scientific, and operational framework for the GVP's field activities. Together the Steering Committee and the Working Groups have well positioned the GVP for this next, exciting step.

With the legal launch of the GVP, the Board of Directors will be responsible for setting the GVP's overarching direction, championing stakeholder engagement, and providing financial oversight. In the coming months, the Board of Directors will be specifically responsible for approving membership to a Scientific Advisory Group and for providing oversight of the operational work of the GVP's secretariat or "Hub". I will provide you with a more detailed

UCDUSR0004287

introduction to the current organizational and strategic plan for the GVP in a separate communication.

As some of you may be aware, I will be retiring from my current position at USAID later this summer. I intend to use my time, as a voluntary member of the Board of Directors, to help accelerate the transition of the GVP into a fully-functioning organization. I strongly believe the GVP has the potential to transform how the global community understands, prepares for, and responds to future viral threats – and in the end will make the world a far safer place. I look forward to working with you to make this vision a reality.

In the coming weeks each of you will receive an email and packet drafted by the law offices of Tarter Krinsky & Drogin LLP including resolutions and bylaws for the new 501 (c) 3. You will be asked to sign and return the resolutions to formally accept your appointment to the Board.

At your convenience I can arrange a phone conversation to provide you additional information and answer any questions you might have.

All the best,

Dennis Carroll
GVP Core Team

UCDUSR0004288

March 29, 2019

Eddy Rubin
Chief Science Officer
Metabiota

Dear Eddy,

I am very pleased to welcome you as a member of the Board of Directors for the Global Virome Project (GVP). The transition of the GVP into a legal and operational reality is both exciting and daunting. The Board of Directors will be critical to ensuring the GVP's long term success. This transition has been a long time in the making. Over the past two years, a network of international partners has been actively guiding the evolution of the GVP from a "scientific" proposal towards an operational reality. This "Steering Committee" has provided a strong 10 year vision that frames the GVP's way forward in three phases – an initial "incubation period", a longer term "steady state", and the "post GVP" period.

The Incubation Period is the critical first phase that is intended to "validate the operational and scientific scalability" of the GVP; mobilize initial funding; and, build out the GVP organization. The incorporation of the GVP and the establishment of the Board of Directors are vital first steps towards building out the GVP's organizational structure. In parallel, the first steps have been taken to launch the "validation" phase in Thailand and China. Both countries are in the process of establishing their respective national Virome projects (the Thai Virome Project and the China Virome Project). Further, a series of scientific and operational working groups, overseen by the Steering Committee and composed of international scientific and legal experts, have provided a sound technical, scientific, and operational framework for the GVP's field activities. Together the Steering Committee and the Working Groups have well positioned the GVP for this next, exciting step.

With the legal launch of the GVP, the Board of Directors will be responsible for setting the GVP's overarching direction, championing stakeholder engagement, and providing financial oversight. In the coming months, the Board of Directors will be specifically responsible for approving membership to a Scientific Advisory Group and for providing oversight of the operational work of the GVP's secretariat or "Hub". I will provide you with a more detailed

UCDUSR0004289

introduction to the current organizational and strategic plan for the GVP in a separate communication.

As some of you may be aware, I will be retiring from my current position at USAID later this summer. I intend to use my time, as a voluntary member of the Board of Directors, to help accelerate the transition of the GVP into a fully-functioning organization. I strongly believe the GVP has the potential to transform how the global community understands, prepares for, and responds to future viral threats – and in the end will make the world a far safer place. I look forward to working with you to make this vision a reality.

In the coming weeks each of you will receive an email and packet drafted by the law offices of Tarter Krinsky & Drogin LLP including resolutions and bylaws for the new 501 (c) 3. You will be asked to sign and return the resolutions to formally accept your appointment to the Board.

At your convenience I can arrange a phone conversation to provide you additional information and answer any questions you might have.

All the best,

Dennis Carroll
GVP Core Team

UCDUSR0004290

From:	Andrew Clements <aclements@usaid.gov>
To:	Jonna Mazet <jkmazet@ucdavis.edu>;djwolking@ucdavis.edu <djwolking@ucdavis.edu>;ealeasure@ucdavis.edu <ealeasure@ucdavis.edu>;Christine Kreuder Johnson <ckjohnson@ucdavis.edu>
CC:	predictmgt@usaid.gov <predictmgt@usaid.gov>
Sent:	3/3/2020 12:38:38 PM
Subject:	Need to remove 3 countries from extension budget

We need to take Cambodia, Egypt, Myanmar out of the extension/coronavirus plan. They have not been notified to Congress.

Where do you want that money to be redistributed?

Andrew P. Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From: Jon Epstein <epstein@ecohealthalliance.org>
Sent: Thu, 19 Mar 2020 21:37:43 -0400
Subject: One Health Workforce-Next Generation Thank you and Invitation to COVID-19 Webinar March 23
To: Mosoka Fallah [redacted], Michael Garbo [redacted]
Cc: Jim Desmond <desmond@ecohealthalliance.org>, Woutrina Miller <wasmith@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, Terra Kelly <trkelly@ucdavis.edu>, [redacted] mcrane@usaid.gov
OHW-NG logo bar v3.png

Dear Drs. Fallah and Garbo,

I hope you are both holding up well during these challenging times.

We are writing to formally express our sincere gratitude for your support and engagement with our successful USAID One Health Workforce – Next Generation proposal and are pleased to report that initial project work plans have recently been approved by USAID. As we all navigate the unprecedented challenges associated with the COVID-19 pandemic, the importance of an educated and engaged One Health workforce is abundantly clear.

Both the AFROHUN (Africa One Health University Network, formerly OHCEA) and SEAOHUN (Southeast Asia One Health University Network) Secretariats, and their university partners, have been hard at work laying the initial foundation and plans, as our teams have all gotten to know each other during our initial startup period. The networks span 15 countries and include nearly 100 universities unified in the mission of transforming the capacity of workforces to prevent, detect, and respond to emerging disease threats of epidemic and pandemic importance. The One Health Workforce – Next Generation (OHW-NG) Consortium global team brings together One Health leaders from institutions worldwide, with core partners including UC Davis, EcoHealth Alliance, Ata Health Strategies, ICAP/Columbia University, UC Berkeley, Project ECHO (University of New Mexico), UC Irvine, and USAID.

Many of our consortium partners, staff, and university network members are on the front lines of the COVID-19 response effort at local, national, and international levels. Our project activities are adapting and responding to meet emergency needs, and on March 23 and March 24, AFROHUN and SEAOHUN and the OHW-NG global team are hosting two online educational platforms (webinars) for network members, partners, and other stakeholders on the One Health approach to COVID-19 with current updates. All are welcome to join, and feel free to circulate the webinar invitation within your professional network. We fully anticipate additional activities oriented around the COVID-19 response effort and most importantly, how to work together to prevent pandemics like this from ever happening again.

We look forward to engaging with you on AFROHUN and SEAOHUN initiatives and activities. If you have any ideas or suggestions regarding engagement or questions or concerns, please do not hesitate to reach out.

Your partnership liaison contacts are:

Dr. Jonna Mazet Executive Director, One Health Institute, University of California, Davis, jkmazet@ucdavis.edu & Dr. Jennifer Lane, One Health Institute, University of California, Davis, jklane@ucdavis.edu

Kind regards,

The One Health Workforce-Next Generation Consortium

Special One Health COVID-19 Response ECHO Session

For AFROHUN Members

Monday, March 23, 2020

US time:
7:30 am - 9:00 am MT
9:30 am - 11:00 am ET

6:30 am - 8:00 am PT

Africa time:
1:30 pm - 3:00 pm GMT
2:30 pm - 4:00 pm WAT
3:30 pm - 5:00 pm CAT/SAST

- **AGENDA**
  - Introductions – [AFROHUN Secretariat; Jonna Mazet, DVM, MPVM, Ph.D.- UC Davis]
  - COVID-19 **Global Epidemiology** - [Minesh Shah, MD, MPH - Africa Regional Lead, International Task Force, CDC COVID-19 Response]
  - COVID-19 **Laboratory Diagnostics** - [Christina Scheel, Ph.D. - Laboratory Advisor, International Task Force, CDC COVID-19 Response]
  - COVID-19 **Infection Control and Prevention** - [Katie Wilson, MPH - Infection Prevention and Control Deputy Lead, International Task Force, CDC COVID-19 Response]
  - COVID-19 **One Health Perspective** - [Brian Bird, DVM, MSPH, Ph.D. - UC Davis]
  - Updates from Africa CDC, WHO AFRO, & ICAN
  - Q&A
- **FACILITATORS**
  - Woutrina Smith, DVM, MPVM, Ph.D. - UC Davis
  - Bruce Struminger, MD, MA - ECHO Institute, UNM

Agenda (English)
Save the date (French)
Save the date (English)

WHO Coronavirus disease (COVID-2019) situation reports:
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

For Connection Information, please click here

Participation Attestation and Access to the Powerpoint Presentations:

Participants will be able to receive a **digital attestation** (proof of participation) immediately after the session by using a mobile App called **PDA-Participant**. The App provides immediate access to all presentations. Please take a minute to install the App before the session as it will help us to track participation in this important session.

Download the app to your phone for Android
Download the app to iOS devices
Detailed PDA-Partner App Instructions
Look for this icon

Zoom Instructions and ECHO Etiquette (English)

This session may be recorded. By joining you consent to being recorded.

Simultaneous English/French interpretation will be available.

At the start of the session, participants requiring French interpretation will be provided a second access number to hear the simultaneous translation. You will need two devices for translation, one to connect to the video features and one for the audio line to hear the French translation.

The University of New Mexico School of Medicine, Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Office of Continuing Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ECHO Resources

Project ECHO in 90 seconds - Video

Project ECHO One-Pager - Our Story and Model

Cheers,
Jon

--

Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street, Ste. 1701
New York, NY 10001
1.212.380.4467 (direct)
REDACTED mobile)

web: ecohealthalliance.org

Twitter: @epsteinjon

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

From: Jennifer Gardy <Jennifer.Gardy@gatesfoundation.org>
To: Peter Daszak <daszak@ecohealthalliance.org>, Samtha Maher <maher@ecohealthalliance.org>, Dennis Carroll [redacted] "cbrechot@gvn.org" <cbrechot@gvn.org> [redacted] Jonna Mazet <jkmazet@ucdavis.edu>, Eddy Rubin <erubin@metabiota.com>, "Dr. Suzan Murray" <MurrayS@si.edu>, "Oyewale Tomori [redacted], "graca@usf.edu" <graca@usf.edu>, "nmercer@gvn.org" <nmercer@gvn.org>, Alison Andre <andre@ecohealthalliance.org>, Cara Chrisman <cchrisman@usaid.gov>
Subject: RE: GVP 501c3 Board meeting minutes and action items
Sent: Thu, 26 Mar 2020 14:49:34 +0000

I'll join for the last 30min – we have an emergency meeting on trying to mitigate some of COVID-19's knock-on effects on malaria in sub-Saharan Africa for the first 30min of the call.

Jonna and Dennis – caught the last few minutes of Spillover on PBS the other week and it was nice to see your faces *

jg

Jennifer Gardy, PhD
Deputy Director, Surveillance, Data, and Epidemiology
Malaria | Global Health
V [redacted]
H
E jennifer.gardy@gatesfoundation.org
Pronouns: she/her/hers

Assistant: Colton Josephson, MFA
Senior Program Assistant, Malaria
V [redacted]
H
Bill & Melinda Gates Foundation
www.gatesfoundation.org

From: Peter Daszak <daszak@ecohealthalliance.org>
Sent: Wednesday, March 25, 2020 11:14 PM
To: Samtha Maher <maher@ecohealthalliance.org>; Dennis Carroll [redacted]; cbrechot@gvn.org; [redacted] Jonna Mazet <jkmazet@ucdavis.edu>; Eddy Rubin <erubin@metabiota.com>; Dr. Suzan Murray <MurrayS@si.edu>; Oyewale Tomori [redacted]; graca@usf.edu; nmercer@gvn.org; Alison Andre <andre@ecohealthalliance.org>; Cara Chrisman <cchrisman@usaid.gov>; Jennifer Gardy <Jennifer.Gardy@gatesfoundation.org>
Subject: GVP 501c3 Board meeting minutes and action items
Importance: High

Hi All,

Ready for our call tomorrow, please see the attached Board meeting minutes that Sam pulled together extremely efficiently and rapidly. I've corrected a few things, and look forward to approving them tomorrow and going through the action items.

Hope everyone's safe and well and see y'all by Zoom tomorrow!

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street
New York, NY 10001
USA

Tel.: +1-212-380-4474
Website: www.ecohealthalliance.org
Twitter: @PeterDaszak

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

From: Samantha Maher <maher@ecohealthalliance.org>
Sent: Tuesday, March 24, 2020 5:58 PM
To: peter@gisaid.org; Dennis Carroll <[redacted]; cbrechot@gvn.org; Peter Daszak <daszak@ecohealthalliance.org>; [redacted]; Jonna Mazet <jkmazet@ucdavis.edu>; Eddy Rubin <erubin@metabiota.com>; Dr. Suzan Murray <MurraySS@si.edu>; Oyewale Tomori [redacted]; Cheryl Bennett <cheryl@gisaid.org>; grace@usf.edu; nmercer@gvn.org; Alison Andre <andre@ecohealthalliance.org>; Cara Chrisman <cchrisman@usaid.gov>; Jennifer Gardy <jennifer.Gardy@gatesfoundation.org>
Subject: monthly GVP BoD Call

Dear Board Members,

We will be having our monthly Board of Directors call this Thursdays at 1pm EST/10am PST as scheduled. We have decided to use Zoom this time instead of the EHA conference line, the link to which has been added to the weekly invite. Also, provided there are no objections to having some guests on the call, we will be joined by Drs. Jennie Lane & Zoe Grange, who have been working hard on our web presence and partnership options. Below is a list of agenda items- please feel free to email me with anything additional.

1. Board Membership updates: Christian Brechot, Peter Bogner, Suzan Murray
2. Board meeting action items
3. Fundraising opportunities
4. Media outreach
5. Website/partnership opportunities (with Drs. Jennie Lane & Zoe Grange)

Additionally, here is a link to the dropbox folder with the documents and powerpoint presentations from the additional Board of Directors meetings.

And the Zoom meeting info:

Join Zoom Meeting
https://zoom [redacted]

Meeting ID: [redacted]

One tap mobile
+13462487799 [redacted] US (Houston)
+16699006833 US (San Jose)

Dial by your location
+1 346 248 7799 US (Houston)
+1 669 900 6833 US (San Jose)
+1 301 715 8592 US
+1 312 626 6799 US (Chicago)
+1 646 558 8656 US (New York)
+1 253 215 8782 US
Meeting ID: [redacted]

Find your local number: https://zoom.us/u/acyJcMESx

I hope everyone is staying healthy!

Sam Maher

--

Samantha Maher, MESc
Research Scientist, Conservation and Health

EcoHealth Alliance
460 West 34th Street Ste. 1701
New York, NY 10001

212.380.4464 (direct)
REDACTED (mobile)
212.380.4465 (fax)
www.ecohealthalliance.org

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation.

From: Jon Epstein <epstein@ecohealthalliance.org>
Sent: Fri, 12 Jun 2020 11:43:34 -0400
To: Vipat Kuruchittham <vipat@seaohun.org>
Cc: Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, Woutrina Miller <wasmith@ucdavis.edu>, Ratsuda Poolsuk <ratsuda@seaohun.org>, OHW NG <ohw-ng@seaohun.org>, onehealthnextgen Sympa List <onehealthnextgen@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>
Subject: [onehealthnextgen] Re: ECHO and Q4 planning in OHW-NG

Excellent, thank you Pat.
Cheers,
Jon

On Fri, Jun 12, 2020 at 11:15 AM Vipat Kuruchittham <vipat@seaohun.org> wrote:

Jon, I just sent out an email to request a nomination from the four OHUNs with the deadline on Friday, 19 June. -Pat
On Thu, Jun 11, 2020 at 12:12 AM Jon Epstein <epstein@ecohealthalliance.org> wrote:

Pat,
Understood, and I appreciate the feedback. What would you suggest would be a reasonable amount of time needed to discuss this with the coordinators and to get the appropriate people involved?

Cheers,
Jon

On Wed, Jun 10, 2020 at 12:47 PM Vipat Kuruchittham <vipat@seaohun.org> wrote:

Dear Jon,

Thank you for the draft email. I won't give OHUNs less than a week to respond as they have to coordinate with their member universities on who should represent their country network. We should be mindful that all faculty members have many other university responsibilities. If you were to request operational staff to get involved, the situation will be different. I would suggest you learn operating contexts of each regional and country networks to foster cooperation and collaboration.

Again, without the proposed meeting date and time, nominated faculty members may not be able to attend the initial meeting due to their teaching responsibility. Let's hope that this will not happen.

If you wish to proceed with the Monday timeline, you may proceed to contact OHUNs yourself. A push of this urgency timeline will not come from the SEAOHUN Secretariat.

Best regards,

Pat

On Wed, Jun 10, 2020 at 8:52 PM Jon Epstein <epstein@ecohealthalliance.org> wrote:

Dear Pat,
Below is a draft email I had prepared to send to the OHUN coordinators, as you had recommended. However, if you would prefer to send the request for nominations, that's no problem. I would just like to confirm the participants by Monday, so that we may proceed with setting up the first steering committee meeting. If you'd prefer that I send this request, let me know. Many thanks for your help with this.

Cheers,
Jon

Dear Professors Hassan, Wiku, Mersoon, and Duc Phuc,

I hope that this email finds you well. I am reaching out to you, as SEAOHUN coordinators, to request your assistance in forming a steering committee for the online One Health Academy that we are developing under Objective 1 of our OHWNG project. The steering committee will provide technical input into the structure and help curate content for the Academy. This will be one of the main mechanisms through which we provide didactic training for participants from across the networks in Africa and Asia.

The steering committee will include 3-4 members from the global team, and 3-4 representatives from each of the OHW networks: AFROHUN and

SEAOHUN. I would be grateful if you could each nominate one person from your country's OHUN who could commit to attending regular zoom meetings (frequency to be determined) and who is familiar enough with your country's one health programs, that they could provide meaningful input into content development and country-specific ideas that will ensure the Academy serves the needs of each of the network partners.

I would appreciate your nominations by ***Monday, June 15th***.

Please feel free to contact me if you have any questions.

Cheers,
Jon

On Tue, Jun 9, 2020 at 10:44 PM Vipat Kuruchittham <vipat@seaohun.org> wrote:

Dear Jon,

Our country networks (OHUNs) are not ware of the OHASC. There is no nominated representative to participate in the first call.

I will wait for your invitation to distribute to OHUNs to nominate at least one person who can attend the call. Without the timing of the regular meetings, a person attending the initial call may or may not be the same person attending subsequent calls. I thought if the time can be determined now, OHUNs will nominate a person who will make themselves available for the OHASC meeting.

Kindly give at least one week between the invitation and the call.

Best regards,

Pat

On Wed, Jun 10, 2020 at 1:45 AM Jon Epstein <epstein@ecohealthalliance.org> wrote:

Hi Pat,
Invitations for nominated folks to join the One Health Academy Steering Committee should go out soon. We're just waiting for confirmation of a few more folks, and then I will send out the invitations to the first meeting. During the initial meeting we'll discuss the objectives of the OHASC and also decide on the timing of the meetings. Thanks for your patience.

Cheers,
Jon

On Tue, Jun 9, 2020 at 11:47 AM Vipat Kuruchittham <vipat@seaohun.org> wrote:

Dear Woutrina,

For the regional speakers, I will ask OHUNs and let you know by Friday morning (Davis time).

For the One Health Workforce Academy Steering Committee, when do you plan for regular bi-weekly calls? May I assume that it will be at the same time (Wed in the US / Thu in SEA) and length (90 mins) like the COVID-19 OH updates? I would like to emphasize that their nominated person should be available every two weeks starting xx June to September for continuity.

Thanks,

Pat

On Tue, Jun 9, 2020 at 2:05 AM Woutrina A Smith <wasmith@ucdavis.edu> wrote:

Hi Pat, thanks for your updates and questions. For the One Health COVID ECHO next Thursday, would you like to recommend up to two speakers from the region who have been active in investigating emerging disease origins

and spillover, COVID or otherwise, or would you like us to handle that planning? Brian or I can moderate this session and then in the future we can look to transition more of the ECHO tasks to your team. We will plan the e-learning pedagogy topics for July/August together.

For the One Health Workforce Academy Steering Committee, Dele and Jon can add in their thoughts but in short yes, having one person from each of the founding OHUNs nominated who can make time to participate in OHW Academy Steering Committee meetings every two weeks from June through September, and can bring in additional folks from their team to help complete specific tasks along the way, would be a very good way to move forward. The goal for September will be to have an internally facing OHW Academy website up that we can be trying out as part of a OHW-NG September Showcase three day mini e-conference (dates TBD) to highlight some of the OHW-NG Year 1 successes, etc. across the SEAOHUN and AFROHUN networks in place of a Year 1 face to face conference given the current travel limitations. Much to come on these ideas so we can plan together! Best wishes, Woutrina

---

From: Vipat Kuruchittham <vipat@seaohun.org>
Date: Friday, June 5, 2020 at 8:57 AM
To: Woutrina A Smith <wasmith@ucdavis.edu>
Cc: [redacted], Irene Naigaga <inaigaga@obcca.org>, Ratsuda Poolsuk <ratsuda@seaohun.org>, Winnie Bikaako <wbikaako@obcca.org>, Milly Nattimba <mnattimba@obcca.org>, Agnes Yawe <ayawe@obcca.org>, onehealthnextgen Sympa List <onehealthnextgen@ucdavis.edu>, OHW NG <ohw-ng@seaohun.org>, Oladele Ogunseitan <oladele.ogunseitan@uci.edu>, Terra Kelly <trkelly@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Bruce B Struminger <BStruminger@salud.unm.edu>, Brian H Bird <bbbird@ucdavis.edu>, Jon Epstein <epstein@ecohealthalliance.org>, "Rabkin, Miriam" <mr84@cumc.columbia.edu>, alexandra zuber <alexandrazuber@atahealthstrategies.com>
Subject: Re: ECHO and Q4 planning in OHW-NG

Dear Woutrina,

Thank you for sharing a well-crafted plan. I agree with the plan overall to make a shift from the discussion to One Health Academy from COVID-19. As for the last COVID-19 session, I would prefer the general format that we have been doing. I am not ready to virtually moderate the large group with limited technical knowledge and limited ability to multitasking to listen and process information while reading the chatbox and screen questions. I wish I could do it in the future.

For OH academy, kindly share what OHUNs should expect. How many people OHUNs should nominate to serve on the steering committee? One each from the four founding countries? How about engaging in bi-weekly calls? I understand that the session will be a closed group working together rather than open like the COVID-19. After receiving your answers, I will contact the OHUNs and request their nominations.

Best regards,

Pat

On Thu, Jun 4, 2020 at 8:31 AM Woutrina A Smith <wasmith@ucdavis.edu> wrote:

Hello AFROHUN and SEAOHUN Secretariat teams,

I wanted to share ideas that we were talking about today amongst the global team, to get your input and so we can plan next steps together. I think this email will also help facilitate the discussion of One Health Academy roadmap and planning, and I look forward to ongoing feedback via email and on zoom.

Current situation: At this point in the year, we find ourselves with much accomplished and much still left to do in the coming months. Year 2 work planning will soon begin, and all our teams face daily challenges associated with COVID-19 to varying extents as countries and communities gradually reopen. Our One Health ECHO sessions focused on COVID-19 have been very successful and have given us good external visibility with the global community in being quick to engage with emerging One Health issues. The planned COVID-19 One Health ECHO sessions end in June.

Next steps: So as we think about the July-September window, I would like to suggest that we plan One Health ECHO sessions every two weeks, but instead of focusing on COVID-19 given the many online COVID resources that have emerged recently, I propose that we focus the ECHO sessions on e-learning best practices and supporting teams to develop effective online training materials, sharing successes and challenges, etc. in our OHW-NG One Health community of practice. I suggest this because it would help address one of the main challenges we have been hearing from many groups about uncertainty in how to go about making the most of online training opportunities, since traditionally we have focused on face to face trainings. We have experts ready to co-lead such ECHO sessions from the global team if paired with interest from regional faculty and students who want to actively engage over the next few months. We could be working towards a September Showcase as a three day online conference (a few hours each day based on best overlap of time zones) where we do a soft launch of the One Health Academy website, provide a forum to showcase country team successes, etc. in place of the Edinburgh or a regional face to face conference in Year 1. I think there are some interesting synergies and momentum that should be explored to achieve our Year 1 deliverables in OHW-NG.

Irene and others have expressed interest in now thinking through the roadmap and steps in developing the One Health Academy. Dele will more formally roll out an overview but as a quick summary to orient us, here is the current thinking:

- Now – steering committee is being formalized with representatives from SEAOHUN, AFROHUN, and the global team.
- Now – global team has been doing pre-work to provide high level structure and function ideas that the steering committee can discuss, decide on, and take forward for next steps in developing the One Health Academy website and plan. The name of the academy will be discussed.
- June – steering committee meetings; global team working group meetings; website development to be shared for feedback and refinement; OH Academy content development as a combination of existing AFROHUN/SEAOHUN training resources as well as global team contributions.
- July – presentation of initial website and OH Academy ideas to broader faculty, board, leadership, and usaid for feedback and planning next steps.
- August – refinement and building out of OH Academy content, website, and processes. This will be iterative over the next year.
- September – soft launch of the OH Academy website, likely paired with the September Showcase online forum I mentioned above.
- Year 2-3 – continuation of OH Academy development.

Please consider these ideas, discuss them internally, and share thoughts with this group over the coming days so we can make some progress and then perhaps discuss on calls next week as you see fit. This is your initiative and we can take it in the directions that you think most useful for One Health University Networks around the world. We will be formally exploring collaborations and synergies with the other academies that are emerging from WHO, ASLM, etc. and we look forward to thinking through engagement strategies together.

Best wishes, Woutrina

Woutrina Smith, DVM, MPVM, PhD
Professor of Infectious Disease Epidemiology
Associate Director, UCD One Health Institute
Technical Director, USAID One Health Workforce - Next Gen
Co-Director, UCGHI Planetary Health Center of Expertise
School of Veterinary Medicine, UC Davis
1089 Veterinary Medicine Dr
Davis, CA 95616
wasmith@ucdavis.edu
+1 530 219-1369 ¢

--
Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street, Ste. 1701
New York, NY 10001
1.212.380.4467 (direct)
REDACTED (mobile)

web: ecohealthalliance.org

Twitter: @epsteinjon

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

--
Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street, Ste. 1701
New York, NY 10001
1.212.380.4467 (direct)
REDACTED (mobile)

web: ecohealthalliance.org

Twitter: @epsteinjon

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

--
Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street, Ste. 1701
New York, NY 10001
1.212.380.4467 (direct)
REDACTED (mobile)

web: ecohealthalliance.org

Twitter: @epsteinjon

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

--

Jonathan H. Epstein DVM, MPH, PhD

Vice President for Science and Outreach

EcoHealth Alliance
460 West 34th Street, Ste. 1701
New York, NY 10001
1.212.380.4467 (direct)
REDACTED (mobile)

web: ecohealthalliance.org

Twitter: @epsteinjon

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation